Acute Lymphoblastic Leukemia

**EVALUATION OF FEBRILE NEUTROPENIC EPISODES IN ACUTE MYELOID LEUKEMIA PATIENTS (SINGLE CENTER)**

Melda Cömert1, İsmet Aydoğan2, Funda Yetkin3, Emin Kayad1, Mehmet Ali Erkurt4, İrfan Kuku4

1EmpaT, School of Medicine, Hematology, İzmir, Türkiye
2Kent Hospital, Hematology, İzmir, Türkiye
3İnönü University, School of Medicine, Infectious Disease, Malatya, Türkiye
4İnönü University, School of Medicine, Hematology, Malatya, Türkiye

Introduction: The most important cause of mortality in febrile neutropenic episodes (FNEs) which mature after chemotherapy is infections. Therefore fewer in neutropenic patients must be accepted as an infection until the contrary is proved and broad-spectrum empiric antibiotic treatment policies must be started immediately as a standard approach.

Patients and Methods: Two hundred and thirty-six febrile neutropenic episodes of 87 patients who have been treated because of acute myeloid leukemia in İnönü University Turgut Özal Medicine Center Adult Hematology Clinic between 2002 and 2010 was evaluated. The infection categories, isolated pathogen microorganisms, mortality ratios and antibiotic therapy regimens in 236 febrile neutropenic episodes which mature after chemotherapy were examined retrospectively in this study.

Results: Fifty-three (61.0%) of the patients were males and 34 (39.0%) were females. The median age of the patients was 52.4. The median follow-up period was 9.5 months. In FNEs, fewer was evaluated as microbiologically defined infection (MDI) in 95 (40.3%) episodes and as fewer of unknown origin (FUO) in 68 (28.8%) episodes. In forty-seven (19.9%) episodes efficient pathogen microorganism was isolated from blood cultures. 91.5% of the pathogen microorganisms were gram-negative bacteria. Pneumonia was the most clinical infection seen in CDI. The mean neutropenia duration was 13.3 days in all episodes, 16.7 days in MDI, 13.1 days in CDI and 10.0 days in FUO. The mortality rate was 8.5% in all episodes, 9.6% in MDI, 11.6% in CDI and 2.9% in FUO. The mean neutropenia duration in exitus patients was 21.6 days and 12.6 days in living patients. This difference was statistically significant.

Conclusion: Prolonged fever and neutropenia was more often accompanied with MDI and the length of the duration of neutropenia was found to be a risk factor for mortality in this study. For a better febrile neutropenia management process, medical centers must follow their infection agents closely and modify their empiric antibiotic treatment policies.

**Keyword:** Acute myeloid leukemia, febrile neutropenia

---

**MRD-VALUES IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

Suzan Cınar, Abdullah Yılmaz, Buşra Aydın, İlhan Tahralı, Umut Can Küçüksesezer, Günbur Deniz

Istanbul University, Institute of Experimental Medicine, Department of Immunology, İstanbul, Turkey

Studies of minimal residual disease (MRD) have a powerful clinical application in the management of acute leukemia patients. Detection of MRD with flow cytometric methods (FCM) is faster and cheaper when compared to molecular methods and it is the main reason for utilization in many centers. According to AIEOP-BFM (Associazione Italiana Ematologia Oncologia Pediatrica - AIEOP and Berlin-Frankfurt-Münster - BFM) protocol, evaluation of MRD with FCM is related to comparison of expression levels of major antigens at different time points of remission induction therapy of B cell precursor Acute Lymphoblastic Leukemia (ALL). Leukemic cells were identified using an immunological gate based on CD19 expression associated with a physical parameter (SSC) and they were discriminated from normal B lymphocytes on the basis of leukemia associated immunophenotypes (i.e. over expression of antigens such as CD10, CD34, CD58 and/or under expression of CD45 and CD11a).

We investigated paired samples from diagnosis and early follow up (day 15) from 139 consecutive B-cell precursor ALL cases for the expression levels of seven antigens, highly relevant for MRD studies, on leukemic cells. Nucleated cell counts were determined by Syto16 staining and blast counts among nucleated CD19+ B cells lower than 0.1% was determined as low risk (FLR), between 0.1% - 10% was termed as medium risk (FMR) and over 10% was determined as high risk (FHR). Of the 139 cases (54 female, 85 male, mean age: 6.67 ± 4.67 years), 19 cases were diagnosed as MRD negative (13.71%) whereas 120 cases were diagnosed as MRD positive (86.3%). According to MRD risks, diagnosis of 47 cases were FLR (33.8%), 73 cases were FMR (52.5%) and 19 cases were FHR (13.7%). When groups were compared, there was no statistical significance between ages of male (6.97 ± 4.52 years) and female (6.20 ± 4.90 years) cases (p=0.153); and between MRD negative (33.8%), 73 cases were FMR (52.5%) and 19 cases were FHR (13.7%). When groups were compared, there was no statistical significance between ages of male (6.97 ± 4.52 years) and female (6.20 ± 4.90 years) cases (p=0.153); and between MRD negative (33.8%), 73 cases were FMR (52.5%) and 19 cases were FHR (13.7%).

These are the findings of the first center in Turkey who received certificate of proficiency from AIEOP-BFM partner in August, 2011 and can evaluate its own cases. Further studies, to investigate relationship between prognosis and survival or correlation of PCR and MRD findings in more detailed studies with contribution of clinics will be more helpful to apply sensitive and accuracy therapy in B-ALL patients.

**Keyword:** MRD, flow cytometry
OVEREXPRESSION OF LYN CONTRIBUTES TO PROLIFERATION IN ALL
Allan Xavier Pernudi, Kevin Dierck, Magdalena Trochimiuk, Martin Horstmann
Research Institute Children’s Cancer Center Hamburg, 20246 Hamburg Germany

The Src family kinases (SFKs) are important intracellular tyrosine kinase signaling mediators that transmit signals from cell surface receptors and are involved in diverse physiological processes as well as many human malignancies. The SFK, Lyn, Blk and Fyn are known to play a critical role in B-cell development upon B-cell receptor (BCR) crosslinking by inducing phosphorylation of many different downstream targets thereby promoting cell growth and differentiation (Fig. 1).

Objective: Quantification and analysis of the protein tyrosine kinase (PTKs) expression in childhood acute lymphoblastic leukemia (ALL) and ALL cell lines and functional assessment of their potential role in leukemogenesis.

Method: Whole cellular lysate from bone marrow (BM) or peripheral blood (PBL) from primary ALL patients and ALL cell lines were analyzed. Detection of the expression and phosphorylation state of PTKs at the protein level was performed by Western Blot. Modulation of the BCR signalling network by using shRNA mediated repression of the predominant PTK Lyn, in the Nalm6 cell line was carried out. Analysis of cell proliferation and apoptosis was monitored by MTT assay and Anexin V/PI staining, respectively.

Results: TK expression in ALL patient samples is characterized by a high degree of heterogeneity and does not correlate with the immunophenotype of ALL. However, unsupervised hierarchical cluster analyses led to the identification of a subgroup of patients showing a relatively high Lyn expression. The Nalm6 cell line was chosen as a model which mirrors Lyn expression status in ALL patients. Tyrosine phosphorylation pattern was greatly diminished in Nalm6 upon Lyn depletion, furthermore the Lyn-depleted cells showed a substantially reduced cell proliferation and preliminary increased apoptosis.

Conclusion: Our findings indicate that aberrant expression of Lyn in ALL may contribute to cell proliferation. Although we have highlighted substantial contribution of Lyn in cell proliferation in leukemic cells, the impact of combining drugs targeting Lyn with conventional chemotherapeutics agents remains to be determined.

Keyword: Src family kinase, ALL

Figure 1. Activation of the pre-BCR signalling leads to a single tyrosine phosphorylation at the immuno-receptor tyrosine-based activation motif (ITAM) (red dash) in the cytoplasmatic portion of Igβ, followed by the recruitment of SFK members like Lyn, Blk, Fyn. Subsequently, the Igβ-ITAMs are double phosphorylated in a SFK dependent manner, then Syk is recruited to the ITAM, where it plays an essential role in proliferation and differentiation1. Contrary, leukemic cells have shown an impaired differentiation2 accompanied by an increased proliferation3. The observed high expression levels of Lyn in ALL cells may substantially increase cell growth suggesting a potential advantage of using Lyn inhibitors in addition to anti ALL chemotherapy-drugs.

PANCREATIC INFILTRATION IN AN ADULT PATIENT WITH COMMON B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Gülsüm Emel Pamuk1, Ümit Tapan2, Mustafa Akker3, Hasan Ümit4, Yahya Çelik5
1Department of Hematology, Trakya University Medical Faculty, Edirne-Turkey
2Department of Internal Medicine, Steward Carney Hospital, Tufts University School of Medicine, Boston, MA-USA
3Department of Internal Medicine, Trakya University Medical Faculty, Edirne-Turkey
4Department of Gastroenterology, Trakya University Medical Faculty, Edirne-Turkey
5Department of Neurology, Trakya University Medical Faculty, Edirne-Turkey

Introduction: Acute lymphoblastic leukemia (ALL) might involve different extramedullary sites either at diagnosis or during disease course. The most frequently involved organ is the central nervous system. Pancreatic infiltration in ALL is quite rare, being limited to a few pediatric case reports.

Case: A 52-year-old male patient was hospitalized in our hospital with the complaints of abdominal pain, nausea and vomiting. Laboratory data were as follows: hemoglobin, 11.6 g/dl; hematocrit, 35.1%; leucocytes, 18000/mm³; platelets, 64000/mm³; glucose, 170 mg/dl; ALT, 117 U/L; AST, 172 U/L; ALP, 474 U/L; GGT, 404 U/L; total protein, 4.9 g/dl; albumin, 1.8 g/dl; LDH, 2617 U/L (N=192); ESR, 119 mm/hr; and CRP, 7.9 mg/dl (N<0.8). Serum amylase was 262 U/L (N: 25-125); and lipase was 796 U/L (N: 8-78). Abdominal tomography demonstrated splenomegaly; there was also diffuse pancreatic enlargement and the pancreas had a heterogenous appearance with some small anechoic cysts (Figure 1). There were 80% lymphoblasts on peripheral blood smear, the bone marrow aspiration showed 92% lymphoblasts. Malignant cells were positive for CD45, HLA DR, cytoplasmic CD79a, CD19, CD22, CD10 and TdT; and they were negative for...
CD2, CD3, CD4, CD7, CD13, CD14, CD33, CD34, and CD56. BCR-ABL and MLL fusion genes were negative with FISH. The patient was administered GMALL (05/93) chemotherapy which included intrathecal prophylaxis. He obtained complete hematologic remission and his control abdominopelvic tomography revealed regression of the pancreatic enlargement. Seven weeks after diagnosis, the patient complained of headache, nausea and vomiting. He had right abducens nerve paralysis; and, a cranial MR revealed an extraaxial tumoral mass of diploe origin in the neurocranium. He was started to be administered GMALL (05/93) chemotherapy for high-risk ALL. Five months after diagnosis, he developed febrile neutropenia and had a pneumatic consolidation on chest X-ray. There were elevations in bilirubin, ALP, GGT levels. Abdominal ultrasonography revealed multiple masses in the liver. He died 6 months after diagnosis.

Conclusion: Pancreatic infiltration causing acute pancreatitis has not been reported in an adult ALL patient until now. Patients with multiple extramedullary organ involvement, including that of the pancreas, might need to be treated with more aggressive chemotherapy protocols.

**Keyword:** Acute lymphoblastic leukemia; pancreatic infiltration; acute pancreatitis; central nervous system relapse

---

**Figure 1:** Abdominal tomography showing diffuse pancreatic enlargement

**Poster No: 005 Abstract:0129**

**ACUTE LYMPHOID LEUKEMIA IN A PATIENT WITH ANKYLOSING SPONDYLITIS AFTER ANTI-TNF-ALPHA TREATMENT: CASE REPORT**

Füsun Özdemirkıran1, Eyüp Çoban2, Kadriye Bahriye Payzın1, Korhan Barış Bayram3

1. Katip Çelebi University, Atatürk Education and Research Hospital, Hematology Department; İzmir
2. Katip Çelebi University, Atatürk Education and Research Hospital, Internal Medicine Department; İzmir
3. Katip Çelebi University, Atatürk Education and Research Hospital, Phisotherapy and Rehabilitation Department; İzmir

Introduction: Tumor necrosis factor alpha (TNF-α) inhibitors are used worldwide in the treatment of several inflammatory diseases, including ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and inflammatory bowel diseases. We report here a 40-year-old man with ankylosing spondylitis who developed Philadelphia chrome-positive (Ph+) ALL after treatment with TNF-α inhibitors (etanercept and adalimumab).

Case report: A 40-year-old man was referred to our hematology department for evaluation of leukocytosis, anemia and thrombocytopenia. The patient's history has revealed that, in 2002, he presented with inflammatory back pain, weakness and weight loss and he was diagnosed with ankylosing spondylitis by the rheumatologist. The patient was given an individual treatment including salazopyrine 2g/day and indomethasine 100 mg/day and he followed all scheduled visits during 9 years with a full patient compliance. In his previous visit performed in April 2011, Etanercept therapy (50 mg/ever week) was started because of active disease and unresponsiveness to existing drugs. In January 2012, treatment with Etanercept was switched to Adalimumab (40 mg/ever 2 week), because of failure to improve disease. In November 2012, the patient was referred to our hematology clinic with the complaints of progressive fatigue, joint pain and asthenia. Physical examination showed significant pallor and spleen were palpable 5 cm below the costal margin palpable Laboratory test was performed; leukocyte count was 315,000 x10⁹/L with 88 % blasts in peripheral blood smear, hemoglobin level was 6.8 g/dl, platelet count was 92 X10⁹ /L. He was admitted to the hospital subsequently and bone marrow aspiration biopsy was done. Bone marrow biopsy showed marked (75%) infiltration with small-sized blast. According to clinical and laboratory results the patient was diagnosed with Philadelphia chromosome-positive acute lymphoid leukemia (Ph+ ALL). He was given an treatment including Glivec (a tyrosine-kinase inhibitor) 400 mg/day and induction of adult ALL regimen (including glucocorticoid, vincristine, anthracycline and asparaginase). During the induction chemotherapy the patient developed fungal pneumonia. Although to treatment with broad-spectrum antibiotics the patient was died because of sepsis and respiratoty failure.

Discussion: We report this patient to add to the growing literature of patients who develop hematologic malignancies after TNF alpha inhibitor treatment. The majority of cases were non-Hodgkin's lymphomas whereas there is only two reports with Ph+ ALL. The mechanism by which TNF-α protects against cancer and thereby how its inhibition may promote cancer, is not well understood. Among the行业 cases were non-Hodgkin's lymphomas whereas there are two reports with Ph+ ALL. The mechanism by which TNF-α protects against cancer and thereby how its inhibition may promote cancer, is not well understood. According to present case and literature knowledge blood counts should be done prior to initiating therapy and during follow up.

**Keyword:** Acute lymphocytic leukemia, Anti-tnf-alpha therapy

---

**Poster No: 006 Abstract:0157**

**PRIMARY GRANULOCYTIC SARCOMA CASES: SINGLE INSTITUTION EXPERIENCE**

Asu Fergun Yılmaz1, Melda Cömert1, Nazan Özsan2, Mine Hekimgil1, Ajda Günes3, Serra Arun Kamer3, Fahri Şahin1, Filiz Vural1, Murat Tombuloğlu1, Güray Saydam1

1. Ege University Faculty of Medicine, Department of Hematology
2. Ege University Faculty of Medicine, Department of Pathology
3. Ege University Faculty of Medicine, Department of Radiation Oncology

Objective: Granulocytic sarcoma is tumor consists of proliferation of immature myeloid cells at extramedullary sites. Although they accompany mostly acute myeloid...
leukemia, myelodysplastic syndrome, chronic myeloproliferative diseases, they might be detected as an isolated infiltrations without systemic disease in a rare cases. In this study, we aimed to document the cases with granulocytic sarcoma without systemic involvement and followed-up in our center.

Method: We documented 25 cases with granulocytic sarcoma between the years of 2000 and 2012. Five of 25 were diagnosed as primary disease without systemic infiltration. At this study we present the primary granulocytic sarcoma cases without bone marrow involvement.

Results: The characteristics of the patients were summarized at table 1.

Conclusion: Granulocytic sarcomas can be localized at any system and organ. They can progress to acute leukaemia. They should be considered during differential diagnosis of soliatry tumors since they can infiltrate especially solid organs and lymph nodes. Since their prognosis become worsened after they progress to acute leukaemia, they should be treated with systemic chemo- or in combination with surgery/radiotherapy.

**Keyword:** granulocytic sarcomas, primary

**Table 1: Characteristics of the patients**

<table>
<thead>
<tr>
<th>patients</th>
<th>age</th>
<th>sex</th>
<th>localization</th>
<th>bone marrow involvement</th>
<th>treatment</th>
<th>follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>49</td>
<td>male</td>
<td>pancreas</td>
<td>no</td>
<td>radiotherapy</td>
<td>Progression to acute myeloid leukaemia after 4 months of the diagnosis. Remission was obtained with chemotherapy followed by alo-IX</td>
</tr>
<tr>
<td>2</td>
<td>24</td>
<td>male</td>
<td>conjunctiva</td>
<td>no</td>
<td>radiotherapy</td>
<td>Progression to AML after 2 years. Treated with chemotherapy and alo-IX but died during transplantation due to infection and sepsis</td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>male</td>
<td>small intestine</td>
<td>no operation</td>
<td>He is at remission for 10 months</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>31</td>
<td>male</td>
<td>axillary region</td>
<td>no radiotherapy</td>
<td>He is followed-up at remission</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>52</td>
<td>female</td>
<td>inguinal region</td>
<td>no radiotherapy</td>
<td>At 16th month after the diagnosis she relapsed with new lesions at inguinal region and breast. She was treated with chemotherapy. Followed up at remission for 14 months</td>
<td></td>
</tr>
</tbody>
</table>

**Poster No: 007 Abstract:0165**

**LOW PLATELET COUNTS AS A PROGNOSTIC MARKER IN ALL TREATMENT IN PLACE OF MRD IN COUNTRIES WITH LIMITED FINANCIAL RESOURCES**

Tiraje Tülin Celkan¹, Aïda Koka¹, Gülşinhal Ozdemir¹, Gülten Tüysüz¹, Hülimi Apak¹, Ethem Erginöz², Müge Sayıştırgılı², Uğur Özbek³

¹Pediatric Hematology-Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Türkiye
²Public Health, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Türkiye
³Department of Genetics, Institute of Experimental Medicine Research, Istanbul University, Istanbul, Türkiye

**Aim:** The aim of this study was to estimate prognostic and early response criteria for the patients treated by BFM ALL regimens.

Patients: There were 242 newly diagnosed non B-ALL patients enrolled into this retrospective study, who were admitted to Cerrahpasa Pediatric Hematology Department during January 1995 to January 2012.

Results: The median age was 6,18y ±3,75years (8 month-17 years). The %59,4% of the group were boys. (boys/girls 1,46). CNS involvement was positive in %7,7. T-cell immunophenotype was shown in11, 8%. Genotypically t(12;21), (t9;22) and t(11,19) were positive in %8, %3 and %3 of patients, respectively. The overall survival of the B-ALL patients was %68±3,1, while that of the T-ALL patients was %62,2±12,4 (p<0.007). The EFS of the patients who had CNS involvement was %47,6±12,1, lower than the ones who had not(0,0001).

The OS and EFS of the whole group was 74,8%±3,9 and 74%±3,1 respectively, while EFS ratios for boys 72% and girls 80.5% (p<0.728).The OS and EFS were lower as the age increase (>10 years OS and EFS were 59,9%±8,4 and 57,4%±8,4(p<0,001)) except <1 year ( OS and EFS 37,5%±28,6). Being a high risk patient was significantly associated with X3 relaps and X7 exitus (OS 22,7%±9,1 and EFS 27,6%±8, p<0,0001). Having splenomegaly, hepatomegaly, t (9,22), CNS involvement (CNS leukemia increased exitus risk X4 times), higher Hb and WBC counts at diagnosis were related with poorer treatment results. ( WBC >100.000 /mm³ OS %53,7±12,8 (p<0,028). Hb >8g/dl and T-ALL patients’ OS 44,4%±13,5 (p<0,01).

Although the platelet counts at diagnosis had no prognostic value, platelet count at 15 and 33th days were <50.000/mm³ had higher risk for exitus (respectively X3 and X7), and had lower OS p<0,008, p<0,0001). Thrombocytopenia usually goes parallel with neutropenia and monocytopenia. Monocytopenia <100/mm³ at day 33 had EFS 67,3%±5. Lymphopenia at this period is strictly correlated with neurological adverse events.

The blast count at 15 and 33 day were a reliable prognostic marker as if the blasts were >5% OS 35,8%±15,9 and 0 % while patients with blasts <5% had 89,7%±2,6 and 80,2±4,1% respectively (p<0,0001).The 13.3 % of the group relapsed, generally in 3.5 years period after diagnosis, and 72% of the relapsed patients were succumbed in 5 months.

As a conclusion, childhood ALL treatment results have reached great improvements in the MRD era. The potential benefit of simple methods such as full blood count and clinical findings, can predict us the outcome. The most striking and important finding of our study is probably the strong association of platelet counts with the prognosis. Having a platelet count less than 50.000/mm³ at the 15 and 33th day of treatment, was associated with high mortality (p<0,0001) and this count would be easily reached great improvements in the MRD era. The potential benefit of simple methods such as full blood count and clinical findings, can predict us the outcome. The most striking and important finding of our study is probably the strong association of platelet counts with the prognosis. Having a platelet count less than 50.000/mm³ at the 15 and 33th day of treatment, was associated with high mortality (p<0,0001) and this count would be easily used just for a marker in countries with limited financial resources where MRD is not available.

**Keyword:** ALL, prognostic markers

**Poster No: 008 Abstract:0184**

**OCCURRENCE OF L-ASPARAGINASE-ASSOCIATED FULMINANT HEPATITIS IN A CASE DIAGNOSED WITH ACUTE LYMPHOBластIC LEUKEMIA AND TREATMENT BY PLASMAPHERESIS**

Özkan Arslan¹, Gülşinhal Özdemir², Çağlayan³, Oktay Bilgir⁴

¹Izmir Bozyaka Training and Research Hospital
²Department of Hematology, Bozyaka/Izmir/Turkey
³Izmir Bozyaka Training and Research Hospital
⁴Izmir Bozyaka Training and Research Hospital

**Introduction:** Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with different subtypes exhibiting...
ABSTRACTS

Poster No: 009  Abstract:0187

QUERCETIN AND EMODIN SYNERGISTICALLY ENHANCED CHEMOTHERAPY ACTIVITY IN HUMAN LYMPHOID AND MYELOID LEUKAEMIA CELL LINES, IN VITRO

Amani A. Mahbub1, Christine L. Le Maitre1, Sarah L. Haywood Small1, Gordon J. Mcdougall2, Neil A. Cross1, Nicola Jordan Mahy1

1Biomedical Research Centre, Faculty of Health and Wellbeing, Sheffield Hallam University, S1 1WB, Sheffield.
2The James Hutton Institute, Environmental and Biochemical Sciences Group, Invergowrie, Dundee DD2 5DA, Scotland.

Objective: The mortality of leukaemia is still high despite the considerable improvements in chemotherapeutic agents. Our previous work has shown that polyphenols and polyacetylenes have potential in the treatment of leukaemia (Dahlawi et al 2012; Zaini et al 2011). Furthermore, in a comparative study of the effect eight polyphenols in eight leukaemia and one non-tumour control cell lines, quercetin and emodin were shown to be the most effective at induction of apoptosis, causing cell cycle arrest and inhibiting ATP levels (as a marker of proliferation), in leukaemia compared to non-tumour cells. Using IC25 and IC10 treatment doses (the concentration which inhibits 25% and 10% of cell ATP levels respectively) an investigation was made of the effects of the quercetin and emodin on five standard chemotherapy treatments (doxorubicin, etoposide, cisplatin, cyclophosphamide and chlorambucil), on cell proliferation, cell cycle and apoptosis at 24hrs-post-treatment in two human myeloid (KG1a and THP-1) and two human lymphoid (JURKAT and CCRF-CEM) leukaemia cell lines.

Methods: The combination effects of polyphenols and chemotherapies on cell ATP levels was measured by CellTiter-Glo® luminescent assay, cell cycle was assessed using propidium iodide (PI) staining and flow cytometry and induction of apoptosis was investigated by caspase-3 activity assay using flow cytometry and by morphological assessment following Hoechst 33342 staining.

Results: Quercetin synergistically inhibited ATP levels, and induced apoptosis and cell cycle accumulation when combined with etoposide, cisplatin and cyclophosphamide in both lymphoid cell lines, whilst having an additive effect in the myeloid cell lines. Quercetin also had an additive effect when used in combined with doxorubicin and chlorambucil, in all cell lines. Similarly emodin produces a synergistic effect when combined with etoposide and doxorubicin, and an additive affect with cisplatin, cyclophosphamide and chlorambucil in both lymphoid cell lines.

Conclusion: This study show that quercetin and emodin have a potential role at enhancing the action of chemotherapy in the treatment of leukaemia, however the levels of action depend on the polyphenol and cell lineage. This suggests that there is a different mechanism of action of these polyphenol-chemotherapy combinations in the treatment in lymphoid and myeloid leukaemia.

Keyword: Leukemia, Quercetin and Emodin

May 22 – 25, 2013 • Istanbul, Turkey

275
ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS OF POLYPHENOLS ON HUMAN MYELOID AND LYMPHOMA LEUKAEMIA

Amani A. Mahbub¹, Christine L. Le Maître¹, Sarah L. Haywood Small¹, Gordon J. Mcdougall², Neil A. Cross¹, Nicola Jordan Mahy¹
¹Biomedical Research Centre, Faculty of Health and Wellbeing, Sheffield Hallam University, S1 1WB, Sheffield. ²The James Hutton Institute, Environmental and Biochemical Sciences Group, Invergowrie, Dundee DD2 5DA, Scotland.

Objective: The mortality of leukaemia is still high despite the considerable improvements in chemotherapeutic agents. For this reason, our study aimed to investigate the polyphenols as alternative agents for leukaemia treatment in which the most recent studies have been focused only on solid tumours. Here, we specifically selected eight compounds from the major classes of polyphenols (quercetin, chrysine, apigenin, emodin, aloe-emodin, rhein, cis-stilbene and trans-stilbene) and their effects were investigated on cell proliferation, cell cycle and apoptosis on a panel of human myeloid (KG1a, HL60 THP-1, and K562) and lymphoid (JURKAT, CCRF-CEM, MOLT-3, and U937) leukaemia cell lines.

Methods: The effect of polyphenols on cell proliferation was measured by CellTiter-Glo® Luminescent Assay and cell cycle was assessed using propidium iodide (PI) staining and flow cytometry. Induction of apoptosis was investigated by caspase 3 activity assay using flow cytometry and Hoescht stain using fluorescence microscopy.

Results: Our study showed that emodin, quercetin, and cis-stilbene were the most effective polyphenols at inhibiting cell proliferation (with IC50 values ranged between 5-22µM, 8-33µM, 30-85µM, respectively) and inducing the apoptosis (with AP50 values ranged between 2-27µM, 19-50µM, 8-50µM, respectively), following 24hr for all the leukemic types. All myeloid cell lines have been more sensitive to apigenin comparing to other compounds in inducing apoptosis while at higher concentrations between 84-235µM. Meanwhile, all lymphoid cell lines showed greatest sensitivity to the all polyphenols comparing to the myeloid cell line.

Conclusions: Our data showed that all eight polyphenols where significantly found to inhibit cell proliferation and arrest the cell cycle for all leukemic cell lines with varied responses in inducing the early and late apoptosis, this variety of action between cell lines suggesting that there is a different mechanism of the action of each of these molecules. In conclusion, our findings suggest that polyphenols could be used as new chemotherapeutic agents in the treatment of leukaemia.

Keyword: Leukemia, Polyphenols
ARE HYPOMETHYLATING AGENTS TO BE GIVEN PREFERENCE IN CMML 1?
Ulku Ergene, Alihsan Gemic, Mehmet Gültekin
Department of Haematology, Celal Bayar University School of Medicine Manisa/TURKEY

Case: 72 year old male patient was examined two years ago at another center and was diagnosed with Myelodysplastic Syndrom (MDS) and then he was monitored without any treatment given. The patient who required intermittent erythrocyte and platelet replacement therapy was receiving iron chelation therapy for the last year. After the blood marrow tests that were performed in September 2012 due to increase in white blood cells and deepening thrombocytopenia, which revealed dysgranulopoiesis, dyserythropoiesis findings and 1-2% blast cells azacitidine chemotherapy was initiated to the patient on 27.11.2012 for Chronic Myelomonocytic Leukemia (CMML). On the 7th day of chemotherapy the patient was admitted to the emergency care clinic of our hospital due to signs of confusion. Thrombocytopenia and intracranial bleeding was detected and subsequently the patient was operated. After the surgery the patient had been monitored by the Hematology Department and his thrombocytopenia could not be resolved inspite of the replacement therapies given. Although corticosteroids, IVIG (intravenous immunoglobuline) and multiple platelet replacements were administered to the patient the bleeding could not be taken under control and the patient died.

Discussion: Chronic myelomonocytic leukemia (CMML) is a heterogen clonal disorder, which is characterized by monocytosis, less than 20% blast cells in the bone marrow, one or more dysplasia and negativity for Philadelphia (Ph) chromosome. World Health Organization (WHO) classified CMML as a ‘mixed Myelodysplastic/ Myeloproliferative disease’ and subgrouped the disease according to the blast cell counts in the peripheral blood and bone marrow. CMML1, <5% blast cells in peripheral blood, <10% blast cells in bone marrow CMML 2; <5-19% blast cells in peripheral blood, <10-19% blast cells in bone marrow. In a trial, average life expectancy is found to be 12-24 months in CMML.

There is no standart approach in treating CML. Appropriate treatment options are effected by patient related (patients choice, performance status of the patient, age and comorbidities) and disease related (cytogenetic condition, number of cytopenies, bone marrow blast count and transfusion requirements) factors.

When using hypomethylating agents and adjuvant therapy are compared for the treatment of CMML, delay in transformation to acute leukemia and increase in overall survival is found with hypomethylating agents but the improvement in overall survival is still not statistically significant and prospective studies are required. Cytopenies (thrombocytopenia, anemia) and complications occurring after usage of azacitidine and decitabine which inhibit the metililation of the DNA should be treated in the centers who are experienced in this field. We believe that using hypomethylating drugs in CMML patients with low blast counts can lead to shorter life expectancy and life losses therefore should be carefully considered.

Keyword: Hypomethylating Agents, Thrombocytopenia

EVALUATION OF PEDIATRIC T-ALL MRD VALUES BY FLOW CYTOMETRY
Suzan Cinar, Abdullah Yilmaz, Umut Can Kucuksezer, Ilhan Tahrali, Burcin Aydin, Gunnur Deniz
Istanbul University, Institute of Experimental Medicine, Department of Immunology, Istanbul, Turkey

Assessment of minimal residual disease (MRD) during the first months of therapy gives information on the timely response to treatment, and proves to be a powerful and independent indicator of treatment outcome in patients with acute lymphoblastic leukemia (ALL). Different study groups indicated that detecting submicroscopic levels of leukemia cells in bone marrow on 15th day of treatment is associated with prognosis. Flow cytometry (FCM) is faster and cheaper than molecular methods, and is performed for leukemia immunophenotyping in many centers today. There are early T cell precursors in bone marrow of T-ALL patients, and these precursors constitute thymocyte subgroups migrate to thymus and is considered that they are derived from hematopoietic stem cells because of their multilineage differentiation potential. They have a distinctive immunophenotype with CD1a-CD8-CD5dim stem cell or myeloid markers. T-ALL MRD results have importance due to patient follow up and chemotherapy dose adjustment. In Turkey, MRD is started to apply as pioneer in our institute, and MRD levels in T-ALL samples were determined by FCM according to Associazione Italiana Ematologia Oncologia Pediatria -Berlin-Franklin-Munster (AIEOP-BFM) protocol.

In this study, blasts were detected in bone marrow samples from T-ALL patients (n=14) on the 15th day of treatment and the MRD ratio and relapse risk were evaluated. CD45, CD3, CD4, CD5, CD7, CD8, CD99, cytoplasmic CD3 and cytoplasmic TdT antigen expressions in bone marrow samples were detected by FACSaria and data were analyzed using DiVa software. After determining the number of nucleated cells by Syto41 staining, leukemic cell ratio (blast or MRD%) detected in nucleated
CD7+ T cell population was scored as; lower than 0.1% was flow low risk (FLR), between 0.1-10% is medium risk (FMR) and higher from 10% is high risk (FHR).

Three of 14 cases (1 female, 13 male, 9.01 ± 5.16 years) were MRD negative (18.75%), 11 were positive. According to MRD risk, cases were grouped as 5 FLR (35.71%), 6 FMR (42.86%) and 3 FHR (21.43%). All of the measurements were confirmed by AIEOP-BFM partner (100%). There were no significant differences between male (9.39 ± 4.69 years) and female (7.37 ± 7.92 years) cases, FLR (10.69 ± 5.13 years), FMR (6.83 ± 3.81 years) and FHR (11.51 ± 4.80 years) and FLR negative (10.92 ± 6.42 years) and positive (10.24 ± 4.72 years) groups, according to their ages.

In this study, flow cytometric T-ALL MRD results on the 15th day of the treatment were discussed.

**Keyword:** MRD, T-ALL

---

**STUDY OF ACUTE LYMPHOCYTIC LEUKEMIA AT TABRIZ ASADABADI CHILDREN HOSPITAL**

Saeed Nasouhi Pur
Dept of Hematology, Faculty of Piropezhshi, Tabriz University of Medical Sciences-Iran

Background: Acute lymphocytic leukemia (ALL) is the most common leukemia in children under 10 years of age. The clinical manifestations of ALL are extremely variable and nonspecific are those due to leukemic cell proliferation, and usually appear 2 to 6 weeks before the diagnosis.

In this study which lasted ten years, 67 cases ALL was seen that include: ALL-L1, ALL-2, ALL-3. In the WHO classification these cases are categorized as lymphoma rather than as acute leukemia, this more accurately reflects the nature of the disease. In L1 ALL the blast cells small to medium in size and are fairly uniform in appearance. Larger cells have diffuse chromat in and sometimes small nucleoli whereas the small blasts have no visible nucleolus and show some chromat in condensation. Cytoplasm is scanty. In L2 ALL the blasts are larger more pleomorphic with irregular nuclei, more prominent nucleoli more abundant cytoplasm. L3 ALL is characterized by moderately intense cytoplasmic basophilia and variable but usually heavy cytoplasmic vacuolation.

ALL is a curable disease for most children. The majority (55%) of cases of this heterogeneous disease are standard-risk ALL of B-cell lineage, and the best prognosis for an overall survival rate for this group of patients is about 90 percent. Complete remission (CR) in children with ALL is one of the greatest achievement of modern oncology.

**Keyword:** Leukemia, Lymphoblast
involvement was detected. She was accepted as isolated cutaneous AML relapse. She was given chemotherapy including idarubicin and fludarabine. Although she developed very severe pancytopenia, skin lesions did not improve, and some of them showed enlargement. Repeated skin biopsy showed persistent leukemic cells infiltration. Electron beam therapy was applied to the skin lesions for 15 days.

The whole skin electron radyotherapy according to Stanford technique was used. She was treated in 6 different position with a distance of 310 cm SSD. A total of 18 Gv, 1.2 daily dose was reached with electron energy of 6 MeV. Since there was no central involvement cranium was protected. After treatment degree 2-3 radiodermitis was seen in hands and feet.

After resolution of the skin findings, biopsy was again taken and showed no blastic cells. Then she underwent bone marrow transplantation from her matched brother. Six months after transplantation she is fine without any event.

Conclusion: According to our experience and review of the literature, an early diagnostic workup is needed in AML patients with unusual skin lesions, considering leukemia cutis as first manifestation of relapse AML. Electron beam therapy seems an effective and safe approach for treatment treatment is recommended soon after diagnosis.

**Keyword:** AML, cutaneous

---

**Poster No: 0017 Abstract:0229**

**SEVERE INVASIVE FUNGAL INFECTIONS IN CHILDREN RECEIVING EMPIRICAL CASPOFUNGIN TREATMENT FOR FEBRILE NEUTROPENIA**

Deniz Yılmaz Karapınar, Nhił Karadaş, Pınar Yazıcı, Muhterem Duyuğ, Yeşim Aydınoğlu, Süleyha Hılimişoğlu Polat, Dilek Metin, Bülent Karapınar, Can BAııkan, Kaan Kavakılı

Ege University Medical School Pediatric Hematology, Bornova- İzmir

Ege University Medical School Pediatric Intensive Care Unit, Bornova- İzmir

Ege University Medical School Pediatric Microbiology, Bornova- İzmir

Invasive fungal infections have significant impact on leukemia patients’ survival. Antifungal drugs are empirically given most of the patients. However breakthrough fungal infections under some antifungal drugs are not uncommon.

Four patients, 3 girls and one boy, aged between 2.5 and 16 (median 4) years old developed rare mycotic breakthrough infections while they were receiving caspofungin treatment. The primary diagnosis of the patients were PreB Cell ALL (n=3) and very severe acquired aplastic anemia (n=1). The median time of severe neutropenia before detection of mycotic agent was 33 days (range 16-55 days). The median time of febrile neutropenia period before detection of the agent was 16 days (range, 14-19) days. All patients were given broad spectrum antibiotic initially. Since the fever persisted empirical changes in antibiotic combinations were made despite any agent was isolated from the cultures. At the median of 5th (range, 4-12 days) day of febrile neutropenia caspofungin was started as empirical antifungal therapy. They all had fever and hepatosplenomegaly. Cutaneous maculopapular rash was seen in 2 of the patients. One had status epilepticus and multiple cerebral abscess at presentation of mycotic infection. Three of these patients required entubation and mechanically ventilation, and entered into pediatric Intensive Care Unit. Trichosporon asahii was detected in 2 patients’ blood culture and Geotrichum capitatum in the others (one also had positive CSF culture).

Median time between initiation of caspofungin and first time for detection of mycotic agent was 14 (11-19) days. Because the patients’ clinical situation worsened, in two patients voriconazole was added to antifungal therapy empirically 3 and 5 days before the agent was detected.

The first sterile blood culture was obtained 3-10 days after the day of first detection of fungal agent, and 3-7th days of voriconazole treatment

All patients reached clear cultures but one patient died. One patient with central infection with T. asahii had severe neurological sequelae.

According to our experience and literature very severe fungal infections could occur during empirical caspofungin treatment. We must evaluate this observation very carefully. Randomized, controlled studies should be planned.

**Keyword:** caspofungin, breakthrough fungal infection

---

**INVASIVE FUNGAL INFECTIONS IN PEDIATRIC ACUTE LEUKEMIA: WHEN TO RESTART CHEMOTHERAPY?**

Sebnem Yılmaz, Hale Oren, Salih Gözmen, Özlem Tüfekçi, Tuba Karapınar, Fatma Demir, Handan Çakmakçı, Gülsera Irken

1 Department of Pediatric Hematology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey

2 Department of Pediatric Radiology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey

Aim: Invasive fungal infection (IFI) is a life-threatening problem that is seen in patients with acute leukemia (AL) despite advances in antifungal treatment. We aimed to describe variations regarding site of infection, clinical features, treatment modalities, time of restarting chemotherapy (CT), and outcome.

Methods: The charts of all patients who were treated as AL in our hematology unit between April 2001 and July 2011 were retrospectively reviewed and data of patients with IFI were analysed.

Results: IFI was defined in 15 (12.4%) children (9 ALL and 6 AML). The median age was 10 years (range 9 months -17 years). Ten of them were male. Seven patients were treated in the high risk treatment group according to the ALL BFM and AML BFM protocols. The phase of CT at the time of IFI diagnosis was induction in 4 (26.7%) and consolidation in 9 (60%) patients. In each one (6.7%) patient IFI was diagnosed during maintenance and after the cessation of CT. The time between the leukemia diagnosis and the definition of IFI was median 105 days (range 15-305 days). Twelve patients (80%) were in remission at the time of IFI. Absolute neutrophil count at the time of the IFI diagnosis was <500/mm³ in 80%. The duration of neutropenia was mean 13.9 days (range 0-47 days). Steroids were given to 10 (66.7%) patients. All patients were febrile at the time of IFI diagnosis. Fourteen patients had isolated pulmonary IFI and 1 patient with Mucor + Aspergillosis had orbitocerebral and pulmonary IFI. Nine patients had abnormal findings on chest x-ray. The most frequent finding on computerized thorax tomography was
ABSTRACTS

280

4th International Congress on Leukemia – Lymphoma – Myeloma

Poster No: 0019 Abstract:0261

HEPATOSPENIC HYALOHYPMYCOSIS: A CASE REPORT
Volkan Karakuş1, Erdal Kurtoğlu1, Ayseğül Uğur Kurtoğlu2, Ali Haydar Akça3, Bekir Torun4, Yasin Şahin Türk4
1Antalya Research and Training Hospital, Department of Hematology, Antalya, Turkey
2Antalya Research and Training Hospital, Department of Biochemistry, Antalya, Turkey
3Antalya Research and Training Hospital, Department of Emergency Medicine, Antalya, Turkey
4Antalya Research and Training Hospital, Department of Internal Medicine, Antalya, Turkey.

Invasive aspergillosis has an increasing incidence worldwide, especially in immune-compromised patients (1). Extrapulmonary aspergillosis cases reported as a considerable morbidity and mortality cause latterly (2). We have mentioned an invasive pulmonary aspergillosis case which progresses to fungus ball in liver and spleen.

A 65-year-old woman with B-acute lymphoblastic leukemia who was under remission for 6 months took medication of low-dose cytosine arabinoside therapy for relapse. On the 13th day of the therapy the patient complained of fever, cough and sputum. Laboratory findings were as follows: hemoglobin 9g/dl, neutrophil 200/ mm³, eosinophil 5/mm³, blasts 400/mm³, platelet count 28000/mm³, sedimentation rate 71 mm/h and C-reactive protein 161 mg/l. Other laboratory values were normal. Broad-spectrum antibiotic therapy and antifungal therapy including liposomal amphotericin B was initiated. The patient persisted febrile and symptoms and radiological findings progressed. Liposomal amphotericin B replaced with itraconazole. On day 26, nausea, vomiting and abdominal pain occurred. Abdominal ultrasonography and computerized tomography showed multiple fungus balls in liver and spleen (Figure 1).

Figure 1. Multiple fungus ball seen in the spleen. Hyper dens central zone and hypo dens peripheral halo clearly viewed. Also hepatic fungus ball seen in the left lobe of the liver.

Surgical therapy recommended but the patient refused operation. Although itraconazole therapy, the disease progressed. The patient is under follow-up with voriconazole therapy. Extra-pulmonary involvement, especially cerebral or sinonasal, is frequently found in immune-compromised patients with pulmonary invasive aspergillosis, occurring as a dissemination from the primary lesions to a variety of organs, via hematogenous spread. Although retrospective autopsy-based studies reported splenic involvement in about 16% of patients with invasive aspergillosis, with pathological findings consistent with either infarction or abscess, splenic invasive aspergillosis is rarely reported and may be underestimated in clinical practice when presenting without symptoms especially (3). In another study, it was shown that 55 of 107 patient with invasive aspergillosis had extrapulmonary involvement in autopsy series (2). In conclusion, extrapulmonary involvement must be thought in drug-resistant invasive fungus infections and surgical therapy should be considered.

Keyword: B-acute lymphoblastic leukemia, Hepatosplenic Hyalohyphomycosis

Poster No: 0020 Abstract:0264

MANAGEMENT OF ACUTE LYMPHOBlastic LEUKemia PREsenting AS Spontaneous SEVERE Tumor Lysis SyndrOme: A CASE Report
Volkan Karakuş1, Erdal Kurtoğlu1, Yasin Şahin Türk2, Ayseğül Uğur Kurtoğlu3, Ali Haydar Akça4, Bekir Torun3
1Antalya Research and Training Hospital, Department of Hematology, Antalya, Turkey
2Antalya Research and Training Hospital, Department of Internal Medicine, Antalya, Turkey.
3Antalya Research and Training Hospital, Department of Biochemistry, Antalya, Turkey
4Antalya Research and Training Hospital, Department of Emergency Medicine, Antalya, Turkey.

Hyperuricemia, mostly seen in tumor lysis syndrome (TLS), is a well-recognized complication of various cancers, especially in patients with hematologic malignancies, such as acute lymphoblastic leukemia (ALL) and Burkitt’s lymphoma mostly (1). Tumor lysis syndrome frequently seen after treatment of hematologic malignancies but may also be seen before treatment (2,3). We here report management of a patient diagnosed as B-ALL with spontaneous tumor lysis syndrome and severe hyperuricemia.

A 48-year-old male presented to our clinic with dyspnea. His physical examination was normal and laboratory
results showed white blood cell count of 44,000/mm³ being %54 lymphoid blasts, 16% neutrophil, 22% lymphocyte, 5% monocyte, 3% eosinophil, hemoglobin 13.8 g/dl, thrombocyte 26,000/mm³, serum creatinine 4.6 mg/dl, BUN 46 mg/dl, Na 138 mmol/L, K 5.9 mmol/L, Ca 10.8 mg/dl, lactic dehydrogenase (LDH) 2861 u/l, and uric acid 60 mg/dl. Bone marrow biopsy detected 44% B cell origin lymphoblasts. Cytogenetic examination revealed t(8:14) abnormality and diagnosed as B-ALL. Because of decreased urine output, very high uric acid levels and nephrotoxic side effects of chemotherapeutic agents chemotherapy was delayed. Allopurinol 75 mg/day and hydration were started. New generation xanthine oxidase inhibitors couldn't be given due to social security problems and within the first 24 hours two leukopheresis and one hemodialysis were performed. One leukopheresis and one dialysis were applied in following 24 hours also. Leucocyte and creatinine values decreased to 25000/mm³ and 2.2 mg/dl, respectively. Uric acid level was 20 mg/dl. HyperCVAD protocol with dose reduction was started after increased urine output. Hemodialysis was performed six times on alternate days and quitted after having normal uric acid level of 5 mg/dl, normal renal function tests and electrolyte levels. Results of bone marrow biopsy and flow cytometry applied on the 23th day of the treatment revealed remission and his renal function tests, LDH and uric acid results were all normal.

TLS sometimes occurs spontaneously before starting cancer chemotherapy. However, presumably due to the limited number of patients experiencing spontaneous TLS, there have been no large-scale cohort studies of spontaneous TLS to date. Hyperuricemia is apparently one of the cardinal manifestations of TLS (1). Four independent risk factors defined for TLS including age>10, splenomegaly, mediastinal mass and initial WBC>20000/mm³. Also our patient classified as grade 3 which means splenomegaly, mediastinal mass and initial WBC>20000/mm³. Also our patient classified as grade 3 which means splenomegaly, mediastinal mass and initial WBC>20000/mm³. Also our patient classified as grade 3 which means splenomegaly, mediastinal mass and initial WBC>20000/mm³.

Introduction and Objectives: Childhood acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children, constituting about 30% of all cancers among children. It constitutes about 75% of pediatric acute leukemia with peak incidence between ages 3 and 4. Genetic factors may predispose children to develop leukemia. Recently, genetic variants of the Methylene tetrahydrofolate reductase (MTHFR) gene have been subject to increasing attention in the etiology of leukemia. Gene polymorphism at the nucleotide 677 in the MTHFR gene PolyMorPhisM anD Risk of chilDhooD acute lymphoblastic leukemia

Nermin Raafat1, Usama Elsafty2, Ebtesam Ahmed2, Tarek Abdel Monem2
1Medical Biochemistry department, faculty of Medicine, Zagazig University, Egypt
2Pediatrics department, faculty of Medicine, Zagazig University, Egypt

Invasive fungal infection (IFI) is an important cause of morbidity and mortality in children with leukemia. The medical records of the patients with acute lymphoblastic (n=112) and acute myeloblastic leukemia (n=26) who were treated at Ege University Medical School, Pediatric Hematology Department between 2005 and 2012 were retrospectively reviewed to determine the rate, causative agents, and the outcome of IFI.

All patients received nystatin oral solution since the diagnosis. None of the patients were given prophylactic antifungal treatment. A total of 53 IFI episodes were recorded in 51 (Male/ Female= 25/26) patients. The rate of IFI among the patients with acute leukemia was 36.9%. The median age of the patients was 8.2 (range 1.5-16) years.

IFI was classified as proven in 17 (32%), probable in 8 (15.1%) and possible in 28 (52.8%) episodes. Ten of the episodes (18.9%) were disseminated fungal infec

Three month survival of these patients after the diagnosis of IFI was 84.3%. IFI was the main cause of death in 4 patients (7.8%).

Keyword: invasive fungal infection, children
ABSTRACTS

ASSESSMENT OF NEUROPSYCHOLOGICAL LATE EFFECTS IN SURVIVORS OF CHILDHOOD LEUKEMIA

Ayişé İpek Kalafatçilar1, Özlem Tüfekçi2, Hale Ören1, Semra Hız3, Handan Güleryüz4, Ayşin Akay1, Esmaahan Orçın5, Yüksel Ölgün2, Gülersu İrken6
1Department of Pediatric Hematology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
2Department of Pediatric Neurology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
3Department of Pediatric Radiology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
4Department of Children and Adolescent Psychiatry, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
5Department of Otolaryngology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye

The neurologic dysfunctions caused by treatment may affect health and quality of life in survivors of childhood leukemia. The objective of this study was to identify the neuropsychological late effects of leukemia treatment to provide an assessment about the degree and incidence of these late effects. Neurological and ophthalmological examination, cranial magnetic resonance imaging (MRI), audition and neurocognitive tests, and questionnaires of quality of life were performed to 44 acute leukemia survivors at least 5 years after diagnosis. Median time since completion of chemotherapy was 7.5 years (2-18) and median age at the time of the study was 16.4 years (8-31). At least one or more late effects detected by physical examination, neurological tests or neurocognitive tests encountered in 80% of the patients, and 64% of the patients specified at least one complaint in the quality of life questionnaire. MRI revealed pathological findings in 18% and EEG abnormalities were present in 9% of the patients. Evaluation of total intelligence scores revealed that 30% of patients’ IQ scores were <80 and 70% of the patients’ scores demonstrated neurocognitive dysfunctions. The patients >6 years at the time of diagnosis were found to have more psychological problems and higher rates of smoking and alcohol consumption. The most frequent complaint was headache and the most common problem in school was denoted as difficulty in concentration. Our study demonstrated that most of the survivors of childhood leukemia are at risk of developing neuropsychological late effects.

Keyword: Acute leukemia, late effect

SERUM CYTOKINE AND ADHESION MOLECULE LEVELS IN PATIENTS WITH ACUTE LYMPHOBlastic LEUKEMIA AND IN HEALTHY SUBJECCTS

Jan M. Horacek1, Tomas Kupsa1, Martina Vasatova2, Pavel Zak2, Ladislav Jebavý1
1Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences, Hradec Králové, Czech Republic
2Department of Internal Medicine, University of Hradec Králové, Czech Republic
3Department of Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Králové, Czech Republic
4Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Králové, Czech Republic

Background: Cytokines and adhesion molecules have been studied as markers of immune system activation in various diseases including hematological malignancies. Alterations in this network may have direct effect on the malignant cells or have indirect effect on leukemogenesis through altered functions of bone marrow stromal elements. The knowledge gained from multiple cytokine and adhesion molecule analysis should allow better diagnosis and disease management.

Objectives: The aim of our study was to evaluate serum cytokine and adhesion molecule levels by biochip array technology in patients with acute lymphoblastic leukemia (ALL) and in healthy subjects.

Methods: Serum samples of 15 newly diagnosed ALL patients (median age 46, range 24 - 63 years, 11 males) and 15 healthy subjects (median age 41, range 25 - 58 years, 11 males) were analyzed. We evaluated serum levels of the following 22 cytokines and adhesion molecules: interleukins (IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-23), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), epidermal growth factor (EGF), monocyte chemotactic protein-1 (MCP-1), E-selectin, L-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1). All biomarkers were measured by biochip array technology on Evidence Investigator analyzer (Randox). Probability values (p) < 0.01 were considered statistically significant.

Results: In newly diagnosed ALL patients, we found significant increase in serum VCAM-1 (1078.54 ± 456.96 mcg/L vs. 328.31 ± 88.66 mcg/L; p < 0.000001), ICAM-1 (499.57 ± 237.53 mcg/L vs. 196.69 ± 36.06 mcg/L; p < 0.0001), L-selectin (2366.33 ± 1035.37 mcg/L vs. 1104.54 ± 243.45 mcg/L; p < 0.0001), IL-8 (34.07 ± 28.52 ng/L vs. 4.87 ± 3.09 ng/L; p < 0.001), MCP-1 (433.99 ± 328.59 ng/L vs. 153.25 ± 53.60 ng/L; p < 0.01). On the other hand, we found significant decrease in serum IL-3 (7.34 ± 3.41 ng/L vs. 11.53 ± 4.66 ng/L; p < 0.01), IL-4 (1.10 ± 1.08 ng/L vs. 3.27 ± 2.21 ng/L; p < 0.01). Serum levels of other evaluated cytokines and adhesion molecules were without significant differences.

Conclusions: Our results indicate that serum levels of some cytokines and adhesion molecules (VCAM-1, ICAM-1, L-selectin, IL-8, IL-3, IL-4, MCP-1) are significantly altered in patients with newly diagnosed ALL, reflecting activity of the disease. Whether these alterations could have a prognostic meaning for ALL is not known. Further studies in a larger number of patients and comparing cytokine and adhesion molecule levels with established prognostic markers will be essential to assess the potential role of these and additional markers in the risk stratification of ALL patients.

The work was supported by a long-term organization development plan 1011 (FMHS).

Keyword: cytokines, acute lymphoblastic leukemia
DETECTION OF MYC GENE REARRANGEMENTS BY FLUORESCENT IN SITU HYBRIDIZATION IN ACUTE LYMPHOBLASTIC LEUKEMIA CASES

Seda Eren1, Ayşe Çırakoğlu2, Dihlan Kurucu3, Zafer Başlar4, Ömer Devcióğlu5, Melihan Naşçan5, Seniha Hacihanefoğlu6

1Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye
2Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Türkiye
3Department of Internal Medicine, Division of Hematology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Türkiye
4Department of Pediatric Hematology, Istanbul University Istanbul Medical Faculty, Istanbul University, Istanbul, Türkiye
5Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul Medical Faculty, Istanbul University, Istanbul, Türkiye
6Department of, Istanbul University Istanbul Medical Faculty, Istanbul University, Istanbul, Türkiye

Abstract:

Objective: The aim of this study, to investigate changes at the region of MYC gene by interphase FISH in patients with acute lymphoblastic leukemia that analyzed by conventional cytogenetic methods.

Material-Methods: The study was carried out on 33 bone marrow specimens of 25 ALL patients were referred to our laboratory between 2007 and 2009. Fourteen childhood ALL and 11 adult ALL cases were examined. For conventional cytogenetic analysis, overnight colcemid incubation and 24 hour culture methods were performed and GTL banding technique was applied. To investigate changes at the region of MYC gene Fluorescent In Situ Hybridization technique with MYC breakapart probe (Cytocell) was used.

Results: FISH analysis was applied successfully in all 33 samples from 25 cases, while in 29 samples out of 33 (88%) cytogenetic results were obtained. We observed MYC rearrangements in one or more samples of 21 cases (84%) by FISH. Abnormal karyotypes were found in 16 out of 29 (55%) samples which cytogenetic examination was performed. In 9 cases, these abnormalities were simple, and complex in 7 cases. The only cytogenetic abnormality that contain MYC region was t(8;14)(q24;q32) which observed in one case.

Conclusion: The rate of MYC rearrangements found by FISH in this study (84%) was higher than literature (47-52%). Findings of t(8;14)(q24;q32), t(9;22)(q34;q22), 6q deletions and 11q23 rearrangements that we observed by karyotyping are reported in literature as common chromosomal abnormalities in ALL. FISH method is more suitable for investigating MYC rearrangements as being easy, fast and sensitive to the submicroscopic rearrangements than karyotyping. Nevertheless, conventional karyotyping has still great value as being informative for the entire genome and enabling to detect the changes other than known target sites.

Keyword: Acute Lymphoblastic Leukemia, MYC

THE OUTCOMES OF TURKISH CHILDREN WITH ACUTE MYELOID LEUKEMIA TREATED ON AML- BERLIN-MUNSTER-FRANKFURT (AML-BFM) PROTOCOL: TURKISH AML-BFM STUDY GROUP

Emel Özürek1, Cenan Vergin2, Mustafa Büyükavcı3, Yurdanur Kılınc4, Çetin Timur3, Namık Özbek5, Tiraj Celkan6, Erol Erduran7, Lale Ocak2, Nazan Çeşingöl8, Türkcan Patroğlu9, Berna Atabay10, Özen Bör11, Selma Ünal12, Elif Güler13, Ahmet Koç14, Hüseyin Gülen15, Emin Kürekçi16, Murat Söker17, Can Balkan18, Aziz Polat19, Bahattin Tune20, Hale Ören21

1Ondokuz Mayıs Üniversitesi, Samsun
2Dr. Behçet Uz Çocuk EAH, İzmir
3Atatürk Üniversitesi, Erzurum
4Çukurova Üniversitesi, Adana
5Göztepe EAH, İstanbul
6Baskent Üniversitesi, Ankara
7İstanbul Üniversitesi Cerrahpasa Tip Fakültesi, İstanbul
8Karadeniz Teknik Üniversitesi, Trabzon
9Dr. Abdurrahman Yurtaslan Onkoloji EAH, Ankara
10Ege Üniversitesi, İzmir
11Erciyes Üniversitesi, Kayseri
12Teperek EAH, İzmir
13Eskişehir Osmangazi Üniversitesi, Eskişehir
14Mersin Üniversitesi, Mersin
15Gaziantep Üniversitesi, Gaziantep
16Harran Üniversitesi, Şanlıurfa
17Celal Bayar Üniversitesi, Manisa
18Gülhane Askeri Tıp Akademi, Ankara
19Dicle Üniversitesi, Diyarbakır
20Fatih Üniversitesi, İstanbul
21Doşkapı Yıldırım Beyazıt EAH, Ankara
22Dokuz Eylül Üniversitesi, İzmir

Aim: Acute myeloid leukemia (AML) is a heterogenous disease in which leukemic blasts proliferate and invade healthy bone marrow. It makes 15 to 20 % of childhood acute leukemias. Recent developments in both the chemotherapeutic regimens and supportive result in a better survival in children with AML. We evaluated the 192 Turkish children with AML treated in 23 different centers, and received AML-BFM protocol.

Patients and Methods: We retrospectively evaluated the medical records of the children with AML, who received AML-BFM regimen, and analysed the data gathered from different centers.

Results: Mean age of the patients were 8.7±7.9 months (10 days–17 year), and male/female ratio was 1.4. The most common French-American-British subgroup among the patients with a known subgroup was M2 with a frequency of 31.3%. Complete remission rate was 98.4%. Eleven percent received hematopoetic stem cell transplantation. Overall survival and event free survivals were 58.8 and 58.4 % respectively. Among them 29.2% died. Infection (57.7%) was the most common cause of death, followed by relapse, resistant disease, and hemorrhage.

Conclusion: Although our patients have a high rate of complete remission, overall and event free survivals were similar to previously reported results. Since the most common cause of death was infection, a standardized and good supportive care plan may improve survival or the patients.

Keyword: AML, treatment
Acute promyelocytic leukemia (APL) is unique clini-co-biologic entity. Loss of HLA-DR and CD34 is characteristic of malignant promyelocytes. But some cases of acute myeloid leukemia (AML) have an immunophenotype that is similar to APL (HLA-DR- CD34+). The objective of the study was to investigate antigenic features in a group of APL with presence of PML-RAR alpha fusion gene and non-APL patients in order that differences to allow more clearly define criteria to separate APL from non-APL.

Methods: We analyzed a series of 30 APL and 32 of non-APL patients who were diagnosed in the last three years at the University Clinic for Hematology in Skopje, Macedonia. The diagnosis of acute leukemia was made by standard morphological examination and cyto-chemical analyses of bone marrow smears according to the criteria established by FAB Cooperative Study Group and confirmed by immunophenotyping of bone marrow aspirates and/or peripheral blood samples following the criteria of the European group for the immunological Classification of acute leukemias (EGL). Flow cytometry analyses were performed by using the FACS Canto II BD flow cytometer analyzer. Acquired data were analyzed with the software FACSDiva version 6.1.2 by using CD45 gating strategy. The immunophenotypic analysis showed deletion of the long arm of chromosome 12 - deletion of ETV6 gene and deletion of the long arm of chromosome 17- deletion of P53 gene. Computed tomography scans did not disclosed any pathologic lymphadenopathy. Histopathology of skin lesions showed infiltration of blastic cells. Immunohistochemical analysis confirmed the presence of cells with the same immunophenotypic features. He started chemotherapy with Zavedos and Aracytin (3+7) and he is now in CR after this induction.

Conclusion: We present a case of a rare clinical entity with cutaneous and bone marrow infiltration with blastic plasmocytoid dendritic cells. The diagnosis relied on the immunophenotypic features of the malignant cells, particularly with the presence of CD4 (+) and CD 56 (+). Several treatment options have been used so far, all with poor results. The ALL-type treatment regimen seems to result to a better outcome, according to recent publication. Unfortunately, our patient couldn’t proceed to bone marrow transplantation which is a better therapeutic option for younger patients with good performance status.

Keyword: APL, immunophenotype

**Chronic Lymphocytic Leukemia**

Poster No: 0029  Abstract:0124

**THE SIMULTANEOUS DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MEGALOBLASTIC ANEMIA SECONDARY TO VITAMIN B12 DEFICIENCY**

Gülşüm Emel Pamuk1, Recep Ak2, Murat Taşçı2, Mehmet Şevki Uyanık1

1Department of Hematology, Trakya University Medical Faculty, Edirne-Turkey
2Department of Internal Medicine, Trakya University Medical Faculty, Edirne-Turkey

Introduction: Cytopenias in chronic lymphocytic leukemia (CLL) might have various causes like bone marrow infiltration, autoimmunity, hypersplenism and drugs. Pernicious anemia is an autoimmune disease which might result in cytopenias; and pernicious anemia as an autoimmune phenomenon has not been described in CLL.

Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematopoietic malignancy that is characterized by cutaneous infiltration with or without bone marrow involvement and further leukemic spread. Its overall incidence is very low, accounting for 0.44% of all hematologic malignancies. The leukemic form of the disease is an extremely rare situation, representing <1% of all cases of acute leukemia. BPDCN predominantly affects males, with a sex ratio of 3:1, and generally occurs in the elderly. Aim: The aim of this presentation was to evaluate symptoms, signs and outcome of one case of BPDCN in our center.

Method: We identified 1 patient with BPDCN presenting with skin lesions. Data regarding clinical presentation, diagnosis, staging, treatment and outcome was collected.

Results: The patient was male, 75 years-old. At diagnosis he had asymptomatic skin lesions. He had a generalized purpurial dermal rash arising from the head to the lower extremities that presented one week before and progressed very rapidly. Laboratory data revealed anemia (hemoglobin: 10, 9 g/dl), thrombocytopenia (100+109/L), WBC: 8.30*103/μL with 42% of morphologically immature atypical cells. Bone marrow aspiration showed 88% infiltration of immature blastic cells with the following immunophenotypic: CD45 (+) low, CD43 (+), CD123 (+), CD56 (+), CD4(+) and CD34 (-). Cytogenetic analysis showed deletion of the long arm of chromosome 12 - deletion of ETV6 gene and deletion of the long arm of chromosome 17- deletion of P53 gene. Computed tomography scans did not disclosed any pathologic lymphadenopathy. Histopathology of skin lesions showed infiltration of blastic cells. Immunohistochemical analysis confirmed the presence of cells with the same immunophenotypic features. He started chemotherapy with Zavedos and Aracytin (3+7) and he is now in CR after this induction.

Conclusion: We present a case of a rare clinical entity with cutaneous and bone marrow infiltration with blastic plasmocytoid dendritic cells. The diagnosis relied on the immunophenotypic features of the malignant cells, particularly with the presence of CD4 (+) and CD 56(+). Several treatment options have been used so far, all with poor results. The ALL-type treatment regimen seems to result to a better outcome, according to recent publication. Unfortunately, our patient couldn’t proceed to bone marrow transplantation which is a better therapeutic option for younger patients with good performance status.

Keyword: dendritic cell, leukemia

**ABSTRACTS**

**4th International Congress on Leukemia – Lymphoma – Myeloma**

**USEFULNESS OF FLOW CYTOMETRY IN DISTINCTION BETWEEN ACUTE PROMIELOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA- SINGLE CENTER EXPERIENCE**

Dusko Dukovski, Lidija Cevreska, Sanja Trajkova, Martin Ivanovski, Marija Popova Simjanovska, Svetlana Stankovik, Irina Panovska Stavridis

**Keyword:** necessary to establish the diagnose of AML.

CD34-. But cytogenetic and molecular characterization is distinguish APL from non-APL patients with HLA-DR- the two groups. Also we noticed increased leukocyte and intensity of CD33, CD13 showed differences between APL and non-APL patients in CD2, CD13, CD33 suggested by the EGIL was utilized.

FACSDiva version 6.1.2 by using CD45 gating strategy anayzer. Acquired data were analyzed with the software performed by using the FAXS Canto II BD flow cytometer analyzer. The EGIL was utilized.

Results: Our results showed significant differences between APL and non-APL patients in CD2, CD13, CD33 reactivity. Aberrant CD2 expression was absent in every patient with non- APL, also we found absent CD15 expression in whole non-APL group. Mean florescence intensity of CD33, CD13 showed differences between the two groups. Also we noticed increased leukocyte and platelets counts in HLA-DR- CD34- non- APL patients.

Conclusion: CD2, CD13, CD33 may be useful to distinguish APL from non-APL patients with HLA-DR-CD34-. But cytogenetic and molecular characterization is necessary to establish the diagnose of AML.

**Keyword:** APL, immunophenotype
Case: A 71-year-old man was hospitalized with the complaints of fatigue, tiredness. On physical examination, he had conjunctival pallor and there was atrophy of tongue papillae. There was no peripheral lymphadenopathy, hepatomegaly or splenomegaly. His whole blood smear was as follows: hemoglobin, 6.4 g/dl; hematocrit, 19%; MCV, 136.5 fL; leucocytes, 30900/mm³; platelets, 35000/mm³. Blood biochemistries were normal, except for a LDH of 729 U/L (N<192). On peripheral blood smear, there were macroovalocytes and hypersegmentation of neutrophil nuclei, with 5% neutrophils and 95% small-appearing lymphocytes. Serum folic acid level was 7.3 ng/ml (N:3-17), and vitamin B12 level was 100 pg/ml (N:140-950). Haptoglobin was <5.83 mg/dl (N:36-195). The corrected reticulocyte count was 3%. Both direct and indirect Coombs tests were negative. Flow cytometric analysis of peripheral blood showed a monoclonal B-cell population which was positive for CD5, CD19, CD20, and CD23 with a dim surface k light chain restriction. Bone marrow aspiration revealed 48% lymphocytes; there were megaloblastic changes of erythroid and myeloid cells, with giant metamyelocytes and stab cells (Figure 1). Thorax and abdominopelvic CT scans demonstrated no lymph nodes or hepatosplenomegaly. Being diagnosed simultaneously with Rai stage 0 CLL and megaloblastic anemia, the patient was administered replacement therapy with intramuscular vitamin B12. The cause for his megaloblastic anemia was assumed to be pernicious anemia because there was no other cause which could explain the vitamin B12 deficiency. On his last follow-up, his hemoglobin was 14.8 g/ dl; hematocrit, 44.8%; MCV, 86.7 fL; leucocytes, 29800/mm³; platelets, 342000/mm³.

Conclusion: Our case was interesting in that there was a co-incidence of CLL and vitamin B12 deficiency. We reported this case to draw attention to the fact that cytopenias in CLL might have rare causes which might even be missed if a bone marrow examination is not performed. We suggest that even if the diagnosis of CLL is straightforward, the bone marrow aspiration should be examined in every patient with CLL.

**Keyword:** Chronic lymphocytic leukemia, megaloblastic anemia

![Figure 1](image)

**Figure 1:** Bone marrow aspiration showing many small, mature lymphocytes, two megaloblastic erythroblasts, and some myeloid cells.

---

**Poster No: 0030 Abstract:0143**

**GROWTH ARREST SPECIFIC (GAS6) LEVEL IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS**

**Dilvin Berrak Güney**, Ayşin Tulunay, Funda Pepedi, İşık Kaygusuz, Cafer Adigüzel, Tunç Tuğlular, Emel Eksişoğlu Demiralp, Fikriye Uras

**Marmara University School of Pharmacy, Department of Biochemistry, Istanbul, Turkey**

**Marmara University School of Medicine, Departments of Hematology, Istanbul, Turkey**

**Marmara University School of Medicine, Departments of Immunology, Istanbul, Turkey**

**Background:** Gas6 (growth arrest-specific gene 6) is from the family of plasma vitamin K-dependent proteins. Gas6 was similar to the plasma anticoagulant protein S. Whereas protein S is as a negative regulator of procoagulant pathways, no such a role has been found for Gas6. Gas6 binds to Tyr3, Axl and Mer tyrosine kinase receptors (TAM receptors). Increased plasma concentration of Gas6 has been found in patients with sepsis and chronic inflammatory neuropathy, whereas decreased in acute coronary syndrome. This contradiction may suggest that Axl/Gas6 pathway varies depending on the type of patient’s illness. The objective of this study was to investigate the total plasma level of Gas6 in patients with B-Cell chronic lymphocytic leukemia (B-Cell- CLL).

**Material-Methods:** B-Cell-CLL patients (grade 0-1, according to the classification of Rai), who were not on a drug treatment, were recruited in this study (n= 24, 11 female, 13 male). Their ages were 39 to 79 years (mean= 63.5). EDTA-plasma (platelet poor) was isolated from 24 healthy volunteers (8 female, 16 male), whose age range was 51-78 years (mean= 63.5). EDTA-plasma (platelet poor) was isolated by centrifugation (3100 x g) and then human Gas6 ELISA Kit (R&D, Minneapolis, MN, US) was used to assay Gas concentration.

**Results:** The quantitative of total plasma Gas6 range in patient group is 4.11-26.44 ng/ml (mean= 14.85 ± 5.77). In the control group, range of total plasma Gas6 was between 9.57-31.28 ng/ml (mean= 16.8±6.18). The concentration of plasma Gas6 in the B-Cell-CLL group was not significantly different than those of the control group (p=0.265).

**Conclusion:** This is a preliminary study with a small group, future studies will show us that whether plasma Gas6 concentrations in patients with CLL are different from control group or not. Further studies focusing on molecular mechanism are required to elucidate the actual role of Gas6/TAM signaling in B-Cell-CLL.

**Keyword:** ELISA, growth arrest-specific gene 6(Gas6)

---

**Poster No: 0031 Abstract:0152**

**CHRONIC LYMPHOCYTIC LEUKEMIA AND CD11C EXPRESSION**

Irfan Yavasoglu, Gürhan Kadıkoçlu, Gökhan Pektaş, Zahit Bolaman

Adnan Menderes University Hematology Department, Aydın Turkey

**Objective:** CD11c belongs to the integrin family which is a group of cell adhesion molecules. There is a clinical significance of CD 11c positivity is in hairy cell leukemia. CD11c has been evaluated in the patients with chronic lymphocytic leukemia (CLL) in a few studies. CD11c positivity has been detected in 13-78% of patients with...
Abstracts

DETECTION OF T(14;18)(Q32;Q21) AND TRISOMY 12 IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

Gül Tokgoz, Gülsüm Özet, Ömer Önder Savaş, Funda Ceran, Simten Dağdaş, Cenk Sunu
Ankara Numune Training and Research Hospital, Department of Hematology, Ankara, Turkey

Summary: Chromosomal abnormalities are observed in most hematologic malignancies. t (14;18) positivity which is diagnosed in 80-90% follicular lymphoma is seen rarely in Chronic Lymphocytic Leukemia (CLL) patients. For this reason, we found this case suitable for presentation.

Case: 53-years-old male patient was admitted to hospital with weight loss, had multiple lymphadenopathy at neck, axilla and hepatosplenomegaly. The patient had leukocytosis and thrombocytopenia. Mature lymphocytosis, basket cells and prolymphocyte 15% respectively was determined in the patient’s peripheral blood smear. The flow cytometric analysis of bone marrow aspiration was considered as CLL with the bone marrow biopsy. Trisomy 12; 85.5% positive, t(11;14); negative, t (14;18) were positive in patients. t (14;18) was repeated twice and positivity was confirmed. Oral Fludarabine, cyclophosphamide therapy was started due to weight loss and thrombocytopenia. After 6 cycles of treatment, complete haematological remission was achieved.

Discussion: t(14;18) translocation is seen in 80-90% of follicular lymphomas. It is often associated with low-grade lymphoma. Bcl2 gene regulates programmed cell death and a small number of patients with CLL (5-10%) t(14,18) positivity is determined. Bcl2 inhibits apoptotic cell death. Course of patients with BCL2-expressing in high-titer can see poor outcome in CLL patients. Only one of 300 patients who were followed in our clinic with the diagnosis of CLL had t (14;18) positivity. Conventional cytogenetic analysis were made to 2215 patients with CLL in M.D. Anderson cancer center, t (14;18) and the trisomy 12 positive found in only two of them. After 8 years of the diagnosis, the patient died due to secondary infection of treatment. t (14;18) were positive at only 3 patients in 640 CLL patients of an international working group.

Chemotherapy was started due to weight loss, and thrombocytopenia. Treatment response was very good. Considering the literature, donor were searched for allogeneic stem cell transplantation because of the possibility of t (14;18) translocation with poor clinical outcome in CLL. Our patient remains in remission after treatment for 2 years.

Keyword: Chronic lymphocytic leukemia, bcl2
remained below 25,000 platelets. In recent studies, response to first-line treatments was 50% to 96%; about 20% was refractory. We think that this refractory group of our patients. Later, the patient was scheduled to receive rituximab at a dosage of 375mg/m² weekly for four consecutive weeks. Maximum platelet count at the end of treatment reached to 95000/mm³, but remained stable in 52900/mm³. Partial response was accepted as. An Italian study; II, in 21 patients with CLL-associated IT, complete response to treatment with rituximab was observed in 57% of cases, partial response in 29% of cases. In the same study 14% of patients were no response. The mean duration of response was observed for 21 months (ranging from 4 months-49 months). We believe that in our case that rituximab is an effective and well-tolerated alternative treatment for CLL-associated IT.

Keyword: CLL, rituximab

Poster No: 0034 Abstract:0203
THE CLINICAL SIGNIFICANCE OF ZAP-70 AND OTHER CELL SURFACE-ANTIGEN EXPRESSION (CD38-CD138-CD56-CD16) PROFILING OF CHRONIC LYMPHOCYTIC LEUKAEMIA
Aynur Uğur Bilgin, Sevilyal Tunçez, İsmail Reisli Necmettin Erbakan University, Meram School of Medicine, Department of Hematology, Konya, Turkey

Objective: Chronic Lymphocytic Leukemia (CLL) is characterized by increased number of mature non-proliferative lymphocytes in blood stream, bone marrow, lymph node and spleen with different clinical course. Family history is an important risk factor for CLL. It is suggested that the malignant transformation of B cells play an important role for CLL development while less than 1 % is caused by T lymphocytes. Although most CLL patients are elderly, 10% of them are younger than 50.

In CLL patients, Rai and Binet classification systems are established for determination of the necessity of treatment and prediction of survival. However, the prognostic value of these classifications is limited in early staged patients. The presence IgVH somatic mutation in the heavy chain variable region of immunoglobulin has been found a valuable prognostic factor. Patients with IgVH mutation shows a better clinical course than those without. After determination of the relationship between expression of zeta-associated protein (ZAP70) and IgVH mutation in CLL cells, a lot of research has been made for the usage of expression of ZAP70 rather than IgVH mutation of an expensive technique.

Finally, CD38 and CD138 are suggested to be important prognostic markers in some studies.

Methods: In this study, ZAP70, CD38, CD138, CD56, CD16 expression levels were measured from bone marrow aspirations of patients with CLL by flow cytometry of an inexpensive and easy method. Expression levels over 20% were considered as positive.

Results: ZAP70 expression was positive in 5 of 35 investigated patients. There was no significant correlation between ZAP 70 expression and patients’ age, sex, hemoglobin and LDH levels, leukocyte, lymphocyte and platelet counts.

CD38 expression was positive in 3 of 35 investigated patients. There was no significant correlation between CD38 expression and patients’ age, sex, hemoglobin and LDH levels, leukocyte, lymphocyte and platelet counts. In only one patient, both ZAP70 and CD38 expressions were positive. There was no significant correlation between ZAP70 with CD38 positivity.

CD138, CD56, CD16 was expressed at low levels in all patients. For demonstrating the relation between the expression of ZAP70 and CD38 over 20% and the prognosis of CLL patients, long-term observational studies are needed.

Conclusion: Long-term clinical observational studies with control groups should be made for understanding the effects of surface antigens in staging and prognosis of CLL.

Keyword: CLL, surface-antigen expression

Poster No: 0035 Abstract:0243
CEREBRAL INVOLVEMENT AS THE INITIAL MANIFESTATION OF CHRONIC LYMPHOCYTIC LEUKAEMIA
Murat Albayrak1, Harika Celebi1, Aynur Albayrak2, Esra Saribacak Can1, Vedat Aslan1, Özge Soyer1, Birgül Öneç1
1Dışkapı Yıldırım Beyazıt Education and Research Hospital, Department of Hematology, Ankara, Turkey
2Dışkapı Yıldırım Beyazıt Education and Research Hospital, Department of Pathology, Ankara, Turkey

Introduction: Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in adults, which is around 24%. Its rate is 6.7% in all non-Hodgkin lymphoma. CLL is a disease caused by monoclonal mature lymphocytes accumulation. The roots of more than 95% of the cases consist of B lymphocytes. The prevalence increases with the age. CLL is more common in men. The median age of the patients is 60 - 65. The cerebral involvement in CLL is very rare. However, it may occur in early stages of CLL.

Case: A male patient with the age of 40 applied to the neurosurgery with the complaints of headache lasting around 20 days, paresthaisis and weakness in the right side of the body, sight impairment in the right eye and seizures, and a cerebral mass has been detected after the examination, and then stereotactic needle biopsy has been performed. As the result of biopsy has been atypical lymphoid cells infiltration, the patient has been sent to the hematology out-patient clinic. When the patient applied to our clinic, there has been symptoms of fever, perspiration, weight loss and B symptoms. The leukocyte count in CBC has been 24.800/µL, and lymphocyte count has been 13.000/µL. Haemoglobin and platelet values have been normal. There has been mature lymphocytosis and smudge cells in peripheral blood smear. Multiple cervical and axillary lymphadenopathy in 20 mm size in maximum has been detected at neck, thorax and abdominal computerized tomography, and splenic size has been 15 cm. Basal ganglia has been detected in left periventricular area and hypodens areas in corona radiata at cranial tomography. CLL has been diagnosed in the patient with flowcytometric examination, bone marrow aspiration and biopsy evaluation. Rai Stage II CLL has been accepted. Even though the patient has been at the early stages, systemic chemotherapy, intrathecal treatment, and cranial radiotherapy has been applied due to B symptoms and symptomatic cerebral mass.

Discussion: The cerebral involvement in CLL is extremely rare. Central nervous system involvement can be observed particularly during the transformation process into aggressive lymphoma, called Richter syndrome. However, it can be rarely observed in early stages of CLL.
There is not any standardized treatment protocol for CLL patients with cerebral involvement. If there is cranial radiotherapy and spinal liquid involvement, the treatment protocol should include intrathecal chemotherapy with methotrexate. In this way, long term remissions can be achieved. This case has been presented because cerebral involvement is very rare in early stages of CLL and so as to review the treatment for CLL cases with cerebral involvement.

**Keyword:** Chronic Lymphocytic Leukemia, cerebral involvement

---

**ABSTRACTS**

**Poster No:** 0038

**Abstract:** 0247

**EVALUATION OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FOLLOWED BY HEMATOLOGY DEPARTMENT OF BASKENT UNIVERSITY: SINGLE CENTER EXPERIENCE**

Emel Kaya1, Sema Karakus2, Ayşun Halaçoğlu2, Ebru Koça2, Selami Koçak Toprak2, Emre Tunalt1

1Baskent University Medical School, Department of Internal Medicine, Ankara, Turkey
2Baskent University Medical School, Department of Hematology, Ankara, Turkey
3Baskent University Medical School, Department of Nephrology, Ankara, Turkey

Objective: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults[1]. It is unclear what aberrations are associated with the disease onset and its strikingly heterogeneous clinical course (2). Multiple factors, measured in standard clinical laboratory tests, affect the clinical course of CLL. Currently, the most important traditional prognostic factor include clinical staging (3); and the most important novel markers include karyotypic aberrations. The 13q14 deletion is the most common genetic abnormality in CLL (4). Patients have a minimum 1 year follow-up. We divided the patients into two groups: the patients who survived at least until the end of follow-up and the patients who died during the follow-up. In this study, we evaluated the demographic and prognostic factors of patients such as age, gender, lymphocyte doubling time (LDT), CD38 and ZAP-70 expression, type of bone marrow infiltration pattern within these two groups in 52 CLL patients who were observed from 2005 to 2012 in hematology department of Baskent University Faculty of Medicine.

Methods: Demographics of 52 patients who admitted to the hematology department between 2005 and 2012 were investigated retrospectively.

Results: 34 patients were male (% 65,4), 18 patients were female (% 34,6). The age range at the onset of chronic lymphocytic leukemia is from 46 to 93. The median age was 69. While 26 patients were being observed without treatment, 26 patients were treated with oral or iv multidrug chemotherapy. At the time of diagnosis, 17 (33%) patients were at Binet stage A, 29 (56%) were at stage B, 6 (11%) were at stage C. After the first line Chemotherapy [iv or oral chemotherapy agents]: partial remission for 12 (%46), complete remission for 7 (%27), progression for 7 (%27) patients were observed. 13 (%25) patients died during the follow-up. Cytogenetic analysis was performed in 45 patients. Of these patients, 30 (58 %) have no cytogenetic abnormality, 9 have (17%) del(13q14), 3 have (6%) trisomy 12, 2 have (4%) del(11q22) and 1 patient (2%) has del(17p13) respectively. There was no relationship between the expression of zeta-associated protein (ZAP-70) (p=0,293) and the β2 microglobulin (β2 MG)(p=0,099) with survival but the serum LDH level (p=0,008), the absolute lymphocyte count more than 50000/μl (p=0,035), the expression of CD38 (p=0,011), the stage of disease (p=0,0001), diffuse infiltration pattern of bone marrow (p=0,033) was inversely related with the survival. Survival in male patients was significantly less than female patients (p=0,018).

Conclusion: Multiple factors affect the clinical course and survival of CLL. Some of these; absolute lymphocyte count, bone marrow infiltration pattern, elevated LDH, lymphocyte doubling time; β2-microglobulin; genetic markers of tumor cells, gene abnormalities, the expression of CD38 and ZAP70. We founded same results mentioned before in literature in our CLL patient group.

**Keyword:** chronic lymphocytic leukemia, prognostic factors

---

**Poster No:** 0037

**Abstract:** 0265

**UNUSUAL CLINICAL SITUATION AND COURSE OF BLASTOID VARIANT T-CELL PROLYMPHOCYTIC LEUKEMIA**

Melda Cömert1, Nur Sinem Şengöz2, Ayhan Dönmez1, Mine Hekimgil2, Murat Tombuloğlu1

1Ege University, School of Medicine, Hematology Department, İzmir, Turkey
2Ege University, School of Medicine, Pathology Department, İzmir, Turkey

Introduction: T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive lymphoid malignancy composed of mature T-cells that usually presents in older people. Prognosis for these patients remains poor, with short survival times and no curative therapy. Case: Seventy-seven years old male was presented to Internal Medicine with weakness in December 2012. Physical examination was revealed bilateral basilar decreased breath sounds. There was no hepatomegaly, splenomegaly or lymphadenopathy. Laboratory tests were revealed WBC 692,06 x 103/mm3, Hb 8.9 g/dL, Htc 27.6 %, Plt 77 x 103/mm³ and LDH 1907 U/L. Leukocytosis, smudge cells, 98 % small to medium sized some of them with single nucleus blastoid variant lymphocytes was detected in peripheral blood smear examination. He interned to intensive care unit with initial diagnosis of acute leukemia. Immunophenotyping of the peripheral blood revealed positivity for CD45, CD2, CD3, CD5, CD7. TDT and the B-cell markers were negative. Bone marrow aspiration was hypercellular and revealed increased number of prolymphocytes. Based on the morphologic features and the immunophenotypic profile, a diagnosis of T-cell prolymphocytic leukemia (T-PLL) was offered. Leukopheresis was performed for 7 days after the diagnosis but sufficient reduction in leukocyte count did not provided. The patient was treated with cyclophosphamide (200 mg/m², 5 days) and prednisone (60 mg/m², 5 days) regimen in addition to leukopheresis but did not respond to treatment. Bone marrow biopsy was reported as TDT negative T-cell lymphoblastic leukemia/lymphoma. After this report the patient was treated with Hoelzer-1 chemotherapy regimen but an adequate response was not achieved. WBC count was still 500 x 109/mm³. The patient was treated with FC (fluorurabina [25 mg/m², 4 days] and cyclophosphamide [200 mg/m², 3 days] as the second line therapy. WBC count was decreased to 21 x 109/mm³. The patient without any sort of compliant was...
Patients discharged to receive fludarabine treatment every for four weeks.

Conclusion: Common clinical features of T-PLL are marked lymphocytosis, generalized lymphadenopathy, and hepatosplenomegaly. The patient was presented with an unusual clinical situation of PLL with blastoid variant hyperleukocytosis which was resistant to initial chemotherapy and also he was asymptomatic except weakness despite of large amount of WBC. Dramatic response was observed with fludarabin treatment similar with classic PLL. Blastoid variant PLL can be described with hyperleukocytosis, blastoid morphology and negative TDT. Fludarabin treatment can be used in blastoid variant PLL.

Keyword: Prolymphocytic Leukemia, Blastoid variant

Figure 1. Aspiration Biopsy, Giemsa

### Poster No: 0038
**Abstract:0269**

**HEMATHEMESIS DUE THE PEPTIC ULCER AS THE FIRST CLINICAL MANIFESTATION OF RICHER’S SYNDROME CAUSED HYPERCALCEMIA**

Zorica Cveticovic1, Bora Cveticovic2, Nikola Djuhic3
1Department of Hematology Clinical Hospital Center Zemun, Belgrade, Serbia
2Department of Urology Clinical Hospital Center Zemun, Belgrade, Serbia
3Department of Gastroenterology Clinical Hospital Center Zemun, Belgrade, Serbia

Background: Richter’s syndrome (RS) is defined as a high grade lymphoma occurring during the course of a low grade lymphoproliferative neoplasms. Its frequency is estimated to be between 3–6% of chronic lymphocytic leukemia (CLL) patients. In patients with RS hypercalcaemia has rarely been seen and is considered to be associated with increased bone resorption. Hypercalcaemia is reported to result in an increase of gastric acid secretion via the activation of stomach calcium sensing receptor (SCAR) on the basolateral membrane of gastric parietal cells by Ca2+

Case: A 60-year-old male patient presented to the Emergency Department (ED) of Clinical Hospital Center Zemun with acute mid-epigastric abdominal pain accompanied by nausea and hematemesis. The patient explained of progressive muscular weakness, lethargy and impaired concentration. Urgent upper gastrointestinal endoscopy revealed peptic ulcer on gastric lesser curvature with an adherent clot and endoscopic haemostasis was performed. Patient was admitted to the Department of gastroenterology for further intravenous proton pump inhibitors treatment and fluid resuscitation. Despite of given therapy his mental status deteriorated to coma shortly after admission. In laboratory analyses mild normocytic anemia (Hb 105 g/L, MCV 89 fL) and leucocytosis (WBC:13700/mL; neutrophils 60% and lymphocytes 21%), hypercalcaemia (4.5 mmol/L) with high urinary calcium excretion (5.48 mmol/L), elevated serum creatinine (337 μmol/L), and blood urea nitrogen (20.1 mmol/L) were present. Serum intact PTH, calcitriol and gastrin levels were within normal values as well as other laboratory analyses. Treatment comprised of intensive rehydration and loop diuretics was immediately initiated but with no clinical and laboratory improvement. Then, his previous medical record was obtained which documented that the diagnosis of Coombs negative B chronic lymphocytic leukemia was established five years ago when patient underwent splenectomy because of massive splenomegaly. He refused any further treatment. According to given history, intravenous pamidronate corrected for creatinine level was given and the bone marrow biopsy was performed. Histological analysis revealed diffuse large B cell infiltration of bone marrow consistent with a diagnosis of RS and 5% of eroded surface. Serum calcium level returned to normal within 72h after pamidronate infusion, and his mental status was completely normalized after one week. Two weeks later, after the complete resolution of peptic ulcer chemotherapy with cyclophosphamide-vincristine-adiamycin-prednisin was initiated in 21day cycles. The patient died after receiving five cycles of chemotherapy because of septicemia occurring during profound neutropenia. On the day of death, his serum calcium level was normal.

Conclusion: Hypercalcaemia in RS is very rare, and we have found no similar documented reports of a patient developing peptic ulcer as a first clinical sign of RS.

Keyword: Richter’s syndrome, peptic ulcer

### Poster No: 0039
**Abstract:0304**

**DISTINGUISHING HAIRY CELL LEUKEMIA FROM B-CELL LYMPHOPROLIFERATIVE DISORDERS WITH HAIRY LYMPHOCYTES: VALIDATION OF DIAGNOSTIC APPROACH**

Dusko Dukovski, Lidija Cevreska, Sanja Trajkova, Martin Ivanovski, Marija Popova Simjanovska, Lazar Cadievski, Irina Panovska Stavridis
University Clinic for Hematology,Skopje, Macedonia

Introduction: Hairy cell leukemia (HCL) and hairy cell leukemia-variant (HCL-v) are rare B-cell lymphoproliferative disorders (B-CLPD) with overlapping clinico-pathological features. However, certain morphological features of HCL, such as villous cytoplasmic projections or characteristic tissue specific infiltrative patterns, including red pulp expansion with pseudosinuses, may be seen in other B-cell lymphoproliferative disorders. A methodical and thorough approach evaluating immunophenotypic features will aid in rendering the appropriate diagnosis. CD123 is an antibody that identifies the Alfa chain of the human interleukin – 3 receptor. It is expressed in hairy cells, also in normal hematopoietic cells The aim of the study was to determine the diagnostic value of CD123 expression in HCL and other B-cell lymphoproliferative disorder cases with hairy lymphocytes.

Design and Methods: We investigated the diagnostic value of CD123 expression in neoplastic cells from 50
patients with B – cell disorder with circulating hairy lymphocytes. We performed flow cytometry analysis (FCM) of 50 cases (30 HCL, 5 HCL-v, 15 splenic marginal zone lymphoma (SMZL)), correlating results with available corresponding clinical and morphological data. Immunophenotypic analyses were performed by the FACS Canto II BD flow cytometer analyzer on 50 samples, from peripheral blood (23) and bone marrow (27). Acquired data were analyzed with the software FACS Diva version 6.1.2 by using CD19 gating strategy using panel for immunophenotype diagnosis of lymphoproliferative disorders according to BSCH (CD11c, CD25, CD103, CD123) combined with B-cell markers (CD19, CD20, CD22).

Results: Our findings show that cells from 100% of typical HCL expressed CD123 with strong intensity, while cells from other other B – cell disorder with hairy lymphocytes did not expressed CD123. HCL expressed bright CD20, bright CD22, bright CD11c, bright CD25, CD103, and bright homogenous CD123(100%). HCL-expressed bright CD20, bright CD22, CD11c(20%) and uniformly lacked CD103(100%), CD123(100%),CD25(100%), SMZL cases were CD103(-) and CD123(-).Detection of BRAFV600E mutation was examined in a subset of cases to further validate FCM diagnostic criteria. HCL-v was negative for BRAFV600E mutation (100%), in contrast to HCL (50% positive for BRAFV600E mutation).

Conclusion: We conclude that CD123 is a useful marker for distinguishing B cell disorder with villous lymphocytes from HCL with high sensitivity and specificity.

Keyword: HCL, CD123

Poster No: 0040 Abstract:0306
DETERMINATION OF TIME TO FIRST TREATMENT IN CLL PATIENTS WITH PROGNOSTIC NOMOGRAM, INDEX AND BIOLOGICAL MARKERS: PRELIMINARY RESULTS FROM SINGLE CENTER EXPERIENCE
Sanja Trajkova1, Irina Panovska Stavridis1, Martin Ivanovski1, Aleksandar Stojanovic1, Dusko Dukovski1, Marija Popova Simjanovska2, Lazar Cadievski1, Aleksandar Efimov2, Aleksandar Dimovski2, Lidija Ceverska1
1University Clinic for Hematology, Skopje, Macedonia
2Faculty of Pharmacy, Skopje, Macedonia

Introduction: The clinical course for patients with chronic lymphocytic leukemia is extremely heterogeneous, one of the most important challenges in the clinical management of those patients is the decision of initiating their treatment, but there is no available prognostic system that will resolve this issue. Usually, criteria for active disease are used to initiate therapy. Recently, some authors proposed prognostic models, scoring systems involving a set of clinical and biological risk factors and estimates individual patient survivals. Here, we report our initial results from a study designed to evaluate the statistical association of the distinct clinical and biological parameters with the prognosis and time to initiating treatment for patients with CLL.

Material-Methods: Our study incorporated 100 consecutive, treatment naïve CLL patients. In each patient all traditional laboratory, clinical and biological prognostic factors were evaluated at their first visit to our Institution. Than we combined the following independent characteristics: age, β-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups, which are included in some of the already published CLL prognostics index, in association with the CD38 expression and mutational status of the IGHV gene regions. Further, we correlate those factors by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram—a weighted tool to calculate 5- and 10-year survival probability and estimate median time to first treatment.

Results: According to prognostic index a classification tree was built that identified three subsets of patients who scores were 1-3 (low risk: 32pts - 32%), 4-7 (intermediate risk:48pts - 48%) and >8 (high risk:20pts - 20%). Estimated median survival at low risk subset of patients is 14,1yars, 10,7 and 4,6 years respectively at intermediate and high risk subsets of patients. Projected survival in respectively low, intermediate and high-risk groups are 100%, 100%, 25%, and 34%, 43%, 25% at 5-year and 10-year, respectively. Also, statistical analyses showed that three involved lymph node sites, increased size of cervical lymph nodes, increased serum lactate dehydrogenase, CD38 expression and unmutated IGHV mutation status are associated with shorter time to first treatment.

Conclusion: Our prognostic model that combines and correlates the distinct clinical and biological markers of CLL patients enables identification of the patients that are at high risk for progression. This prognostic model may facilitate clinical decision for initiating treatment.

Keyword: CLL, prognostic model

Poster No: 0041 Abstract:0316
RESTORATION OF THE MiR-181A/B AND THE MiR-130A EXPRESSION IN B CLL CELLS BY ACTIVATED CD4+ T CELLS
Serena Veschi1, Angelo Veronesi1, Luca Laurenti2, Sara Pagotto2, Paola Lanuti2, Felice Pepe1, Mario Di Gioacchino2, Giuseppe Leone3, Renato Mariani Costantini1, Rosa Visone1
1Department of Medicine, Dentistry and Biotechnology, “G. d’Annunzio” University, Chieti- Pescara, 66100, Italy
2Ageing Research Center (Ce.S.I.), “G. d’Annunzio” University Foundation, Chieti, Italy
3Section of Human Morphology, Department of Medicine and Aging Science (D.M.S.I.), “G. d’Annunzio” University, Chieti- Pescara, 66100, Italy

To date one of the major challenges in Chronic lymphocytic leukemia (CLL) is to identify genes responsible for the progression of the disease and functionally characterize them. We previously found that the miR-181b significantly decreases during the progression of CLL as specific effect and its expression inversely correlated with protein levels of the anti-apoptotic target genes MCL1 and BCL21. Based on our data, we aim at identifying the stimuli that regulate the expression of miR-181b and other miR-NAs involved in the progression of the disease, such as the miR-181a and the miR-130a. Progression of CLL is characterized by gradual reduction of the ratio T/B cells, along with immune cell dysfunction due in part to the T cell defects, such as decreased expression of CD40L and reduced signaling via the TCR CD3. This compromise the ability of T cells to eliminate leukemic cell from CLL patients. Since enhanced activation of either the allogenic or autologous T cells can drive the death of CLL cells in vitro and in few human subjects2-3, we speculate that
this death is due, at least in part, to increased expression of the 3 miRs in B cells.

To investigate the effect of T cells on the expression of the candidate microRNAs, we co-cultured allogeneic pure CLL-B cells with either activated (CD2, CD3 and CD28 antibodies, used to mimic antigen-presenting cells) or not activated CD4+ T cells from healthy donors. We observed a significant increase of mir-181b/a and mir-130a expression in CLL-B cells after co-culture with activated CD4+ T cells in 8 out of 11 cases. A significant increase of these miRs was also determined in purified CLL-B cells after 4 days activation of peripheral blood mononuclear cells (PBMCs) from CLL patients, even if in minor rate. By the use of specific antibodies, co-culture with Hela CD40 expressing cells and transwell experiments, we established that this effect is a T/B contact-dependent signal mediated through CD40L-CD40 interaction.

In conclusion, our preliminary data show that an efficient activation of CD4+ T cells through CD3-complex pathway and a right CD40L-CD40 interaction lead to a significant increase of the candidate miRs, which are extremely down-regulated in the disease.

These findings open up the possibility of intervening in the management of CLL patients through the restoration of the activity of the mir-181b and consequently the decrease of the protein levels of the anti-apoptotic MCL1 and BCL2 genes, thereby reestablishing, at least in part, a proper apoptosis rate of the CLL B-cells.

**Keyword:** CLL, microRNA

---

**Hodgkin’s Lymphoma**

**Poster No: 0042**  
**Abstract:**

**Figure 1.** Activation of T cells from healthy donors increase the expression of the miR-181b and miR-130a in B-CLL. MI-181b and MI-130a expression in purified B-CLL cells after 24hrs of co-culture with either activated or not activated T cells from healthy donors in presence of either the blocking anti-CD40L, or the control IgG. Ratio was 1:1 for T:B cells. The expression has been determined by stem-loop real-time qPCR. Each sample of data was normalized to the endogenous reference RNU44 with the use of the 2-Δct method.

**BRENTUXIMAB BEFORE THE ALLOGRAFTING FOR RELAPSED/REFRACTORY Hodgkin Lymphoma**

Hakan Gökçe, Eylem Eliaciğ, Ibrahim C. Haznedaroğlu, Sahil Aksu, Nilgün Saynalp, Ayşe Işık, Yahya Büyükaşık, Osman I. Öztebe  
Hacettepe Medical School, Ankara, Turkey

Brentuximab vedotin may be useful in relapsed/refractory Hodgkin lymphoma (HL) in relation to hematopoietic cell transplantation (HSCT). Graft versus lymphoma devoid of GVHD with chimerism-mediated immunotherapy (CMI) is the goal of allogeneic HSCT in HL. Brentuximab vedotin (anti-CD30) seems to be a promising agent in this context. In our institution, we have performed allo-HSCT for a 19-year-old male patient with nodular sclerosing Hodgkin lymphoma (HL) relapsed after auto-HSCT. Before transplantation, he had received multiple chemotherapy regimens (ABVD, ICE, DHAP and BEACOPP). After the auto-HSCT, his disease recurred within 5 months. Since he relapsed quickly, the disease was considered as relapsed/refractory HL. Brentuximab vedotin was administrated intravenously twice prior to allografting; one month had elapsed between the last dose of brentuximab vedotin and allo-HCT. He went into complete remission after anti-CD30 treatment just prior to allo-HCT. He had achieved engraftment successfully. The median time to neutrophil recovery was 9 days (range, 0-21 days) as defined by absolute neutrophil count 500 cells/L. The median time to platelet recovery was 11 days (range, 0-21 days) as defined by platelet count >20 000 cells/L without transfusion support. Brentuximab vedotin treatment seemed to have no adverse impact on engraftment. He is currently in good health and in complete remission 7 months following transplant. We have observed that allo-HCT with reduced intensity conditioning after brentuximab vedotin was safe in our heavily pretreated relapsed HL patient. Brentuximab vedotin was generally well tolerated in our patient. We did not observe any delays in the engraftment time, severe transplant toxicity, or signs of acute GVHD.

Several clinical trials have evaluated monoclonal antibodies or receptor antagonist therapy for steroid-resistant acute GVHD, with different outcomes in a variety of settings. Anti-CD30 seems to be a great candidate based on both its anti-neoplastic efficacy and its possible modulation of GVHD in HL.

**Keyword:** Brentuximab, Hodgkin Disease
after ASCT. Brentuximab Vodotin (ADCETRIS®), an anti-CD30 antibody conjugated by a protease cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), induces apoptotic death of CD30-expressing cells by binding, internalizing and releasing MMAE. A pivotal phase 2 study was conducted to determine the efficacy and safety of Brentuximab Vodotin in 102 pts with RR HL following ASCT (NCT00848926). Long-term survival data from this ongoing trial are described.

Methods:Pts received 1.8 mg/kg Brentuximab Vodotin Q3wk as a 30-min IV infusion for <=16 cycles. Primary endpoint: objective response rate (ORR) per independent review. Long-term follow-up assessments to determine survival and disease status: every 3 yrs, 2 yrs, every 6 mos during years 3 to 5, then annually.

Results:Median time to relapse after ASCT was 6.7 mos (range, 0–131). Pts received a median 9 cycles of Brentuximab Vodotin. The ORR was 75% (76/102 pts), with complete remissions (CRs) in 34 pts (33%). At time of analysis (July 2012), the median time from first dose was 29.5 mos (range, 1.8–36.9). 60/102 pts (59%) were alive at the time of last follow up and median overall survival (OS) has not been reached. The estimated 24-mo OS was 65% (95% CI: 55, 74). The median OS by best clinical response was 31.6 mos for pts with partial remission (PR, n=42), 20.6 mos for pts with stable disease (SD, n=22), and 10.2 mos for pts with progressive disease (PD, n=3); median OS for pts with CR (n=34) has not been reached. Evaluation of demographic and baseline characteristics found that pts with a baseline ECOG score of 0 vs 1, respectively). There was no difference in OS for ECOG scores of 0 vs 1, respectively). There was no significant difference in OS for pts who had relapsed within a year of ASCT compared with pts relapsing >1 year after ASCT. The most common (>15%) Brentuximab Vodotin-related AE of any grade: peripheral sensory neuropathy, nausea, fatigue, neutropenia and diarrhea. AE Grade >=3 related AE of any grade: peripheral sensory neuropathy, thrombocytopenia and anemia.

Conclusions: After 1.8 mg/kg Brentuximab Vodotin Q3wk as a 30-min IV infusion for <=16 cycles, 60/102 pts (59%) were alive at the time of last follow up and the median OS has not been reached. Brentuximab Vodotin is associated with prolonged OS compared with historical controls. Brentuximab Vodotin can be accepted as cheap and available prognostic marker and used for clinical follow-up of the lymphomas. Brentuximab Vodotin treatment (24-mo OS: 81% vs. 47% for pts with complete remissions (CRs) in 34 pts) was more effective than historical controls. Brentuximab Vodotin Q3wk as a 30-min IV infusion for <=16 cycles is associated with prolonged OS compared with historical controls. Brentuximab Vodotin can be accepted as cheap and available prognostic marker and used for clinical follow-up of the lymphomas. Brentuximab Vodotin treatment (24-mo OS: 81% vs. 47% for pts with complete remissions (CRs) in 34 pts) was more effective than historical controls.

**Keyword:** Hodgkin lymphoma, brentuximab vedotin

---

**Figure 1.** Overall Survival by Best Clinical Response

---

**Table 1**

<table>
<thead>
<tr>
<th>Clinical stage</th>
<th>Monocyte count (mm³)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HL (n=70) Early stage (n=31)</td>
<td>590±74</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HL (n=70) Late stage (n=39)</td>
<td>679±449</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

---

**Table 1**

<table>
<thead>
<tr>
<th>Clinical stage</th>
<th>MPV (fl)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHL (n=89) Early stage (n=26)</td>
<td>7.5±1.1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>NHL (n=89) Late stage (n=63)</td>
<td>8.3±1.2</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>
IGA NEPHROPATHY ASSOCIATED WITH HODGKIN’S DISEASE: A CASE REPORT

Cenk Sunu1, Gülşüm Özet1, Simten Dağdaş1, Funda Cenan1, Ömer Önder Sağav2, Aysun Gönderen2, Berna Öztürk1, Fatih Dede2

1Ankara Numune Eğitim ve Araştırma Hastanesi Hematoloji, Ankara, Turkey
2Ankara Numune Eğitim ve Araştırma Hastanesi Nefroloji, Ankara, Turkey

IGA nephropathy (IgAN) is the most common cause of glomerulonephritis, and is characterized by mesangial proliferation and deposition of IgA. Secondary IgAN is associated with several diseases, including immunological disorders, infections and cancers. Malignancies that have been reported to be associated with IgAN include renal cell carcinoma, cancers of the lung, larynx and esophagus, cutaneous T-cell lymphoma, Hodgkin’s disease and non-Hodgkin lymphoma. Secondary IgAN in patients with Hodgkin’s lymphoma is very rare and its pathogenetic mechanisms remain unclear. We aimed to report a patient with secondary IgAN associated with Hodgkin’s disease.

32 years old man was admitted to our hospital weakness and signs of anemia. On physical examination multiple lymphadenopathies were found both side of the neck. CT showed multiple lymphadenopathies in both mediastinum and the abdomen. Splenic and hepatic involvment was suspected. Lymph node excision from the neck was diagnosed with lymphocyte depletion type hodgkin lymphoma. Chemotherapy was performed with an ABVD (adriamycin, bleomycin, vinblastin, dacarbazine) regimen two cycles. Then he had abdominal pain, arthralgia, purpura and edema of both legs. The patient had proteinuria 13 g/day and increased serum creatinin level. Skin biopsy showed leukocytoclastic vasculitis and renal biopsy diagnosed IgA nephropathy. The patient received pulse methylprednisolone for 3 days, cyclophosphamide 1 day. After this therapy, chemotherapy was performed with EPOCH (etoposide, vincristin, Adriamycin, cyclophosphamide, prednison) regimen two cycles. His therapy has been continued.

The association between Hodgkin’s lymphoma, particularly the mixed-cellularity type and glomerular diseases is well recognized. In Hodgkin’s disease, the most common paraneoplastic glomerular abnormality is minimal change nephropathy, although other glomerular diseases occasionally have been described. A case report of extracapillary immunoglobulin A glomerulonephritis presenting as acute renal failure in a woman with newly diagnosed Hodgkin’s disease. Treatment with the bleomyacin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednison regimen resulted in complete hematologic and renal remission for more than 1 year after diagnosis. The possible explanations could be either T cell dysfunction that causes local damage to the glomerulus by formations by immune complexes or impairment of the basement membrane by the lymphokines by tumor cells. Several case reports have shown complete recovery of renal function after chemotherapy and this strengthens the pathogenetic relationship between Hodgkin’s lymphoma IgAN.

Studies have low evidence-based value. There is no widely accepted experimental model of the association of glomerulopathy and cancer. Thus, epidemiologic and mechanistic studies are needed to determine the true prevalence of paraneoplastic glomerulopathies and investigate new pathophysiological approaches.

Keywords: IgA nephropathy, Hodgkin’s disease
Molecular Hematology–Cytogenetics

Poster No: 0048 Abstract:0162

**CDS6 ANTIGEN EXPRESSION AS THE MOST IMPORTANT PROGNOSTIC FACTOR IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA**

Irena Djunic1, Nada Suvajdijc Vukovic2, Marijana Virijevic1, Aleksandra Novkovic3, Nada Kraguljac Kurtovic1, Mirjana Mitrovic1, Natasa Colovic2, Ana Vidovic2, Dragica Tomin2

1Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
2Clinic for hematology, Clinical Center of Serbia; Medical Faculty of Belgrade University, Belgrade, Serbiaa
3Clinical Hospital Center “Zemun”, Belgrade, Serbia

**Objectives:** Patients with normal karyotype acute myeloid leukemia (NK-AML) without the FLT3 internal tandem duplication (FLT3-ITD) mutation account for approximately 30% of all AML cases and exhibit a heterogeneous clinical outcome. The prognostic factors in this subgroup of AML patients are still unknown. The aims of this study were to estimate the prognostic factors for complete remission (CR) rate, overall survival (OS) and disease-free survival (DFS) in patients with NK-AML in the absence of the FLT3-ITD mutation as well as to determine the relevance of CD56 antigen expression, an immunophenotypic marker, on outcome in this cohort of patients.

**Methods:** The study involved 143 subjects with NK-AML without the FLT3-ITD mutation during a follow-up period of 54 months. As risk factors for rate of CR, OS and DFS in months in this cohort of patients the following were evaluated: age, ECOG performance status (PS), leukocytosis (<30x10^9/L vs >=30x10^9/L), lactate dehydrogenase (LDH) more than 1.5 x upper limit of normal, and CD34 expression (<10% vs >=10%). For CD56 antigen expression, detected by flow-cytometry, the cut-off value >=20% was taken as positive (CD56+). Patients were treated by the Medical Research Council (MRC) 12 regimen. Risk factors were identified using univariate and multivariate analysis.

**Results:** The mean age of the patients was 53 years (range 18-79). Univariate analysis showed that the following risk factors were significant for CR rate: age >=55 years (p = 0.014), leukocytosis (p = 0.050), and CD56+ (p = 0.003). Multivariate analysis indicated CD56+ as the most important risk factor for CR rate: p = 0.001, HR 2.114 (95%CI 1.376-3.249). Significant factors for OS in univariate analysis were: age >=55 years (p = 0.01), leukocytosis (p <0.001), LDH (p = 0.050) and CD56+ (p < 0.001). Multivariate analysis indicated CD56+ as the most important risk factor for OS: p = 0.001, HR 1.948 (95%CI 1.306-2.905). Significant factors for DFS in univariate analysis were: leukocytosis (p = 0.034), LDH (p = 0.050) and CD56+ (p = 0.001). Multivariate analysis indicated CD56+ as the most important risk factor for DFS: p = 0.005, HR 3.857 (95%CI 1.495-9.952).

**Conclusions:** This study showed that CD56 antigen expression on leukemic cells in patients with NK-AML without the FLT3-ITD mutation predicts shorter OS and DFS as well as a lower rate of CR in comparison with patients from the same subgroup without CD56 positivity. Therefore, more intensive therapeutic regimens should be considered in such cases.

**Keyword:** CD56 antigen, NK-AML

---

**PROGNOSTIC IMPACT OF LEUKOCYTOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MUTATED NPM1 AND FLT3-ITD**

Marijana Virijevic1, Nada Suvajdijc Vukovic2, Irena Djunic1, Aleksandra Novkovic3, Natasa Tosic4, Mirjana Mitrovic1, Natasa Colovic2, Ana Vidovic2, Dragica Tomin2

1Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
2Clinic for hematology, Clinical Center of Serbia; Medical Faculty of Belgrade University, Belgrade, Serbiaa
3Clinical Hospital Center “Zemun”, Belgrade, Serbia
4Institute of Molecular Genetics and Genetic Engineering, University of Belgrade

**Objectives:** Mutation in nucleophosmin (NPM1) is the most frequently observed molecular abnormality, present in about 50% of acute myeloid leukemia (AML) cases, and is associated with a favorable outcome. Internal tandem duplication of the fms-related tyrosine kinase 3 gene (FLT3-ITD) is another frequent molecular abnormality and can be observed in about 25% of patients with AML. The presence of FLT3-ITD is generally considered as an unfavorable prognostic factor. The aim of this study was to investigate the prognostic impact of white blood cell (WBC) count at diagnosis on outcome within specific AML subgroups of patients with mutated NPM1 (as a favorable risk factor) and FLT3-ITD (as a poor risk factor).

**Methods:** This single-center study involved 32 AML patients with mutated NPM1 and FLT3-ITD. The follow-up period was 3 years. Patients with all other cytogenetic abnormalities and AML patients without cytogenetic abnormalities were excluded from this investigation. Patients were divided into three groups according to their WBC count: 1) a WBC count <20x10^9/L; 2) a WBC count 20-100x10^9/L and 3) a WBC count >100x10^9/L. Cox regression analysis was applied to determine the association of WBC and overall survival (OS) in months.

**Results:** The mean age of the patients was 51 years (range 21-71). There was a strong correlation between the NPM1 mutation and a high WBC count, p = 0.004. Also, differences in OS between the three groups of patients divided according to WBC count (<20x10^9/L vs 20-100x10^9/L vs >100x10^9/L) were statistically significant, p = 0.003.

**Conclusions:** This study demonstrated that leukocytosis is an important unfavorable risk factor for OS in the subgroup of patients with AML and mutated NPM1 and FLT3-ITD.

**Keyword:** mutated NPM1 and FLT3, AML
Objectives: CCAAT/enhancer binding protein alpha (C/EBPa) is a transcription factor involved in the regulation of myelopoiesis. C/EBPa expression occurs predominantly in myelomonocytic cells and is specifically upregulated during granulocyte differentiation. It is an intronless gene located on chromosome 19q13.1. The importance of CEBPa in hematopoiesis can be attributed to its crucial role during the development of granulocytes and its deregulation associated with myeloid transformation. Mutations in CEBPa are found in 5-14% of AML patients. Most CEBPa mutant AML patients simultaneously exhibit 2 mutations. These mutations largely fall into two major categories: one comprises those mutations that prevent C/EBPa DNA binding via alteration of its COOH-terminal bZIP, and the other comprises those that disrupt translation of the C/EBPa NH2 terminal, leading to reinitiation of translation at an alternative internal ATG codon located 351 nucleotides downstream of the main AUG initiation codon, and as a result, formation of a 30-kDa C/EBPa 30 isoform. This isoform has the capacity to further reduce wild-type C/EBPa activity by inhibiting its DNA binding and transactivation of the target genes in a dominant-negative effect. Our study group consisted of children with acute leukemia.

We aimed at screening the whole C/EBPa gene by NGS analysis, in order to find clinical and prognostic genetic markers for acute leukemia.

Methods: Study population consisted of 4 patients aged between 1 and 15 years who were admitted to our hospital with the diagnosis of acute leukemia. Blood samples were drawn into EDTA-containing tubes and DNAs were extracted from peripheral blood leukocytes with MagNA Pure automatic DNA isolation instrument. Amplification of gene was performed by PCR (amplicon preparation - sequencing techniques) and amplified fragments were sequenced by NGS analysis (GS Junior Sequencing) and the results were analyzed using AVA software. For DNMT3A gene variations, perfect well-matched primers were used to amplify the target exon 23. Region variation and detection were performed by DNA sequencing (Beckman Coulter) analysis. FLT3-ITD variations were screened with real-time PCR using fluorescence high resolution melting analysis.

Conclusion: Identified variants in the C/EBPa gene could disturb function and regulation of transcription factor that lead to development of leukemia. Identified variants in the 5' UTR and exon regions of the gene are responsible for gene m-RNA stability and formation of protein. FLT3 gene mutations are strongly associated with leukocytosis and poor prognosis in AML patients. DNMT3A mutations are recurrent in patients with AML and are associated with poor event-free and overall survival, independently of age and the presence of FLT3 or NPM1 mutations and regardless of the type of mutation or genetic location. These variations (C/EBPa,FLT3/ITD,DNMT3A) probably are relevant to the pathogenesis of AML. Further studies are on the way.

Keyword: Pediatric AML, C/EBPa-DNMT3A-FLT3 genes

Table 1. Distribution, classification and characterization of the gene variants in C/EBPa gene in our study

<table>
<thead>
<tr>
<th>No.</th>
<th>Status</th>
<th>Variant</th>
<th>Coverage</th>
<th>Strand</th>
<th>Number</th>
<th>Detection</th>
<th>Intron/Exon</th>
<th>Localisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>negative</td>
<td>275</td>
<td>100</td>
<td>+</td>
<td>-</td>
<td>positive</td>
<td>5'UTR</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>positive</td>
<td>275</td>
<td>100</td>
<td>+</td>
<td>-</td>
<td>negative</td>
<td>5'UTR</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>positive</td>
<td>275</td>
<td>100</td>
<td>+</td>
<td>-</td>
<td>positive</td>
<td>5'UTR</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>negative</td>
<td>275</td>
<td>100</td>
<td>+</td>
<td>-</td>
<td>positive</td>
<td>5'UTR</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2. Clinical and molecular characteristics of 4 pediatric patients with AML in our study

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yrs)</th>
<th>Diagnoses</th>
<th>Karyotype</th>
<th>C/EBPa Variations</th>
<th>DNMT3A Variations</th>
<th>FLT3-ITD Variations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>2</td>
<td>AML-M2</td>
<td>Karyotype</td>
<td>negative</td>
<td>positive</td>
<td>positive</td>
</tr>
<tr>
<td>P2</td>
<td>5</td>
<td>AML-M2</td>
<td>Karyotype</td>
<td>positive</td>
<td>positive</td>
<td>positive</td>
</tr>
<tr>
<td>P3</td>
<td>7</td>
<td>AML-M3</td>
<td>Karyotype</td>
<td>negative</td>
<td>negative</td>
<td>negative</td>
</tr>
<tr>
<td>P4</td>
<td>10</td>
<td>M3</td>
<td>Karyotype</td>
<td>positive</td>
<td>positive</td>
<td>negative</td>
</tr>
</tbody>
</table>

Objective: Leukaemia is the most common childhood blood malignancy and its treatments are associated with serious side effects. Thus, new therapies are urgently needed to improve leukaemia patient’s health and survival. This study investigated the effects on apoptotic induction and cellular proliferation inhibition on lymphoid leukaemia cell lines following 24 h treatment with Falcarinol- a polyacetylene from carrots (Daucus carota) alone and in combination with chemotherapy and apoptotic inducer agents to investigate their additive, synergistic or inhibitory effects. Moreover, expressions of some pro-apoptotic proteins, which play crucial roles in intrinsic apoptotic pathway, were investigated.

Methods: Three Leukaemia cell lines (Jurkat, MOLT-3 and CCRF-CEM) were investigated following treatment with Falcarinol alone or in combination with apoptosis inducers or chemotherapy agents. Flow cytometric analysis was used to detect active caspase 3 following 24 h treatment and apoptotic morphology was confirmed using Hoechst stain. Inhibition of cellular proliferation was assessed by cell titre glo, which measures the ATP level within viable cells, and cell cycle analysis using propidium iodide staining of DNA content using flow cytometry. Caspase Glo 8 and 9 was used to investigate activation of caspases, and cytochrome C, Bax and SMAC/Diablo antibodies were used to detect any activated proteins.
during the cascade of events associated with apoptosis induced by Falcarinol.

Results: Jurkat cells showed a significant synergistic response following combination treatment with Falcarinol and DR5 agonist after 24 h. The percentage of caspase 3 activity was increased with 13% and 30% after 24 h treatment with Falcarinol and DR5 respectively, whereas the combination treatment showed 58% apoptotic cells. These were confirmed by morphological examination. However, CCRF-CEM showed only an additive response after 24 h treatment with Falcarinol combined with DR5, Bortezomib, Leptomycin B or Sulforaphane. MOLT-3 cells demonstrated a significant synergistic response indicated by a significant decrease in cellular viability and significant increase in caspase 3 activity with Falcarinol combined with 2.5 nM Bortezomib or 25 µM Sulforaphane. In addition, treatment with 10 µM 6-MP alone and combined with Falcarinol arrested the cells at G0/G1 phase. The activities of both caspase 8 and 9 were significantly increased after 6 h post treatment with 12 and 25 µM Falcarinol. The expression of active Bax was increased in Jurkat cells 3 h after treatment with 12 µM Falcarinol followed by significant increase in cytochrome C and SMAC/Diablo after 6 h.

Conclusion: For the first time, we have shown that Falcarinol acts in a synergistic, additive or inhibitory manner with different agents in human leukaemia cell lines. The apoptosis was induced through both intrinsic and extrinsic pathways and the pro-apoptotic proteins Bax, cytochrome C and SMAC/Diablo were involved.

**Keyword:** Falcarinol, Synergistic

**Poster No:** 0052  **Abstract:**0198

**SCREENING OF FLT3 GENE MUTATIONS (FLT3-ITD AND D835) IN CHILDHOOD ACUTE LEUKEMIA PATIENTS**

Dilara Fatma Akın¹, Didem Torun², A. Emin Kürekçi³, Nejat Akar⁴

¹Losev Losante The Hospital For Children With Leukemia, Ankara, Turkey.
²Department of Pediatric Genetics, Ankara University, Ankara, Turkey.
³Department of Pediatric Haematology, Gülhane Military Medical Academy, Ankara, Turkey.
⁴TOBB-ETU Hospital, Ankara, Turkey

Objective: AML is a clonal disorder characterized by various genetic abnormalities and variable response to treatment. The discovery of an internal tandem duplication (ITD) in the FLT3 gene was a significant step in the process of understanding the genetic background of AML. The FLT3 gene encodes the tyrosine kinase receptor critical for normal hematopoiesis. The FLT3 gene is located on chromosome 13. There are two types of FLT3 mutations an ITD and a point mutation (D835), which both have constitutively active tyrosine kinase, thereby promoting proliferation and inhibiting apoptosis in leukemic cells. FLT3 is aberrantly expressed in the most of AML patients. Approximately 20 to 30% of AML cases carry an ITD mutation and 8 to 12% an D835 mutation. AML patients with an ITD mutation appear to have poorer clinical outcome. In our study we aimed to investigate the status of FLT3 (ITD and D835 mutations) in 15 pediatric AML patients, a patient’s family member and 183 ALL patients were categorized into karyotype and identified for FLT3 mutation status.

Methods: For screening FLT3-ITD mutation: The study population consisted of 16 children with AML aged between 1 and 15 years of age who were admitted to our hospital with the diagnosis of AML and a patient’s their immediate healthy parents (2). Blood samples were collected and DNA were extracted from MagNA Pure automatic DNA isolation instrument (Roche). FLT3-ITD variation was screened with real time PCR (Roche) using fluorescence HRM (High Resolution Melting) analysis.

For screening FLT3-D835 mutation: The study population consisted of 183 children with ALL aged between 1 and 15 years of age who were admitted to our hospital with the diagnosis of ALL. Amplifications of gene were performed by PCR and amplified fragments were digested with appropriate restriction endonucleases (EcoRV) and sequencing of different band profiles were performed by sequencer (Beckman Coulter, USA). Sequencing of the gene revealed a heterozygous “C/A” variation at c.32705 resulted with a transition of Serin to Serin. Results: We worked in 17 children 8 (50%) of them were defined FLT3-ITD mutation. ALL were diagnosed in 183 children 14 (7,6%) of them were carried heterozygote genotype. One (5,8%) of the 17 patients carried both mutations. Sequencing of the gene revealed a heterozygous “C/A” variation at c.32705 resulted with a transition of Serin to Serin.

Comment: FLT3 mutations are poor prognostic markers of AML. Ozbek et al (TJH 2012) reported that their patients (4 %) had FLT3-ITD mutation and FLT3-D835 point mutation heterozygosity was observed in only 1 patient (2%). Cytogenetic prognostic factors are more precise and in wide clinical use. But there is a need to improve molecular factors (the mutation status of genes such as FLT3, MLL, NPM1, CEBPA), especially in cases with normal karyotype. FLT3/ITD, which is known to be a poor prognostic factor, is present in 20–30% of AML patients with different karyotype status.

**Keyword:** Childhood AML, FLT3 gene mutations( ITD/ D835 mutations)

Table.1. Classification and characterization of the FLT3 gene mutations

**EFFECT OF POMEGRANATE ANTHOCYANIDINS (DELPHINIDIN, CYANIDIN AND PELARGONIDIN) ON INHIBITION OF PROLIFERATION AND INDUCTION OF APOPTOSIS IN HUMAN LEUKAEMIA CELL LINES**

Hyatham Ahmad Dahlawi, Christine Le Maitre, Nikkie Jordan Mahy, Malcolm Clench

Bioscience, Health and wellbeing, Sheffield Hallam University, Sheffield, United Kingdom

Methodology: The anti-cancerous effect of three different anthocyanidins was investigated on four leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60 and THP-1). Cells were treated with 0µM to 100µM of each anthocyanidins...
for 24 hours. Cell proliferation was assessed using CellTiter-Glo® Luminescent Cell Viability Assay. The pro-apoptotic actions of anthocyanidins were assessed by two assays: Annexin V/Propidium iodide staining and staining for caspase-3 activity using flow cytometry. Cell cycle arrest was investigated using flow cytometry. The caspase-Glo® 8 and 9 assays were used to measure the effect of delphinidin on caspase-8 and caspase-9 activity. The effect of Delphinidin on expression of some apoptotic proteins (Cytochrome C, SMAC/Diablo and Bax) were investigated using immunocytochemistry.

Results: Delphinidin was found to have the greatest inhibitory effect on cell proliferation which was found to be significantly greater than that shown by cyanidin and pelargonidin (Figure 2). Delphinidin also significantly induced apoptosis in all four cell lines. Cyanidin induced apoptosis only in CCRF-CEM and pelargonidin failed to induce apoptosis in any cell lines. Delphinidin increased both caspase 8 and 9 activity following 6 hr. treatment. Expression of Bax, cytochrome C and SMAC/Diablo were also activated following treatment with delphinidin.

Conclusion: Taken together, our data suggest that delphinidin could be developed as an agent against leukemia.

Keyword: anthocyanins, apoptosis

Poster No: 0054

SEX, ABO BLOOD GROUPS, AND SECRETOR STATUS FREQUENCY IN HEMATOLOGICAL MALIGNANCIES
Mohamad Salih Jaff
Hematology Department, Council of Diagnostics, KBMS, Erbil, Iraq.

Background: Associations of sex, ABO blood groups with some diseases including leukemia have been described earlier and their role in influencing the etiology, pathogenesis and prognosis of these diseases have been speculated. Despite the profound differences in the incidence of hematological malignancies in both sexes, the pathophysiology of these relations are often overlooked. The aim of this study was to examine such associations and the possibility of explaining it.

Subjects: In Nanakaly Hematology hospital, Erbil, Iraq, during 2010-2012; (566) patients were studied; (174) patients with myeloid malignancies; AML, CML, and (392) patients with lymphoid malignancies; ALL, CLL, HL, NHL, and MM. Compared to (196) blood donors as controls.

Methods: Standard conventional techniques were used for ABO, Rh and Lewis blood grouping and haemagglutination inhibition test for secretor status.

Results: (table 1 and 2): A significant lower incidence of females was found in lymphoid malignancies (M:F=1.42:1) (P=0.0002), while no sex difference in myeloid malignancies (M:F=0.93:1) (P=0.203) and even a significantly higher female incidence in CML (0.7:1) (P=0.047).

ABO & Rh blood groups and secretor status results showed no significant difference from controls, except in patients; blood group A incidence was significantly (P: 0.006) higher (54.3%) and O blood group was significantly (P: 0.036) lower (22.9%). Regarding the secretor status there was no significant difference between different diseases and between males and females patients.

Lymphoid malignancies have higher O blood group incidence (P: 0.067) than myeloid malignancies.

Discussion: The secret of women’s resistance to lymphoid malignancies and stronger immunity lies in having (a) two X-chromosomes, which might provide women with extra protection against cancer, as X chromosomes carry micro-RNA molecules which are very important for cell growth and cancer control through regulating proteins which are also major regulators of the immune system, (b) the gene encoding for sex steroid is located on chromosome 9 near the ABO locus which could protect O blood group women against acute leukemia, through (17-b estradiol in women) which has anti-proliferative control effect on leukemia cells, and (c) the indoor lifestyle of women with less exposure to environmental and occupational hazards. The low frequency of O group in CML in this study can possibly be explained partially, by the higher frequency of secretor status in O blood group (from previous study), conferring some protection from myeloid carcinogens and possibly a milder disease.

Conclusion: Larger prospective trials are necessary to evaluate these factors and possibly prevention/treatment could be tailored to clinical profiles and genetic background including gender and blood groups.

Keyword: ABO, Secretors

Poster No: 0055

LENALIDOMIDE IN ACUTE MYELOID LEUKEMIA; TWO CASES
Burhan Turgut¹, Mustafa Oran², Tarkan Yetişyiğit¹, Duygu Bayır²
¹University of Namik Kemal, Medical Faculty, Department of Internal Medicine, Division of Hematology
²University of Namik Kemal, Medical Faculty, Department of Internal Medicine

Lenalidomide, which is an immunomodulatory agent, is highly effective in myelodysplastic syndrome with 5q deletion (del). There are some studies purposed that lenalidomide can also be effective in AML with 5q del. We presented two AML patients with 5q del treated with lenalidomide.

Case 1: A 72-year-old female who had diagnosed as acute myeloid leukemia with myelodysplasia-related changes was admitted to our clinic for treatment. Before admission the patients had skin lesions and diagnosed as Sweet syndrome and started metil-prednisolon by a dermatologist. Cytogenetic analysis on bone marrow revealed 46XX, t(3;5;3) (q21,q13,p25), inv(9)((p11q13) [2], moreover FISH analyses showed 75% 5q deletion. Induction treatment (high dose cytarabine and mitoxantrene day 1 and day 5) was administrated. In spite of a decrease in blast count, no remission is provided. Considering 5q del positivity, the treatment of lenalidomide (25mg/day) is highly effective in myelodysplastic syndrome with 5q del and pelargonidin failed to induce apoptosis in any cell lines. Delphinidin increased apoptosis only in CCRF-CEM and pelargonidin failed to induce apoptosis in any cell lines. Delphinidin increased both caspase 8 and 9 activity following 6 hr. treatment. Expression of Bax, cytochrome C and SMAC/Diablo were also activated following treatment with delphinidin.

Conclusion: Taken together, our data suggest that delphinidin could be developed as an agent against leukemia.

Keyword: anthocyanins, apoptosis

Poster No: 0227

LENALIDOMIDE IN ACUTE MYELOID LEUKEMIA; TWO CASES
Burhan Turgut¹, Mustafa Oran², Tarkan Yetişyiğit¹, Duygu Bayır²
¹University of Namik Kemal, Medical Faculty, Department of Internal Medicine, Division of Hematology
²University of Namik Kemal, Medical Faculty, Department of Internal Medicine

Lenalidomide, which is an immunomodulatory agent, is highly effective in myelodysplastic syndrome with 5q deletion (del). There are some studies purposed that lenalidomide can also be effective in AML with 5q del. We presented two AML patients with 5q del treated with lenalidomide.

Case 1: A 72-year-old female who had diagnosed as acute myeloid leukemia with myelodysplasia-related changes was admitted to our clinic for treatment. Before admission the patients had skin lesions and diagnosed as Sweet syndrome and started metil-prednisolon by a dermatologist. Cytogenetic analysis on bone marrow revealed 46XX, t(3;5;3) (q21,q13,p25), inv(9))(p11q13) [2], moreover FISH analyses showed 75% 5q deletion. Induction treatment (high dose cytarabine and mitoxantrene day 1 and day 5) was administrated. In spite of a decrease in blast count, no remission is provided. Considering 5q del positivity, the treatment of lenalidomide (25mg/day) with 5-acazitidine combination was decided. After 2 month treatment any response was provided; blast count was increased under treatment. Patient died after six month with 5-azacitidin combination was decided. After 2 month treatment any response was provided; blast count was increased under treatment. Patient died after six month from the diagnosis with progression of leukemia.

Case 2: 39 years old woman admitted to our clinic with long-term anemia and concomitant thrombocytopenia and leucocytosis and diagnosed as acute myeloid leukemia with myelodysplasia-related changes. Cytogenetic analysis on bone marrow revealed 45XX, rob(13;15) (q10;q10), moreover FISH analyses showed %14 5q31del. Induction treatment (high dose cytarabine and mitoxantrene day 1 and day 5) was administrated. In spite of a decrease in blast count, no remission is provided. Considering 5q del positivity, the treatment of lenalidomide (25mg/day) with 5-acazitidine combination was decided. After 2 month treatment any response was provided; blast count was increased under treatment. Patient died after six month from the diagnosis with progression of leukemia.

Conclusion: Larger prospective trials are necessary to evaluate these factors and possibly prevention/treatment could be tailored to clinical profiles and genetic background including gender and blood groups.

Keyword: ABO, Secretors
observed. After that, we tried clofarabine combining with high dose cytarabine, unfortunately no response again was provided. After follow up with palliative treatment for a while, we decided to give lenalidomide because of Sqi del positivity. Lenalidomide 50mg/day was started and continued for 21 days. Peripheral blast count increased under lenalidomide treatment, so the treatment was not continued. The patient still is alive and allogenic stem cell transplantation is being planned.

Discussion: We experienced lenalidomide on two patients; both of them were acute myeloid leukemia with myelodysplasia-related changes and with Sqi del. We did not observe any objective response to lenalidomide.

**Keyword:** acute myeloid leukemia, lenalidomide

---

**Figure 1. MTT assay on the control, scramble and test groups. OD of the tests is shown in the below row.**

---

**EVALUATION OF MIR-155 INHIBITION EFFECTS ON JURKAT CELL LIN**
Shaban Alizadeh1, Zahra Kashani Khatib2, Fatemeh Kouhkan3, Saied Kaviani4, Masoud Soleimani5

1Hematology Department, Allied Medical Sciences School, Tehran University of Medical Sciences, Tehran, Iran
2Students Scientific research center (SSRC),Allied Medical Sciences School, Tehran University of Medical Sciences, Tehran, Iran
3Hematology Department, Trabiat Modares University, Tehran, Iran

Objectives: MicroRNAs are small non-coding RNA molecules with approximately 22 nt in length and cause inhibition of translation or degradation of mRNA. Mir-155 is a molecule with different functions, such as role in proliferation and immunity. Overexpression of this miRNA has been found in a number of cancers. One of its best known functions is apoptosis that affects caspase-3 activity. The main aim of this study was evaluation of LNA mir-155 inhibitor effect in apoptosis.

Methods: In this study, Jurkat cells were used and for evaluation of sensitivity to varied concentrations (25, 50 and 75 nmol) of mir-155 inhibitor using MTT assay. Mir-155 expression level was analyzed using the quantitative real-time polymerase chain reaction (QRT-PCR). Caspase-3 activity was measured by caspase-3 colorimetric activity assay kit. Unpaired t test were used for analysis of the MTT and apoptosis results. Probability of 5% was assumed as statistically significant.

Results: According to our results, the use of mir-155 inhibitor increased activity of caspase-3 by 2 fold in 75 nmol concentrations. In this research, we found that the proper increase of mir-155 inhibitor concentration can inhibit mir-155 and consequently increase caspase-3 activity and induce apoptosis in the Jurkat cells leading to cell death ultimately.

Conclusions: Apoptosis stimulation by miRNAs is probably will be one of the best and low risk ways of cell death induction in malignancies. Due to role of mir-155 in several cancer cells, it may be used as a therapeutic tool in future.

**Keyword:** mir-155 inhibitor, Apoptosis

---

**THE MOLECULAR ANALYSIS OF B-THALASSEMIA MUTATIONS IN NORTHEAST EGYPT**
Othman Soliman1, Saher Yahia2, Amany Shouma3, Hala Shafiek4, Ashraf Fouda5, Hanan Azzam6, Enas Goda7, Nashwa Abou Samra8, Rabab Mahfouz9, Solafa Abd Elraouf Elshrawy10

Background: β-Thalassemia (β-thal), the most common genetic disorder in Egypt, is widely distributed particularly in Mediterranean and Middle Eastern countries. β-globin alleles were studied by different molecular methods which are known to be difficult, time consuming and more liable to contamination. The β-Globin StripAssay method is reported to be rapid, simple, reproducible and less expensive.

Aim: Our study aimed to evaluate The β-Globin StripAssay method based on reverse hybridization for detection of β-thal mutations in Egyptian children living in Northeast Egypt, and detect possible genotype/phenotype correlation.

Subjects & Methods: For this purpose forty children with β-thal major (20 males and 20 females) with mean age of 10.33±4.75 years were recruited consecutively from outpatient Hematology Clinic of Mansoura University Children’s Hospital. In addition to full history, clinical and routine laboratory evaluation, mutation analysis was performed by the β-Globin StripAssay MED (Vienna Lab, Vienna, Austria).

Results: The most common genotypes encountered were; homozygous IVS 1.110 (6 patients, 15%) and IVS 1.1 (5 patients, 12.5%) while compound heterozygous genotypes were detected in the remainder mainly IVS 1.110/IVS 1.6 (8 patients 20%), IVS 1.110/IVS 1.1 (5 patients, 12.5%). The most frequent mutant alleles detected were; IVS 1.110, IVS 1.1 and IVS 1.6 accounting for 33.75%, 27.5% and 18.75% respectively while the least frequent was Codon 39 that represented 2.5% of recovered alleles. The detection rate of the used method in our population was 90% where 8 alleles out of 80 (10%) remained uncharacterized. No genotype/phenotype correlation was demonstrated in studied patients.

Conclusion: β-Globin StripAssay is a fast, easy-to-perform and reliable method for genetic screening of β-thalassemia patients in Egypt. IVS 1.110, IVS 1.1 and...
The Aurora A kinase interacting protein 1 (AURKAIP1), is a negative regulator of Aurora-A, and promotes proteasome-independent mechanism. Studies analyzing Aurora A expression in leukemia are very few and the AURKAIP1 gene has not been analyzed in leukemias at all. In this study we aimed to investigate expression of the Aurora A an AURKAIP1 genes in patients with AML.

Methods: 41 patients with AML and 23 healthy controls were studied. RNA was isolated and complementary cDNA was synthesized. Real time PCR was performed using the ABI7500 system. Expression levels of the Aurora A and AURKAIP1 genes were compared with Zinc finger protein 207 (ZNF207) expression as the reference gene. The results were analyzed by the ∆∆Ct method.

Results: In this study Aurora A expression levels were significantly higher in the patients when compared to the control group (2-∆∆Ct =1,95). Likewise, AURKAIP1 expression levels were much lower than the control groups (2-∆∆Ct =0,03).

Conclusion: Overexpression of the Aurora A gene supports the role of Aurora A in leukemia development and progression. The decrease in AURKAIP1 is consistent with lack of Aurora A degradation and stimulation of cell proliferation by increased kinase activity due to high Aurora A expression.

Keyword: Acute myeloid leukemia, Aurora A
leukemia samples are substantially shifted to larger sizes as compared to healthy ones.

Thus our DIC-microscopy measurements for living blood cells demonstrated that mononuclear size distributions can be used as an additional criterion in leukemia diagnostics. The advantage of the method proposed - there is no need of any staining or other labeling procedures which are potentially toxic or interfere with normal cell functions. Method allows to study the same cells simultaneously with other approaches to cell diagnostics.

In conclusion, optical and morphometric characterization of mononuclear cells may become useful and perspective method in diagnostics of clonal (leukemia) and polyclonal (hepatitis B/C) cell proliferation.

**Keyword:** leukemia, differential-interference contrast microscopy

---

**Multiple Myeloma**

We report a challenging case who was first presented with vasculitic symptoms and microscopic hematuria and underwent renal biopsy revealing Ig a and kappa deposition. Despite having no symptoms or signs rather than the renal biopsy findings he was diagnosed with multiple myeloma due to bone marrow aspiration and biopsy. Initial diagnostic workup involving skeletal surveys showed no sign of active disease but PET scan revealed multiple bone lesions attributable to plasma cell dyscrasia. A 56 years old male patient who was previously well admitted to an outpatient clinic with the complaint of purpuric lesions involving the distal extremities. Skin biopsy was performed and revealed leucocytoclastic vasculitis. Patient was put on to steroid therapy. The etiological cause of vasculitis was investigated and microscopic hematuria and non nephrotic proteinuria was detected while the glomerular filtration rate was in normal range during diagnostic workup. Patient was referred to our nephrology clinic with the pre-diagnosis of nephritic syndrome. Renal biopsy was performed, and revealed Ig a and kappa light chain deposition in mesangial matrix. Patient had no symptoms or signs which could be attributable to plasma cell dyscrasia. However, bone marrow aspiration revealed 40% plasma cells with some bizarre shaped cells. Bone marrow biopsy has proved the cells to be monoclonal and staining predominantly with kappa. Serum protein electrophoresis showed monoclonal gammopathy which was identified as Ig a kappa in immunofixation. Ig A level was 1262 mg/dl and kappa light chain was 535 mg/dl. His purpuric lesions...
resolved and steroid therapy was stopped. Considering the active (symptomatic) myeloma criteria he had no anemia, his creatinine level was under 2 mg/dl and calcium level was under 11.5 mg/dl and skeletal surveys revealed no lesions which may be attributable to multiplet myeloma. Instead having heavy and light chain deposition in kidneys he had no worsening renal dysfunction. With regard to criteria proposed to initiate myeloma treatment the patient was naive and had to be regularly followed up. But in systemic evaluation the patient complained about bone pain concerning the extremities. PET scan was ordered to search for any undetectable bone lesions under skeletal surveys. PET results revealed multiple lytic sclerotic lesions at costal, vertebral and femoral regions with SUV max values changing between 3.5 and 7.5 (figure 1). Because of the documented bone lesions patient was put on to combination chemotherapy.

Sometimes simply "renal insufficiency" defined as having a serum creatinine level of more than 2 mg/dl should not be enough to describe active renal and systemic disorder. In such situations some further investigations should be done in order to better identify end-organ involvement and active (symptomatic) disorder. PET scan could be considered as one of these studies in some circumstances.

**Keyword:** multiplet myeloma, renal disease

---

**Figure 1.** PET Scan with multiplet bone lesions

---

**CENTRAL NERVOUS SYSTEM RELAPSE AFTER HIGH DOSE CHEMOTHERAPY IN A PATIENT WITH MULTIPLET MYELOMA**

Abdullah Katgül, Ömür Gökmen Sevindik, Şerife Medeni Solmaz, Özden Pişkin, İnci Alacacıoğlu, Mehmet Ali Özcan, Hayri Güner Özsan, Bülent Ündar, Fatih Demirkran

Dokuz Eylül University Hematology Department, İzmir, Turkey

We report a case of central nervous system relapse with intraparenchymal, dural and leptomeningeal involvement after high dose chemotherapy and autologous stem cell transplantation. A 51 year old man received two cycles of bortezomib with partial response, high dose chemotherapy with autologous stem cell transplantation was performed at the 4th month of diagnosis. Very good partial remission achieved after high dose chemotherapy and patient began to be followed up with only biphosphonate treatment. 11 months after high dose therapy the patient admitted with sudden transient loss of vision, headache and palpable temporomandibular mass. Magnetic resonance and pet imaging revealed mass lesion occupying right infratemporal fossa and another mass lesion occupying left petrous apex, extending through the sphenoid sinus and infiltrating cavernous sinus involving the 6th cranial nerve. Heterogenous dural and leptomeningeal infiltration was detected. In the cerebrospinal fluid analysis monomorphic plasma cells were seen (Figure 1). FISH analysis did not reveal deletion 17p or deletion 13q. Both localized radiotherapy and combined systemic chemotherapy (cyclophosphamide, bortezomib, doxorubicin and dexamethasone) initiated. Intrathecal methotrexate was also applied for 4 times concurrently. After 3 cycles of systemic chemotherapy a reasonable response was achieved and considering the side effects of combination regimen (severe peripheral neuropathy related with bortezomib) patient put on to lenalidomide and dexamethasone therapy. After six cycles of lenalidomide therapy symptoms related with central nervous system involvement and cytopenias related with bone marrow infiltration got worse and patient was lost from multiorgan failure and sepsis.

Considering the initiation of symptoms, patient has survived for 9 months after diagnosed with leptomeningeal infiltration. In the literature there is no standard therapeutic approach regarding the central nervous system relapse after high dose therapy and median survival of patients with CNS relapse is 2 to 3 months. Several systemic conventional combination regimens, radiotherapy and intrathecal chemotherapy were tried, but never achieved a long survival. The impact of novel therapeutic drugs like lenalidomide remains unclear. As in our case lenalidomide may prolong the survival of patients with CNS relapse.

**Keyword:** CNS, myeloma
Multiple myeloma (MM) is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. MM accounts for approximately 1 percent of all cancers and slightly more than 10 percent of hematologic malignancies in the United States.

Approximately 60% of myeloma patients have detectable monoclonal IgG, 20% monoclonal IgA and 20% percent have only monoclonal immunoglobulin light chains. Myelomas producing monoclonal IgD, IgE, IgM, or more than one immunoglobulin class are rare. This case with IgD lambda light chain disease was a rare entity and has expending clinical features that we concerned to share in this report.

A 39 year of man admitted our internal medicine policlinic with the complaint of anorexia, weight loss, severe back pain and immobilization. Routine blood tests revealed hypercalcemia (13.7mmol/dl), hyperuricemia (109.1 mg/dl, creatinin 2.3mg/dl) and anemia (Hg: 7.0 g/dl). Sedimentation rate was 120 mm/hour. Radiographic examinations showed multiple lytic lesion of ribs and diffuse osteoporosis.

Serum albümin was 4.5 gr/dl and serum globulin was 4.2 gr/dl, Ig A, G and M levels were low. Serum protein electrophoresis showed a gamma globulin peak. Urine immunfixation electrophoresis showed no monoclonal bands but detected Lambda light chain.

Bone marrow aspiration specimen revealed an abnormal proliferation of atypical plasma cells (75%) Bone marrow biopsy interpreted IgD/Lambda Multiple Myeloma and grade III-IV reticulin and collagen fibre rise. Peripheral blood FISH analysis remained negative for del [13q], del [17p] t[14;16] t[11;14].

We maintain his hydration and diuresis in order to correct hypercalcemia and decrease blood urea and creatinine levels. He also needed packed RBCs transfusion for increasing hemoglobin levels above 8 mg/dl. Dexametason infusion therapy was given for four days following a pause of four days repeated 4 cycles.

Multiple myeloma is a plasma cell disorder usually seen at 5-6 th decade. Malignant plasma cells synthesize monoclonal immunoglobulins most commonly IgG, IgA or only light chains. About 1 percent of cases are IgD myeloma. Osteolytic lesions or diffuse osteoporosis occurs by the mass effect of plasmacytomas, or by the cytokines that are secreted by malignant plasma cells.

In our case with multiple myeloma secreting IgD lambda light chain, diffuse osteoporotic lesions was seen at X-ray graphs at skull, ribs, vertebra. Pathological bone fractures was demonstrated at multiple levels of vertebra with a CT screening.

The presence of low concentration of serum monoclonal immunoglobulin should alert to the possibility of the IgD myeloma isotype, especially when associated with excess lambda light chains in the serum and light chain proteinuria.

**Keyword:** Multiple Myeloma, IgD Lambda

---

**A RARE ENTITY: IGD LAMBDA MULTIPLE MYELOMA**

Mesut Ayer1, Fatma Aylin Ayer2, Aysegul Yilmaz Karaca2, Makkule Ulusoy2, Yesim Gurkan2, Onur Kirkizlar3

1Haseki Training and Research Hospital, Hematology Department, Istanbul
2Haseki Training and Research Hospital, Department of Internal Medicine, Istanbul
3Dr. Ersin Arslan State Hospital, Hematology Department, Gaziantep

**LOCAL RENIN-ANGIOTENSIN SYSTEM IN NORMAL HEMATOPOIETIC AND MULTIPLE MYELOMA-RELATED PROGENITOR CELLS**

Burak Uz1, Suzin Çantal Tatonyan2, Muge Sayitoğlu2, Yücel Erbilgin2, Özden Haturnaz Ng2, Salih Aksu1, Yahya Büyükaşık1, Nilgün Sayınalp1, Hakan Göker1, Osman İhmalı Özcebe1, Uğur Özbek2, İbrahim Celalettin Haznedaroğlu1

1Department of Internal Medicine, Hematology Division, Hacettepe University Faculty of Medicine, Ankara, Türkiye
2Department of Genetics, Institute for Experimental Medicine Research, Istanbul University, Istanbul, Türkiye

**Objective:** The prominent functions of local rennin-angiotensin system (RAS) in primitive hematopoiesis further support the hypothesis that local autocrine BM RAS could also be active in the neoplastic hematopoiesis. The aim of this study is to search critical RAS elements in normal CD34+ hematopoietic stem cells and multiple myeloma (MM)-related progenitor cells.

**Patients and Methods:** The study group comprised the total bone marrow cells (CBM) of 10 hematologically normal people and the CD34+ stem cell samples (CD34+CBM) of 9 healthy donors for allogeneic peripheral stem cell transplantation, and the CD34+ stem cell samples (CD34+MM) of 9 MM patients undergoing autologous peripheral stem cell transplantation. We searched for the gene expression of the major RAS components in healthy hematopoietic cells and myeloma cells by qRT-PCR.

**Results:** RENIN, angiotensinogen (ANGTS), and angiotensin converting enzyme-I (ACE I) mRNA expression levels of CBM were significantly higher than those in myeloma patients (p<.03, p=.002, and p=.0008, respectively). Moreover, RENIN and ANGTS mRNA expression levels were significantly higher in CD34+ stem cell samples of healthy allogeneic donors compared to those in myeloma patients (p=.001 and p=.01). However, ACE I expression levels were similar in CD34+CBM and CD34+MM hematopoietic cells (p=.89).

**Conclusion:** Although it was found to be lower then the CBM and CD34+CBM hematopoietic cells, the local RAS components were also expressed from CD34+MM hematopoietic cells. This point should be kept in mind while focusing on the immunobiology of MM and processing of autologous cells during the formation of the transplantation treatment protocols.

**Keyword:** Renin-angiotensin system, multiple myeloma
SCLEROMYXEDEMA: A RARE VARIANT OF LICHEN MYXEDEMATOSUS ASSOCIATED WITH MONOCLONAL GAMMAPATHY OF UNDETERMINED SIGNIFICANCE
Ipek Yonal1, Oner Ibrahim Dogan2, Can Baykal3, Meliha Nalcaci1
1Istanbul University Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology
2Istanbul University Istanbul Medical Faculty, Department of Pathology
3Istanbul University Istanbul Medical Faculty, Department of Dermatology

A 54-year-old female presented with a one-year history of papules and erythematous skin induration, initially limited to the head and upper extremities and subsequently spread to the knees and lower extremities over the last three months. On physical examination, characteristic leonine facial changes including deep longitudinal facial furrows and intense erythema of the glabella were noted (Figure 1). In addition, physical examination revealed 2 to 5 mm waxy papules, fusing into plaques on the glabella, dorsum of the nose, perioral region (Figure 1) and erythematous plaques on the knees, dorsal area of her hands and feet. Histopathologic analysis of two skin punch biopsy specimens showed proliferation of fibroblasts and diffuse mucin deposition within the upper reticular dermis. The blood count revealed a hemoglobin of 12 g/dl, a white blood cell count of 6000/mm³ and a platelet count of 250000/mm³. A serum monoclonal protein of 0.22 g/dl was detected. Serum immunofixation electrophoresis confirmed the monoclonal gammopathy of IgG-lambda type and on urine electrophoresis monoclonal lambda free light chain was detected. Nodular and interstitial neoplastic plasma cell infiltration (5%) with monotypic CD38 expression was detected in bone marrow biopsy. On skeletal survey, no destructive lesions were present. The patient was diagnosed as scleromyxedema and monoclonal gammopathy of undetermined significance. Oral methylprednisolone was started and after 15 days, oral isotretinoin was added to the therapy. After ten weeks of treatment, skin lesions located on the upper and lower extremities resolved while edema and deep longitudinal furrows improved only slightly. The patient is still under follow-up in our Hematology and Dermatology departments.

Scleromyxedema, a generalized papular and sclerodermoid form of Lichen myxedematous, is characterized by waxy yellow-red papules on the head, neck, arms, and upper trunk commonly developing over thickened and indurated skin. Specific areas typically involved include the posterior-auricular area, the forehead and glabella, posterior neck, fingers, and forearms. It is a rare fibromucinuous connective tissue disorder characterized by mucin deposition, fibroblast proliferation, and fibrosis, monoclonal gammopathy in the absence of thyroid disease. Patients have variable organ involvements (e.g. gastrointestinal, musculoskeletal, cardiac, pulmonary, neurological and renal complications) that mimic scleroderma. A monoclonal gammopathy of undetermined significance predominantly of the IgG lambda light chains is present. It may be associated with multiple myeloma in only 10% of patients. Various therapies (e.g. corticosteroids, melphelan, thalidomide, high dose intravenous immunoglobulin and autologous stem cell transplantation) have been described to treat symptoms of scleromyxedema and reduce the paraprotein. Currently, therapy of patients with scleromyxedema are often a challenge.

Keyword: monoclonal gammopathy of undetermined significance, scleromyxedema

Figure 1. Leonine facial changes accompanied by papules coalescing into plaques on the glabella, dorsum of the nose and the perioral region.

Poster No: 0065 Abstract:0114

SINGLE CENTER EXPERIENCE OF MYELOMA PATIENTS TREATED WITH LENALIDOMIDE
Fahri Sahin, Melda Cömert, Ajda Güneş Ersoy, Asu Fergun Yılmaz, Filiz Vural, Güray Saydam
Ege University Hospital, Hematology, Bornova Izmir TR

We have aimed to evaluate myeloma patients in terms of demographic features and clinical status treated with lenalidomide.

Data of thirty-four patients who have been treated with lenalidomide with diagnosis of multiple myeloma in our center between 2010 and 2012 were evaluated. The relationship between the variables; age, sex, first, second and third line chemotherapy regimens, daily lenalidomide dose, overall survival (OS), mortality were analyzed.

The median age of the patients was 61.3 years (45-78 years), and of 22 (64.7%) males and of 12 (35.2%) females. Eighteen patients were stage 3A, 10 were 3B, 4 were 2A, 1 (2.9%) was 2B and 1 (2.9%) of the patients was stage 1A. Most of the patients were IgG/kapa myeloma. ASCT was performed in 15 patients before the lenalidomide treatment. Median time from diagnosis to use of lenalidomide was found 33.1 months. In all cases, lenalidomide was combined with dexametason. Lenalidomide treatment was used as a second line therapy in 9 (26.4%), as a third line treatment in 17 (50%) and as a fourth line

Poster No: 0066 Abstract:0115
therapy in 8 (23.5%) patients. The median lenalidomide dose was 18.3 mg/day (5-25 mg). OS was 44 months. Lenalidomide was ceased in 4 (11.7%) patients because of progression and in 4 (11.7%) patients because of persistent cytopenias. One (2.9%) patient died under lenalidomide. Lenalidomide treatment still continues in 25 (73.5%) patients.

According to our results, lenalidomide was provided to our patients at least after 2 or 3 prior therapies with lesser efficacy and relatively high side effects

Keyword: Myeloma, lenalidomide

Abstract 0116

MAY HEMOGLOBIN VALUES IN PATIENTS WITH MULTIPLE MYELOMA BE AN EARLY PREDICTIVE INDICATOR FOR RESPONSE?

Güray Saydam, Melda Cömert, Ajda Güneş Ersoy, Asu Fergun Yılmaz, Murat Tombuloglu, Fahri Şahin
Ege University Hospital, Department of Hematology, Bornova Izmir TR

Thalidomide is an immunomodulatory drug which provides improvement in overall survival in multiple myeloma. In this study, we aimed to evaluate myeloma patients under treatment of thalidomide and investigate the potential predictive value of increase in hemoglobin levels as an indicator for response to thalidomide therapy.

Thirty-four myeloma patients treated with thalidomide between 2001 and 2012 in our center were enrolled to this analyses. The relationship between the variables (age, sex, first and second chemotherapy regimens, daily thalidomide dose, complete blood count with first 3 months after initiation of thalidomide) and overall survival (OS), progression free survival (PFS) and mortality were evaluated. After thalidomide prescription, the first 3 months hemoglobin levels were extracted for evaluation. Statistical evaluation was performed with the SPSS 17.0 program and the threshold level of significance was accepted as p = 0.05.

Twenty-eight (82.3%) of 34 multiple myeloma patients were stage 3A, 3 (8.8%) of them were stage 3B, 2 (5.8%) of them were stage 2A and 1 (2.9%) of the patients was stage 1A. Fourteen (41.1%) of the patients were Ig G-kappa myeloma, 6 (17.6%) of them were Ig G-lambda, 4 (11.7%) of them were Ig A, 2 (5.8%) of them were Ig A-kappa, 2 (5.8%) of them were Ig A-lambda, 3 (8.8%) of them Ig G, 1 (2.9%) patients was Ig kappa myeloma and two of them were unknown. Autologous hematopoetic stem cell transplantation was performed in 17 (50.0%) patients before the thalidomide treatment. The time from diagnosis to the use of thalidomide was found as 26.1 months. The median thalidomide dose was 285 mg/day and the median duration of thalidomide use was 20 months. The median values of the patients before the use of thalidomide were; Hb: 11.6 g/dl, Htc: 34.8%, WBC: 4587/µl, Plt: 182,000/µl. The median values of the first month after initiation of thalidomide were; Hb: 11.5 g/dl, Htc: 35.2%, WBC: 4430/µl, Plt: 197,000/µl, second month values were; Hb: 11.8 g/dl, Htc: 35.2%, WBC: 4650/µl, Plt: 212,000/µl, 3rd month values were; Hb: 12.0g/dl, Htc: 36.2%, WBC: 4730/µl, Plt: 212,600/µl There were no statistically significant difference in hemoglobin levels, hematocrit and WBC before and after thalidomide OS was 65.5 months, survival after initiation of thalidomide was 39.2 months and PFS was 20.3 months. Thalidomide was stopped in 17 (50.0%) patients because of progression and in 2 (5.8%) patients because of neuropathy. Three (8.8%) patients died while using thalidomide. Five (14.7%) patients left the follow-up. Thalidomide treatment still continues in 7 (20.5%) patients. 18 patients died during the follow-up.

Although there was no difference in patients with stable and progressive disease status under treatment with thalidomide in terms of hemoglobin levels, it is needed to have longer follow-up period. Hemoglobin levels might be good indicator for evaluation of response to thalidomide therapy for patients treated for longer period.

Keyword: Myeloma, Thalidomide

Abstract 0119

ASCITES FORMATION AND RESPONSE TO INTRA-PERITONEAL DEXAMETASONE IN THE COURSE OF REFRACTORY MYELOMA

Melda Cömert¹, Fatma Keklik¹, Nazan Özsan², Güray Saydam¹, Filiz Büyükekececi¹
¹Ege University, School of Medicine, Hematology Department, İzmir, Türkiye
²Ege University, School of Medicine, Pathology Department, İzmir, Türkiye

Introduction: Ascites is a rare complication of multiple myeloma and generally occurs because of portal hypertension due to the infiltration of liver by plasma cells. Infrequently, ascites is detected as a result of peritoneal infiltration by myeloma cells. We, hereby, present a case with sudden ascites due to peritoneal infiltration by malignant plasma cells and responded to intra-peritoneal dexametasone application.

Case: Forty-eight years old male was diagnosed with stage 2A non-secretory myeloma in December 2008 and treated with four courses of VAD. He relapsed in July 2009 and treated with bortezomib containing VCD regimen. After 8 cycles, renal failure has developed and he was undergone regular hemodialysis programme. He was followed-up with stable disease until development of abdominal distation and ascites was detected in the abdomen at May 2012. Small lymphocytes, polymorphonuclear leukocytes, mesotelial cells and atypical plasma cells were detected in cytological examination of the ascites. Bone marrow biopsy revealed persistant atypical plasma cells Patient was accepted as peritoneal infiltration of multiple myeloma and regular paracentesis was performed every other day for palliation. But ascites was refractory to regular paracentesis and forty miligrams of dexametasone was given as intraperitoneal injection after each paracentesis for 3 times. Ascites decreased and plasma cells disappeared. But, patient died due to septic shock.

Discussion: Peritoneal involvement by plasma cells is rare but it should be considered in patients with refractory ascites. When peritoneal involvement detected, intra-peritoneal dexametasone injection can be used as palliation.

Keyword: Multiple myeloma, Ascites
patients with no additional treatment following autoSCT, progression of disease was found during 2-7 months after autoSCT in 4 patients with PR and within 3-13 months in 6 patients with VGPR. Assessment of time to disease progression after autoSCT showed a duration of 15 months in patients who received DC cancer vaccine, 12 months in patients treated with thalidomide and 6 months in patients followed up without any further treatment. While time to disease progression after autoSCT were longer in DC cancer vaccine and thalidomide groups, in untreated patients was significantly shorter than DC cancer vaccine group (p<0.05). Treatment-associated side effects were observed in all patients treated with thalidomide, leading to stop of treatment in 2 patients. Side effects in DC cancer vaccine group were transient and tolerable while no stop of treatment was observed.

In conclusion, DC cancer vaccine was demonstrated to be safe and effective as a maintenance treatment following autoSCT in MM cases and it is suggest that utilization of new cytokines and adjuvants in formulation of cancer vaccine and reduction of T regulatory cells (Treg) will be able to provide more improvement in efficacy.

**Keyword:** multiple myeloma, cancer vaccine

---

**THE COINCIDENCE OF THREE SOLID TUMORS IN A PATIENT WITH MULTIPLE MYELOMA: A RARE CASE**

Muzaffer Keklik1, Serdar Sivgin1, Kemal Deniz2, Halit Karaca3, Ölgün Kontaş4, Süleyman Balkanlı5, Celalettin Eroğlu6, Ümmühan Abdülbrezak6, Gülfügan Kuzu6, Leylagül Kaynar1, Mustafa Çetin1, Ali Ünal1, Bülent Eser1

1Erciyes Stem Cell Transplantation Hospital, Department of Hematology, Kayseri, Turkey
2Erciyes University, Department of Pathology, Kayseri, Turkey
3Erciyes University, Department of Medical Oncology, Kayseri, Turkey
4Erciyes University, Department of Radiation Oncology, Kayseri, Turkey
5Erciyes University, Department of Nuclear Medicine, Kayseri, Turkey
6Erciyes University, Department of Internal Medicine, Kayseri, Turkey

The incidence of Multiple Primary Cancer (MPC) is very low, and it is even less common than synchronous presentation of a solid tumor with a hematological malignancy. The precise mechanism of MPC has remained unknown. The treatment modality should be determined using the doctor experience and close attention to the characteristics of the patient's illness and performance status. Multiple myeloma is rarely developed, although bone metastasis are commonly seen in many of the solid tumors. In this study, we presented a case diagnosed as multiple myeloma in addition to colon cancer, gastrointestinal stromal tumor and lung adenocarcinoma association; since it doesn’t exist in the literature. A 67-years old male presented to Gastroenterology Department with abdominal pain and nausea lasting for 2-3 months. A dynamic liver abdominal CT scan was performed which suggested that solid mass is consistent to liver metastasis. In the colonoscopy, an annular mass was detected at descending colon, where a biopsy was done. Sigmoid resection, metastasectomy and left hemicolectomy were performed in the patient who underwent surgery with a
Objective: Immunoglobulin (Ig)D multiple myeloma (IgD MM) is a rare subtype of myeloma, accounts for less than 2% of all myelomas. An estimate of the prevalence of IgD MM is 0.2%-0.3% of all patients having a monoclonal protein. For the last 7 years 7 cases were diagnosed as IgD MM in our laboratory. The disease is often associated with relatively high frequencies of renal failure, extraosseous disease, hypercalcemia, amyloidosis and Bence-Jones proteinuria. These patients appeared to have significantly worse survival than patients with non-IgD MM.

The IgD MM is mainly type λ, the IgD κ is rare, the predominance of λ light chains could be explained by rearrangements at the immunoglobulin genes. Bence-Jones proteinuria is almost constant in the IgD MM, and mainly type λ, reflecting excess production of light chains by plasma cells. The marrow is invaded by plasma cells in very different proportions of up to 95%. IgD MM is usually misdiagnosed as a light chain types MM by using routine laboratory examination. We present the laboratory examination characteristics of two patients to improve the recognition and reduce the mis-diagnosis of IgD MM.

Case 1: 61 years old female patient presented with expansive bone aches in January 2010. The imaging indicated multiple bone lesions. The bone marrow biopsy revealed 30% lambda monoclonal plasma cells. The serum IgD level was 160 IU/mL (reference <100). The serum immunofixation shows 2 bands on lambda column but no bands on Immunoglobulins G, A and M. On urine immunofixation one of them was found. Further IgD and IgG specific immunofixation test performed and a paraprotein band was found on IgD column.

Case 2: 61 years old female patient presented with abdominal pain, nausea, lumbar ache and fatigue. Laboratory findings were consistent with acute renal failure. Increased lambda light chains in the serum (3390mg/L) and urine (266mg/L) were reported in the serum and urine. Regarding the monoclonal band in the serum protein electrophoresis (SPE) bone marrow biopsy performed and indicated IgD/lambda myeloma, with a 45% of atypical plasma cells.

Conclusion: IgD monoclonal protein is not easy to be detected owing to its low protein level. It is resulting in missed diagnosis particularly when low homogeneous band on electrophoresis goes unnoticed for an inexperienced eye or when immune serum anti-IgD was not used during the immunotyping.

Because of indistinct clinical presentation of IgD Myeloma, its laboratory diagnosis is important. It may not be easy to recognize a faint band on SPE. With immunofixation if a band only appears on light chain columns, a urine immunofixation must be performed to rule out the diseases with monoclonal free light chain. An Immunofixation electrophoresis using Anti-IgD serum which is highly sensitive and specific for diagnosis of IgD MM, enhance accuracy of diagnosis for this rare disease.

**Keyword:** Immunoglobulin D, Multiple myeloma

---

**Figure 1.** Pathological figures. (a) Neoplastic tissue composed of adenoid structures infiltrating the intestinal wall (H&E staining,x40). (b) Palisading spindle cells in gastrointestinal stromal tumor (inset showing CD17 positivity in neoplastic cells) (H&E staining,x10). (c) Trucut biopsy of the lung showing neoplastic adenoid structures (inset showing TTF1 positivity) (H&E staining,x200). (d) Bone marrow biopsy showing neoplastic infiltrating of plasma cells (inset showing CD138 positivity) (H&E staining,x00).

**ABSTRACTS**

**Poster No: 0070 Abstract:0155**

**RECOGNITION OF IMMUNOGLOBULIN D MULTIPLE MYELOMA: CASE REPORT AND SHORT REVIEW**

Cagatay Kundak¹, Murat Özbalak², Serdar Ornek³, Ahmet Burhan Ferhanoglu¹, Yahya Rauf Laleli¹

¹Duzen Laboratories Group, Ankara, Turkey

²Istanbul University Cerrahpasa Medical School, Internal Medicine, Istanbul, Turkey

³VKV American Hospital, Istanbul, Turkey

**Objective:** Immunoglobulin (Ig)D multiple myeloma (IgD MM) is a rare subtype of myeloma, accounts for less than 2% of all myelomas. An estimate of the prevalence of IgD MM is 0.2%-0.3% of all patients having a monoclonal protein. For the last 7 years 7 cases were diagnosed as IgD MM in our laboratory. The disease is often associated with relatively high frequencies of renal failure, extraosseous disease, hypercalcemia, amyloidosis and Bence-Jones proteinuria. These patients appeared to have significantly worse survival than patients with non-IgD MM.

The IgD MM is mainly type λ, the IgD κ is rare, the predominance of λ light chains could be explained by rearrangements at the immunoglobulin genes. Bence-Jones proteinuria is almost constant in the IgD MM, and mainly type λ, reflecting excess production of light chains by plasma cells. The marrow is invaded by plasma cells in very different proportions of up to 95%. IgD MM is usually misdiagnosed as a light chain types MM by using routine laboratory examination. We present the laboratory examination characteristics of two patients to improve the recognition and reduce the mis-diagnosis of IgD MM.

**Case 1:** 61 years old female patient presented with expansive bone aches in January 2010. The imaging indicated multiple bone lesions. The bone marrow biopsy revealed 30% lambda monoclonal plasma cells. The serum IgD level was 160 IU/mL (reference <100). The serum immunofixation shows 2 bands on lambda column but no bands on Immunoglobulins G, A and M. On urine immunofixation one of them was found. Further IgD and IgG specific immunofixation test performed and a paraprotein band was found on IgD column.

**Case 2:** 61 years old female patient presented with abdominal pain, nausea, lumbar ache and fatigue. Laboratory findings were consistent with acute renal failure. Increased lambda light chains in the serum (3390mg/L) and urine (266mg/L) were reported in the serum and urine. Regarding the monoclonal band in the serum protein electrophoresis (SPE) bone marrow biopsy performed and indicated IgD/lambda myeloma, with a 45% of atypical plasma cells.

**Conclusion:** IgD monoclonal protein is not easy to be detected owing to its low protein level. It is resulting in missed diagnosis particularly when low homogeneous band on electrophoresis goes unnoticed for an inexperienced eye or when immune serum anti-IgD was not used during the immunotyping.

Because of indistinct clinical presentation of IgD Myeloma, its laboratory diagnosis is important. It may not be easy to recognize a faint band on SPE. With immunofixation if a band only appears on light chain columns, a urine immunofixation must be performed to rule out the diseases with monoclonal free light chain. An Immunofixation electrophoresis using Anti-IgD serum which is highly sensitive and specific for diagnosis of IgD MM, enhance accuracy of diagnosis for this rare disease.

**Keyword:** Immunoglobulin D, Multiple myeloma
MULTICENTRIC EXTRAMEDULLARY INVOLVEMENT OF MULTIPLE MYELOMA

Güçhan Alanoğlu1, Süreyya Çerçi2, İhsan Karadoğan3
1Süleyman Demirel University School of Medicine Division of Hematology, Isparta, Turkey
2Süleyman Demirel University School of Medicine Department of Nuclear Medicine, Isparta, Turkey
3Akdeniz University School of Medicine Division of Hematology, Antalya, Turkey

Extramedullary disease (EMD) is an uncommon manifestation in multiple myeloma (MM) and either accompany newly diagnosed disease (15-20%) or develop with disease progression or relapse (+15%). The extramedullary disease confers a poorer prognosis. Hereby we will present a patient presented with multicentric extramedullary involvement at the presentation of MM and another one who relapsed with extramedullary disease.

Case1: 59-year-old man presented with mass after a trauma of the chest. An excisional biopsy which then revealed plasmacytoma had been performed. Bone marrow aspirate noted 70% plasma cell. The patient diagnosed with lambda light chain MM, stage 3A. Physical examination showed a 13x8 cm fix mass on the left part of the chest. PET analysis revealed obliteration of left nasal cavity with hypermetabolic massive lesion, another mass infiltrating all adjacent muscles and costas on the left chest. PET analysis revealed obliteration of left nasal cavity with hypermetabolic massive lesion, another mass infiltrating all adjacent muscles and costas on the left chest.

Case2: 61-year-old man diagnosed stage 3B lambda light chain MM in 2008 when we was on 3/7 dialysis programme. He was put on 2 cycles of VAD and then switched to PAD. On the 9th month of the therapy he had become dialysis off. We had very good response but the patient refused to be autologous transplant. Maintenance therapy with thalidomide 100 mg initiated. But he had relapsed after 10 months. Four cycles of PAD again applied. Very good response again achieved. But on the second year of the disease myeloma relapsed at the occipital part of the skull as a 5x10 cm soft tissue mass infiltrating the skull also and testicular mass. There was no increase in bone marrow plasma cells. The VRD treatment initiated. After the first month of the treatment the lesion regressed. After the 6th month of the treatment his light chain in the urine immunofixation increased. He developed urinary infection and pneumonia and had been lost because of the disease progression and sepsis.

Conclusion: EMD of MM has increased as the availability of sensitive imaging techniques. It has poor prognosis. High dose treatment regimens must be applied as a first line therapy for extramedullary disease.

Keyword: multiple myeloma, extramedullary disease
Breast Plasmocytoma on Treatment

Case: A 82-year-old female patient presented to the emergency due to impaired overall status and widespread bone pain on 19.11.2012. Upon detecting a high level of urea, creatinine level and hypercalcemia, she was admitted to the internal disease unit. As a result of the consultation requested from the hematology department, the patient was detected to have anemia, a high sedimentation level, hypercalcemia and renal failure and thus she underwent bone marrow aspiration and biopsy at our unit under the diagnosis of multiple myeloma. The bone marrow showed normocellular bone marrow, 50% plasma cell infiltration; the biopsy result was consistent with multiple myeloma. Serum and urine immunoelectrophoresis detected a high kappa light chain. Treatment with melphalan, prednisolone, and thalidomide started. Since our patient developed breast plasmocytoma while under treatment and there are no such reports in the literature, we present this case.

Discussion: Breast plasmocytomas are quite rare. The breast biopsy performed while the patient was under treatment for multiple myeloma revealed findings consistent with plasmocytoma. If the patient’s pre-treatment performance status were better, change in treatment or concomitant radiotherapy could have been administered. We presented this patient since the case occurred during the treatment course and is very rarely reported in the literature.

**Keyword:** multiple myeloma, extramedullary plasmocytomas

---

Decompensated Liver Cirrhosis

Case: The 81-year-old male patient has been diagnosed with cryptogenic liver cirrhosis 5 years ago. The patient, who presented to the emergency with the complaints of itching, abdominal swelling and confusion on 07.03.2012 was admitted to the internal diseases unit under the diagnosis of decompensated liver cirrhosis. Upon detection of normochromic normocytic anemia, hypercalcemia, high sedimentation, and a reversing of the albumin/ globulin ratio at the hematology consultation requested due to anemia and high sedimentation, an investigation of the immunoglobulins was requested; the following were detected: Ig G: 700, Ig A: 2920, Ig M: 31.2 mg/dl. The bone marrow aspiration and bone marrow biopsy detected approximately 50% plasma cell infiltration; the biopsy result was consistent with multiple myeloma. Serum and urine immunoelectrophoresis detected a high kappa light chain. Treatment with melphalan, prednisolone, and thalidomide started. Since our patient developed breast plasmocytoma while under treatment and there are no such reports in the literature, we present this case.

Discussion: The association of multiple myeloma and decompensated liver cirrhosis is reported very rarely in the literature. While ascites is a very rare complication of multiple myeloma, most of the cases are associated with IgA type myeloma. Our patient also had IgA multiple myeloma. Development of ascites through peritoneal infiltration of the myeloma cells is less common. In cases of myeloma-associated liver, liver function test the upper respiratory tract and gastrointestinal tract, they may also occur in the bladder, central nervous system, testicles, parathyroid, lymph nodes, thyroid, breasts and the skin. While the primary plasmocytomas are generally of good prognosis, plasmocytomas that are secondary to the myeloma progression are aggressive. Breast plasmocytomas are quite rare. The breast biopsy performed while the patient was under treatment for multiple myeloma revealed findings consistent with plasmocytoma. If the patient’s pre-treatment performance status were better, change in treatment or concomitant radiotherapy could have been administered. We presented this patient since the case occurred during the treatment course and is very rarely reported in the literature.

**Keyword:** multiple myeloma, extramedullary plasmocytomas
abnormalities may be more common. While infiltration of the liver by the plasma cells may also occur, the patients are mostly asymptomatic clinically. Myeloma may very rarely manifest with findings of acute liver disease; findings of liver failure may be observed in this period.

Before the consultation, normochromic normocytic anemia, high sedimentation and the reversing of the albumin globulin ratio were attributed potentially to the liver cirrhosis, and the patient was not investigated for multiple myeloma. This case was presented since detection of IgA type multiple myeloma in this patient, who has had cryptogenic decompensated liver cirrhosis for the last 5 years, was very rare

**Keyword:** multiple myeloma, liver cirrhosis

---

**PLEURAL EFFUSION FORMATION IN THE COURSE OF MYELOMA**

Mahmut Töbü, Melda Çömert, Soner Gürsoy, Mine Hekimgil

1. Ege University, School of Medicine, Hematology Department, İzmir, Türkiye
2. Saúde Seren Research Hospital, Pulmonary Medicine Department, İzmir, Türkiye
3. Ege University, School of Medicine, Pathology Department, İzmir, Türkiye

**Introduction:** Pleural effusion is a rare complication of multiple myeloma. The most common type of Immunoglobulin in myelomatous pleural effusion is IgA. We present a case with sudden onset pleural effusion due to infiltration of pleura by malignant plasma cells.

**Case:** Sixty-two years old male was diagnosed with stage IA, Ig G-kappa myeloma in June 2010 and was treated with two courses of bortezomibe in another hospital. 13q del was negative in cytogenetic examination. Autologous hematopoietic stem cell transplantation was performed at September 2010. He was treated with 50 mg/day cyclophosphamide as maintenance therapy and applied to our hospital. Multiple bilateral rib fractures, splenomegaly, hepatomegaly and a 3,5x2.5 cm soft tissue mass in the apical of right hemitorax and pleural thickness in left hemitorax was occured in August 2012. After 3 courses of revlimide 25 mg/day and dexametasone 40 mg (12 days/ cycle), bortezomibe was added to the treatment. After two courses of combination therapy, thorax computerized tomography revealed 68x44 mm irregular shaped soft tissue mass in the apikal of right hemitorax and pleural thickness in left hemitorax at November 2012. Small lymphocytes, polymorphonuclear leukocytes, mesotelial cells and atypical plasma cells were detected in cytological examination of the pleural effusion.

**Conclusion:** Pleural effusion can be seen almost 10% in myeloma patients. Plasmatic cell involvement is extremely rare but it should be considered in patients with pleural effusion. The extramedulller complications of MM are usually unresponsive to conventional chemotherapy and rapidly fatal with a median survival of 3 months. Thus, more aggressive chemotherapy regimens may be indicated in myeloma with involvement of pleural cavities.

**Keyword:** Multiple Myeloma, Pleural Effusion
ABSTRACTS

310

4th International Congress on Leukemia – Lymphoma – Myeloma

ABSTRACTS

310

4th International Congress on Leukemia – Lymphoma – Myeloma

ABSTRACTS

310

4th International Congress on Leukemia – Lymphoma – Myeloma

Poster No: 0078

Abstract:0215

**Bortezomib related reversible cerebellar ataxia**

Güldane Cengiz Seval¹, Fahrettin Ege², İşın Ünal Çevik², Meltem Aylı¹

¹Ufuk University Faculty of Medicine Department of Hematology
²Ufuk University Faculty of Medicine Department of Neurology

Introduction: Bortezomib is a proteasome inhibitor effective in the treatment of multiple myeloma. The drug may induce an axonal neuropathy. We here present a case of standard dose bortezomib-related severe cerebellar ataxia.

Case: In December 2011, this 62-year-old man received a diagnosis of multiple myeloma IgGκ. At the same time, he was diagnosed with the alcoholic cirrhosis, therefore off-label approval bortezomib therapy was administered at the dose of 1.3 mg/m²/day 1, 4, 8 and 11.days with 40 mg/day dexamethasone on the same and next day of bortezomib. On the 8th day of 2 cycles of bortezomib/dexamethasone (VD) combination therapy, the patient began to complain of difficulty in walking, pain in his legs and gait unsteadiness. In his first neurological examination, a marked dysmetria in four extremities with dysdiadochokinesia and intentional tremor in upper limbs were present. Patient was severely ataxic. Cranial MRI yielded normal findings. Nerve conduction studies and needle EMG have not revealed any pathological data. Based on these findings we concluded that the bortezomib therapy may engender a cerebellar ataxia. Bortezomib was discontinued; 30 days after, a dramatical improvement in neurological findings was detected that the patient was able to walk a short way without crutches.

Discussion: Bortezomib is a proteasome inhibitor beneficial in treatment of multiple myeloma. Bortezomib may cause mainly a sensory, painful, axonal, dose-related neuropathy which worsens through the treatment cycles and is often reversible after drug dose reduction or discontinuation. At best of our knowledge, there is only one report describing a sensory ataxia associated with high dose bortezomib neuropathy. In current case however, we here describe a standard dose bortezomib-induced cerebellar ataxia which is reversible with drug discontinuation.

**Keyword:** bortezomib, cerebellar ataxia

---

**Poster No: 0079**

Abstract:0231

**Elevated Serum Thymidine Kinase Levels (TK1) May Identify Patients at high Risk of Disease Progression in newly Diagnosed Multiple Myeloma**

Tuğrul Elverdi¹, Sonay Temurhan², Emre Osmanbaşoğlu³, Sebahat Usta Akgül², Filiz Aydin², Meliha NaLCarı¹, Sevgi Kalayoglu Beşışık¹

¹Istanbul University, Cerrahpasa Medical Faculty, Hematology, Istanbul- Turkey
²Istanbul University, Istanbul Medical Faculty, Medical Biology, Istanbul- Turkey
³Istanbul University, Istanbul Medical Faculty, Hematology, Istanbul- Turkey

Objective: Multiple myeloma (MM) shows a remarkably heterogeneous biological and clinical outcome which affect survival ranges from a few years in advanced stages to 10 years. The DS and IPS staging systems distinguish...
some prognostic subgroups. More accurately cytogenetic aberration and microRNAs are important factors in anticancer drug activity and resistance and may predict the individual risk of disease progression for newly diagnosed MM. Thymidine kinase (TK) is the enzyme which catalyzes deoxythymidine phosphorylation before incorporation in DNA and supports DNA synthesis under conditions of increased cell proliferation. In clinical chemistry it is used as a proliferation marker in the diagnosis, control of treatment and follow-up of malignant disease, mainly of hematological malignancies. Little is known about the prognostic significance of TK1 activity in MM. This study aimed to assess the prognostic value of as a simple test, the serum TK (s-TK) in previously untreated symptomatic MM patients.

Methods: TK1 activity was measured by means of ELISA (Biovica, Sweden). Measurements were performed prospectively at diagnosis in 53 consecutive MM patients. 47 healthy volunteers were also included as a control group. The clinical significance were assessed according to the stage.

Results: The mean TK1 level in the study group was significantly higher than the controls (respectively 8532,09±22 1099,59 vs. 10143,81±11030,70; \( p<0.001 \)). TK1 level did not change according to the age. TK1 activity levels in advanced stages were higher. TK levels in patients having 13th chromosom abnormality seemed to be higher compared who did not have the abnormality (22125,50±1307,44 vs 129940,12±299772,67) which was not statistically significant.

Conclusion: The results demonstrate that TK1 may add an independent prognostic information to the definitions of clinical outcome of MM among staging. In addition, evaluation of TK1 levels can be a valuable simple test for monitoring maintenance of response and may identify biologically aggressive disease at early stages.

Keyword: multiple myeloma, thymidine kinase

MULTIPLE MYELOMA AND GIOBLASTOMA MULTIFORME COMMUNITY; A CASE REPORT

Selda Kahraman1, Firuzan Çağar Doğer2, Özlem Erdal Özdemir2
1Hematology Clinic, Aydın State Hospital, Aydın, Turkey
2Department of Pathology, Adnan Menderes University Hospital, Aydın, Turkey

Glioblastoma multiforme (GBM) is the most malignant astrocytum tumour that can be multifocal, is usually supratentorial localized, can intensively infiltrate to peripheral tissues. A case will be presented in which GBM was thought to be available in the right frontal area during chemotherapy treatment owing to multiple myeloma and mass lesion was followed. A 74 year-old female patient applied to physical therapy polyclinic with low back pain, weakness and fatigue complaints was evaluated due to sedentimation and CRP elevation at Hematology Polyclinic on September 2012. The patient values were as follows: hb.7.2 g/dl, hct 22.1%, MCV.75 Fl, leucocyte 4330, thrombocyte 68000, creatinine 0.7 mg/dl, ferritin 580 ng/ml, sedimentation 148 mm-hour, Ca. 11.5 mg/dl, Ig A 6684mg/dl. Ig A kappa monoclonal gammopathies were determined in her serum immunofixation, >680 plasma cell proliferation was observed in the bone marrow aspiration and biopsy, the case was assessed as Multiple Myeloma. Owing to the imagings carried out, the patient in whom there were lytic areas in all bones and collapse fracture in the L2,L4,L5 vertebrae was evaluated as Durie Salmon stage 3A Multiple myeloma. Radiotherapy was performed in lumbar region on account of low back pain and then MPV treatment was initiated. During the 2nd cure of MPV treatment, a severe headache developed in the patient accompanied by nausea and vomiting. Around the 47 mm area in the right frontoparietal region, mass lesion occupying an environmental contrast was observed in the cranial MR and the patient was evaluated by neurology and neurosurgery. Antiedema treatment was commenced, however, no biopsy could be performed on the tissue by taking into consideration patient’s performance and accompanying comorbid cardiovascular disease. Cranial radiotherapy was applied to the patient as palliative. MPV chemotherapy of the patient schema was continued after radiotherapy. The patient for whom VGPR response was obtained following two cure treatments had a generalized tonic-clonic seizure attack in the follow-up. In the cranial MR two months after the radiotherapy, mass progressed to 9 cm and caused a 2 cm shift from midline to left and developed a severe edema around it. Antiedema treatment was initiated again. The patient whose condition was deteriorated and consciousness was lost developed respiratory failure and then cardiac arrest and died.

As a conclusion; GBM is seen as an irregular restricted mass around which is edematous, binding contrast and in the middle of which has necrotic cavity. The localization of tumor in our case was evaluated as GBM when its radiological appearance, its fast progression despite radiotherapy and the clinical condition of the patient were taken into consideration. In patients with multiple myeloma, plasmocytoma determined within mass lesions in brain and also GBM, the most common malignant brain tumor in adults, should be considered.

Keyword: glioblastoma multiforme, multiple myeloma

CYTOGENETIC ANALYSES IN TURKISH PATIENTS WITH MULTIPLE MYELOMA

Engin Kelkitli1, Hilmi Atay2, Elif Akyazi5, Günel Ogur5, Nil Güler3, Düzgün Öztatlı3, Mehmet Turgut1
1Erzurum Regional Training And Research Hospital
2Van Regional Training And Research Hospital
319 Mayis University Medical School Department of Hematology, Samsun Turkey
419 Mayis University Medical School Department of Genetic, Samsun Turkey
519 Mayis University Medical School Department of Internal Medicine, Samsun Turkey

Multiple Myeloma is a clonal disorder characterized by accumulation, and proliferation of plasma cells and secretion of monoclonal immunoglobulin. Genetic abnormalities is quite important in multiple myeloma in terms of showing the prognosis such as in hematologic malignancies. In recent years, many recurrent genetic abnormalities have been reported by the conventional cytogenetic and molecular cytogenetic studies in MM. In this study we aimed to determine the incidence of chromosomal anomalies by interphase FISH and conventional chromosome analysis in MM patients that are followed and treated in 19 Mayis University of Hematology Department.
Material-Method: A total of 53 patients with a diagnosis of multiple myeloma classical cytogenetic and molecular cytogenetic (FISH) analyzes were evaluated. Demographic data and the results of FISH analysis are shown in Table 1 and 2.

Results: Conventional cytogenetic analysis of the cases could be performed in 31 of 53 patients and in 24 cases (45.3%) with normal karyotype, 3 cases (5.7%), chromosome aberrations, and in 1 patient hypodiploidy and in 1 case complex anomalies were observed. FISH analysis of the cases, 30 patients (56.6%) had normal results and at least one abnormality was observed in 43.4% of cases (23/53). 30.3% of the cases (16/52) chromosome 13 aberrations have been observed.

Conclusion: Recent studies have shown that the identification of genetic factors, is important in diagnosis, etiopathogenesis, prognosis, and the decision of treatment protocols. For this reason, we think that in the use of treatment and prognosis of MM cases conventional cytogenetic and especially FISH are significant methods.

Key word: Cytogenetic Analyses, Multiple Myeloma

Table 1. Demographic data of patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>53</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>62 (35-85)</td>
</tr>
<tr>
<td>Sex</td>
<td>Male 25 (52.8%), Female 28 (47.2%)</td>
</tr>
<tr>
<td>M protein Type</td>
<td>IgG Kappa 18 (34%), IgA Kappa 11 (20.8%), IgG Lambda 9 (17%), Kappa or Lambda 15 (28.3%)</td>
</tr>
<tr>
<td>ISS stage</td>
<td>ISS stage I: 6 (11.4%), ISS stage II: 27 (50.9%), ISS stage III: 20 (37.7%)</td>
</tr>
</tbody>
</table>

Table 2. FISH analyses of patients

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>del13q14-del13q34</td>
<td>10  18.9</td>
</tr>
<tr>
<td>del13q14</td>
<td>1  1.9</td>
</tr>
<tr>
<td>del13q34-del13q11</td>
<td>1  1.9</td>
</tr>
<tr>
<td>del13q34</td>
<td>2  3.8</td>
</tr>
<tr>
<td>del1q32</td>
<td>1  1.9</td>
</tr>
<tr>
<td>del6q</td>
<td>1  1.9</td>
</tr>
<tr>
<td>hyperdiploidy</td>
<td>1  1.9</td>
</tr>
<tr>
<td>monoclonal Lambda</td>
<td>1  1.9</td>
</tr>
<tr>
<td>Normal</td>
<td>30  56.6</td>
</tr>
<tr>
<td>Trisomy11</td>
<td>2  3.8</td>
</tr>
<tr>
<td>Trisomy11 del13q</td>
<td>1  1.9</td>
</tr>
<tr>
<td>Total</td>
<td>53  100.0</td>
</tr>
</tbody>
</table>

Poster No: 0082

A CASE OF MULTIPLE MYELOMA DIAGNOSED BY PLEURAL INVOLVEMENT

Funda Pependil Tanrikulu, Ali Eser, Burcu Sanlam, Cafer Adiguzel, Işık Kaygusuz Atagündüz, Güven Yılmaz, Bülent Kantarcıoğlu, Tülin Fıratlı Tuğlular

Marmara University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey

Background: Multiple myeloma is a malign disease characterised by neoplastic proliferation of plasma cells and monoclonal immunoglobulin synthesis. The clinical manifestations are due to the infiltration of bone and bone marrow by plasma cells or renal injury caused by light chains. Extramedullary plasmacytomas can be seen in %7 of patients at the time of diagnosis, however pleural involvement is extremely rare and if present, it is usually together with progressive disease.

Aim: We aimed to present a case of multiple myeloma who presented with myelomatous pleural effusion.

Methods: Case presentation

Results: Sixty-five year-old female patient was admitted due to back pain. Physical examination revealed decreased respiratory sounds on the left side and there was opacity on the chest X-ray compatible with pleural effusion. Thoracentesis resulted in exudative effusion, while cytological examination showed atypical malign cells. Pleural biopsy was performed and neoplastic infiltration of plasma cells were seen on the specimen. Laboratory examination revealed hemoglobin 7.7 g/dL, hematocrite 22%, creatinine 0.6 mg/dL, calcium 8.2 mg/dL, albumin: 2.1 g/dL, LDH: 280U/L, IgG:69 g/L, IgM:0.1 g/L, IgA:0.2 g/L and there was monoclonal IgG kappa on serum immunofixation electrophoresis. With the diagnosis of multiple myeloma we performed bone marrow biopsy and found infiltration of plasma cells. Bone X-ray showed compression fracture of the vertebra and palliative radiotherapy was given for back pain. After radiotherapy the patient was hospitalised for chemotherapy including vincristine, adriamycin and dexamethasone. Before chemotherapy because of respiratory distress torax tube was placed. On the third day of treatment, chemotherapy was interrupted due to fever. Cultures resulted in staphylococal infection of lung and antibiotic was prescribed. After antibiotherapy pleurectesis with bleomycin was done. After all, the patient was no more candidate for autologous transplantation and treatment with bortezomib, melphalan and prednisolone (VMP) was started. After 3 cycles of chemotherapy, M protein was negative and there was no new lesion on the chest X-ray. This patient is still on therapy with VMP protocol and the follow-up is in the outpatient clinic.

Conclusion: Pleural effusion is a rare complication during the course of myeloma and various conditions may be the cause: nephrotic syndrome, pulmonary emboli, amyloidosis, heart failure, etc. On the other hand, malignant effusion because of pleural involvement is very rare (<%1) which is usually together with advanced diseases indicating poor prognosis. There are a few case reports in the literature like our case who is presenting with myelomatous effusion, however our case is unique because the disease has responded to chemotherapy and the patient is still alive.

Key word: multiple myeloma, pleura

Keywords: pleural effusion, multiple myeloma
Mental Nerve Neuropathy as First Manifestation of Plasmacytoma with Breast Involvement Followed by Overt Recurrent Myeloma

Emre Osmanbaşoğlu1, İpek Yöнал1, Alp Saruhanoglu2, Sevgi Kalayoglu Beşişik1, Istanbul University, Istanbul Medical Faculty, Division of Hematology, Istanbul, Turkey
2Istanbul University, Faculty of Dentistry, Dental/Mouth/Jaw-Surgery, Istanbul, Turkey

Objective: A rare case of multiple myeloma (MM) was reported which was diagnosed from an intraoral gingival lesion on the lower mandible following mental nerve neuropathy related neuralgic symptoms characterized by hypoesthesia, paresthesia or anesthesia of the skin of the chin and lower lip, limited to the region served by the mental nerve. Extramedullary disease in MM occurs mostly in advanced disease or relapse. Outcome is poor and prognostic factors predicting the development of extramedullary disease have not been defined. Primary extramedullary plasmacytomas (EP) are generally pursuing an indolent clinical course but may, rarely, convert to overt MM.

Methods: A 34-year-old woman was presented with numbness in the jaw. Panoramic radiography examination revealed a moth-eaten shape, and radiolucent appearance. Biopsy of the lesion revealed plasmacytic infiltration. During evaluation for occult disease, a right breast lesion with axillary lymph node involvement was documented suspecting metastatic breast tumor. Initial workup discovered multiple lytic bone lesions, liver involvement and anemia. Biopsy of the breast mass and bone marrow displayed plasmacytoid/plasmablastic cells, expressing high percentage Ki-67 antigen. Conventional karyogram showed multiple cytogenetic aberrations including 13q deletion. Immunofixation studies showed serum IgG,kappa positivity. As having MM staged DSIIIA, ISSII, bortezomib and dexamethasen (VD) with zoledronic acid was started which was complicated by increased paraprotein level and long bone fracture of large lytic lesions. Surgical reconstruction was instituted. Treatment was changed as adding cyclophosphamide (Cy) and radiotherapy to involved bones. She rapidly achieved nearly complete response after 4 courses of VAD, zoledronic acid and radiotherapy. High dose vepevid and G-CSF were used as mobilization. She underwent ASCT provided donor hematopoiesis but persistence of autologous peripheral blood stem cell transplantation. Five months after transplantation she developed swelling on multiple sites of scalp. Biopsy of the lesions consisted of monoclonal plasma cells. A bortezomib based combination chemotherapy was used for tumor cell debulking. A rapid response was followed by disease progress as emerging EP on different regions including the presentation site, right breast. She has no donor. Results: Salvage therapy as different type’s chemotherapy was always terminated by short duration of response and aggressive progression. She is still alive since 3 years and experienced tumor lysis syndrome after bendamustine which again showed high tumor proliferation rate.

Conclusion: Nearly all body regions can be involved by EP. The prognosis is very poor once the diagnosis of EP is concurrent with MM. Mental nerve neuropathy may be forerunner to malignancy progression and relapse, but it may also precede the diagnosis of cancer. In adults, metastatic breast cancer (64%) and lymphoproliferative disorders (14%) account for most cases can mimic each other as in our case.

Keyword: plasmacytoma, oral cavity

Plasmacytoma of the jaws

Figure 1. Panoramic radiography examination revealed a moth-eaten shape, and radiolucent appearance.

A Unique Transformation in Plasma Cell Myeloma Following Autologous Stem Cell Transplantation, Further Treated with Allogeneic Stem Cell Transplantation

Sevgi Kalayoglu Besisik1, Sebnem Izmir Guener3, Gulven Cetin2, Filiz Aydin1, Ozden Ozer1
1Istanbul University, Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey
2Private Bahcelievler MedicalPark Hospital, Adult Bone Marrow Transplantation Unit, Istanbul, Turkey
3Bezmialem Vakif University, Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey
4Istanbul University, Istanbul Medical Faculty, Department of Medical Biology, Istanbul, Turkey
5Bilim University, Florence Nightingale Hospitals, Department of Hematopathology, Istanbul, Turkey

Objective: Herein, we report a unique transformation process of plasma cell myeloma that developed following autologous stem cell transplantation (ASCT). Allogeneic SCT provided donor hematopoiesis but persistence of myeloma with dedifferentiated morphology. This transformation with its unusual clinical, morphologic and immunophenotypic characteristics, may be the result of reemerging aggressive biology. Method: A 46-year-old woman with MM (IgG, kappa, DSIIIB, IPSS:III) achieved complete remission after 4 courses of VAD, zoledronic acid and radiotherapy. High dose vepeside and G-CSF were used as mobilization. She underwent ASCT following high dose melphalan.

Results: On 11th month of ASCT, she complained of severe generalized bone pain, skin and mucosal bleeding and rapid onset constitutional symptoms. A gross hepatosplenomegaly with pancytopenia, increased serum beta2microglobulin, IgG, kappa levels, and laboratory data consistent with DIC were documented. PET-CT
confirmed multiple bone lesions and hepatosplenomegaly. Bone marrow examination revealed morphologically very heterogenous infiltrate. The cellular spectrum comprised cells ranging from plasmablasts, to monoblast like cells and more primitive cells reminiscent of myeloblasts. By immunohistochemistry, the cells were uniformly and strongly CD138(+) supporting plasma cell origin. Flow-cytometry showed that the cellular composition widespread expressed myeloid markers (CD117+, CD33+, CD13+, CD15+) also. High dose steroid was started as tumor cell reduction and allogeneic transplantation was decided. Her brother was found to be HLA full-matched. She directly underwent SCT after conditioning with fludarabine and melphalan. Leukocyte engraftment was noted within the first month followed by late developed thrombocyte engraftment. The bone marrow at that point showed persistent neoplastic infiltration on the trephine biopsy while FISH analysis on the hemodilute aspirate proved to be 100% XY. Immunsuppressive treatment was tapered. Gradually red blood cell and trombocyte transfusion need was ceased.

Conclusion: It has been known for decades that extended therapy with alkylating chemotherapy agents, such as melphalan, carries an increased risk of therapy-related myelodysplastic syndrome and/or AML. The typical secondary leukemias after MM show aggressive behavior and all patients on follow-up die within a period of one month. For our case, we avoided to call the transformation process as AML since diffuse and strong CD138 positivity namely regarded as a reliable plasma cell marker. In the era of emerging novel drugs with allo- geneic SCT provided cellular immunotherapy, the eradication of the clones were planned.

**Keyword:** plasma cell, undifferentiated Bone marrow morphology

---

**Figure 1.** Bone marrow examination revealed morphologically very heterogenous infiltrate; plasmablasts, monoblast like cells and more primitive cells reminiscent of myeloblasts

---

**Poster No: 0085**

**Abstract:0280**

**A CASE OF MULTIPLE MYELOMA WITH PLASMACYTOMA IN THE LIVER AND MYELOMATOUS ASCITES**

Ali Esar, Funda Pepedi Tanrikulu, Çafer Adığüzêl, İşık Kaygusuz Atâgündûz, Güven Yılmaz, Bülent Kantarcıoğlu, Tülin Fırat Tuğlular

Marmara University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey

Extraduillary infiltration of multiple myeloma (MM) is relatively frequent in the autopsy series (670), however clinical manifestations before death are rarely seen. Considering liver involvement diffuse hepatic infiltration is common, while the nodular form as liver plasmocytoma is extremely rare. If present, plasmocytoma in the liver is associated with aggressive disease and indicates poor prognosis despite intensive treatment. On the other hand, ascites is an unusual complication of multiple myeloma and myelomatous ascites due to peritoneal infiltration of malign plasma cells is very rare. Most of the reported cases are Ig A type MM and these patients are reported to have Ig A paraproteinemia without bone abnormalities which is a different clinical entity.

Our case is a 51 year-old female patient. She was diagnosed with multiple myeloma 1 year ago and autologous stem cell transplantation was performed after 2 cycles of chemotherapy including vincristine, adriamycin, dexamethasone which was preceding 4 cycles of chemotherapy including bortezomib and dexamethasone. Six months after transplantation she was admitted because of neck swelling and icterus. Biopsy of the mass in the neck revealed plasmocytoma. Concurrently, two masses in the liver was detected by computed tomography and the biliary tract proximal to these masses were found to be dilated. Laboratory examination was as follows: Hgb 10.9, wbc 5900, trombosit 227000, AST 255, ALT 472, ALP 709, GGT 458, total bilirubin 7.9, direct bilirubin 7.1. Serum protein electrophoresis showed M spike and there was Ig A lambda in the immunofixation electrophoresis. After 4 cycles of chemotherapy with bortezomib and dexamethasone partial remission was achieved, however progression developed soon after 5th cycle. Biopsy from the mass in the liver revealed plasmocytoma and radiotherapy was initiated. After a short period of partial regression, abdominal distention due to ascites was evolved. There were atypical plasma cells on the microscopic examination of the ascites, therapy with lenalidomide was started, but patient was lost shortly after.

Amyloid deposition and biliary obstruction by plasmocytoma of the pancreas or biliary tract may result in liver dysfunction in MM. On the other hand, involvement of the liver by diffusely infiltrating malign plasma cells or in the form of plasmocytoma may also rarely occur. Ascites in multiple myeloma may be due to heart failure, renal disease, portal hypertension, infectious peritonitis and rarely because of liver infiltration or peritoneal infiltration by neoplastic plasma cells. In the literature, there are reported MM patients with liver involvement or myelomatous ascites, however there is no reported case having both together. Our case is unique, since liver plasmocytoma is seen together with myelomatous ascites.

**Keyword:** liver plasmocytoma, myelomatous ascites
MACROPHAGES AS AN ABUNDANT COMPONENT OF MYELOMA MICROENVIRONMENT: A CASE REPORT

Hülya Öztürk Cazılıoğlu1, Rıdvan Ali2
1Department of Pathology, Uludag University School of Medicine, Bursa, Turkey
2Department of Internal Medicine, Division of Hematology, Uludag University School of Medicine, Bursa, Turkey

Introduction: Multiple myeloma (MM) is a malignant B-cell tumor characterized by proliferation of monoclonal plasma cells in the bone marrow. MM remains an incurable disease. One of the major problems is that myeloma cells develop drug resistance on interaction with bone marrow stromal cells. Tumor associated macrophages are one of these stromal cells. Macrophages found in bone marrow may be preventing MM cell death.

Case: A 56-year-old woman presented with fatigue. Physical examination, imaging studies and laboratory investigations revealed anemia, trombocytopenia and splenomegaly. Bone marrow trephine biopsy was performed. Bone marrow was heavily infiltrated with monocytic Kappa expressing neoplastic plasma cells accompanied by benign appearing macrophages partly obscuring the neoplastic component. Immunohistochemically macrophages expressed CD68 antigen and lacked S-100 and CD1a. The patient was treated with 2 cures of VAD followed by 2 cures of Veldex chemotherapy. After completion of therapy, a control bone marrow trephine biopsy was performed. The time interval between the two marrow trephine biopsies was five months. Bone marrow was still infiltrated by neoplastic plasma cells and accompanying macrophages and the percentage of involvement was not significantly reduced.

Conclusion: We report a myeloma case heavily infiltrated by benign appearing macrophages. Neoplastic infiltration was continuing after the completion of the chemotherapy. Macrophages found in bone marrow may be keeping MM cells from dying. Myeloma-macrophage relationship should be investigated to determine their role in supporting myeloma growth because this information may provide additional potential opportunities for the development of novel approaches to myeloma therapy.

Keyword: myeloma, macrophage

Myeloproliferative Disorders

Poster No: 0087 Abstract:0109
BLASTIC PHASE CHRONIC MYELOID LEUKEMIA SUCCESSFULLY TREATED WITH RE-ALLOGENEIC STEM CELL TRANSPLANTATION FROM SAME DONOR
Omür Gökmen Sevindik, İnci Alacacioglu, Abdullah Katgi, Şerife Medeni Solmaz, Celal Acar, Özden Pişkin, Mehmet Ali Ozcan, Fatih Demirkiran, Bülent Ündar, Güner Hayri Özsan
Dokuz Eylül University Department of Hematology, İzmir

We report a challenging case with blastic phase chronic myeloid leukemia (cml) and treated with re-allogeneic stem cell transplantation with the same donor after 10 years from the previous one.

A 31-years-old male patient was first diagnosed as chronic phase cml in 2002 and treated with allogeneic stem cell transplantation from the full HLA matched brother. After transplantation he was followed up for a period of 5 years with remission. On May 2007 he relapsed with chronic phase cml. He did not respond to donor lymphocyte infusion (DLI) and was put on to imatinib therapy. While receiving imatinib, he achieved complete hematologic, cytogenetic and major molecular response. However, in 2010 he progressed to the accelerated phase and was put on to nilotinib therapy. While receiving nilotinib he could achieved complete hematologic response, complete cytogenetic response but could never achieved major molecular response. The mutation analysis revealed no T315I mutation, and cytogenetic analysis showed no additional chromosomal abnormality. At the 6th month of nilotinib therapy, because of insufficient molecular and cytogenetic response, nilotinib was stopped and he had switched to dasatinib therapy. While receiving dasatinib therapy he achieved partial cytogenetic response at 6 months of therapy. He admitted with increased leukocyte count and peripheral smear revealing blastic cells at the 10th month of dasatinib therapy. Bone marrow aspiration showed 35% blastic cells with myeloid morphology. Immediately he was hospitalized and 7+3 AML induction regimen was initiated. Remission was achieved, unrelated hstc was offered but the patient refused. Finally stem cells from his brother, who was his previous donor, were reinfused. After leukocyte and trombocyte engraftments achieved he was discharged at the 28th day of reinfusion. After transplantation his BCR-ABL IS values decreased dramatically (Table 1). Full donor chimerism was achieved. He is now on 138th day of reinfusion and is followed up with complete hematologic, complete cytogenetic and significant molecular response.

With imatinib and second line tyrosine kinase inhibitors the need for stem cell transplantation has decreased significantly. But still it is an option in patients who are resistant to tyrosine kinase inhibitors. Our patient is a good candidate for novel TKI inhibitors like ponatinib regarding not yet achieved major molecular response after transplantation. We planned to apply to the ministry of health to access the aforementioned drug.

Keyword: cml, allogeneic stem cell transplantation

Table 1. BCR-ABL IS values before and after transplantation

<table>
<thead>
<tr>
<th>Time</th>
<th>BCR-ABL IS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to stem cell transplantation</td>
<td>399,16</td>
</tr>
<tr>
<td>3 weeks after stem cell transplantation</td>
<td>3,89</td>
</tr>
<tr>
<td>2 months after stem cell transplantation</td>
<td>0,25</td>
</tr>
<tr>
<td>3 months after stem cell transplantation</td>
<td>0,42</td>
</tr>
<tr>
<td>4 months after stem cell transplantation</td>
<td>0,37</td>
</tr>
</tbody>
</table>

Poster No: 0088 Abstract:0113
SERUM LEVELS OF MULTIPLE CYTOKINES AND ADHESION MOLECULES IN PATIENTS TREATED FOR ACUTE MYELOID LEUKEMIA
Jan M. Horacek1, Martina Vasatova2, Tomas Kupsa1, Ladislav Jechavy1, Pavel Zak2
1Department of Internal Medicine, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic
2Department of Internal Medicine – Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

1Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic

May 22 – 25, 2013 • Istanbul, Turkey
Background: Cytokines and adhesion molecules have been studied as markers of immune system activation in various diseases including hematological malignancies. Alterations in this network may have direct effect on the malignant cells or have indirect effect on leukemogenesis through altered functions of bone marrow stromal elements. The knowledge gained from multiple cytokine and adhesion molecule analysis should allow better diagnosis and disease management.

Objectives: The aim of our study was to evaluate serum levels of multiple cytokines and adhesion molecules in patients treated for acute myeloid leukemia (AML).

Methods: A total of 15 AML patients (mean age 48.7 ± 12.1 years, median 51, 8 males and 7 females) treated with cyclic chemotherapy (3+7, 2+5, HiDAC) alone or in combination with high-dose chemotherapy (preparative regimen Bu/Cy2 or Cy/TBI) followed by autologous hematopoietic stem cell transplantation were studied. We evaluated serum levels of the following 22 cytokines and adhesion molecules: interleukins (IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-23), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), epidermal growth factor (EGF), monocyte chemotactic protein-1 (MCP-1), E-selectin, L-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1). All biomarkers were measured by biochip array technology on Evidence Investigator analyzer (Randox) at the diagnosis of AML (active leukemia) and in durable complete remission (CR) at circa 6 months after completion of chemotherapy. Probability values (p) < 0.01 were considered statistically significant.

Results: Comparing serum cytokine and adhesion molecule levels in active leukemia and in durable CR, we found significant increase in serum IL-7 (5.34 ± 4.32 ng/L vs. 19.62 ± 12.05 ng/L; p < 0.001), EGF (16.48 ± 33.50 ng/L vs. 64.42 ± 35.33 ng/L; p < 0.001) and VEGF (63.93 ± 67.85 ng/L vs. 114.39 ± 54.90 ng/L; p < 0.001). On the other hand, we found significant decrease in serum E-selectin (30.19 ± 20.46 mcg/L vs. 12.99 ± 8.00 mcg/L; p < 0.01). Plasma levels of other evaluated cytokines and adhesion molecules were without significant differences.

Conclusions: Our results indicate that serum levels of some cytokines and adhesion molecules (IL-7, EGF, VEGF, E-selectin) are significantly altered in patients treated for AML, showing activity of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies in a larger number of patients and comparing cytokine and adhesion molecule levels with established prognostic markers (cytogenetics, molecular genetics) will be needed to define the potential role of these and additional markers in the risk stratification of AML patients.

The work was supported by a long-term organization development plan 1011 (FMHS).

Keywords: cytokines, acute myeloid leukemia

ABSTRACTS

3rd International Congress on Leukemia – Lymphoma – Myeloma

POSTER SESSION

Poster No: 0089

Abstract:0131

MAST CELL TRYPATSE ACTIVITY AND CD34 POSITIVE CELL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Hakan Keski1, Abdullah Hachanefioğlu1, Elif Birtaş Ateşoğlu1, Pınar Tarkun1, Ayfer Gedikü1, Özgür Mehtap1, Samet Kaymaz2

1Hematology Department, Medical School, Kocaeli University, Kocaeli, Turkey
2Internal Medicine Department, Medical School, Kocaeli University, Kocaeli, Turkey

Objective: The aim of this study is to determine the relationship between increased reticulin staining (reticulin fibrosis) in bone marrow biopsies of bcr-abl negative myeloproliferative neoplasm patients and mast cell proliferation and CD34 positive cell expression.

Methods: A total of 77 patients were included in the study. 47 patients with bcr-abl negative myeloproliferative neoplasm and 30 controls were examined. The patients were diagnosed according to WHO diagnostic criteria revised in 2008. Bone marrow biopsy were performed in all patients and specimens were evaluated in the division of pathology. Each specimen was stained with Gomory and graded for reticulin fibrosis. Then they were stained with mast cell tryptase and CD34 immunostain. Specimens were observed under a light microscope at 40x magnification. The number of mast cells and CD34+ cells seen in 20 different areas were averaged. The average CD34+ cells and mast cells were correlated with the degree of the reticulin fibrosis by Kruskal Wallis test. P value <0.05 was statistically significant.

Results: Mean age of patients was 54,71 years, whereas mean age of the control group was 52,63 years. There was statistically advanced level of significance between reticulin fiber levels and mean mast cell count in patients with bcr-abl negative chronic myeloproliferative neoplasm (p<0,05). While there was no statistically significant difference between means of CD34+ cell counts of cases according to reticulin fibers levels (p<0,05); mean CD34+ cell count in cases with intense reticulin fibers was lower than those cases without reticulin fibers. Means of mast cells in JAK2 positive cases were significantly higher than those cases with the negative cases (p<0,05).

Discussion and Conclusion: It has been demonstrated that many substances and cytokines produced in mast cells contribute to fibrogenesis. In this present study, we showed that reticulin fiber increase and mean mast cell count in patients with bcr-abl negative chronic myeloproliferative neoplasm subtypes, was correlated with mast cell increase. Moreover, we detected the decrease in CD34+ stained cell number in the bone marrow as the intensity of reticulin fibers was increased. CD34+ cell counts were increased in patients with mildly fibrotic, predominantly hypercellular bone marrows. According to these results, drugs inhibiting mast cells in myeloproliferative neoplasms might modify fibrosis. Possibly, increase in CD34+ cells secreted from fibrotic bone marrow to the circulation can be guiding us for the disease progression.

Keywords: myeloproliferative neoplasm, mast cell
ABSTRACTS

RETROSPECTIVE ANALYSIS OF 114 PATIENTS WITH PH (-) CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Zafer Gökgöz, Füsun Özdemirkıran, Filiz Büyükkeçeci, Fahri Şahin, Ayhan Dönmez, Güray Saydam
Ege University Faculty Of Medicine

Chronic myeloproliferative neoplasms (CMN) are disorders of hematopoetic stem cells with uncontrolled proliferation, inability to differentiation and also maturation. This disorders first described by Damashek in 1951. World Health Organisation (WHO) reclassified and renamed CMN in 2008. By this classification this disorders are considered distinct entities and the name ‘disorders’ changed as ‘neoplasms’. Polycythemia vera, essential thrombocytosis, myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia and mastocytosis are included in this group of myeloproliferative neoplasms. The most important common specialites of these neoplasms are; transformation to leukemia, fibrosis of the bone marrow and thrombosis. Altough recent developments leads to treat more than last years there is no cure yet. In our study we investigated 114 patients age, sex, physical examination, laboratry values, thrombosis episodes, with Ph (-) CMN. 56 ( 49 % ) patients were male and 58 (51 % ) were female. There were 52 essential thrombocytosis (ET) patients, 39 polycytemia vera (PV) patients and 23 primer myelofibrosis (MF) patients. In all subtypes of CMN 29 ( 25,4 %) of patients administered with ischemic events ( loss of vision, Budd Chiari Syndrome and cerebrovascular events ). Jak 2 was heterozygote positive for 36,5% patients and homozygote positive for 1,9 % patients,84,6 % of PV patients were positive for heterozygote and 2,6 % for homozygote patients the ratios for MF were 61 % for heterozygote, 4,3 % for homozygote and negative for 34,7 %.Many of the thrombotic events occur at diagnosis or in 2 years after the first diagnosis. We report our other results in tables and graphics.

Table 1. Evaluation of CD34 positive cell an mast cell according to degree of reticulin fibrosis.

<table>
<thead>
<tr>
<th>Reticulin fiber</th>
<th>Mast cell tryptase</th>
<th>CD34+ cell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average±SD (Median)</td>
<td>Average±SD (Median)</td>
<td></td>
</tr>
<tr>
<td>Reticulin fiber negative</td>
<td>15.22±18.24 (7.8)</td>
<td>2.79±2.14 (2.2)</td>
</tr>
<tr>
<td>Reticulin fiber mild</td>
<td>30.24±15.18 (31.8)</td>
<td>2.04±1.70 (1.4)</td>
</tr>
<tr>
<td>Reticulin fiber moderate</td>
<td>26.76±27.07 (20.4)</td>
<td>2.28±1.60 (1.6)</td>
</tr>
<tr>
<td>Reticulin fiber severe</td>
<td>41.46±25.98 (44.4)</td>
<td>1.17±0.85 (1)</td>
</tr>
<tr>
<td>p value</td>
<td>0.001**</td>
<td>0.080</td>
</tr>
</tbody>
</table>

Table 1. Splenomegaly Ratios

<table>
<thead>
<tr>
<th></th>
<th>ET</th>
<th>PV</th>
<th>MF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Splenomegaly Ratios</td>
<td>61 %</td>
<td>66%</td>
<td>73%</td>
</tr>
</tbody>
</table>

Table 2. Thrombosis Ratios

<table>
<thead>
<tr>
<th></th>
<th>ET</th>
<th>PV</th>
<th>MF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis Ratios</td>
<td>23 %</td>
<td>33%</td>
<td>8 %</td>
</tr>
</tbody>
</table>

ESSENTIAL THROMBOCYTOSIS DEVELOPING IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION: A CASE REPORT

Engin Onan1, Semra Paydaş2, Melek Ergin3, Arbil Açıklalm
1Internal Medicine, cukurova university, adana
2Oncology, cukurova university, adana
3Pathology, cukurova university, adana

We know that the JAK2-V617F mutation is found in approximately half the cases with essential thromcytosis. Although the mutation is sometimes present in all the myeloid cells in ET and the XCIP pattern is fully clonal (analogous to PV), more often the JAK2-V617F mutation is present in only a subpopulation of neutrophils and platelets, and the XCIP in these mutant-positive patients is frequently nonclonal. In our case essential thrombocytosis developed in a patient with acute lymphoblastic leukemia while he is in complete response and Jak-2 mutation was found to be heterozygous.

Keyword: Jak2 mutation, myeloproliferative disorders bone marrow aspiration

Figure 1. Essential thrombocytosis developing in a patient with acute lymphoblastic leukemia in remission, megacaryocytes are seen in bone marrow aspiration.
JAK2 V617F mutation status of 232 patients diagnosed as CMPDs

Kadriye Bahriye Payzın1, Kaan Savasoglu2, Inci Alacagiözü3, Füsün Ozdemirkiran1, Belgin Berber Mutlu1, Sadi Bener4, Aylin Orgen Çalli4, Betül Bolat Kückzeybek4

1Division of Hematology, Department of Internal Medicine, Atatürk Training Hospital, İzmir, Turkey.
2Medical Genetics Laboratory, Atatürk Training Hospital, İzmir, Turkey.
3Department of Hematology, Dokuz Eylul University Medical School, İzmir, Turkey.
4Department Of Pathology, Atatürk Training Hospital, İzmir, Turkey.

JAK2 V617F mutation has been a key molecular marker of the diagnosis of Philadelphia chromosome negative chronic myeloproliferative diseases (CMPDs). During the twelve years period between November 2000 to November 2012, 233 patients (110 Male, 123 Female, M/F: 0.9/1) diagnosed having CMPDs followed at our center's hematology outpatient clinic. Median age is 63 years (range 18-89). We are presenting here demographics, presence and quantitation of JAK-2 mutation, clinical course, therapy and follow up time, and survival of the patients diagnosed as polycytemia vera (PV) and essential thrombocytemia (ET) according to WHO 2008 criteria, and patients diagnosed as primary myelofibrosis (PMF) according to WHO criteria. One male patient excluded from the chronic myelomonocytic leukemia diagnosis who has JAK-2 mutation with splenomegaly, anemia, absolute monocytosis but no bone marrow fibrosis. All data summarised in Table 1 to 3. One patient who developed post-PV-MF (1.2%) after 52 months, and three patients who developed postET-MF (2.9%) after 44, 66 and 92 months respectively, were diagnosed increased reticular fibrosis with bone marrow biopsy. Estimated survival rates were respectively 75% for 134 months in PV patients and 50% for 62 months in MF patients. Four patients with ET who are 40 years old or younger and have thrombosis or vasomotor complications and heterozygous JAK-2 mutation had additional hereditary thrombophilia.

Keyword: CMPDs, JAK-2 V617F mutation

Table 1. Clinical characteristics of Ph(-) CMPDs patients (n=232)

<table>
<thead>
<tr>
<th>no</th>
<th>gender</th>
<th>splenomegaly</th>
<th>thrombosis</th>
<th>bleeding</th>
<th>CVA</th>
<th>digital</th>
<th>diabetes</th>
<th>hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>PV</td>
<td>(81)</td>
<td>(69/96)</td>
<td>(46/137)</td>
<td>(4/14)</td>
<td>(13/56)</td>
<td>(7/44)</td>
<td>(12/41)</td>
<td>(15/16)</td>
</tr>
<tr>
<td>ET</td>
<td>(151)</td>
<td>(63/64)</td>
<td>(57/147)</td>
<td>(25/104)</td>
<td>(9/57)</td>
<td>(8/62)</td>
<td>(16/12)</td>
<td>(25/18)</td>
</tr>
</tbody>
</table>

Table 2. JAK2 presence of CMPDs(’s=232)

<table>
<thead>
<tr>
<th>no</th>
<th>gender</th>
<th>splenomegaly</th>
<th>thrombosis</th>
<th>bleeding</th>
<th>CVA</th>
<th>digital</th>
<th>diabetes</th>
<th>hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>PV</td>
<td>(77)</td>
<td>(22/75)</td>
<td>(30/65)</td>
<td>(21/17)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>34</td>
</tr>
<tr>
<td>ET</td>
<td>(158)</td>
<td>(11/53)</td>
<td>(23/108)</td>
<td>(24/14)</td>
<td>2</td>
<td>65</td>
<td>(550)</td>
<td>(547)</td>
</tr>
<tr>
<td>PMF</td>
<td>(17)</td>
<td>(6/32)</td>
<td>(11/55)</td>
<td>(6/32)</td>
<td>0</td>
<td>0</td>
<td>(527)</td>
<td>(527)</td>
</tr>
<tr>
<td></td>
<td>(179)</td>
<td>(14/67)</td>
<td>(73/322)</td>
<td>(52/18)</td>
<td>(16)</td>
<td>(96)</td>
<td>(547)</td>
<td></td>
</tr>
</tbody>
</table>
gene influences its expression. Concerning BCL2L12 gene, results presented in this study support the possible pro-apoptotic role of these gene.

**Keyword:** Myeloproliferative neoplasms, apoptosis

**Poster No:** 0094 Abstract:0194

**RETROSPECTIVE EVALUATION OF CHRONIC MYELOID LEUKEMIA CASES: SINGLE CENTER EXPERIENCE**

Öykü Arslan, Gülsüm Ağ günd Çağhylan, Nur Soyer, Oktay Bilgir
Izmir Bozyaka Training and Research Hospital Department of Hematology Bozyaka/İzmir/Turkey

**Objective:** Chronic myeloid leukemia (KML) is a clonal hematopoietic pluripotent stem cell disorder characterized by the presence of Philadelphia (Ph) chromosome. In this study, 42 CML patients monitored in Izmir Bozyaka Training and Research Hospital, Hematology Clinic were retrospectively evaluated in terms of demographic attributes, treatments and response statuses.

**Material and Method:** 42 patients monitored with Ph (+) KML diagnosis in Hematology Clinic of Izmir Bozyaka Training and Research Hospital between 2005 and 2012 were retrospectively evaluated in terms of tyrosine kinase inhibitor treatment and response attributes.

**Findings:** 21 of 42 patients (50%) were females and 21 of patients (50%) were males. Median age was identified as 56.5 (33-83) during diagnosis. The median leukocyte count of patients at the time of diagnosis was 64.904/mm³ (113.000-1.910.000). The median spleen count of patients at the time of diagnosis was 64.904/mm³ (33-83) during diagnosis. The median leukocyte count of patients (50%) were males. Median age was identified in inhibitor treatment and response attributes.

**Results:** Retrospective evaluation of chronic myeloid leukemia cases: single center experience. In this study, 42 CML patients monitored in Izmir Bozyaka Training and Research Hospital between 2005 and 2012 were retrospectively evaluated in terms of demographic attributes, treatments and response statuses.

**Conclusion:** Inhibitor treatment and response attributes were retrospectively evaluated in terms of tyrosine kinase inhibitor treatment and response attributes.

**Keyword:** chronic myeloid leukemia

**Poster No:** 0095 Abstract:0222

**UNUSUAL PRESENTATION OF A RARE DISEASE: A CASE REPORT OF MYELOID SARCOMA**

Aptullah Haholu¹, Ufuk Berber¹, Ismet Gün²
¹GATA Haydarpaşa Training Hospital Pathology Department, Istanbul Turkey
²Gynecology Department, Istanbul Turkey

Myeloid sarcoma is a tumoral mass consisting of myeloid blasts with or without maturation occurring at an anatomical site other than the bone marrow. Infiltrates of any site of the body by myeloid blasts in leukaemic patients are not classified as myeloid sarcoma unless they present with tumor masses in which the tissue architecture is affected. The tumours also known as extra-medullary myeloid tumor, granulocytic sarcoma, chlormyeloma. In this study, we present a 52 years old patient admitting to gynecology clinic with the complaining of difficulty with urination. In physical examination, a mass located anterior wall of vagina was detected. An incisonal biopsy from the mass revealed a monoton infiltration of small-medium size cells under the squamous epithelium. Immunohistochemical staining was negative for pancytokeratin, CD3, CD20, CD79a, Bcl-2, EMA, S 100, CD30, cytokeratin 7 and 20, desmin, SMA, HMB-43, kromogranin expression. Immunostaining for MPO, LCA, CD68, CD99, CD117 were positive. Ki-67 (MIB1) proliferation index was over 80%. Bone marrow aspiration biopsy revealed myeloid blasts. White blood cell count was 46x10⁹/µl. With clinical, laboratory, histopathological and immunohistochemical findings, the patient was diagnosed as acute myeloid leukemia presenting as a myeloid sarcoma.

**Keyword:** myeloid sarcoma, vagina

**Poster No:** 0096 Abstract:0232

**JAK2 MUTATION PROFILE, JAK2 46/1 HAPLOTYPE AND CLINICAL FEATURES IN MACEDONIAN ESSENTIAL THROMBOCYTHEMIA PATIENTS**

Irina Panovska Stavridis¹, Lidija Čevreska¹, Martin Ivanovski¹, Sanja Trajkova¹, Aleksandra Pivkova Veljanovska¹, Dusko Dukovski², Marija Popova Simjanovska¹, Nadača Matevska², Aleksandar Eftimov³, Aleksandar Dimovski²
¹University Clinic of Hematology-Skopje, Medical Faculty-Skopje
²Center of Biomolecular Sciences, Faculty of Pharmacy-Skopje
³University Clinic of Hematology-Skopje, Medical Faculty-Skopje

It is predicted that the inherited genetic background in the individual patients with myeloproliferative neoplasm (MPN) influences the disease susceptibility and the phenotype expression of the MPN. Several groups discovered that the germline JAK2 46/1 haplotype, tagged by the “C” allele of single nucleotide polymorphism (SNP) rs12343867 (C/T) is associated with the JAK2V617F positive MPN. Moreover, some recent studies showed equal distribution of this SNP among JAK2V617F negative MPN and questioned his role in MPN patients.
In order to extend further those observations we designed a study to examine the association of the JAK2V617F mutation with Essential thrombocythemia (ET) in Macedonian population. We also evaluate the association of 46/1 with the JAK2 mutation profile and the clinical features in the series of patients with ET that were diagnosed and treated at the University Clinic of Hematology-Skopje, Republic of Macedonia.

One hundred and seven consecutive patients diagnosed with ET according to proposed criteria for diagnosis in 2008 by the World Health Organization were included in our study. The 46/1 tag SNP rs12343867 (C/T) was genotyped on a MxPro 3005P real-time PCR system (Stratagene, La Jolla, CA, USA) using the TaqMan SNP genotyping assay (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. The JAK2 V617F mutation was analyzed by fluorescent allele-specific PCR followed by CE on ABI 310 Genetic analyzer.

JAK2 V617F mutation negative patients were further analyzed by using RNA based direct sequencing protocol for JAK2 that encompass entire JAK2 exons, from 12 through 15 and DNA based protocol for MPL sequencing that encompass only exon 10. Associations with risk of MPN were estimated by odds ratios and their 95% confidence intervals using logistic regression.

The fluorescent allele-specific PCR analyses revealed that JAK2 V617F mutation was present in 58 (54.2 %) of patients with ET. In one (out of 9 already tested) of our ET JAK2V617F negative patient a G571S mutation point was detected at the exon 13 of JAK2 gene. The incidence of 46/1-linked C allele was significantly higher in ET (genotype: CC 13%, CT 60%, TT 27%; C-allele frequency: 43.7%) than in population control (C-allele frequency 29%).

Genotype distribution were similar among JAK2V617F positive/ JAK2V617F negative patients (genotype: CC 7/14%, CT 22/29%, TT 67/57%; C-allele frequency: 41/43%; P=0.07). The clinical characteristics of 46/1 positive and negative ET were comparable regarding all tested parameters such as blood counts, NAP score, rate of thrombotic and hemorrhagic complications, disease transformation and survival.

Our results confirmed latest observations that the “C” allele of JAK2 rs12343867 designate the genetic basis of ET in Macedonian population independent of the JAK2V617F mutational status and also showed that JAK2 46/1 haplotype does not further affect the clinical course and prognosis of the disease.

**Keyword:** Essential thrombocythemia, JAK2 46/1 haplotype
antiangiogenic properties. THAL monotherapy at such
doses produces approximately a 20 % response rate in
anemia but is poorly tolerated.

A sixty five year-old female patient with myelodysplastic
syndrome who was treated with THAL-PRED (predni-
zone) after transformation to myelofibrosis was presented.
The patient was diagnosed as refractory anemia in 1997.
There was no splenomegali in her physical examination
and there was not any fibrosis in her bone marrow at the
time of the diagnosis. In 2007 she developed 5 cm hapato-
megali and 5 cm splenomegali. Re-evaluation of the bone
marrow biopsy showed severe increase in collagen fibers
and moderate increase in reticulin fibers. Early satiety,
weight loss and fatigue were prominent symptoms and
her hemoglobin level was 7.9 g/dl. She was treated with
mainly transfusions. Her transfusion requirement was 2
units/month. THAL 50 mg/day and PRED, 0.5 mg/kg/
day was started in 2009. Grade 3 peripheral neuropathy
was observed in the 3rd weeks of therapy. Thalidomide
dose was reduced to 50 mg every other day and steroid
dose was tapered gradually and lowered to 10 mg/day at
3 rd month of therapy. In the fourth month of therapy
liver and spleen were nonpalpabl. Her hemoglobin level
increased gradually and reached 9-11 g/dl.

THAL-PRED was well tolerated and an objective
clinical response was demonstrated in our patient. She
became transfusion independant. The dose of THAL in
this patient (50 mg/d) was better tolerated than the
higher doses used in previous studies. Adverse events
associated with corticosteroid therapy were mild and
transient. Low dose THAL-PRED is well tolerated and can
be effective in myelofibrosis with myeloid metaplasia.

**Keyword:** myelofibrosis with myeloid metaplasia, thalidomide
and prednisone therapy

---

**Poster No: 0099 Abstract:0248**

**TETRASOMY 5 SHOWED FOR THE FIRST TIME AS CYTOGENETIC ABNORMALITY IN AN ADULT PATIENT WITH MYELODYSPLASTIC SYNDROMES**

Mahmut Töbü, Emin Karaca, Nazan Özsan, Özgür Çağolu

1Ege University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Izmir, Turkey
2Ege University Faculty of Medicine, Department of Medical Genetics, Izmir, Turkey
3Ege University Faculty of Medicine, Department of Pathology, Izmir, Turkey

Myelodysplastic syndromes (MDS) comprise a group of
heterogeneous clonal hematopoietic cell disorders
characterized by cytopenias, bone marrow hypercellular-
ity, and increased risk of transformation to acute leukemia’s. Approximately 50% of MDS patients have clonally
abnormal abnormalities. The karyotypic differences
turned out to be one of the most important prognostic
parameters in these patients. 5q-deletions, monosomy 7,
trisomy 8 and complex abnormalities are the most
common cytogenetic anomalies in MDS. Rare abnormalities
occurring in a substantial portion of patients with MDS
is still unknown. Here we present a case of 72-year-old
women who applied with fatigue and headache. Her leu-
cytose 5160 /μL, Hg: 10.6 gr/dL, platelet. 336000/Ul.
Bone marrow aspiration demonstrated hypocellularity.
She was diagnosed as MDS. Her Fluorescence in situ
hybridization (FISH) revealed a tetrasomy 5 clone that
could not be detected by conventional cytogenetic. In

---

**Poster No: 00100 Abstract:0257**

**ACHIEVEMENT OF MAJOR MOLECULAR RESPONSE WITH IMATINIB THERAPY IN AN ALLO-TRANSPLANTED CHILDHOOD CHRONIC MYELOID LEUKEMIA PATIENT AFTER RELAPSE**

Eser Turan Erkek, Emre Osmanbaşoğlu, Ipek Yönal,
Mehlika Nalçı, Akif Selim Yavuz

Department of Hematology, Istanbul Medical Faculty,
Istanbul University, Istanbul, Turkey

Childhood chronic myelogenous leukemia (CML) is a
rare malignancy, accounting for less than %3 of all pediatric leukemias. Allogeneic hematopoietic stem cell
transplantation (allo-HSCT) was considered as the only
curative treatment before 2000 for CML patients. CML
treatment has greatly changed after the introduction of
tyrosine kinase inhibitors (TKIs). In the TKI era, only the
minority of the patients with advanced phase at diagnosis
or resistant to TKIs are candidates for allo-HSCT. A
relapse risk as high as 5% to 20% has been reported after
allo-HSCT for chronic phase CML. The choice of
treatment for CML patients relapsed after allo-HSCT is
controversial. Both imatinib mesylate(IM) or donor lym-
phocyte infusions (DLI) are effective in inducing remis-
sions in patients with relapsed CML following allo-HSCT.
Since DLI might induce life-threatening graft versus host
disease, it may be reasonable to postpone DLI, when IM
therapy failed optimal molecular response in relapsed
CML patients

Case: A 26-year-old woman was admitted to hematol-
yogy department with asymptomatic leukocytosis. She had
been diagnosed with Philadelphia chromosome-positive
(Ph+) childhood CML, as she was 12 years old in 1998.
Because pediatric CML scoring systems hasn’t yet been
established, adult prognostic scoring system for CML
were applied. She was in low risk group (risk score:0.41)
according to Sokal risk score. Interferon alpha and
hydroxyurea was used before performing an allo-HSCT from her HLA matched sibling in 1999. She achieved complete chimerism (CC) after the allo-HSCT and didn’t lose CC for 5 years during her follow up, which was then interrupted for 7 years.

During her admission clinical examination didn’t show any specific features. Her hemogram had been as follows; Hb:11g/dl, Htc:29%, WBC:20700/µL, Plt:274000/µL. Her peripheral blood film revealed leucocytosis with a predominance of myelocytes, metamyelocytes, segmented neutrophils. The bone marrow examination showed myeloid hyperplasia with predominance of myelocytes and metamyelocytes. Cytogenetic analysis for the Ph [46XX, t9;22]] was 75% positive and real time polymerase chain reaction (PCR) for BCR-ABL/ABL was 243][IS]. She had relapsed 12 years later after the allo-HSCT. Since she lost donor related hematopoiesis, which was shown by cytogenetic analysis, we didn’t treat her with DLI. IM 400 mg/day was initiated. She achieved complete hematologic response, complete cytogenetic response, major molecular response(MMR) after 1,3 and 6 months, respectively. In the first year of IM treatment follow up MMR was sustained and mixed chimerism (90% donor cells and 10% recipient cells) was detected by FISH. We are planning to repeat her chimerism analysis using short tandem repeats (STR)-PCR and molecular response. Without achieving CC or having complete molecular response, DLI therapy will gain priority.

Here we report a childhood CML patient who relapsed 12 years after allo-HSCT and had MMR with IM treatment.

**Keyword:** childhood CML, relapse after Allo-HSCT

Poster No: 00101 Abstract:0259

**NON-INFERIORITY OF ANAGRELIDE COMPARED TO HYDROXYUREA IN WHO-ESSENTIAL THROMBOCYTHYEMIA, A PHASE III TRIAL**

Heinz Gisslinger

Internal Medicine I, Hematology, General Hospital Vienna, Vienna, Austria

High platelet counts in essential thrombocythemia (ET) can be effectively lowered by treatment with either anagrelide or hydroxyurea. However, the data on this treatment stem from PVG classified ET and it is still unknown whether these recommendations can be applied to ET patients diagnosed following the World Health Organization (WHO) classification (WHO-ET). The data of the ANAYDRET study provide evidence that anagrelide is non-inferior to hydroxyurea in the treatment of WHO-ET. In 259 previously untreated, high-risk ET patients, diagnosed according to the WHO classification system, efficacy and tolerability of anagrelide compared to hydroxyurea was investigated in a prospective randomized non-inferiority phase III study in an a-priori ordered hypothesis. Confirmatory proof of non-inferiority of anagrelide was achieved after 6 months using the primary endpoint criteria and further confirmed after an observation time of 12 and 36 months for platelet counts, hemoglobin levels, leukocyte counts (p<0.001) and ET related events (HR[95%CI]=[1.19(0.61-2.30], 1.03[0.57-1.81] and 0.92[0.57-1.46] respectively). During the total observation time of 730 patient-years, there was no significant difference between the anagrelide and hydroxyurea group regarding incidences of major arterial (7 vs. 8) and venous (2 vs.6) thrombosis, severe bleeding events (5 vs. 2), minor arterial (24 vs. 20) and venous (3 vs. 3) thrombosis and minor bleeding events (18 vs. 15), or discontinuation rates (adverse events 12 vs. 15 or lack of response 5 vs. 2). Disease transformation into myelofibrosis or secondary leukemia was not reported. Anagrelide as selective platelet lowering agent is not inferior compared to hydroxyurea in preventing thrombotic complications in patients with WHO-ET. These data provide evidence that anagrelide can be considered as first line therapy for lowering of platelet count in WHO-ET. This trial was registered at www.clinicaltrials.gov as #NCT01065038. Prepublished online, Blood, Jan. 11, 2013

**Keyword:** Anagrelide, Hydroxyurea

Poster No: 00102 Abstract:0268

**USE OF THYROSINE KINASE INHIBITORS IN SETTING OF RELAPSE AND AS MAINTENANCE THERAPY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH RISK PHILADELPHIA POSITIVE MYELOID NEOPLASMS**

Fehmi Hindilerden1, Nuri Barış Hasbal1, Serkan Güvenç2, Veysel Sabri Hançer2, Reyhan Diz Küçükayaka1, Tülay Özçelik1, Mutlu Arat1

1İstanbul Bilim University, Department of Internal Medicine, Division of Hematology, Istanbul turkey

2İstanbul Bilim University, Department of Medical Biology and Genetics, Istanbul turkey

**Eastern Oncology, Hematopoietic Stem Cell Transplantation Unit, Istanbul turkey**

Outcome of HSCT for AP or BP CML is disappointing with a 2-year survival of 47% and 16% for AP and BC-CML,respectively. Ph (+) AML, comprising 1–2% of AMLs, has high risk of treatment failure and relapse even after HSCT. 1st and 2nd generation TKIs are suggested as options after transplantation in advanced CML, but algorithms for dosage, intervals from HSCT, duration of application, and combination with DLI are not yet defined.

Two BP CML, 1 Ph+ de novo AML and 1 relapsed/refractory Ph+ AML were included. Case 1 presented with blastic crisis 6 years after diagnosis of CP-CML following loss of molecular and hematological response under imatinib and dasatinib. Minimal residual was present prior to allo-HSCT. On day +38, CHR, CCyR, CMR and complete chimerism were achieved. On day +100, dasatinib 2x70 mg was begun to preserve CMR. Ten months after HSCT, CHR, CCyR and CMR are maintained. Case 2 showed loss of hematologic and molecular response under imatinib, nilotinib and dasatinib and finally presented with blastic crisis 12 years after diagnosis of CP CML. On day +32 after allo-HSCT, CHR, CCyR and MMR were obtained in presence of complete donor chimerism. On day +90, molecular relapse and decrease of molecular chimerism was observed. CsA was tapered; dasatinib 2x50 mg was started and increased to 2x70 mg by day +120. On day +180, MMR and complete molecular chimerism were reestablished. Dasatinib was reduced to 2x50 mg due to pancytopenia. Case 2 diagnosed with de novo Ph+ AML-M0 obtained CHR and CCyR after 7+3 and imatinib 600 mg/day and CMR after 2 courses of HD-ARA-C. 6 months after diagnosis, consolidation treatment was completed by autologous HSCT. By day +100 after auto-HSCT, imatinib 400 mg/day was reintiated. One year after HSCT, imatinib was cesseated in presence of CHR, CCyR and CMR. On month +15 after auto-HSCT, molecular relapse was detected and imatinib 400 mg/day was started. Search for unrelated donor is underway. Case 4 diagnosed as...
relapsed/refractory Ph+ AML showed 10% blasts in bone marrow on day +35 after allogeneic HSCT. CSAs was tapered and dasatinib 140 mg/day was started. Because of oral intolerance due to grade II GI tract acute GVHD, dasatinib was suspended until day +58 and started at 70 mg/day due to cytopenias in presence of CMV infection. CHR, CCyR and CMR was achieved on day +75. By day +300, CHR, CCyR and CMR were maintained.

Optimal strategy for advanced CML needs to be defined. In advanced CML, CMR appears to be crucial in providing long term control yet for relapse after HSCT, there is limited data on association between CMR and survival. Our cases indicate TKI with chemotherapy followed by autologous or allogeneic HSCT and TKI maintenance is associated with favorable outcome for Ph+ AML. Experience with 2nd generation TKIs in relapsed Ph+ AML is limited; studies with larger number of patients and longer follow-up should be considered.

**Keywords:** Ph chromosome, thyrosine kinase inhibitors

### Table 1. Patients characteristics

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No.</th>
<th>Gender (female/male)</th>
<th>Age, median (range), years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph-positive de novo AML</td>
<td>3</td>
<td>1 (75%)</td>
<td>48.5 (29-58)</td>
</tr>
<tr>
<td>Relapsed/refractory Ph-positive AML</td>
<td>1</td>
<td>1 (25%)</td>
<td>48.5 (29-58)</td>
</tr>
</tbody>
</table>

### Table 2. Pre- and post-transplant TKIs for high-risk Ph(+) myeloid malignancies

<table>
<thead>
<tr>
<th>Case</th>
<th>Diagnosis</th>
<th>IM</th>
<th>Other treatment</th>
<th>Response</th>
<th>TKI</th>
<th>Relapse after</th>
<th>Diagnosis status at last follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CML in BC</td>
<td>4L</td>
<td>Dasatinib + CCR</td>
<td>6-9 m</td>
<td>Dasatinib + CCR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>Ph-positive de novo AML</td>
<td>6L</td>
<td>Dasatinib + CCR</td>
<td>6-9 m</td>
<td>Dasatinib + CCR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>CML in BC</td>
<td>6L</td>
<td>Dasatinib + CCR</td>
<td>6-9 m</td>
<td>Dasatinib + CCR</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>Relapsed/refractory Ph-positive AML</td>
<td>6L</td>
<td>Dasatinib + CCR</td>
<td>6-9 m</td>
<td>Dasatinib + CCR</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Abstract:**

**ACUTE MYELOID LEUKEMIA SUBSEQUENT TO AUTOIMMUNE HEMOLYTIC ANEMIA: A REPORT OF THREE CASES**

Füsun Özdemirkıran, Zafir Gökgöz, Gülten Sop, Seçkin Çağırın.

1. Ege University Faculty of Medicine, Izmir, Turkey
2. İzmir Bozyaka Research and Training Hospital, İzmir, Turkey

Autoimmune conditions are associated with an increased risk of acute myelocytic leukemia (AML) and myelodysplastic syndrome (MDS). Autoimmune hemolytic anemia (AIHA) is considered to be a complication of several lymphoproliferative disorders, such as chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL). AIHA has rarely been reported in patients with B-cell acute lymphoblastic leukemia (ALL). As MDS and myeloproliferative disorders (MPDs) are indolent and may be present years before diagnosis, it is possible that AIHA arose as a result of these conditions. Herein, we report three cases of AML developed subsequent to AIHA. A 58-year-old man, a 70-year-old woman, a 43-year-old woman are first diagnosed as AIHA before AML.

**Keywords:** AIHA, AML

**Abstract:**

**ESSENTIAL THROMBOCYTOSIS AS A CAUSE OF ARTERIAL COMPLICATIONS**

Tuba Özkan, İskender Ekcini, Güven Çetin, Mitat Büyükakba, Mühsil Cem Ar.

1. Bezmüdem Vakif University, Faculty of Medicine, Department of Hematology, Istanbul, Turkey
2. İstanbul Training and Research Hospital, Department of Hematology, Istanbul, Turkey

Essential thrombocythemia (ET) is a clonal disease characterized by thrombocytosis, splenomegaly and proliferation of megakaryocytes in the bone marrow. The disease may be asymptomatic or may present with severe complications such as thrombosis and haemorrhage. It is usually diagnosed through the incidental finding of increased platelet counts during routine check-up. ET is a slowly progressive disease but it can lead to life-threatening complications. Unusual course of a patient with ET is presented here.

A 61-year-old female patient with no previous complaint was intubated after a hypertensive pulmonary oedema attack three months ago and was followed up in the intensive care unit. One month later she was hospitalised for acute myocardial infarction in the coronary intensive care unit. After coronary angiography and renal artery angiography revealed, PTCA and stent implantation was done for the right renal arterial stenosis.

The patient was referred to the haematology for consultation because of detected high platelet levels (Plt: 820,000/mm3) during a routine cardiology outpatient visit. On physical examination she was normotensive except a 4 cm palpable spleen below the left costal margin. Her WBC was 13,000/mm3, haemoglobin was 14.8 g/dl, and platelet count was 820,000/mm3, blood chemical analysis including immunoglobulins was normal except increased levels of LDH, uric acid, calcium, direct and indirect coombs tests were negative.
Thrombophilia testing including homocysteine, protein C, protein S and factor V Leiden was unremarkable. JAK2-V617F mutation was positive. Bone marrow biopsy was hypercellular consistent with chronic myeloproliferative disease favoring ET. Hydroxyurea together with acetyl salicylic acid was begun.

ET is a clonal disorder affecting mostly women in adult ages. Increased bone marrow megakaryocytes and peripheral thrombocytosis accompanied by sphenomegaly and 30-70% JAK 2 gene mutation positivity are the cardinal physical and laboratory findings. A retrospective study performed by Vannuchi et al. showed an increase of cardiovascular events in association with the JAK2 gene mutation. JAK-2 gene mutation was linked to increased bleeding and thrombosis in a retrospective study with 90 patients. Our case had all the risk factors described in these studies and showed a poor clinical course. Outside the context of this particular patient, one should also consider that the complications that occurred during the course of thrombosis and therapeutic agents used in the treatment of these complications might lead to temporary increase in platelet counts. Thus the increased platelet counts may be the result rather than the cause in thrombosis. But in our patient the diagnosis (ET) was established and the disease seems to be the underlying disease. In patients with recurrent arterial thrombosis ET should be included in the differential diagnosis.

**Keyword:** acute myocardial infarction, essential thrombocythosis

---

The first patient was a male who had the diagnosis of JMML when he was 16 months old. He had recurrent febrile lower and upper respiratory tract infections, bloody diarrhea attacks, periodic febrile episodes lasting 4-5 days and relapsing and remitting vasculitic lesions. The symptoms didn't fade with cytoreductive treatment. Genetic work-up revealed somatic NRAS mutation. As soon as full matched unrelated donor was found, the patient was referred to another center for allogeneic HSCT.

The second patient had the diagnosis of JMML when she was 17 months old. She had recurrent lower respiratory tract infections, typical facial features, marked hypertelorism, short upturned nose, prominent philtrum, thick lips, mild retrogrowth, developmental delay, and predisposition to JMML. As this patient harbored germ-line C-CBL mutation and has a chance of spontaneous resolution, HSCT was not planned as initial treatment. A cytoreductive treatment with 6-mercaptopurine was started and she had shown clinical improvement in the follow-up period.

In conclusion, JMML is phenotypically and genotypically a heterogeneous disease. Recent developments in identifying the molecular lesions have revealed the importance of genotype phenotype correlation in this disease which is very important for tailoring the management.

**Keyword:** childhood, juvenile myelomonocytic leukemia

---

**Figure 1:** Thrombocythosis and complications

**Poster No:** 00105  
**Abstract:** 0310

**MANAGEMENT OF TWO JUVENILE MYELOMONOCYTIC LEUKEMIA PATIENTS ACCORDING TO CLINICAL AND GENETIC FEATURES**

Özlem Tüfekçi, Hale Ören, Fatma Demir Yenigürbüz, Salih Gözmen, Tuba Hilkay Karapınar, Gülensu İrken  
Dokuz Eylül University Faculty of Medicine Department of Pediatric Hematology

Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder of childhood. Major progress has been achieved in diagnosis and understanding the pathogenesis of JMML by identifying the genetic pathologies that occur in patients. Mutations of RAS, NF1, PTPN11, and CBL are found in approximately 80% of the JMML patients. Distinct clinical features have been reported to be associated with specific gene lesions. The advent in genomic studies and recent identification of novel genetic mutations in JMML are important not only in diagnosis but also in prognosis and clinical management of the disease. Herein we present two patients with JMML harboring different mutations, NRAS and C-CBL respectively, with distinct clinical features and different clinical courses.

**Poster No:** 00106  
**Abstract:** 0283

**MANAGEMENT OF ESSENTIAL THROMBOCYTHEMIA WITH INTERFERON ALFA- SINGLE CENTER EXPERIENCE**

Marija Popova Simjanovska, Sanja Trajkova, Irina Panovska Stavridis, Aleksandar Stojanovic, Dusko Dukovski, Martin Ivanovski, Lazar Cadievski, Lidija Cevreska  
University Clinic for Hematology, Skopje, R. Macedonia

Background: The Philadelphia-negative chronic myeloproliferative neoplasms encompass essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). A major breakthrough in the understanding of the pathogenesis of this neoplasm’s occurred in 2005 by the discovery of the JAK2 V617F mutation. A number of studies have shown that the “tumour burden” may be monitored at the molecular level in JAK2-positive patients using highly sensitive quantitative PCR. During the last 25 years several studies have shown that interferon-alpha (IFN-alpha) induces complete haematological remissions in a large proportion of the patients. However, its use in clinical practice has unfortunately been limited due to side effects with high drop-out rates in most studies. Recently, IFN-alpha has been shown to induce deep molecular remissions and also normalization of the bone marrow in PV, which may be sustained even after discontinuation of IFN-alpha therapy. The aim of the study is to present our experience in treatment of this subset of patients with IFN-alpha therapy.

**Design and methods:** In University Clinic of Hematology during 2005-2010 year, 35 patients, with
essential thrombocythemia diagnosed according WHO classifications were treated with Interferon-Alfa 2b subcutaneous. Treatment scheme was consisted of two phases: a) induction phase with interferon alpha 3million units (MU) per day and b) a maintenance phase. The pretreatment mean platelet counts were 923 x 10 9/1 and megacaryocytes in bone marrow were increased in all cases. Splenomegaly was present in 15% of the patients, and SpTs have had vascular complication like thrombosis in pretreatment phase.

Results: During the induction phase, the results showed that using 21MU of IFN Alfa weekly (3MU/day) platelet counts were 500 x 10 9/1 in 100% of the patients. During the maintenance phase 25pts required 3MU three times a week, and 10 pts required 9MU three times a week. V617F mutation of JAK2 gene was positive in 17pts. During a long-term treatment of 5 years subjective side effects were tolerable. Until now 31 pts have stable platelet counts below 500 x 10 9/1 and only 2 had died because of acute myocardial infarction and two had died because of acute mesenteric thrombosis.

Conclusions: We conclude that Interferon-Alfa can correct thrombocythosis in pts with essential thrombocythemia over a period of years and prevent morbidity attributable to this disease.

Keyword: Essential thrombocythemia, Interferon-Alfa

Poster No: 00107 Abstract:0313

EVALUATION OF THE AMOUNT OF THE NEOPLASTIC CLONE IN THE BONE MARROW SAMPLES OF MYELOPROLIFERATIVE DISORDERS AND ITS RELATION WITH THE DISEASE STATUS

Senay Boyacigil1, Yesim Dogan Alakoc1, Yasemin Yuyucu Karabulut1, Beyza Doganay Erdogan1, Gunhan Gurman2, Isimsu Kuzu1
1Ankara University School of Medicine, Department of Pathology, Ankara
2Ankara University Institute of Biotechnology, Ankara
3Ankara University School of Medicine, Department of Biostatistics
4Ankara University School of Medicine, Department of Haematology

Biology and disease status of Myeloproliferative disorders (MPD) can be interpreted by the amount of neoplastic clone. This evaluation can be made on JAK2 mutated cases by using sensitive molecular methods.

In this study, we aimed to investigate JAK2 exon 14 (JAK2V617F), JAK2 exon 12 and MPLW515L, MPLW515K, MPLAS06T and MPLAS19T mutations, on pathology archival material using Next Generation Sequencing Technologies. The amount of the mutated clone was compared with the histopathological parameters and the clinical data in order to evaluate the relationship between disease presentation and the “allele burden” status on bone marrow samples. For this purpose, the bone marrow biopsies and smears of 56 patients with median age 57.8 (22-80) (45.8% male, 54.2% female) diagnosed as MPD (ET, PV, PMF) between 2001-2011 in Ankara University Faculty of Medicine Department of Pathology were selected for the study. The clinical and laboratory data were collected from the hospital records. Roche 454 GS Junior system was performed for detection of JAK2 and MPL mutations sequencing.

Our series showed compatible age, gender and laboratory findings with the stages of the disease groups. JAK2 exon 14 V617F mutation was examined in %79.2 of the patients (ET 84.2%, PV 91.7%, PMF 64.7%). One of the cases carried JAK2 exon 12 mutation. MPL exon 10 mutation was examined only on one ET case (%2,9) case also carrying JAK 2 exon 14 mutation. “Allel burden” which represents the amount of JAK2V617F mutated clone ratio was lowest among PMF cases, followed by ET. The ratio was highest among PV cases. A positive relation between cellularity (p=0.032), white blood cell count (p=0.007) and allele burden status was examined. The amount of mutated allele was less than %10 for five patients.

Our results confirmed that the ratio of Jak mutated cases for different clinical presentations of MPD is higher than the literature when the bone marrow samples were examined by pyrosequencing. Cellularity in the bone marrow biopsies and white blood cell count in blood are the most reliable reflectors of the amount of neoplastic clone for MPD as expected.

Keyword: MPD, Jak2 mutation

Poster No: 00108 Abstract:0327

PATHOPHYSIOLOGY OF PLATELET MEDIATED THROMBOSIS AND BLEEDING IN THROMBOCYTHEMIA

Jan Jacques Michiels1, Alain Gadiesseur2
1Goodheart Institute Rotterdam, Netherlands
2University Hospital Antwerp, Belgium

Erythromelalgic thrombotic thrombocythemia (ETT), caused by a thrombotic occlusion of the acral digital (erythromelalgia) and the cerebral end-arterial circulation (migraine-like microvascular cerebral transient ischemic attack; MIA)s are the far most frequent aspirin-sensitive microvascular complication in ET and PV. If left untreated, major thrombosis of the peripheral, cerebral and the coronary circulation do occur usually in the absence of pre-existing vascular disease as a main cause of death. In cases of reactive thrombocytosis, erythromelalgia, MIAs and major thrombosis do not occur, indicating not only a quantitative but also a qualitative hypersensitive platelet defect in thrombocythemia. It is postulated that hypersensitive platelet in thrombocythemia are caused by the JAK2V617F or MPLS15 gain of function mutations in thrombocythemia. Correction of the hemotocrit to normal by platelet by agents (interferon or anagrelide) reduces the minor and major thrombotic complication to near zero. An association between spontaneous hemorrhages and pronounced thrombocythemia (hemosorrhagic thrombocythemia: HT) is caused by an acquired von Willebrand Disease (AVWS due to platelet induced proteolysis of the von Willebrand fator (VWF)) at platelet counts near zero. An association between spontaneous hemorrhages and pronounced thrombocythemia (hemosorrhagic thrombocythemia: HT) is caused by an acquired von Willebrand Disease (AVWS due to platelet induced proteolysis of the von Willebrand factor (VWF)) at platelet counts near zero. An association between spontaneous hemorrhages and pronounced thrombocythemia (hemosorrhagic thrombocythemia: HT) is caused by an acquired von Willebrand Disease (AVWS due to platelet induced proteolysis of the von Willebrand factor (VWF)) at platelet counts near zero.
initiate platelet thrombi formation and VWF proteolysis. It is a matter of the increased degree of thrombocytopenic platelet counts whether erythromelalgic thrombotic (at platelet in excess of 350x10^9/L) or bleeding (at platelet count in excess of 1000x10^9/L) do occur. There is a third component of a peculiar type of bleeding related to 'increased platelet-mediated blood clot retraction' disturbance with erythrocyte fall out, that causes painful subcutaneous hematomas with a central swelling (clot) after a blow, trauma and/or surgery.

**Keyword:** MIAs

**Poster No:** 00109  **Abstract:**0328

**BONE MARROW RETICULINE FIBROSIS (RF) AND RETICULIN-COLLAGEN FIBROSIS (RCF) IN MYELOFIBROSIS IS NOT A DISEASE BUT SECONDARY TO THE CLONAL MEGAKARYOCYTIC/GRANULOCYTIC PROLIFERATION IN MYELOPROLIFERATIVE DISORDERS**

Jan Jacques Michie1, Hendrik De Raeve2, Jon Van Der Walt3

1Goodheart Institute Rotterdam, Netherlands  
2Free University Brussels, Belgium  
3University College London, Medical School London, England

Myelofibrosis is not specific for a disease and seen in patient with hairy cell leukemia, Ph-positive chronic myeloid leukemia (CML), in essential thrombocythemia (ET), polycythemia vera (PV), primary (dys)megakaryocytic granulocytic myeloproliferation (PDGM), and many other conditions. The term chronic idiopathic myelofibrosis (CIMF) or primary myelofibrosis (PMF) is derived from reticulin staining of bone marrow biopsies which only shows you in the microscope black fine or coarse fibers and is only of minor prognostic significance. According to the 1990 Hannover Bone Marrow Classification for CML and MPD, Georgii concluded that CIMF is secondary, misleading and scientifically not sound.

Myelofibrosis (MF) itself is not a disease because reticulin and collagen fibrosis are produced by polyclonal fibroblasts in response to cytokines released from the clonal granulocytic and megakaryocytic proliferative cells in both PV and CMF. The sequential occurrence of reticulin fibrosis (RF) and irreversible reticulin/collagen fibrosis (RCF) is well documented in JAK2V617F mutated PV and PDGM, in MPL515 mutated PT, in BCR/ABL-positive thrombocythemia and CML and in many other conditions. The transition of RF into RCF is rare in heterozygous JAK2V617F positive ET and does occur in about one third of heterozygous/homozygous or homozygous JAK2V617F positive PV and does occur in the majority of patients with JAK2 wild type PDGM during long-term follow-up.

Grading of reticulin fibrosis using the reticulin silver stain according to the polycythemia vera study group (PVSG) and UK guidelines is world-wide used. A scoring system based on morphometric analysis (point intersection with an ocular grid) and quality of fibers (reticulin and collagen fibers) and the bone marrow fiber density (fine or coarse reticulin and some or course bundles of collagen) has been proposed by German institutes of pathology (Hannover Bone Marrow Classification of MPD and CML). The different scoring systems for RF, RCF and MF use different criteria for grading of reticulin and collagen, are subjective and not always comparable by lack of strict criteria. A standardized semiquantitative grading of reticulin and collagen fibrosis in the bone marrow, myelofibrosis (MF) is proposed by a panel of pathologists.

**Keyword:** JAK2V617, CML

**Poster No:** 00110  **Abstract:**0329

**CLASSIFICATION AND NATURAL HISTORY OF BCR/ABL-POSITIVE THROMBOCYTENOMA AND CHRONIC MYELOID LEUKEMIA AS COMPARED TO THE BRC/ABL-NEGATIVE MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTENOMA (ET)**

Jan Jacques Michie1, King Lam2

1Goodheart Institute Rotterdam  
2University Hospital Antwerp, and Departments of Pathology

The Philadelphia chromosome (Ph1) originates from a translocation (t) of a large part of 22q to the long arm of chromosome 9, and the translocation (t) of a small part of 22q to 9q; the t(9;22)(q34;q11). The Ph1 chromosome breakpoints on chromosome 22 in CML patients appeared to be clustered within a limited region, the breakpoint cluster region (BCR) on chromosome 22. The BCR/ABL fusion gene is found in classical CML patient with the t(9;22)(q34;q11) translocation but also in CML patients with complex chromosomal translocations. The BCR/ABL fusion gene has a high tyrosinekinase activity. Ninety five percent of patients with the clinical phenotype of CML are BCR/ABL+; 90% are Ph1+/BCR/ABL+; and 5% are Ph1-/BCR/ABL+. Five percent are Ph1-/BCR/ABL-, and diagnosed as atypical CML, juvenile CML, chronic neutrophilic leukemia or chronic myelomonocytic leukemia. Three phenotypes of BCR/ABL-positive disease can be distinguished; CML with megakaryocyte predominance (CML.M) and CML of common type (CML.CT) and BCR/ABL-positive essential thrombocytenia (ET) without features of CML. In BCR/ABL-positive thrombocytenia, platelets are small and indolent (non-reactive) and megakaryocytes are smaller than normal with hypolobulated nuclei. In contrast, platelets and megakaryocytes in Ph1-negative ET and PV are large. According to strict morphological, biochemical, and molecular criteria, BCR/ABL-positive CML is a malignant disease (neoplasia) with an obligate transition into acute leukemia. BCR/ABL-positive ET may progress to overt CML and usually show a high tendency to myelofibrosis and blastic transformation near to 100%. Despite high platelet count around 1000x10^9/L and far in excess of 1500x10^9/L, patients with BCR/ABL-positive thrombocytenia do not present erythromelalgic thrombotic or bleedings manifestations. In the MPDs ET and PV, erythromelalgic thrombotic events are frequent due hypersensitive large platelets with a high risk of platelet-mediated inflammation and thrombosis in the end-arterial circulation. caused by the JAK2V617F point mutation.

**Keyword:** BCR/ABL, CML
ABSTRACTS

PATHOPHYSIOLOGY OF PLATELET-MEDIATED MICROVASCULAR DISTURBANCES AND MAJOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: REVERSAL BY ASPIRIN, PLATELET REDUCTION, BUT NOT BY ANTICOAGULATION

Jan Jacques Michiels1, Peter J. Koudstaal2, Alain Gadsisseur3
1Goodheart Institute Rotterdam
2European Working Group on myeloproliferative Neoplasms
3University Hospital Antwerp, Belgium

Essential thrombocythemia (ET) and polycythemia vera (PV) frequently present with erythromelalgia and acrocyanotic complications, migraine-like microvascular cerebral and ocular transient ischemic attacks (TIAs) and/or acute coronary disease. The spectrum of TIAs in ET range from poorly localized symptoms of transient unsteadiness, dysarthria and scintillating scotoma to focal symptoms of transient monocular blindness, transient monoparesis or hemiparesis or both. The attacks all have a sudden onset, occur sequentially rather than simultaneously, last for a few seconds to several minutes and are usually associated with a dull, pulsatile or migraine-like headache. Increased hematocrit and blood viscosity in PV patients aggravate the microvascular ischemic syndrome of thrombocythemia to major arterial and venous thrombotic complications. Phlebotomy to correct hematocrit to normal in PV significantly reduces major arterial and venous thrombotic complications, but fails to prevent the platelet-mediated erythromelalgia and TIAs. Complete long-term relief of the erythromelalgic microvascular disturbances, TIAs and major thrombosis in ET and PV patients can be obtained with low dose aspirin and platelet reduction to normal, but not with anticoagulation. Skin punch biopsies from the erythromelalgic area show fibromuscular intimal proliferation of arterioles complicated by occulsive platelet-rich thrombi leading to acrocyanotic ischemia. Symptomatic ET patients with erythromelalgic microvascular disturbances have shortened platelet survival, increased platelet activation markers β-thromboglobulin, (β-TG) platelet factor 4 (PF4) and thrombomodulin (TM), increased urinary thromboxane B2 (TXB2) excretion, and no activation of the coagulation markers thrombin fragments F1+2 and fibrin degradation products. Inhibition of platelet cyclooxygenase (COX1) by aspirin is followed by the disappearance and no recurrence of microvascular disturbances, increase in platelet number, correction of the shortened platelet survival times to normal, and reduction of increased plasma levels of β-TG, PF4, TM and urinary TXB2 excretion to normal. These results indicate that platelet-mediated fibromuscular intimal proliferation and platelet-rich thrombi in the peripheral, cerebral and coronary end-arterial microvasculature are responsible for the erythromelalgic ischemic complications, TIAs and splanchic vein thrombosis. Baseline platelet P-selectin levels and arachidonic acid induced COX1 mediated platelet activation showed a highly significant increase of platelet P-selectin expression (not seen in ADP and collagen stimulated platelets), which was significantly higher in JAK2V617F mutated compared to JAK2 wild type ET.

Keyword: TIAs

1975 PVSG, 2008 WORLD HEALTH ORGANISATION (WHO) AND THE 2008 EUROPEAN CLINICAL, MOLECULAR AND PATHOLOGICAL (ECMP) CRITERIA FOR THE DIAGNOSIS AND CLASSIFICATION OF MEYLOPROLIFERATIVE DISORDERS

Jan Jacques Michiels1, Wilfried Schroyens2, Freek Bot1
1Goodheart Institute Rotterdam
2University Hospital Antwerp
3University of Maastricht

The present critical appraisal integrates the world wide used criteria of the Polycythemia Vera Study Group (PVSG), thrombocythemia Vera (TVSG) and the 2007 World Health Organization (WHO) into a new set of 2008 WHO bone marrow features and European clinical molecular and pathological (WHO-ECMP) criteria for the diagnosis and classification of JAK2V617 mutated trilinear myeloproliferative disorders essential thrombocythemia (ET), polycythemia vera (PV), and JAK2 wild type primary (Dys)megakaryocytic granulocytic myeloproliferation (PMGM/PDGM) and primary advanced agnogenic myeloid metaplasia with myelofibrosis (PAMM). The 1975 PVSG, the 2008 WHO and the 2008 WHO-ECMP classifications agree upon the diagnostic criteria for PV and PDGM or primary myelofibrosis (PMF). The clinical diagnosis of ET according PVSG and TVSG criteria comprises three variants of JAK2V617F mutated ET when the 2008 ECMP criteria are applied. These include normocellular ET phenotype 1, ET phenotype 2 with features of early PV (prodromal PV), and ET phenotype 3 with a hypercellular bone marrow due to megakaryocytic, granulocytic myeloproliferation (MGM), but with no anaemia and with the absence of leukoerythroblasticosis. ET 2 or prodromal PV will progress to overt PV. Evolution of myelofibrosis is rare in normocellular ET 1 and does occur in patients with ET 3 (ET.MGM) and in PV after long-term follow-up. The detection of JAK2V617F in granulocytes with sensitive PCR techniques plays a key-role in the diagnostic work-up and staging of patients with ET, PV and PMF or MMM. Spontaneous endogenous erythroid colony (EEC) formation, low serum erythropoietin (EPO) levels and JAK2 mutations are highly specific for early and overt PV but not sensitive enough for true ET and CMF. The JAK2V617F mutation burden in heterozygous mutated ET and in heterozygous/homozygous or homozygous mutated PV is of major clinical and prognostic significance. The combination of a careful clinical work-up, JAK2V617F mutation screening and pre-treatment bone marrow histopathology is highly sensitive and specific to classify and stage each the MPDs ET, PV, PDGM and PAMM as a sound basis for prognosis assessment and therapeutic implications. Myelofibrosis (MF) itself is not a disease because reticulin fibrosis (RF) and reticulin/collagen fibrosis (RCF) are secondary serious irreversible event induced by polyclonal fibroblasts in response to cytokines released from the clonal granulocytic and megakaryocytic proliferative cells in ET.MGM, PV and PDGM.

Keyword: PMGM, PDGM
The clinical diagnoses based laboratory tests including blood cell counts, serum erythropoietin (EPO), endogenous erythroid colony formation (EEC), and JAK2 mutation for the diagnosis of myeloproliferative neoplasm (MPN) without use of bone marrow pathology were essential thrombocytopenia (ET) in 6 and polycythemia vera (PV) in 4 patients. Three PV patients were homozygous and one PV and all ET cases revealed a heterozygous JAK2V617F mutation of less than 40%. The bone marrow histopathology diagnosis by expert pathologists without use of clinical data was PV in 7 (of which 3 ET with features of early PV) and PV in 4. The European Clinical Molecular and Pathology (ECMP) criteria distinguish three sequential stages or phenotypes of JAK2V617F mutated ET: normocellular ET-1; ET-2 with and clinical bone marrow features of PV (prodromal PV) in 3 ET-3 with a hypercellular dysmorphic megakaryocytic and granulocytic myeloproliferation (ET-MGM).

Bone marrow histopathology is a powerful tool to differentiate MPN of various molecular etiologies from all variants of primary or secondary erythrocytosis and reactive thrombocytosis with a sensitivity and specificity near to 100%. Three cases with prodromal PV developed a slow onset PV after long-term follow-up of about 10 years. Red cell counts are below 6x10^{12}/L in separates JAK2V617F onsets PV after long-term follow-up of about 10 years. Increased erythrocyte counts at a cut off level of 6x10^{12}/L separates ET and prodomal PV from overt PV and can replace increased red cell mass for the diagnosis of PV. The JAK2 wild type ET carrying one of the thrombopoietin receptor or MPL515 mutation is featured by increase of clustered small and giant megakaryocytes with hyperlobulated stag-horn-like nuclei, in a normal cellular bone marrow, and has no laboratory and bone marrow features of prodromal PV or overt PV at diagnosis and during follow-up. A third entity of pronounced JAK2 wild type thrombocytopenia presents with prefibrotic primary dysmegakaryocytic and granulocytic myeloproliferation (PDGM) characterized by a hypercellular dual myeloproliferation of granulopoiesis and dense clustered enlarged immature dysmorphic megakaryocytes with bulky (bulbous) hyperchromatic nuclei, which are never seen in JAK2V617F mutated ET, prodromal PV, EMGM and PV, and also not in prefibrotic MPL515 mutated ET.

**Keyword:** JAK2V617F
with various degrees of clinical and laboratory features of primary myeloid metaplasia of the spleen.

Half of PVSG/WHO defined ET patients show spontaneous endogenous erythroid colony formation (EEC), low serum erythropoietin (EPO) levels, and carry the JAK2V617F mutation, indicating prodomal PV when the European Clinical, Molecular and Pathological (ECMP) criteria are applied. EEC and low serum EPO are specific JAK2V616F mutated MPN, but not sensitive enough as isolated markers for the diagnosis of PV. The positive predictive value of a JAK2V617F PCR test for the diagnosis of WHO defined PV is high (95%). About half of the PVSG/WHO defined ET and EMGM are JAK2V617F positive (sensitivity 50%). So-called heterozygous MPN with allele load less than 50% in fact are hetero/homozygous in PV and true heterozygous in ET at the EEC blood and bone marrow level. The JAK2V617F mutation load is related to MPD disease burden: heterozygous in normocellular ET and prodomal PV and hetero/homozygous in ET.MGM, trilinear PV, and advanced PV. The proposed WHO-ECMP on top of JAK2V617F and MPL515 mutation screening will much better characterize the early, intermediate, overt and advanced clinicopathological stages of normocellular ET, prodomal PV, trilinear PV, ET.MGM and its various degrees of fibrosis on bone marrow histology in patients with JAK2V617F positive and JAK2 wild type MPD.

**Keyword:** Thrombocytopenia

### Non-Hodgkin’s Lymphoma

**Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single Center, Retrospective Study Reporting on Young Patients**

Murat Özbalak¹, M. Cem Ar², Nükhet Türüzner³, Ayşe Salihoglu⁴, A. Emre Eszkazan⁴, Seniz Öngören Aydin⁴, Zafer Başlar⁴, Teoman Soysal⁴, Yıldız Aydın⁴, Anıl Barak Dolgun⁵, Önder Ergönül⁶, Burhan Ferhanoğlu¹

1Division of Haematology, Department of Internal Medicine, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, TURKEY
2Haematology Unit, Department of Internal Medicine, Istanbul Training and Research Hospital, Istanbul, TURKEY
3Division of Haematopathology, Department of Pathology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, TURKEY
4Division of Haematology, Department of Internal Medicine, Diyarbakır Training and Research Hospital, Diyarbakır, TURKEY
5Department of Biostatistics, Hacettepe University Medical Faculty, Ankara, TURKEY
6Department of Infectious Diseases, V.K.V. American Hospital, Istanbul, TURKEY

**Objectives:** The aim of this single-center, retrospective study was to investigate the impact of rituximab on DLBCL, to reconsider the validity of the IPI, and to evaluate the prognostic role of the cell of origin (CoO) in a relatively young cohort of patients.

**Materials-Method:** We retrospectively analyzed 312 de novo DLBCL patients; 54 received CHOP and 258 received R-CHOP.

**Results:** Rituximab increased 3-and 5-year OS rates from 71% to 77.3% and 67% to 74.5%, respectively (p=0.264). Rituximab significantly improved the 3-and 5-year PFS (41% vs. 70% and 36% vs. 65%, respectively, p<0.001).

Among young, low risk patients (aaIPI=0&1) in our cohort (n=129), 107 patients received R-CHOP and 22 patients received CHOP treatment. Three- and 5-year OS rates were 90% for R-CHOP and 72% for CHOP group (p=0.048). Similarly, 3- and 5-year PFS were 93% vs. 53% and 5-year PFS were 91% vs. 53% for R-CHOP and CHOP groups, respectively (p<0.001).

The studies on young high risk patients are scarce. Analyzing 71 young, high risk patients (aaIPI =2&3), the majority received R-CHOP (n=58); the 3- and 5-year OS were both 71%, and 3 and 5-year PFS rates were 75% and 64%. For the high-intermediate aaIPI group, the 2-year OS rates were 83% and PFS rates 79%. In the high aaIPI group, 2-year OS rates were 59% and PFS rates 75%.

Comparing 2-year survival results with the literature, we may conclude that our OS data for high IPI group was worse than transplantation results, although the results of high-intermediate IPI group were comparable with high dose therapy literature.

CoO data were available in 190 patients. The 3-year OS rates in GC and non-GC subgroups were 79% and 64%, respectively. The 3- and 5-year overall survival rates were significantly better in GC group (p=0.014). In multivariate analysis all IPI parameters except extranodal involvement were significantly associated with prognosis. Even though CoO was significant in univariate analysis, it was no longer significant in multivariate analysis.

**Conclusion:** This retrospective cohort study confirmed the validity of IPI scoring in the rituximab era and showed that rituximab leads to improved survival rates even in poor risk DLBCL patients. In our hands, CoO, as defined by immunohistochemistry, occurred as an IPI independent prognostic factor in univariate but not in multivariate analysis. The survival advantage and a lower mortality rate in GC group were independent of rituximab usage. In the literature, it is obvious that the high dose chemotherapy has no OS advantage but some PFS advantage in young high risk population. In our analysis, OS data for high aaIPI group was worse than first line high dose treatment with autologous stem cell support in rituximab era, although the results of high-intermediate IPI group were comparable with high dose therapy literature. To our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort of patients.

**Keyword:** Diffuse large B cell lymphoma, young high risk cohort
Objective: Hairy cell leukemia is a disease that is indolent and B-cell chronic lymphoproliferative. The disease occurs around the age of 52. The disease is four times more common in men. This one is a rare type of leukemia in all leukemia that has a ratio of 2%. Typical hairy cells in the peripheral blood and bone marrow, neutropenia and monositopeni, splenomegaly are usually available at diagnosis. Today, cladribine (2-klorodeoksiadenozin, 2-CdA) and pentostatin are used at first-line treatment.

Materials-Methods: Between 2000 and 2012, 15 patients treated were evaluated retrospectively in our clinic with the diagnosis of hairy cell leukemia. 11 patients (74%) were male and 4 (26%) were female. Median age was 51 (35-66) years. Pancytopenia in 12 patients and bicytopenia in 3 patiens were determined. The 12 patients had splenomegaly (Splenectomy had been performed in 2 patients outside the center) and 3 patients had hepatomegaly. The mean spleen size 18 (9-27) cm. All patients were diagnosed with hairy cell leukemia after examination of the blood, assessment of bone marrow biopsies, peripheral blood and / or bone marrow flow cytometry analysis and tartrate resistant acid phosphatase (TRAP) staining.

Results: All patients were treated with cladribine. Cladribine 0.1 mg / kg / day (for 7 days as a continuious IV infusion) was administered. A relapse developed in S of 15 HCL patients (33%), 2 of them after splenectomy. 3 of them(20%) had relapsed after cladribine treat- ment. 2. cycle cladribin was given to the patients who had relapsed. One patient have been followed without medication due to being asymptomatic. After follow-up cladribin treatment, the polycytemia emerged in one of our patients. Intermittent, phlebotomy was performed. 14 patient are followed in complete remission. Due to the good general condition and laboratory values, the patient are followed up without medication. One of our patients could not be reached.

Discussion: Hairy cell leukemia is a slowly progressive disease. Today, cladribine that is purine nucleoside analogue (2-CdA) or pentostatin are used for the first-line treatment. Purine nucleoside analogues and a complete remission rate are approximately 80% to 90. The results of treatment with cladribine in our clinic are quite good. A complete remission were obtained in the ratio of 77% with cladribine treatment in our patient group. Number of patients who had relapsed were 40% in the literature, same as 33% patients had relapsed in our group.

Keywords: Hairy cell leukemia, Cladribine

### Table 1: Patient Characteristics

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Mean Age (range)</th>
<th>Median Age</th>
<th>Sex/Female (N=104)</th>
<th>Age &lt;60 (N=86)</th>
<th>Age ≥60 (N=18)</th>
<th>Sex Female (N=86)</th>
<th>Sex Male (N=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Patients</td>
<td>51.3 / 52 (17-83)</td>
<td>54.9   / 55</td>
<td>48.3 / 47.5</td>
<td>58 / 60 (22-83)</td>
<td>4 / 11 (8)</td>
<td>10 / 20</td>
<td>26 / 4</td>
</tr>
<tr>
<td>1Group</td>
<td>50 / 258</td>
<td>15 / 38</td>
<td>146 / 59</td>
<td>44 / 28</td>
<td>0.022</td>
<td>0.002</td>
<td>0.033</td>
</tr>
<tr>
<td>2Group</td>
<td>22 / 252</td>
<td>22 / 25</td>
<td>148 / 53</td>
<td>44 / 26</td>
<td>0.022</td>
<td>0.002</td>
<td>0.033</td>
</tr>
<tr>
<td>3Group</td>
<td>26 / 252</td>
<td>27 / 3</td>
<td>173 / 32</td>
<td>57 / 19</td>
<td>0.090</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Group</td>
<td>67 / 252</td>
<td>7 / 5</td>
<td>116 / 33</td>
<td>43 / 33</td>
<td>0.754</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: OS and PFS rates in different subgroups

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Median Follow-up Period (n=30)</th>
<th>OS-3year (95% CI)</th>
<th>OS-5year (95% CI)</th>
<th>PFS-3year (95% CI)</th>
<th>PFS-5year (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GC Subgroup</td>
<td>38 months (n=104)</td>
<td>0.79 (0.69-0.86)</td>
<td>0.76 (0.69-0.86)</td>
<td>0.70 (0.60-0.78)</td>
<td>0.61 (0.48-0.71)</td>
</tr>
<tr>
<td>Non-GC Subgroup</td>
<td>31 months (n=86)</td>
<td>0.64 (0.53-0.74)</td>
<td>0.64 (0.51-0.72)</td>
<td>0.61 (0.49-0.70)</td>
<td>0.61 (0.49-0.70)</td>
</tr>
</tbody>
</table>

Comparison between GCB and Non-GCB Subgroups

p=0.014
p=0.014
p=0.573
p=0.573
There has been sparse information about primary breast lymphoma (PBL). Recently, several studies suggested some common features: predominant diffuse large B-cell lymphoma (DLBCL) histology, significant risk of central nervous system (CNS) relapse.

The aim of this study is to investigate the clinical features and outcomes of PBL and also to find the factors associated with CNS relapse.

We analyzed the data of 63 patients diagnosed with PBL from 1994 to 2009, who were identified from our nationwide survey. The median age was 45 years (range, 20-73) and all were female. The Ann Arbor stage was I(37, 59%)/II(22, 35%)/III(4, 6%). ECOG performance status was 0 or 1 in 58 patients (92%) and serum LDH level was elevated in 23 (37%).

The most common subtype identified was DLBCL (49, 78%), with the second most common subtype being extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT; 6, 10%). Follicular lymphoma was identified only in one. T-cell lymphoma consisted of peripheral T-cell lymphoma, unspecified (PTCL-U; 4, 6%) and anaplastic large-cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK) positive (1, 2%); ALCL, ALK negative (2, 3%). T-cell lymphoma had significantly more unfavorable characteristics such as presence of B symptom and poor performance status.

The majority of patients (91%) received systemic chemotherapy +/- radiotherapy as a curative treatment. Primary surgical resection +/- axillary node dissection was performed in 29 patients (46%). Five of the 6 patients with MALT lymphoma were only treated with surgical resection.

With a median follow-up of 49.6 months (range, 4.4-186.0), estimated 5-year PFS and OS was 53.1% (95%CI, 45.9-60.3) and 64.8% (95%CI, 57.8-71.8). The PFS and OS of the B-cell lymphoma were significantly better than those of the T-cell lymphoma (PFS, 57.3% vs 17.9%, P=0.007, respectively; OS, 71.3% vs 17.9%, P=0.001, respectively). In multivariate analysis for OS, T-cell phenotype (hazard ratio [HR], 3.41; 95% CI, 1.12-10.31) and low-intermediate/high-intermediate IPI (HR, 3.89; 95% CI, 1.26-12.06) were independent prognostic factors for worse OS.

Twenty-one patients experienced progressive disease following first-line therapy. Of these, 7 experienced CNS relapse, and cumulative incidence of CNS relapse at 3-year was 13.1% (95% CI, 8.5-17.7). In multivariate analysis, serum LDH level was only independent predictor for CNS relapse (HR, 10.31; 95% CI, 1.20-88.65). Interestingly, six patients (10%) received prophylactic intrathecal chemotherapy using methotrexate, and there was no CNS progression in these patients.

DLBCL is the most predominant subtype in agreement with previous series. Distant extranodal failures, especially in the CNS, are a major problem. And, elevated serum LDH level was identified as a risk factor for CNS relapse. Thus, despite the role of CNS prophylaxis are still not clear, it should be considered in PBL patients with elevated serum LDH level.

Keyword: primary Breast Lymphoma, CNS relapse
Erdheim–Chester disease, Interferon α-2a

With cranial involvement, which is rarely seen. IFN-a was a very effective treatment in our ECD patient been reported as very effective therapy in some studies. In this disease. But, in recent years, IFNa has also been reported to manage well tolerated. Dexamethazon was stopped and 3 million units in 3 days for a week interferon α-2a and oral iron treatments were started. Interferon treatment was well tolerated. There was a marked regression on cranial MRI scan after 3 months. There was no mass almost completely disappeared and the impression of the mass and edema were not seen.

Steroids has been the most common medical treatment in this disease. But, in recent years, IFNα has also been reported as very effective therapy in this treatment. IFN-a was a very effective treatment in our ECD patient with cranial involvement, which is rarely seen.

**Keyword:** Erdheim–Chester disease, Interferon α-2a

Langerhans cell histiocytosis in adult patients: single institution experience

Asu Fergun Yılmaz1, Melda Cömert1, Ayşen Ersoy Güneş1, Mehmet Argoğ1, Yavuz Anacak1, Nazan Özsar1, Mine Hekimgil2, Serra Arun Kamer3, Fahri Şahin1, Filiz Vural1, Gürey Saydam1

1Ege University Faculty of Medicine, Department of Hematology, İzmir Turkey
2Ege University Faculty of Medicine, Department of Radiology, İzmir Turkey
3Ege University Faculty of Medicine, Department of Nuclear medicine, İzmir Turkey
4Ege University Faculty of Medicine, Department of Pathology, İzmir Turkey

Objectives: Langerhans cell histiocytosis (LCH) is characterized by abnormal proliferation of histiocytes. It is rare disease with an incidence of 1 -2/ million. Although it is more frequent in children at 1-3 years old, it can be diagnosed in all ages. Disease can be presented by multifocal or localized organ infiltrations. Although all systems and organs might be infiltrated, main sites for disease is bone, especially skeletal bones. Treatment options differs according to its presentation as local or multifocal. At local disease, only radiotherapy can be effective modality but patients with multifocal disease should be treated with systemic chemotherapies or with combination.

Method: At this study, we aimed to retrospectively analyse our adult LCH patients diagnosed between 1992-2012.

Results: Twenty-one patients, 13 male and 8 female, were retrospectively analyzed. Median age was 29 (range, 18-53). All of the patients had bone involvement and bone pain has been most prominent complaint according to the involvement site. We documented polyuria and polydipsia in one patient due to hypophysis involvement in addition to bone. 13 (%15 female, %85 male) patients were presented with local disease and 8 (%25 male, 75 female ) patients had multifocal disease. The characteristics of the patients were given at table 1. The patients with local disease were treated with only radiotherapy and then followed up. The patients with systemic disease were treated with both radiotherapy and chemotherapy. During the treatment period, any grade 3-4 hematological side effects were not documented.

The median period of follow-up was 19 (range, 4-120) months. We determined 7 relapses in 4 patients. All of the relapses were detected with bone lesions and they were treated with radiotherapy successfully. Median overall survival was 19 months. 6 patients were lost to follow up. No deaths were recorded during follow up.

Conclusion: At this retrospective study with relatively limited number of patients, we reported that adult onset LCH patients were mostly presented as a focal disease with bone pain. The radiotherapy was an effective treatment modality at these patients. Although, LCH is a rare disease in adult age groups, it should be considered in patients with bone lesions.

**Keyword:** langerhans cell, histiocytosis
Poster No: 00122  Abstract:0159

SURVIVAL OF DLBCL PATIENTS TREATED WITH R-CHOP
Özgür Mehtap¹, Pınar Tarkun², Elif Birtaş Ateşoğlu³, Hakan Keski², Ayfer Gedük², Abdullah Hachanefioglu²
¹Derince Eğitim Araştırma Hastanesi, Hematoloji, Kocaeli, Türkiye
²Kocaeli Üniversitesi Tıp Fakültesi, Erişkin Hematoloji BD, Kocaeli, Türkiye

Aim: In this study we aimed to search R-CHOP treatment responses and event free survival (EFS) of patients with DLBCL. We also aimed to compare our results with literature, and to explain the reasons of differences.

Method: Total 130 patients were investigated. The study was performed retrospectively. Treatment responses were compared according to disease stage and event free survival was analyzed. Non responders, partial response, progression of disease, relapse of disease and death in treatment were considered as event. Survival analyses were calculated by Kaplan Meier’s method. Differences in survival between prognostic groups were evaluated in univariate analysis by log-rank test. The differences of treatment responses were evaluated by Chi-square method and p value <0.05 was considered statistically significant.

Results: The mean age was found 58.48 years and 52.46 years for females and males respectively. The basic characteristics of patients are shown in table 1. The patients were followed minimum 1.23 month and maximum 190.53 months after treatment. Complete response (CR), partial response (PR), non-responder and death were found 70.8%; 5.4%; 12.3% and 11.5% respectively. Relapsed disease (RD) is evaluated in 22.3% of patients. In the stages I, II, III and IV the CR rate is observed 82.7% (43), 94.45 % (17), 64.7% (22) and 38.5 % (10) respectively. The EFS was found significant between disease stages, IPI scores, age and B symptoms (p=0.000) (Figure). The median EFS are shown in table 2.

Discussion: Near the same response rates are found in GELA study with RCHOP treatment (76%, 7%, 9%, 1%, 10% and 10% for CR, PR, Progressive disease, Stable disease, RD and death, respectively). On the other hand Pfreundschuh M et al. found 86% CR rates in their study which was higher than our result. However in this study the mean age was 47 years and all patients had low IPI scores unlike our study.

We found similar CR rates as RICOVER 60 study. In this study investigators showed significant survival times patients with normal serum LDH level, early stage, age <60 years and low IPI score.

Conclusion: Stage, IPI score, age and B symptoms are still maintaining their importance effect on treatment response and EFS in DLBCL. Patients who have advanced stage and high IPI scores should be followed carefully at diagnosis.

Keyword: DLBCL, event free survival

Table 1: Characteristics of the patients

<table>
<thead>
<tr>
<th>Sex</th>
<th>female (%)</th>
<th>male (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median, range)</td>
<td>8 (38)</td>
<td>13 (62)</td>
</tr>
<tr>
<td>Age &gt;=60</td>
<td>81 (62.3)</td>
<td>49 (37.1)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>52 (40.0)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>18 (13.8)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>34 (26.2)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>26 (20.0)</td>
<td></td>
</tr>
<tr>
<td>IPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>23 (17.7)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>28 (21.5)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>26 (20.0)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>31 (23.8)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>21 (16.2)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>B symptom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>51 (39.2)</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>79 (60.8)</td>
<td></td>
</tr>
<tr>
<td>Extramedial involvement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E positive</td>
<td>66 (50.8)</td>
<td></td>
</tr>
<tr>
<td>E negative</td>
<td>64 (48.2)</td>
<td></td>
</tr>
<tr>
<td>LDH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>45 (34.6)</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>85 (65.4)</td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Median Survival

<table>
<thead>
<tr>
<th>Median Survival (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
</tr>
<tr>
<td>&lt; = 60</td>
</tr>
<tr>
<td>&gt; 60</td>
</tr>
<tr>
<td>Stage</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>IV</td>
</tr>
<tr>
<td>IPI</td>
</tr>
<tr>
<td>Low</td>
</tr>
<tr>
<td>Low-intermediate</td>
</tr>
<tr>
<td>High-intermediate</td>
</tr>
<tr>
<td>High</td>
</tr>
<tr>
<td>B symptom</td>
</tr>
<tr>
<td>Negative</td>
</tr>
<tr>
<td>Positive</td>
</tr>
<tr>
<td>LDH</td>
</tr>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>High</td>
</tr>
</tbody>
</table>

**PRIMARY EFFUSION LYMPHOMA IN AN ELDERLY, HIV & EBV NEGATIVE PATIENT: CASE REPORT**

Murat Özbalak1, Serdar Örnek2, Metin Özdemirli5, Ilyas Tokatlı1, Aykut Köröglü1, Tulay Tecimer4, Yahya Laleli6, Burhan Ferhanoğlu1

1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2VKV American Hospital, Department of Haematology, Istanbul, Turkey
3VKV American Hospital, Department of Haematopathology, Istanbul, Turkey
4Georgetown University Hospital, Department of Haematopathology, Washington, USA
5Duzen Laboratories, Istanbul, Turkey

Introduction: Primary effusion lymphoma (PEL) is a HHV8 associated lymphoproliferative disease characterized by effusions in body cavities, lack of tumor mass, and is commonly seen in HIV and EBV(+), AIDS patients[1]. PEL can also occur in the absence of AIDS, particularly in elderly patients, mostly from areas with high endemic HHV8 infection such as Mediterranean region[2]. Here we present a case of EBV and HIV(-), HHV8(+) PEL patient.

Case: A 79 year-old male patient was presented with dyspnea, bilateral ankle edema, and abdominal distension. He had decreased breathing and heart sounds, ascites. The serology for HIV, HBV, and HCV was negative. The PCR analysis of the serum for HSV1 and HSV2, EBV DNA was also negative.

Cytologic evaluation of ascites and pleural fluid showed large atypical lymphocytes some with plasmacytoid morphology. IHC performed on the cell block showed that the large atypical cells were positive HHV-8, CD138, MUM-1, CD38 and negative for CD20, CD79a, Pax5, EMA, ALK-1, kappa, lambda, T cell markers (CD3, CD5, CD43, CD4, CD8, CD7), CD30, calretinin, and cytokeratin. In situ hybridization for EBV-encoded RNA was negative. The flow cytometric analysis of the pleural fluid revealed seventy percent of the viable cells were bright positive for CD38 and CD138, dimly positive for CD45, negative for CD3, CD2, CD5, CD4, CD8, CD34, CD10, CD11c, CD23, HLA-DR, CD117, CD33, CD13, CD57, CD64, CD25, CD56, CD24, CD16, CD15, CD58, glycophorin A, CD61, CD14, CD19, CD20, CD22, surface and cytoplasmic kappa and lambda proteins. The PCR of the pleural fluid was EBV-DNA(-) and HHV8 DNA(+).

HHV8(+) EBV(-) PEL was diagnosed. HHV8 replication, especially important in the induction and maintenance of KS, PEL, and MCD, is reduced by oral valganciclovir[3]. The patient started on oral valganciclovir 450mg twice daily as he was not suitable for cytotoxic chemotherapy. At the 1st week of the treatment, the blood HHV8 DNA was 16.013 eq-gen/ml(4.20log) and decreased to 3.754 eq-gen/ml(3.57log) at the 4th week by RT-PCR.

Discussion: PEL can occur in the absence of AIDS, mostly from areas with high endemic HHV8 infection such as Mediterranean region[2]. The survival varies from 1 week to 5 years. However, it is obvious that the prognosis is poor and the disease responds poorly to chemotherapy. PEL should be in the differential diagnosis of the anasarca type edema especially in the elderly immune suppressed population.

**Keyword:** Primary effusion lymphoma, HIV (-) EBV(-) HHV8(+)

---

**ZIDOVUDINE-BASED LYTIC-INDUCING CHEMOTHERAPY FOR EBSTEIN-BARR VIRUS-RELATED LYMPHOMAS**

Ulas Darda Bayraktar1, Luis A. Diaz1, Brittany Ashlock1, Ngoc Toomey1, Lisa Cabral1, Soley Bayraktar1, Denise Pereira1, Dirk P. Dittmer2, Juan C. Ramos1

1University of Miami Miller School of Medicine, USA
2University of North Carolina at Chapel Hill, USA

Treatment of Epstein Barr virus (EBV)-related lymphomas with lytic-inducing agents is an attractive targeted approach for eliminating virus infected tumor cells. Zidovudine (AZT) is an excellent substrate for EBV-thymidine kinase; can induce EBV lytic gene expression and apoptosis in primary EBV+ lymphoma cell lines. We hypothesized that the combination of AZT with lytic-inducing chemotherapy agents would be effective in treating EBV+ lymphomas. We report a retrospective analysis of 9 patients with various subtypes of aggressive EBV+ non-Hodgkin’s lymphoma treated with AZT-based chemotherapy.
Ten patients with aggressive EBV+ NHL subtypes were treated with first-line methotrexate (MTX) (3.0-4.5 g/m² IV on day 1) and AZT 1.5 g IV q12 hours (days 2-5) every 3 weeks or upon recovery of blood counts at the discretion of the physician. This regimen was used alone or alternated with dose adjusted EPOCH (DA-EPOCH) or hyper-CVAD chemotherapy. Four patients had PBL, 3 had BL, 1 had DLBCL, and one had a solid PEL variant. Of 8 patients who were HIV+, 6 had a CD4 cell count of less than 200/μL at the time of lymphoma diagnosis. Seven patients had stage IV disease. Two patients received radiotherapy in addition to chemotherapy. Seven of 9 patients (78%) achieved a CR, and 2 patients (22%) had refractory disease. During a median follow-up period of 47.3 months (range 1.3-95.2), 3-year OS and PFS were 77.8% (95% CI: 54.8% - 100.0%) and 67.5% (95% CI, 43.0%-100.0%). The regimen was highly tolerable with only 2 patients (20%) experiencing grade 3-4 adverse events including mucositis and neutropenic fever.

AZT-based combination approaches could add efficacy to standard lymphoma chemotherapy and improve the treatment of γ-herpesvirus related lymphomas.

**Keyword:** non-Hodgkin lymphoma, EBV

---

**PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A CASE REPORT**

Gülsüm Akgün Çağlayan, Öykü Arslan, Oktay Bilgir
Izmir Bozyaka Training and Research Hospital, Department of Hematology Bozyaka/Izmir, Turkey

Objective and Introduction: Primary central nervous system lymphoma (CNS) is a very rare hematologic malignancy that belongs to the group of non-Hodgkin Lymphoma (NHL). It represents 1% of all the lymphomas and is of B lymphocyte origin. It is more commonly observed with immune disorders. Here we present a case of primary CNS lymphoma in a patient with a healthy immune system.

Case: A 67-year-old female patient presented with complaints of speech disorder and inability to walk. Cranial magnetic resonance (MR) imaging requested for diagnostic purposes detected a lesion that is 41 x 23 x 30 mm in size in lateral adjacency to the frontal horn in the left frontal lobe. Stereotactic brain biopsy revealed the presence of diffuse large B-cell NHL. The patient, who had normal ophthalmologic examination results, and negative anti-HIV and hepatitis test results was diagnosed with primary CNS lymphoma. The whole-body PET/CT detected no pathologic-size lymph nodes. Bone marrow aspiration and biopsy showed a normocellular bone marrow. Cranial MR showed no leptomeningeal involvement. After receiving radiotherapy for 11 days as performed at the radiation oncology unit, we administered the DeAngelis protocol. This protocol included the following: methotrexate (MTX) 2000 mg once weekly at the 1st, 3rd, 5th, 7th and the 9th weeks; folinic acid 4 x 40 mg administered for 3 days after MTX; vincristine 2 mg once weekly at the 1st, 3rd, 5th, 7th and the 9th weeks and dexamethasone started at a dose of 16 mg at the 1st and continued by weekly 2-mg dose reductions. Meanwhile, MTX 12 mg was administered via intrathecal route at the 2nd, 4th, 6th, 8th and 10th weeks. Radiotherapy was administered between the 11th and 15th weeks followed by 3000 mg/m² cytosine arabinoside 2x1 at the 16th and 19th weeks. The 41x23x30-mm lesion revealed by the cranial MR taken at the time of diagnosis was observed to regress to 17 x 10 x 11 mm in size at the control cranial MR following the DeAngelis protocol and also motor aphasia and muscle weakness that were present at the time of diagnosis completely returned to normal. The whole-body PET/CT performed after the treatment revealed normal results.

Discussion: It’s interesting that lymphoma of the brain occurs when the brain doesn’t have a lymphatic system. Lymphoma in the CNS may manifest as the spread of the systemic lymphoma or primarily. While the most common site of involvement is the brain in the primary CNS lymphoma, the meninges, eyes and the spinal cord may also be affected. In our case, lymphoma was detected primarily in the brain, left frontal lobe. The patient developed no complications during treatment. The control PET/CT was normal; the patient is under follow-up without receiving any treatment. We present this patient as a case of CNS lymphoma with a normal immune system, who experienced a regression in the marked neurologic complaints with treatment, in order to contribute to the literature.

**Keyword:** central nervous system lymphoma, primary

---

**CONCOMITANT FOLLICULAR LYMPHOMA IN A CASE OF SMALL-CELL LUNG CANCER**

Öykü Arslan, Gülsüm Akgün Çağlayan, Oktay Bilgir
Izmir Bozyaka Training and Research Hospital Department of Hematology Bozyaka/Izmir, Turkey

Introduction and Objective: Small-cell lung cancer represents 15-25% of all the lung cancers. Since disease time is very high, the tumor grows very rapidly; and this condition is considered as a systemic disease since it exhibits distant organ metastasis in the early period. Here we present a patient, who was receiving treatment for small-cell lung cancer and was referred to our department upon developing pancytopenia following treatment and was detected to have follicular lymphoma at the investigations performed for the etiology of the pancytopenia.

Case: A 57-year-old female patient has been diagnosed with small-cell lung cancer a year ago and received 10 days of thoracic radiotherapy following four courses of carboplatin +etoposide chemotherapy and two courses of Campto chemotherapy. Upon failure to achieve improvement in pancytopenia, the patient was referred to our department for further hematologic investigation. The hemogram revealed the following: leukocytes: 900, hemoglobin 8gr/dl and platelets:16,000; the peripheral smear revealed anisocytosis, marked leukopenia, normochromic normocytic erythrocytes and a platelet count of 15,000-20,000. The patient underwent bone marrow aspiration and biopsy. Aspiration revealed a hypocellular bone marrow. Biopsy showed no findings of small-cell lung cancer metastasis by cytokeratin staining, however the case was observed to have CD20, PAX5, bcl-2 positive cluster-type lymphoid cells. Based on these findings, the bone marrow biopsy result was reported as follicular lymphoma bone marrow involvement by the pathology department. The tomographies performed revealed multiple intra-abdominal thoracic lymph nodes. Since the patient had last-stage small-cell lung cancer, she refused treatment and was discharged without any treatment prescribed.
ABSTRACTS

Discussion: Pancytopenia may be related to various reasons including infections, auto-immune diseases, chemotherapy, radiotherapy, solid tumors, hematologic malignancy, chronic liver diseases, hypersplenism, aplastic anemia, storage diseases and megaloblastic anemia. In this patient with small-cell lung cancer, chemotherapy-radiotherapy history, bone marrow involvement due to medication or disease were primarily considered in case of pancytopenia. Upon failure to achieve improvement in pancytopenia following chemotherapy and radiotherapy, the patient was referred to our department and the investigational bone marrow biopsy revealed follicular lymphoma bone marrow involvement and no cancer metastasis was detected. There are no reports on association of small-cell lung cancer and follicular lymphoma in the literature. We present this patient since such association is very rare.

Keyword: follicular lymphoma, small cell lung cancer

Poster No: 00127 Abstract:0191
DO BCL-6 AND CD138 EXPRESSIONS CORRELATE WITH PROLIFERATIVE CAPACITY IN DIFFUSE LARGE B CELL LYMPHOMA?
Ufuk Berber, Aypullah Hatoholu
GATA Haydarpaşa Training Hospital Pathology Department, Istanbul Turkey

Objective: Diffuse large B cell lymphoma is a heterogeneous disease and can be categorized into prognostically significant subgroups as germinal center B-cell-like, and activated B-cell-like, by using immunohistochemical panels. One of these panels include CD10, bcl6, MUM1, and CD138 expression patterns for subdividing diffuse large B cell lymphoma. CD138 expression alone is accepted as an independent poor prognostic factor, whereas bcl-6 expression is associated with a better outcome. Since high Ki67 index is associated with increased growth fraction and correlates well with poor prognostic factors in majority of human cancers, we aimed to assess the correlation of CD138 or bcl-6 immunoreactivities and Ki67 index in our diffuse large B cell lymphoma case series.

Methods: Twenty nodal and 22 extranodal de novo diffuse large B cell lymphoma cases were included in the study. Study group was consisted of 26 male and 16 female patients with a mean age of 54.6 ±22.3 (range 8-95). None of the patients had a known history of HIV infection. Pathological diagnosis of all cases were confirmed by an experienced pathologist based on recent WHO classification. Tissue sections were cut from tissue macroarray blocks of formalin fixed, paraffin embedded pretreatment tumor samples. Ki67 index was determined as positive stained cell percentages using monoclonal MIB1 antibody. For CD138 and bcl-6 expressions, immunoreactivity in >10% of lymphoma cells were defined as positive. Mann Whitney U test was used to compare the difference of Ki67 indices and continuous variables between positive and negative staining groups. Chi square tests were used to analyze categorized variables.

Results: Out of 42 DLBCL samples, 29 (69.0%) were defined as positive and 13 (31%) were defined as negative for bcl-6 staining. Ki67 indices varied in a wide range between 45% and 95%. Mean Ki67 indices of bcl-6 positive cases were slightly lower than the mean Ki67 indices of bcl-6 negative cases, however, the difference was not statistically significant (p=0.19). The distributions of patient demographics between bcl-6 positive and negative cases were similar. Bcl-6 expression frequency was slightly more common in extranodal disease (77.3%, n=17 vs 60.0, n=12) but did not reach the significance level (p=0.05). All cases were defined as negative for CD138 expression in our study group. Therefore we could not analyze its association with proliferative capacity of lymphoma cells.

Conclusion: Although it has been implied as a poor prognostic marker, our results revealed that CD 138 expression is not common in DLBCL. Therefore, its utility in recognizing patients to have a more aggressive disease, is limited. In contrast, Bcl-6 expression is observed in majority of the cases, however, we did not find a significant difference in proliferative capacity of the lymphoma cells with regard to bcl-6 immunostaining, which suggests its inability to discriminate a prognostic subgroup alone.

Keyword: Lymphoma, immunohistochemistry

Poster No: 00128 Abstract:0195
PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN IMMUNOCOMPETENT INDIVIDUALS: A SINGLE CENTER EXPERIENCE
Caner Saygın1, Didem Uzunaslan1, Hilal Ak2, Büge Öz3, Tuğrul Elverdi1, Seniz Öngören1
1Istanbul University Cerrahpasa Medical Faculty, Istanbul
2Istanbul University Cerrahpasa Medical Faculty, Department of Pathology, Istanbul
3Istanbul University Cerrahpasa Medical Faculty, Department of Hematology, Istanbul

Introduction: Primary central nervous system lymphoma (PCNSL) is defined as the involvement of brain, leptomeninges, cerebrospinal fluid, eyes or spinal cord by non-Hodgkin lymphoma without evidence of a systemic lymphoma. After the introduction of highly active antiretroviral therapy into clinical practice and close monitoring with heightened awareness in immunosuppressed individuals, the incidence of PCNSL decreased substantially in these patients. Today, the frequency of PCNSL is much higher in immunocompetent individuals. Whether the disease has a different course in immunocompetent patients is still unclear. The role of various immunophenotypic markers in predicting adverse outcome for this particular group is debated.

Objectives: To investigate the clinical and immunohistochemical findings of immunocompetent PCNSL cases diagnosed at the study center, and evaluate the influence of potential prognostic factors on overall survival (OS) of patients.

Methods: All consecutive cases diagnosed with PCNSL between 1997 and 2012, at Cerrahpasa Medical School, were investigated and only the patients who were immunocompetent at the time of diagnosis were enrolled in this study. Data regarding clinical features and follow-up were obtained from patient records. The strength of the association between OS time and potential prognostic variables was investigated by Kaplan-Meier OS curve and log-rank test. A Cox proportional hazards model was developed to investigate the relationship between five prognostic variables, which had been shown to have an impact on survival in different studies, and OS.

Results: 42 cases were included in the study. Mean age at diagnosis was 51.8 years with a male/female ratio of 1.17/1 (21:18). The majority of the cases presented with headache (n=12), paresthesias/hemiparesis (n=9), 4th International Congress on Leukemia – Lymphoma – Myeloma
seizures (n=6), and signs of raised intracranial pressure (n=5). Parietal lobe was the most commonly involved site (11/39), followed by temporal lobe (8/39), frontal lobe (7/39), and cerebellum (4/39). Multifocal involvement was evident in 23% of the cases (9/39). 33 cases (%84.6) belonged to non-germinal cell subtype. All of the patients had a high Ki-67 index, ranging from 80 to 100% (mean, 93.5%). EBV was positive in 2 cases only. Median follow-up and survival times were 16 and 18 months, respectively. In univariate analysis, patients who received combined chemotherapy and radiotherapy had a significantly better OS when compared to chemotherapy alone (p<0.001)(Table 1). On multivariate analysis, combined therapy was found to be an independent factor affecting the OS (HR=0.088, 95% CI=0.028–0.277)(Table 2).

Conclusion: Combined therapy was superior to chemotherapy alone, but none of the immunophenotypic markers had a statistically significant influence on OS of patients with PCNSL. Prospective studies with large patient series are needed to elucidate prognostic factors, as well as optimum treatment regimens.

**Keyword:** primary central nervous system lymphoma, immunocompetent

---

**Table 1. Univariate Analysis for Various Clinicopathologic Variables (Log-Rank test)**

<table>
<thead>
<tr>
<th>Prognostic Factor</th>
<th>No (%)</th>
<th>Median survival (months)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;= 60 years</td>
<td>8 (22.8) 27 (77.2)</td>
<td>16 18</td>
<td>0.940</td>
</tr>
<tr>
<td>Gender Male</td>
<td>18 (51.4) 17 (48.6)</td>
<td>14 22</td>
<td>0.170</td>
</tr>
<tr>
<td>Multifocal involvement Yes</td>
<td>9 (25.7) 26 (74.3)</td>
<td>14 19</td>
<td>0.503</td>
</tr>
<tr>
<td>Deep-site involvement Present</td>
<td>11 (31.4) 24 (68.6)</td>
<td>19 18</td>
<td>0.383</td>
</tr>
<tr>
<td>Bcl-2 Positive</td>
<td>15 (42.8) 20 (58.2)</td>
<td>14 18</td>
<td>0.107</td>
</tr>
<tr>
<td>CD10Positive</td>
<td>6 (17.1) 29 (82.9)</td>
<td>19 17</td>
<td>0.494</td>
</tr>
<tr>
<td>MUM1Positive</td>
<td>27 (77.1) 8 (23.9)</td>
<td>17 19</td>
<td>0.856</td>
</tr>
<tr>
<td>EBV Positive</td>
<td>2 (5.7) 33 (94.3)</td>
<td>6 19</td>
<td>0.131</td>
</tr>
<tr>
<td>GC status GC phenotype</td>
<td>6 (17.1) 29 (82.9)</td>
<td>19 17</td>
<td>0.494</td>
</tr>
<tr>
<td>Treatment CTx alone CXt + RTx</td>
<td>18 (29.4) 24 (70.6)</td>
<td>9 37</td>
<td>0.000</td>
</tr>
</tbody>
</table>

GC, germinal center; NGC, non-germinal center; CTx, chemotherapy; RTx, radiotherapy

**Table 2. Multivariate Cox regression analysis for prognostic factors**

<table>
<thead>
<tr>
<th>Prognostic Factor</th>
<th>HR (% 95 CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;= 60 years</td>
<td>1.376 (0.509–3.715)</td>
<td>0.529</td>
</tr>
<tr>
<td>Multifocal involvement Yes</td>
<td>0.566 (0.168-1.916)</td>
<td>0.361</td>
</tr>
<tr>
<td>Deep-site involvement Present</td>
<td>0.464 (0.141-1.523)</td>
<td>0.206</td>
</tr>
<tr>
<td>Bcl-2 positivity</td>
<td>1.567 (0.620-3.958)</td>
<td>0.342</td>
</tr>
<tr>
<td>Combined therapy</td>
<td>0.088 (0.028-0.277)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence interval

---

**Figure 1.** Kaplan-Meier overall survival curve of patients with primary central nervous system lymphoma. Patients who received combined chemotherapy and radiotherapy had significantly better overall survival when compared to those who received chemotherapy alone (p<0.001). Two-year survival rate for patients who received combined therapy was 33% while all patients who received single therapy were dead of disease at 17 months follow-up.

**Poster No: 00129**

**Abstract:0199**

**CORRELATION OF MICROVESSEL DENSITY AND TUMOR CELL KINETIC PARAMETERS IN DIFFUSE LARGE B CELL LYMPHOMA**

Üfuk Berber, Aptullah Haholu

GATA Haydarpaşa Training Hospital Pathology Department, Istanbul Turkey

Objectives: Increased proliferation and apoptosis are shown to be correlated with aggressive behavior in majority of the human cancers including diffuse large B cell lymphoma. Tumor microenvironment plays a critical role in the development and progression of the disease and modifies survival and proliferative capacity of the malignant cells partly by regulation of angiogenic processes. In this study we aimed to evaluate the correlation of microvessel density (MVD) and tumor cell kinetic parameters in diffuse large B cell lymphoma.

Methods: Pretreatment tumor samples of 42 diffuse large B cell lymphoma cases (20 nodal and 22 extranodal) were included in the study. MVD score was semiquantitatively assessed as low and high after immunostaining with CD31 antibody. Proliferative indices were assessed by using monoclonal MIB1 antibody. Apoptotic cells were labelled by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) technique. Positive stained cell percentages were used for apoptotic and Ki67 indices. The associations between MVD
score and Ki67 or apoptotic indices were analysed by Spearman’s correlation test.

Results: In 27 (64.3%) cases, MVD scores were defined as high, and in 15 (35.7%) cases MVD scores were defined as low. Ki67 indices varied in a wide range between different DLBCL samples (range 45% - 95%). We observed a significant correlation between MVD and Ki67 index (r=0.312; p<0.04). However, there was no statistically significant correlation between apoptotic index and MVD. There was no correlation between MVD and clinical parameters such as age, localization, or gender.

Conclusion: The prognostic value of increased MVD has been shown in various tumors. However, the data about its value in DLBCL is limited. We found a positive correlation between MVD and proliferative capacity of the tumor cells, which suggests the utility of vascularization as a prognostic marker for this heterogeneous disease group. We were also interested in the associations of MVD and apoptotic index, however, our study did not show a significant correlation between them. In addition, the apoptotic indices were low in all cases, which revealed that irrespective of the clinicopathological features, anti-apoptotic mechanisms play a major role in DLBCL pathogenesis. Although mean MVD scores were slightly higher in patients with young ages, or in extranodal disease, the differences did not reach the significance level. Our results did not show any significant correlation between MVD and other clinical parameters.

Keyword: Lymphoma, Microvessel Density

Poster No: 00131 Abstract:0201

PRIMARY GASTRIC LYMPHOMAS: INTER OBSERVER AGREEMENT BETWEEN PATHOLOGISTS
Didem Uzunaslan1, Caner Saygın1, Ahu Senem Demirözd2, Gülen Doğusoy2, Suha Gökssel2, Hilal Akı3, Seniz Öngören3
1Istanbul University Cerrahpasa Medical Faculty, Istanbul Turkey
2Istanbul University Cerrahpasa Medical Faculty, Department of Pathology, Istanbul Turkey
3Istanbul University Cerrahpasa Medical Faculty, Department of Hematology, Istanbul Turkey

Introduction: Primary gastric lymphoma (PGL) is a rare tumor that constitutes 1-5% of all gastric malignancies. Presenting symptoms of the patients are usually non-specific and B-type symptoms including palpable mass and gastrointestinal bleeding are seen only in minority of the cases. Considerably low diagnostic rate of barium-contrast studies and various non-specific endoscopic patterns make biopsy the most important tool in diagnosis of PGL. Due to the progressive increase in the incidence of PGL during last decades and improvement of diagnostic endoscopy in optics, pathologists encounter this tumor more than they did. PGL is a treatable cancer in a high percentage of cases, thus, pathologists should be able to diagnose this tumor accurately from gastric biopsy specimens.

Objective: Detecting the discrepancies and concordance between gastropathologist, hematopathologist and general pathologist in the diagnosis of primary gastric lymphomas.

Materials-Methods: 47 patients were diagnosed as PGL at Cerrahpasa Faculty of Medicine between 2000-2008. Hematoxylin-eosin stained slides of these patients were retrieved and two gastropathologists, one hematopathologist and one general pathologist evaluated the
parameters including tumoral infiltration pattern, infiltration area, infiltrative cell type, Russel and Dutcher cell bodies, lymphoepithelial lesion, intraepithelial lymphocyte amount, reactive lymphoid follicles and follicular colonization without knowing anything about the immunohistochemical results. Spearman correlation coefficient was used to evaluate agreement between pathologists. r value between 0-0.3 was accepted as no agreement, 0.3-0.5 as weak, 0.51-0.74 as intermediate, 0.75-1 as strong agreement.

Results: Concordance between pathologists for all parameters are summarized in the table. Overall, there was a weak concordance for tumoral infiltration pattern, but for diffuse large B cell lymphoma alone, concordance could not be detected at all. There was a strong agreement for glandular localization, but it was not observed for other localizations including foveola, muscularis mucosa and submucosa. Additionally, there was a weak concordance for monocytoid cells, intermediate concordance was seen in large cells, no concordance was detected for transformed cells and centrocytes. Pathologists did not make a strong agreement for Dutcher and Russel bodies. A weak concordance was shown in lymphoepithelial lesion. Intraepithelial lymphocytes, reactive lymphoid follicles and follicular colonization did not have a significantly high level of agreement between pathologists.

Conclusion: Since the immunophenotyping is not a specific tool in the diagnosis of PGL, morphologic evaluation has a critical importance in the diagnostic process. Our study highlighted the level of concordance and discrepancies in the evaluation of diagnostic parameters between pathologists.

Keyword: primary gastric lymphoma, pathologist

<table>
<thead>
<tr>
<th>Tablo 1. Interobserver agreement between pathologists for different morphological variables (Spearman Correlation test)</th>
<th>r value, MALT lymphoma (n=18)</th>
<th>r value, DLBCL (n=21)</th>
<th>r value, all cases (n=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumoral infiltration pattern</td>
<td>0.42</td>
<td>0.02</td>
<td>0.34</td>
</tr>
<tr>
<td>Tumor localization</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tumoral infiltration pattern</td>
<td>0.19</td>
<td>0.28</td>
<td>0.89</td>
</tr>
<tr>
<td>Monocytoid cells</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Large cells</td>
<td>0.42</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>Transformed cells</td>
<td>-</td>
<td>0.01</td>
<td>0.12</td>
</tr>
<tr>
<td>Centrocytes</td>
<td>-</td>
<td>0.27</td>
<td>0.29</td>
</tr>
<tr>
<td>Dutcher bodies</td>
<td>0.1</td>
<td>0.14</td>
<td>0.16</td>
</tr>
<tr>
<td>Russell bodies</td>
<td>0.35</td>
<td>0.24</td>
<td>0.40</td>
</tr>
<tr>
<td>Lymphoepithelial lesion</td>
<td>0.34</td>
<td>0.05</td>
<td>0.17</td>
</tr>
<tr>
<td>Intraepithelial lymphocyte count</td>
<td>0.43</td>
<td>0.33</td>
<td>0.28</td>
</tr>
<tr>
<td>Presence of reactive lymphoid follicles</td>
<td>-</td>
<td>-</td>
<td>0.11</td>
</tr>
</tbody>
</table>

* Spearman correlation test could not be performed because more than one observer had the same answers for all specimens.
confused with T cell lymphomas microscopically, thus it should be excluded before making the diagnosis of lymphoma in pediatric age group.

**Keyword:** ALPS, NHL

**Poster No:** 00133  **Abstract:**0218

**HAIRY CELL LEUKEMIA PRESENTING WITH ISOLATED SKELETAL INVOLVEMENT SUCCESSFULLY TREATED BY RADIATION THERAPY AND CLADRIBINE: REPORT OF A CASE**

İpek Yönal1, Fehmi Hindilerden2, Sanem Dereli Bulut3, Burcu Kurt3, Eren Yıldız4, Ibrahim Öner Doğan5, Meliya Naçacı1

1Istanbul University Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey
2Istanbul Bilim University, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey
3Istanbul University Istanbul Medical Faculty, Department of Radiology, İstanbul, Turkey
4Istanbul University Istanbul Medical Faculty, Department of Orthopaedics and Traumatology, İstanbul, Turkey
5Istanbul University Istanbul Medical Faculty, Department of Pathology, İstanbul, Turkey

Hairy cell leukemia (HCL) characterized by infiltration of peripheral blood, bone marrow (BM) and spleen by ‘hairy cells’ represents 2% of leukemias. Skeletal involvement resulting in lytic or mixed lytic/blastic lesions in HCL is rare, with frequencies ranging from 0% to 13%.

A 55-year-old male was admitted with 3-month history of severe pain in right femur extending to his right leg. On physical examination, there was no lymphadenopathy or organomegaly. Blood count was as follows: haemoglobin: 13 g/dl, WBC: 6030/mm³ and platelet: 267000/mm³. Biochemical tests showed increased ESR (50 mm/h) and hypergammaglobulinemia; LDH was normal. Anteroposterior radiographs of both femurs revealed mixed lytic-sclerotic lesions and lytic destructive process with eccentric localization and narrow zone of transition at diaphysis of left femur extending to left subtrochanteric region. On MRI scan, multiple hypointense metastatic bone lesions on T1-weighted coronal imaging and hyperintense metastatic lesions on T2-weighted coronal imaging dominantly located in both femoral heads, necks and trochanters with largest of diameter 2 cm were present. Abdominal MRI revealed 1 cm wide heterogeneous metastatic lesion at left side of posterior L2 and L3 vertebrae corpus on T1-weighted axial imaging. Histopathological examination of biopsy from right femoral region showed diffuse neoplastic infiltration consisting of cells with round, oval, regular nuclei and mediumsized, clear cytoplasm. Neoplastic cells expressed CD20, LCA, CD79 alpha, TRAP, CD11c, CD68 and annexin. Diagnosed with HCL, patient was referred to our hematology department. Blood smear showed 54% neutrophils, 40% lymphocytes and 6% monocytes. Lymphocytes appeared normal. Bilateral BM aspirates revealed normal bone marrow elements with no hairy cells. Flow cytometry of BM aspirates revealed no abnormal clone of lymphoid cells or aberrant antigen expression. Bilateral BM trephine biopsies showed normocellular BM. On PET scan, there was increased FDG uptake in axial skeleton, sacrum, pelvis and bilateral femurs (Figure 1a). Patient underwent radiotherapy to bilateral proximal femur at a dose of 20 Gy and obtained complete clinical response with resolution of pain. Four weeks after completion of radiotherapy, 7-day course of 0.1 mg/kg/day cladribine was administered. Follow-up PET scan performed 8 weeks after chemotherapy showed marked metabolic response with decrease in uptake of multiple metastatic lesions on bilateral proximal humerus, right lamina of C6 vertebrae and bilateral first ribs (Figure 1b). Repeat PET scan 12 months after chemotherapy showed normal recovery of skeletal disease, with no evidence of residual enhancement. There is no disease recurrence 14 months after chemotherapy.

Skeletal involvement is infrequent in HCL and almost associated with extensive involvement of BM. Isolated skeletal involvements with no BM involvement or splenomegaly as in our case is a rarely reported entity.

**Keyword:** Hairy cell leukemia, skeletal involvement

![Figure 1](image)

**Poster No:** 00134  **Abstract:**0220

**A CASE OF SIMULTANEOUSLY OCCURRING DIFFUSE LARGE B CELL LYMPHOMA AND SQUAMOUS CELL LUNG CANCER**

Eda Tanrıku1, Özlem Şahin Balci, Ali Koşar1, Zeki Yıldırım2

1Turgut Özal University, School of Medicine, Department of Chest Diseases, Ankara, Türkiye
2Turgut Özal University, School of Medicine, Department of Pathology, İstanbul, Turkey

Diffuse large B-cell lymphoma (DLBCL) and squamous cell lung cancer (SCLC) has been rarely seen together at the same time. Due to the common planned treatment for SCLC and DLBCL, this case, in which both malignities have been seen simultaneously, is found appropriate to the presentation. Sixty two years old man who followed with the diagnosis of chronic obstructive lung disease was admitted with a diameter of 4 cm left axillary lymphadenopathy (LAP). According to our investigations, opacity with a diameter of 45 mm in his right lung parahilar has been monitored in his chest X-ray. Then chest computed tomography (CT) has been performed and multiple lymphadenopathy in the left axilla with the largest 39x27 mm, mediastinal multiple LAP with the largest 26x11 mm, 44x35 mm mass in the parahilar side of the right upper lobe, three nodules in the lower lobe of the right lung with the largest 13 mm, two nodules in the lower lobe of left lung with the largest 8 mm were observed. In addition, 45x47 mm (SUV max 9.3) nodule in the upper lobe of the right lung, 3 nodules in the lower lobe of the right lung with the largest 25x16 mm (SUV max 9.3), 37x32.5x22 mm (SUV max: 22) LAP in the left axilla were detected in the PET-CT. According
to tru-cut biopsy to axillary LAP, DLBCL was diagnosed with CD20+, CD79a+, CD5-, CD3 - diffuse cell infiltration. CT-guided biopsy was performed of lesion of lung parenchyma. Squamous cell carcinoma was diagnosed with keratin5+, keratin14+, P63+ malignant epithelial tumor. Treatment of patient has been decided with pneumologists. Rituximab, carboplatin, paclitaxel-containing chemotherapy was planned collectively. Treatment of patient is ongoing.

**Keyword:** Diffuse large B-cell lymphoma, squamous cell lung cancer

---

**A LGL CASE DEVELOPING LONG TERM AFTER ALLOGRAFT REJECTION**

Özlen Bektaş1, Aynur Uğur Bilgin2, İbrahim Güney3

1Meram Training and Research Hospital, Department of Hematology, Konya
2Necmettin Erbakan University, Meram School of Medicine, Department of Hematology, Konya
3Meram Training and Research Hospital, Department of Nephrology, Konya

The chronic use of immunosuppressive agents in solid organ transplantation increases the long-term risk of malignancy. This reports describes a T-cell Large Granulocytic Leukemia (LGL) case developed following chronic renal allograft rejection. Case: 48 year-old male patient who had been diagnosed with chronic renal failure 21 years before. He had received dialysis for 9 years and then had a renal transplantation. At the end of the first year of the transplant chronic rejection had occurred. He received 1U/week eritrocite transfusion for a year since he had a erythropoetin unresponsive anemia. He has been a dialysis since last five years. At the last 6 months the patient re-developed erythropoetin unresponsive anemia and a need for transfusion. In the physical exam skin was urochromic with pale conjunctiva and mucosas, liver and spleen are palpable under 3 cm of costal margin and a left radial aneurysmatic fistula. Hb 6.7 gr/dl, WBC: 3630 U/L, MCV: 80, platelets:149000 U/L and reticulocyte was <%1. Ferritine: 1890 ng/ml and B12: 281. In abdominal USG liver was 160 and spleen was 154 mm. Bone marrow was normocellular with a noticeable decrease in erythroid progenitor cells and with lymphocyte cell percentage was 28% and these cells have prominent granular cytoplasm. In flow-cytometric analysis CD3: 90%, CD4: 6%, CD8: 82% and CD20 was 3%. T-clonality was positive. With these findings the patient was diagnosed with T-LGL.

T-cell LGL is a heterogeneous disorder characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. In most cases the clinical course is indolent. There is frequently severe neutropenia with or without anemia. Severe anemia due to red cell aplasia has also been reported in association with T-LGL. Moderate splenomegaly is the main physical finding. The etiology of T-cell LGL has not been entirely elucidated, but chronic antigenic stimulation with exogenous antigens or putative endogenous autoantigens may be responsible for inducing the activation and clonal expansion of effector CD8+ LGL. In chronic allograft injury of renal transplantation, there is evidence to show that CD4+ and CD8+ T cells play roles. The proposed mechanism of malignancy developing in the post transplantation period is usually immunosuppression. T-cell stimulation following transplantation may also contribute to the post-transplant malignancy development.

**Keyword:** LGL, renal transplantation

---

**BONE MARROW INVOLVEMENT OF A PATIENTS WITH ANAPLASTIC LARGE CELL LYMPHOMA: MORPHOLOGIC AND IMMUNOPHENOTYPIC FEATURES**

Tarkan Yetişyiğit1, Mustafa Oran1, Meltem Özner2, Turgut Burhan3

1University of Namik Kemal, Medical Faculty, Department of Internal Medicine, Tekirdağ, Turkey
2University of Namik Kemal, Medical Faculty, Department of Medical Pathology, Tekirdağ, Turkey
3University of Namik Kemal, Medical Faculty, Department of Internal Medicine, Division of Hematology, Tekirdağ, Turkey

Anaplastic large cell lymphoma (ALCL), which is a T-cell lymphoma type, usually presents with nodal involvement. Leukemic from is extremely rare. In spite of well known CD30 positivity which is usually detected with immunohistochemistry, there is scary literature about immunophenotypic which is performed with flow cytometry. We herein report the morphologic and immunophenotypic features of a case of ALCL presented with a leukemic relapse.

A 16-year-old girl who admitted to our hospital with suddenly appeared high fever, sore throat, and mild cervical lypphenadenomagely. The patient was originally diagnosed with ALK-positive ALCL of the cervical lymph node. Bone marrow biopsy was negative at that time. She was treated with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone) chemotherapy for eight cycles and had a remission confirmed with PET-CT. Relapse appeared two months after end of the chemotherapy.

After admission, the health condition of the patient did get worse in a few days. Anemia, thrombocytopenia, leukocytes large granular lymphocytes, without a clearly identified cause. In most cases the clinical course is indolent. There is frequently severe neutropenia with or without anemia. Severe anemia due to red cell aplasia has also been reported in association with T-LGL. Moderate splenomegaly is the main physical finding. The etiology of T-cell LGL has not been entirely elucidated, but chronic antigenic stimulation with exogenous antigens or putative endogenous autoantigens may be responsible for inducing the activation and clonal expansion of effector CD8+ LGL. In chronic allograft injury of renal transplantation, there is evidence to show that CD4+ and CD8+ T cells play roles. The proposed mechanism of malignancy developing in the post transplantation period is usually immunosuppression. T-cell stimulation following transplantation may also contribute to the post-transplant malignancy development.

**Keyword:** anaplastic large cell lymphoma, immunophenotype
ABSTRACTS

Figur 1. ALCL cells in bone marrow.

LOSS OF CD20 ANTIGEN EXPRESSION AFTER RITUXUMAB THERAPY OF CD20 POSITIVE B-CELL LOW-GRADE NON HODGKIN LYMPHOMA

Svetlana Stankovic
University Clinic of Hematology, Skopje, Macedonia

Background: Rituximab is a key molecular targeting drug for CD20 positive B-cell lymphomas. Recently, resistance to Rituximab has been recognised to be a considerable problem in re-treatment patients. The mechanism of resistance to Rituximab retreatment in non-responding patients is unknown, but it is possible that loss of CD20 expression in the relapsed NHL could be important in some cases.

Aims: Here we present a patient with CD20 positive low grade B-cell NHL that lost the CD20 expression at relapse after Rituxumab therapy.

Case presentation: A 39-year-old female was admitted at our hospital with a diagnosis of Non-Hodgkin lymphoma (CLL/SLL). Immunohistochemical analysis on diagnostic samples of the axilar lymph node biopsy showed CD20 positive expression with proliferative centres positive for Ki67 that responds to pseudofollicular variant. The patient was treated according to R-CVP protocol (Rituxumab 375mg/m² on day 1, Vincristine 2 mg on day 2, Cyclophosphamide 400mg/m² and Prednisolon 50mg daily on days 2-6, every 28 days, eight courses). Maintenance therapy with Rituxumab was continued on three months intervals. At ten months from initial therapy conclusion, a relapse of the lymphoma was found. The second-line therapy according to R-CHOP protocol was started (Rituxumab 375mg/m² on day 1, Vincristine 2 mg, Cyclophosphamide 750mg/m², Doxorubicin 50mg/m² on day 2 and Prednisolon 100mg daily on days 2-6). Partial remission was achieved after 8 cycles of therapy that lasted one year when further recurrence of the lymphoma occurred consisting of lymph nodes enlargement and WBC 94000/mm³. The patient was then treated with 6 new cycles of chemo-immunotherapy according to FCR protocol (Rituxumab 375mg/m² on day 1 and Fludarabine 25mg/m² and Cyclophosphamide 250mg/m² on days 2-4). The achieved partial response lasted 4 months when new lymph node enlargement and leucocytosis of up to 220000/mm³ occurred. Flow cytometric analysis of peripheral blood demonstrated loss of CD20 expression on malignant lymphocytes, while CD19 and CD5 were positive in 80% cells. Father therapy with high-dose Methyl-prednisolon was started.

Conclusions: Our observation confirmed the hypothesis already described in literature, that a CD20 negative phenotypic change could occur in certain number of patients with CD20 positive B-cell lymphomas. As such, CD20 expression by both flow cytometry or immunohistochemistry should be undertaken to document CD20 expression prior to considering repeated courses of Rituxumab in relapsed Non-Hodgkin lymphomas.

Keyword: Non Hodgkin lymphoma, CD20 antigen

HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEGATIVE AND HUMAN HERPES VIRUS-8 (HHV-8)-POSITIVE PRIMARY EFFUSION LYMPHOMA: A CASE REPORT AND REVIEW OF THE LITERATURE

1Turgut Özal University, School of Medicine, Department of Internal Medicine, Ankara, Turkey
2Turgut Özal University, School of Medicine, Department of Pathology, Ankara, Turkey
3Turgut Özal University, School of Medicine, Department of Hematology, Ankara, Turkey

Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma that presents with serosal effusion in body cavities, without obvious tumor masses. Although PEL occurs in immunocompromised patients that are human immunodeficiency virus (HIV) positive, it also occurs in immunocompetent human herpes virus-8 (HHV-8)-positive patients. Herein we present an immunocompetent, HIV-negative, CD-20-negative, HHV-8-positive patient with pleural effusion that was diagnosed as PEL. The CHOP protocol and talc pleurodesis were administered. HHV-8 plays a causative role in PEL and is important for differentiating PEL from other types of lymphoma. As such, in addition to pleurodesis antiviral treatment should be considered for optimal treatment outcome.

Keyword: Human herpes virus-8, Primary effusion lymphoma

PRESENTATION: CASTLEMAN DISEASE WITH POLYMYOSITIS

Zoran Milojevic, Maja Perunicic, Branka Bonaci Nikolic, Katarina Markovic, Nevenka Markovic, Dusica Filic, Stanko Radulovic
1Department of Hematology and Oncology, KBC Zvezdara, Belgrade, Serbia
2Pathology Department KCS Belgrade, Serbia
3Immunology & Alergology Clinic KCS Belgrade, Serbia

Introduction: Castleman Disease or Angiofollicular Lymph Hyperplasia is a rare illness that can occur clinically in an unicentric or localized form with an isolated enlargement of the lymph nodes (often located in the mediastinum) or in a multicentric form as a systemic disease with generalized lymphadenopathy and organomegaly. It occurs histologically in three forms: hyaline vascular, plasma-cellular and transitional (mixed) form. This case-report presents a patient with a multicentric appearance of the disease, histologically plasma-cellular form including polymyositis.
Case: The patient, 71 years old, was admitted in May 2010 with fever, sweating, loss of body weight, pain, weakness in the muscles, and generalized lymphadenopathy (large lymph nodes in the neck and in both axillae and individual lymph nodes in the groins). A CT scan showed a slightly enlarged liver, the hilum and retroperitoneal lymph nodes were up to 20mm in size and an enlarged spleen of up to 18cm. He did not have enlarged mediastinal lymph nodes. The lab findings showed he had SE 90, a moderate immune hemolytic anemia (+direct Coombs test) HGB 115 g / L, thrombocytopenia 76x10^9/L, total protein 137g / L, albumin 25 g / L, an increase of polyclonal IgG 52.4 g / L, preserved global renal function, CRP 52, HBsAg, HCV, HIV negative. Biopsy of the neck lymph nodes and histopathological findings indicate that it was a case of plasmacytoid form of the M. Castlenu, ruling out lymphoproliferative disease. According to the clinical appearance it is a case of multicentric Castleman disease. Immunological tests showed the existence of a systemic connective tissue disease, most likely type Polymyositis, ANA (IgG) tests showed the existence of a systemic connective tissue disease. According to the clinical appearance it is a case of Castleman’s disease as a primary or secondary phenomenon.

**Keyword:** Castleman, Polymyositis

**Poster No:** 00140

**Abstract:**

**NON-HODGKIN’S LYMPHOMA: IS 1G/M2 METHOTREXATE AS EFFECTIVE AS 5 G/M2 IN ADVANCED STAGE NONLYMPHOSTATIC NON-HODGKIN Lymphoma?**

Rejin Kebudi1, Ömer Görğün1, Fatma Betül Çakır2, Inci Ayhan3, Bülent Zülfikar1, Öner Doğan4

1Istanbul University, Cerrahpasa Medical Faculty, Division of Pediatric Hematology-Oncology, Istanbul University, Oncology Institute, Istanbul
2Bezmialem Vakif University Medical Faculty, Pediatric Hematology-Oncology, Istanbul, Turkey
3Istanbul University, Oncology Institute, Istanbul, Turkey
4Istanbul University, Department of Pathology, Istanbul, Turkey

Background: Survival rates in non-Hodgkin’s lymphoma (NHL) have increased significantly in the last decades. Objectives: This study aims to assess the demographic data and treatment results of children with non-lymphoblastic NHL treated in a single institution.

Methods: 106 children (74 male, 32 female), treated in Istanbul University, Oncology Institute, between 9/1989-12/2012 were evaluated retrospectively.

Results: The median age was 8(2-19) years. Histopathologic subtypes: 81 Burkitt and Burkitt like, 25 large cell. The primary location was abdomen in 51, mediastinum 4, head/neck 31, 20 other (bone 8, breast 2, ovaries 2, skin 2, paravertebral 2, other 4). Bone marrow was involved in 10, CNS in 2. Forty patients had stage I+II, 44 stage III, and 22 had stage IV disease. Until 1991, non-lymphoblastic NHL received COMP. After then, all received BFM protocols. Non-lymphoblastic NHL patients received BFM protocols with 5 g/m2 methotrexate (MTX) until 1995 and 1 g/m2 MTX thereafter.

34 patients died, due to toxicity. Ten year survival and event-free-survival in the whole group was 76 and 76 % respectively. Ten year survival was 100, 94.3, 71.3 and 50% in stage I, II, III, and IV. Considering only advanced stage non-lymphoblastic NHL patients, 10 year survival was significantly higher in patients receiving BFM regimen with 1 g/m2 MTX, than in ones receiving COMP or BFM protocol with 5 g/m2 MTX (10 year survival 81%, 46.7%, 44.4% respectively). Burkitt type patients had also significantly higher 10-yr survival with 1 gr/m2 MTX than 5 gr/m2 or COMP treatment (78.5%, 41.7% and 40%). When deaths due to toxicity are excluded from the analysis, 10-yr survival is significantly higher in 1 gr/m2 than 5 gr/m2 and COMP treatment (88%, 51.3% and 50.9% respectively).

Conclusions: Survival rates in the whole group are in parallel with advances attained in the world in NHL. The significantly higher survival rates achieved in patients with advanced stage non-lymphoblastic patients receiving modified BFM (1g/m2MTX) may be due to the decreased toxicity seen in this group and to the advances in supportive care in the last decade. In another major center in the same university that uses the same protocol with 5 g/m2 MTX in the same time period, similar survival rates suggest that 1 g/m2 MTX which is cheaper and less toxic is also as effective as 5 gr/m2 in these patients.

**Keyword:** Non-Hodgkin Lymphoma; Burkitt Lymphoma; Methotrexate; Advanced stage
organomegaly, but with a palpable tumor mass in the lower pelvis, 10 cm in diameter. ECOG PS 3.

Laboratory data included mild anaemia (Hb 109 g/L), normal total and differential leucocyte count, mild thrombocytosis (477 x 10^9/L), positive inflammatory syndrome (ESR 56/h, CRP 18 mg/L, ferritine 891 ug/L, borderly elevated LDH – 452 U/L). Abdominal CT scan revealed a tumor mass sized 11x10 cm in the lower pelvis, involving right ovary and spreading towards the uterus, small and large intestine, right kidney with the signs of the first degree stasis. Other analyses were within the normal range, thoracal CT and bone marrow histology without pathological features.

Abdominal surgery was performed in March 2010 and revealed tumor mass involving the right ovary and spreading to the external uterus wall, small and large intestine. Operative performance included: Hysterectomy totisum cum adnexectomiam bill et hemicolectomiam dextram cum ileocoloanastomisis termino-terminalis. Histopathological diagnosis: NHL DBCL of the anaplastic type, with Ki 67 positive in >90% cells. Clinical staging classified the patient as IV cl stage, with IPI – 5(high risk).

After the surgery, patient received chemotherapy according to the R-CHOP regime, total eight cycles resulting with the complete remission.

28 months after the completion of the chemotherapy, complete remission persists.

Primary ovarian NHL shares the same therapeutical modality as well as the prognosis with other NHLs.

**Keyword:** ovarian lymphoma

---

**Poster No:** 00142  **Abstract:** 0256

**99MTC-HYNIC-RITUXIMAB: A PROMISING MOLECULAR IMAGING AGENT IN NON-HODGKIN’s LYMPHOMAS**

Ximena Camacho, Agustina Banchero, María Fernanda García, Marcelo Fernández, Williams Porcal, María Moreno, José A. Chabalgoity, Juan Pablo Gambini, Pablo Cabral, Eloisa Riva

1Centro de Investigaciones Nucleares, Facultad de Ciencias, UdelaR, Montevideo, Uruguay.
2Centro de Medicina Nuclear, Facultad de Medicina, UdelaR, Montevideo, Uruguay
3Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Montevideo, Uruguay
4Instituto de Higiene, Facultad de Medicina. UdelaR, Montevideo, Uruguay
5Cátedra de Hematología, Hospital de Clínicas, Facultad de Medicina. UdelaR, Montevideo, Uruguay

**Background:** Anti-CD20 (Rituximab®), a chimeric monoclonal antibody directed against B lymphocytes surface CD20 antigen is a major therapeutic agent in CD20+ non-Hodgkin’s lymphomas (NHL).

**Objectives:** Labeling 99mTc -Rituximab through bifunctional chelant agent Suc-HYNIC. Evaluate this as a potential imaging agent in NHL.

**Methodology:** Rituximab was derivatized through Suc-HYNIC and labeled with 99mTc using Tricine/SnCl2.2H2O. Radiochemical purity was determined by ITLC-SG and HPLC. In vitro stability was evaluated in solution and serum up to 24 h. Specificity of binding was performed in Raji cells. Biodistribution was evaluated in BALB/c normal mice at 4 and 24 h (n = 5).

*Results:* HYNIC-rituximab was easily separated from free HYNIC with >90% recovery of the initial antibody. Efficacy of 99mTc-HYNIC-Rituximab binding was > 90 %. Radiochemical purity was >90% in solution and serum, remaining stable after incubation at 37º during 24 h. Specificity of 99mTc-HYNIC-rituximab binding to CD20 antigen was demonstrated, as shown in Fig.1. Biodistribution of the conjugate is similar to that of labeled antibodies, remaining stable in vivo with a low uptake in thyroid and stomach, as shown in fig 2.

**Conclusion:** 99mTc-HYNIC-rituximab represents a promising molecular imaging agent in NHL. Experiments in tumoral models will be the next step in our research.

**Acknowledgements:** Roche, Pro.In.Bio.

**Keyword:** Rituximab, 99mTc

---

**Table 1. Biodistribution**

<table>
<thead>
<tr>
<th>Tissue</th>
<th>1h</th>
<th>4h</th>
<th>24h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>18.35 ± 0.33</td>
<td>16.61 ± 1.78</td>
<td>10.65 ± 1.94</td>
</tr>
<tr>
<td>Liver</td>
<td>5.35 ± 3.85</td>
<td>7.37 ± 1.09</td>
<td>9.37 ± 3.00</td>
</tr>
<tr>
<td>Heart</td>
<td>3.11 ± 1.03</td>
<td>6.93 ± 0.77</td>
<td>4.89 ± 1.35</td>
</tr>
<tr>
<td>Lungs</td>
<td>3.61 ± 1.81</td>
<td>6.38 ± 0.99</td>
<td>4.78 ± 1.61</td>
</tr>
<tr>
<td>Spleen</td>
<td>1.78 ± 0.54</td>
<td>4.89 ± 0.78</td>
<td>3.92 ± 1.91</td>
</tr>
<tr>
<td>Kidneys</td>
<td>3.04 ± 1.56</td>
<td>6.22 ± 1.33</td>
<td>4.73 ± 1.55</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.95 ± 0.57</td>
<td>0.93 ± 1.10</td>
<td>0.21 ± 1.01</td>
</tr>
<tr>
<td>Muscles</td>
<td>0.47 ± 0.23</td>
<td>1.30 ± 0.37</td>
<td>0.69 ± 0.33</td>
</tr>
<tr>
<td>Bone</td>
<td>0.92 ± 0.42</td>
<td>1.55 ± 0.44</td>
<td>1.14 ± 0.46</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.22 ± 0.43</td>
<td>0.74 ± 0.70</td>
<td>0.70 ± 0.46</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>1.26 ± 0.70</td>
<td>6.89 ± 2.92</td>
<td>3.94 ± 0.53</td>
</tr>
</tbody>
</table>

Percentage of dose injected (g (%DI)/g)*

**Table 2. Biodistribution2**

<table>
<thead>
<tr>
<th>Tissue</th>
<th>1h</th>
<th>4h</th>
<th>24h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guts</td>
<td>2.70 ± 0.92</td>
<td>12.22 ± 4.05</td>
<td>7.30 ± 1.95</td>
</tr>
<tr>
<td>Bladder + Urine</td>
<td>3.02 ± 0.16</td>
<td>14.08 ± 3.32</td>
<td>23.63 ± 2.21</td>
</tr>
</tbody>
</table>

Percentage of dose injected (%DI)*

---

**4th International Congress on Leukemia – Lymphoma – Myeloma**
A RARE CASE OF LYMPHOMATOID GRANULOMATOSIS PRESENTED WITH AUTOIMMUNE HEMOLYTIC ANEMIA

Anıl Tombak, Mehmet Ali Uçar, Aydan Akdeniz, Burcu Boztepe, Eyüp Naci Tiftik
Mersin University Medical Faculty Internal Medicine
Hematology Department, Mersin, Turkey

Introduction: Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites. It is an EBV-driven disease and pulmonary involvement occurs in over 90% of patients. Patients frequently present with symptoms related to respiratory tract. Here, we report a patient diagnosed as LYG 1.5 years after the presenting symptom of autoimmune hemolytic anemia.

Case: A 47 years old male admitted to our hospital with a fatigue. At this admission, laboratory tests were as: WBC: 980 /mm³, Hb: 8.5 gr/dL, MCV: 97.1, Plt: 177.000 /mm³, LDH: 320 U/L, and few small pulmonary nodules were seen on posterior-anterior chest X-ray. On thoraco-abdominopelvic computed tomography (CT), multiple hypodense nodular pulmonary parenchymal lesions (largest one is 3x2.5 cm) were seen, and the longitudinal length of liver was 17.5 cm, spleen’s was 13.5 cm. Wedge biopsy of the pulmonary nodule was performed and reported as “coagulation necrosis continued with lung parenchyma”. RF, ANA, dsDNA, p-ANCA and c-ANCA, anti-CCP, HBsAg, anti-HCV, anti-HIV were (-). After 1.5 months of the biopsy, Hb level fell to 4.9 gr/dL and the patient was consulted to our hematology department. During this period, direct coombs (+) immune hemolytic anemia was determined with IgG type warm antibodies. 1 mg/kg/day methyl prednisolone was prescribed, but anemia did not respond to this treatment. Three months later, splenectomy was performed and reported as extra-medullary hematopoiesis. After splenectomy, symptoms related to respiratory tract were improved and multiple lymphadenopathies were developed and on thoraco-abdominopelvic CT; multiple conglomerated cervical, axillary, mediastinal, abdomino-pelvic lymphadenopathies, multifocal solid lesions in liver and lungs were seen (Picture). Anti-CMV-IgG, anti-toxoplasma-IgG were (+) and monospot heterophile antibody test was (-). Excisional cervical lymph node biopsy was performed and reported as “lymphomatoid granulomatosis, grade III”. The patient died due to sepsis a few days after the biopsy.

Discussion: The most common underlying diseases of secondary autoimmune hemolytic anemia are lymphoproliferative disorders and immune diseases. LYG is a rare EBV-driven lymphoproliferative disorder and as in our patient, immune hemolytic anemia was the presenting symptom of the disease. The patients with immune hemolytic anemia without any etiologies at the time of diagnosis should be followed for the possible underlying diseases, especially for the lymphomas.

Keyword: lymphomatoid granulomatosis, immune hemolytic anemia
to a number of different infections, autoimmune disorders, or coincident with a number of malignancies. HLH should be suspected in those with fever, splenomegaly, cytopenias, elevated triglyceride and ferritin levels, and hemophagocytosis demonstrated in bone marrow, spleen, or lymph nodes. Treatment should be initiated immediately with the HLH-2004 protocol when the patient fulfills the clinical criteria for HLH, since delay of therapy may lead to irreversible multi-organ failure. On the other hand, HS is an extremely rare non-Langerhans histiocytic disorder of unknown cause. Cytopenias are seen in approximately one-third of HS cases, a minority of which will demonstrate hemophagocytosis on bone marrow biopsy as in our patient. There is no standardized therapy for HS. CHOP like regimens can be used for multisystem disease.

**Keyword:** Hemophagocytic lymphohistiocytosis, histiocytic sarcoma

---

**Figure 1.** Histiocytes phagocytizing platelets and normoblasts on bone marrow.

---

**Poster No: 00145 Abstract:0263**

**WE REPORT ON PRIMER MEDIASTINAL B CELL LYMPHOMA WITH ELEVATED SERUM LEVEL OF BETA HCG**

Serife Solmaz Medeni, Ömür Gökmen Sevindik, Abdullah Katgi, Celal Acar, Inci Alacacioglu, Özden Piškin, Mehmet Ali Özcan, Fatih Demirkar, Güber Hayri Özsan, Bülent Ündar

Dokuz Eylul University Hematology Department, Izmir, Turkey

Primary mediastinal B cell lymphoma (PMBL), first recognized in the 1980s, has been accepted as a distinct subtype of diffuse large B cell lymphoma in the World Health Organisation classification. It represents approximately %2-3 of all non-hodgin lymphoma cases. It is mostly seen in female patients and presents with a bulky anterior mediastinal tumor. Twenty-year-old female patient was admitted to our hospital with cough, sore throat, fatigue, fever, significant weight loss and a mediastinal bulky tumor. She was diagnosed as as primary mediastinal B cell lymphoma with the biopsy of anterior mediastinal mass. Because the patient was at child-bearing age she was evaluated with serum beta-hCG level before R-CHOP chemotherapy. The result was 12.53 mlU/mL (normal range 0-5 mlU/mL) and after that the pregnancy has been excluded with ultrasonographic screening and gynecological examinations. Other etiological factors of beta-hCG elevation were investigated and the etiological factor could not be detected. After the chemotherapy, serum level of beta-hCG was repeated as normal serum b-hcg levels with the reduction of the mass (beta-hCG:<0.1 mlU/mL). Patient achieved full remission after 6 cycles of R-CHOP chemotherapy and beta-hCG values were within normal limits at that time. In review ing the literature; the case which Fraternal-Orciani G et al had been reported also showed high beta-hCG levels in the patological specimens by immunochemistry. On top of that elevation of serum beta-hCG at the time of diagnosis and decrease in the level after treatment, we thought elevated levels of beta-hCG may be disease related in our case. As a result, elevated levels of b-hcg may be rarely seen in female PMBCL patients at the child bearing age. Therefore this case is presented for the aim of contribute the literature.

**Keyword:** Primary mediastinal B cell lymphoma, serum beta-hCG level

---

**Poster No: 00146 Abstract:0266**

**CLINICAL FEATURES AND TREATMENT OF SPLENIC MARGINAL ZONE LYMPHOMA**

Gülđane Cengiz Seval, Pervin Topçuğlu, Mehmet Özen, Önder Arslan, Günhan Gürman, Akin Uysal, Muheit Özcan

Ankara University Faculty of Medicine Department of Hematology

Aim: Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy, with no standard treatment other than splenectomy. The aim of this retrospective single-center study was to evaluate the clinical characteristics and prognosis of SMZL.

Patients: Between 2008 and 2013, we analyzed a total of 36 patients being considered as appropriate diagnostic criteria for SMZL in our hematology clinic. Among them only 21 individuals who had at least 3 months of follow-up period were included. There were 13 (62%) female and 8 (38%) male patients. Median age was 58.8 years (range, 37-88 years). The median time of follow-up was 19.3 months (range, 3.9-77 months).

Results: We retrospectively assessed 21 patients from single center, who received splenectomy, either alone or with chemotherapy. The presence of splenomegaly (95.2%) was recorded as the most frequent symptom at diagnosis. Of the patients, 18 (85.7%) had bone marrow involvement and 6 (28.6%) had lymph nodes involvement. Tumor involvement of peripheral blood defined as the presence of absolute lymphocytosis or 5% of tumor lymphocytes in peripheral blood was detected in 5 patients (23.8%). Because of the high frequency of bone marrow involvement, most patients in the series were Ann Arbor stage IV. Data concerning the presence of hypogammaglobulinemia was obtained from only 9 patients (42.9%). Obviously, 20 patients underwent splenectomy. In 7 patients (33.3%) chemotherapy was received apart from splenectomy (Table-1). The number of patients reaching clinical complete remission after splenectomy with/out therapy was 18 (85.7%) and partial remission 3(14.3%). The probability of 5 year-overall survival was 87.5%±11.7%. When we analyzed the patients with...
splenectomy alone the probability of overall survival was 83.3%±15.2%.

Conclusion: In conclusion, although the options of new treatment modality in SMZL have been debated today, splenectomy seems to be safe and effective in controlling long-term disease.

**Keyword:** splenic marginal zone lymphoma, splenectomy

### Table 1. Patients' characteristics and clinical outcome

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value (Mean ± Standard Deviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender: male/female (n)</td>
<td>8/13</td>
</tr>
<tr>
<td>Median age (years, range)</td>
<td>58.8 (37-88)</td>
</tr>
<tr>
<td>Haemoglobin concentration (g/dl)</td>
<td>10.6±1.9</td>
</tr>
<tr>
<td>Platelet count (x10^9/L)</td>
<td>147.1±67.9</td>
</tr>
<tr>
<td>Leucocyte count (x10^9/L)</td>
<td>7.6±4.4</td>
</tr>
<tr>
<td>Lymphocyte count (x10^9/L)</td>
<td>3.6±4.0</td>
</tr>
<tr>
<td>Lactate dehydrogenase (U/L)</td>
<td>412.2±170.2</td>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>3.4±0.7</td>
</tr>
<tr>
<td>Hypogammaglobulinemia (n)</td>
<td>9</td>
</tr>
<tr>
<td>Therapy received: Splenectomy only (n)</td>
<td>13</td>
</tr>
<tr>
<td>Splenectomy + chemotherapy (n)</td>
<td>7</td>
</tr>
<tr>
<td>CHOP</td>
<td>1</td>
</tr>
<tr>
<td>R-CHOP</td>
<td>2</td>
</tr>
<tr>
<td>Rituximab alone</td>
<td>1</td>
</tr>
<tr>
<td>Fludarabine alone</td>
<td>2</td>
</tr>
<tr>
<td>Rituximab and Fludarabine</td>
<td>1</td>
</tr>
<tr>
<td>Chemotherapy only (n): Rituximab alone</td>
<td>1</td>
</tr>
</tbody>
</table>

---

**EXTRANODAL NK CELL LYMPHOMA NASAL TYPE**

Güven Çetin1, Tuba Özkınay1, Iskender Ekinson1, Turan Aslan2, Yasemin Akkoyunlu2
1Bezmialem Vakif University, Faculty of Medicine, Department of Hematology, Istanbul, Turkey
2Bezmialem Vakif University, Faculty of Medicine, Department of Infection Disease, Istanbul, Turkey

Extranodal NK/T cell lymphoma (ENKL), nasal type is a rare type of non-Hodgkin's lymphoma originating in the nasal cavity or in the paranasal sinuses (1,2). Rarely, other sites of the upper aerodigestive tract (e.g. nasopharynx, palate), the skin, the gastrointestinal tract or the testis may be involved (1,2). Tissue biopsies often contain necrotic material making precise diagnosis difficult; thus excisional biopsy is usually required for correct diagnosis (3).

A 35 year-old male was admitted to the Department of Infectious Diseases due to an infected palatal ulceration of about 11/2 months. He was consulted with Haematology Department for bicytopenia that appeared after initiation of antibiotherapy. Recurrent punch biopsies from velum revealed fungal infection which did not respond to antifungal therapy. On examination there was a deep ulcerated-necrotic showed inflammatory granulation, vascular proliferation and active chronic inflammation. Tuberculosis ruled out and mould cultures taken from the lesion were reported as a fungal infection.

Immunoglobulins levels excluded immunodeficiency. Negative microbiological findings ruled out infectious nature of the lesion. VDRL, TPHA tests were found negative. Cranial CT was normal, parasal sinus CT showed obliteration in right osteomatal complex and a soft tissue mass which causes filling completely the right maxillary sinus and partially both of the ethmoids and left maxillary sinus. Repeat biopsy from the ulcerated-necrotic showed inflammatory granulation, vascular proliferation and active chronic inflammation. Tuberculosis tested via PCR and acid-fast staining bacilli was negative on tissue biopsy. Bone marrow biopsy obtained due to bicytopenia was reported to be normocellular without atypical infiltration.

To prevent necrosis deep debridement was advised. Morphological and immunophenotypic findings of the excisional biopsy revealed ENKL. Oncological PET-CT showed high- dense FDG staining in the nasal cavity around the velum, on right tonsillar part, and in cervical lymph nodes. High-dose chemotherapy with autologous hematopoietic stem cell transplantation was planned but the patient died on the seventh day of the treatment.

Mid facial involvement with ulcerations should alert physicians to think of NK cell lymphoma. Diagnosis may be difficult and late due to necrosis in the tissues.

**Keyword:** NK cell lymphoma, nasal

---

**POLYPLOIDY IN SMALL LYMPHOCYTIC LYMPHOMA(SLL) / CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) WITH RELATIVE PS3 DELETION DETECTED BY FISH: A CASE REPORT**

Emin Karaca1, Murat Tombuloglu2, Haluk Akin1, Mine Hekimgil1, Ferda Ozkayn1
1Ege University Faculty of Medicine, Department of Medical Genetics, Izmir, Turkey
2Ege University Faculty of Medicine, Department Of Internal Medicine, Division Of Hematology, Izmir, Turkey

SLL is a diffuse form of non-Hodgkin’s lymphoma representing the neoplastic proliferation of well-differentiated B lymphocytes, with focal lymph node enlargement or generalized lymphadenopathy and splenomegaly.
Here we present a case of 55-year-old women who applied with presented multiple bilateral cervical lymphadenopathies. Her leukocyte 14 400 /uL, Hg: 11.6 gr/dL, platelet. 205000/Ul. Bone marrow and lymphadenopathies. Her Fluorescence in situ hybridization (FISH) revealed a polyploidy with relative p53 deletion that could not be detected by conventional cytogenetic. There were 4 centromeric chromosomes 17 signal but only 2 p53 region signal. In this study, bone marrow and peripheral blood cells were collected analyzed by FISH with DNA probes for chromosomes 5, 7, 8, 13, 14, 21, and X. All of them showed different percentages of trisomy and tetrasomy which was supporting polyploidy. This is the first reported case of small lymphocytic lymphoma with polyploidy and relative p53 deletion that is reported till date. Our findings indicate the utility of FISH analysis in cytogenetic monitoring of small lymphocytic lymphoma patients are important to discover new cytogenetic aberrations.

**Key word:** SLL/CLL, polyploidy with 17p deletion

**Poster No:** 00149 **Abstract:**0115

**ANALYSIS OF THE EFFICACY AND SIDE EFFECTS OF BEXAROTENE IN THE TREATMENT OF MYCOSES FUNGOIDES**

Mehmet Yılmaz1, Serhat Inalöz2, Salih Subari1, Mesut Özçay3, Didar Yanardag Açık1, Handan Haydaroğlu Şahin1, Özhan Uygun1, Mustafa Pehlivan1, Vahap Okan1

1Gaziantep University, Faculty of Medicine, Department of Hematology, Gaziantep, Turkey
2Gaziantep University, Faculty of Medicine, Department of Dermatology, Gaziantep, Turkey
3Gaziantep University, Faculty of Medicine, Department of Endocrinology, Gaziantep, Turkey

**Background:** Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphomas in adults. It is a low-grade cutaneous lymphoma characterized by skin-homing CD4+ T cells. It is notable for highly symptomatic progressive skin lesions, including patches, plaques, tumors, and erythroderma in which has a poor prognosis in advanced stages. Management of MF should use a “stage-based” approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy.

**Objective:** The present study was aimed to evaluate the efficacy and effects of bexarotene, treatment and disease progression in MF patients.

**Method:** Five patients diagnosed with MF in different stages, who received PUVA and steroid treatment before including the study. Bexarotene (initial dose 300 mg/day, decreasing to 225 or 150 mg/day if signs of toxicity appeared). All received atorvastatin and levetocoxin sodium. We measured AST, ALT, bilirubin, triglyceride, VLDL, LDL, FT3, FT4 and TSH levels at the beginning and monthly for 3 months. We compared the the results of biochemical parameters with beginning and after 3 months of the bexarotene treatment.

**Results:** AST level was increased above the normal level (N; 5-32 U/L) in 1, TG (N; 10-200 mg/dl) and LDL(N; 57-129 mg/dl) in 4 of the 5 MF patients. FT3 level (N; 1.71-3.71 pg/ml) was decreased from the normal level in 1 and FT4 (N; 0.7-1.48 pg/ml) level 2 of the 5 patients (Table 1). Patient 3 started bexarotene treatment 15 days ago. We observed bexarotene caused partially clearing of the cutaneous lesions of MF for 3 months.

**Conclusion:** Our study together with the other studies with bexarotene has shown that this agent is effective in the treatment of MF in patients who have failed on a number of other therapies and can produce long-lasting response. The common side-effects of hypertriglyceridemia, hypercholesterolemia and hypothyroidism associated with bexarotene therapy require monitoring, but can readily be managed with concomitant medication, using a strategy similar to that suggested above. However, patients should be aware of the importance of making changes to their diet and lifestyle. It should be stressed on patients that their diet and lifestyle also have a key role to manage MF with bexarotene treatment.

**Keyword:** Bexarotene, Mycosis fungoides

**Poster No:** 00150 **Abstract:**0290

**THE ROLE OF RITUXIMAB AND OPTIMAL TREATMENT MODALITY IN PRIMARY GASTRIC DIFFUSE LARGE CELL LYMPHOMA: A STUDY BY THE ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY**

Mehmet Küçüköner1, Sener Şener2, Ümmügül Çetin3, Mustafa Benekli4, Ali İnal5, Salih Subari1, Handan Haydaroğlu Şahin1, Mustafa Pehlivan1, Mehmet Yılmaz1, Serhat Inalöz2, Salih Subari1, Mesut Özçay3, Didar Yanardag Açık1, Handan Haydaroğlu Şahin1, Özhan Uygun1, Mustafa Pehlivan1, Vahap Okan1

1Gaziantep University, Faculty of Medicine, Department of Hematology, Gaziantep, Turkey
2Gaziantep University, Faculty of Medicine, Department of Dermatology, Gaziantep, Turkey
3Gaziantep University, Faculty of Medicine, Department of Endocrinology, Gaziantep, Turkey
4Kartal Hospital, Medical Oncology Department, Istanbul, Turkey
5Selcuk University, Medical Oncology Department, Konya, Turkey
6Gazi University, Medical Oncology Department, Ankara, Turkey
7Dicle University, Medical Oncology Department, Diyarbakır, Turkey
8Ankara Numune Hospital, Medical Oncology Department, Ankara, Turkey
9Kartal Hospital, Medical Oncology Department, Istanbul, Turkey
10Selcuk University, Medical Oncology Department, Konya, Turkey
11Gazi University, Medical Oncology Department, Ankara, Turkey
12Gaziantep University, Medical Oncology Department, Gaziantep, Turkey
13Dicle University, Hematology Department, Diyarbakır, Turkey

**Background:** In this study we have compared treatment modalities for gastric lymphoma and examined independent factors contributing to survival and whether rituximab is effective drug in gastric lymphoma.

**Patients and Methods:** This retrospective study included 146 primary gastric diffuse large B-cell lymphoma (DLBCL) patients diagnosed at a multicenter analysis. A combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab was applied to 109 of the patients. Thirty-one patients had received chemotherapy without rituximab.
ABSTRACTS

Poster No: 00151 Abstract:0307

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma-Single Center Experience

Sanja Trajkova1, Gordana Petruzevska2, Aleksandar Stojanovic3, Irina Panovska Stavridis1, Dusko Dukovski4, Martin Ivanovski1, Borce Georgievski3, Aleksandra Pivkova1, Lazar Cadievski3, Marija Popova Simjanovska1, Svetlana Stankovik1, Lidija Cevreska1

1University Clinic for Hematology, Skopje, Macedonia
2Institute for Pathology, Medical Faculty, Skopje, Macedonia

Introduction: Rituximab maintenance treatment after achieving response to induction therapy appears to be an effective approach to extending response duration in follicular lymphoma patients. In literature, investigators have reported improved event-free (EFS) and progression-free survival (PFS) with maintenance rituximab in patients with newly diagnosed follicular lymphoma. But in diffuse large B-cell lymphoma patients Rituximab administered as induction therapy in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival. However, continued use of rituximab after R-CHOP failed to demonstrate benefit. High-dose therapy followed by autologous stem cell transplantation is the treatment of choice for patients with relapsed DLBCL who are still responding to salvage therapy. Although rituximab is effective, its role in salvage therapy after autologous transplant remains unclear. Maintenance therapy with rituximab in patients with complete remission after autologous transplant may be a useful novel approach capable of eradicating minimal residual disease. However, there are currently no data confirming this hypothesis. In line with these facts we conducted this retrospective study to investigate benefit from rituxomab maintenance therapy in patients with aggressive lymphoma after induction therapy and after autologous transplantation.

Methods: Our study enrolled 50 CD20+ DLBL patients diagnosed and treated at the University Clinic of Haematology in the period between January 2002 and January 2010. The most common initial treatments was R-CHOP. Patients were required to have a CR following initial treatment to continue with Rituximab maintenance therapy which was administered as 375 mg/m² doses every 3 months for 2 years. Eight patients with aggressive subtype- non Germinal centre DLBL were treated with high-dose chemotherapy/autologous stem cell transplantation (HDT/ASCT) and received rituximab maintenance therapy every 2 months for 2 years.

Conclusions: The benefit of rituximab treatment in gastric DLBL is still a controversial subject. Additional prospective trials are definitely required in order to clarify the use of rituximab in the treatment of gastric DLBL.

Keyword: Gastric lymphoma, rituximab

Figure 1: Comparison of the Overall survival curves of patients with and without Rituximab therapy

Results: The median follow-up period was 25.5 months. The 5-year EFS (Event Free Survival) and OS (Overall Survival) rates for the patients were 55% and 62.3%. In multivariate analysis of OS and EFS, we have identified low albumin, complete response to treatment, nonsurgical treatment, and stage I-II disease as factors independently contributing to the survival. There was no statistically significant difference in terms of survival between the different treatment modalities (EFS and OS) (p = 0.707 and p = 0.124 respectively). Also, no statistically significant difference regarding the OS was found between the chemotherapy modalities with and without rituximab (p=0.332). Significantly better EFS was observed in the group that had received chemotherapy without rituximab (p=0.041). In the subgroup analysis, the addition of rituximab to the treatment did not result in statistically significant changes in the EFS or OS for the group of 63 patients who received chemotherapy alone (p= 0.145 and p=0.384).

Conclusions: Rituximab maintenance therapy appears to be an effective approach to extending response duration in follicular lymphoma patients. In literature, investigators have reported improved event-free (EFS) and progression-free survival (PFS) with maintenance rituximab in patients with newly diagnosed follicular lymphoma. But in diffuse large B-cell lymphoma patients Rituximab administered as induction therapy in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival. However, continued use of rituximab after R-CHOP failed to demonstrate benefit. High-dose therapy followed by autologous stem cell transplantation is the treatment of choice for patients with relapsed DLBCL who are still responding to salvage therapy. Although rituximab is effective, its role in salvage therapy after autologous transplant remains unclear. Maintenance therapy with rituximab in patients with complete remission after autologous transplant may be a useful novel approach capable of eradicating minimal residual disease. However, there are currently no data confirming this hypothesis. In line with these facts we conducted this retrospective study to investigate benefit from rituxomab maintenance therapy in patients with aggressive lymphoma after induction therapy and after autologous transplantation.

Methods: Our study enrolled 50 CD20+ DLBL patients diagnosed and treated at the University Clinic of Haematology in the period between January 2002 and January 2010. The most common initial treatments was R-CHOP. Patients were required to have a CR following initial treatment to continue with Rituximab maintenance therapy which was administered as 375 mg/m² doses every 3 months for 2 years. Eight patients with aggressive subtype- non Germinal centre DLBL were treated with high-dose chemotherapy/autologous stem cell transplantation (HDT/ASCT) and received rituximab maintenance therapy every 2 months for 2 years.

Conclusions: The benefit of rituximab treatment in gastric DLBL is still a controversial subject. Additional prospective trials are definitely required in order to clarify the use of rituximab in the treatment of gastric DLBL.

Keyword: Gastric lymphoma, rituximab
ABSTRACTS

**EPSTEIN-BARR VIRUS (EBV) POSITIVE DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY; EXPERIENCE OF A SINGLE CENTER FROM TURKEY**

Nazar Özsan1, Seckin Çağırgan2, Güray Saydam3, Ajda Günes4, Mine Hekimgil5

1Department of Pathology Ege University Faculty of Medicine, Izmir, Turkey
2Department of Hematology Ege University Faculty of Medicine, Izmir, Turkey

In the 2008 World Health Organization (WHO) Classification of tumours of haematopoietic and lymphoid tissues ‘EBV positive diffuse large B cell lymphoma (DLBCL) of the elderly’ is included as a new provisional entity; and it is defined as the EBV+ clonal B-cell lymphoid proliferation occurring in patients older than 50 years of age, without any known immunodeficiency or prior lymphoma. This new entity had been introduced after the studies from Far East, based on Asian population; several studies coming from different geographical locations of the world followed them. In this study, we aimed to determine and evaluate the morphological, immunophenotypic, and clinical characteristics of the cases diagnosed as ‘EBV positive diffuse large B cell lymphoma of the elderly’ in a single center, to assess the diagnostic and morphological criteria in comparison with the literature.

EBV status was detected by Epstein-Barr early RNA (EBER) in situ hybridization analysis. The EBER expression in the majority of tumour cells (> 20 %) was required to consider the cases as EBV+ DLBCL of the elderly. By immunohistochemistry, a panel of antibodies for CD10, Bcl-2, Bcl-6, IRF4/MUM1, CD30 and Ki67 was performed. The cases were classified as germinal center B-cell (GCB) or non-germinal center B-cell (non-GCB) phenotype according to ‘Hans criteria’.

Eight patients who fulfill the criteria were re-evaluated. Five patients were male, and three were female with a median age of 67.6 years (range 60-87 years). Four patients presented with lymph node involvement; others presented with bone and surrounding soft tissue infiltration, bone marrow, and spleen infiltrations. Five of the cases revealed predominantly monomorphic morphology with sheets of large cells, one also contained focal areas consistent with polymorphous subtype; and three patients revealed a polymorphous infiltrate. When the cases were classified according to ‘Hans criteria’, five patients were non-GCB cell phenotype, and three cases were classified as GCB cell phenotype. All of the four cases with polymorphous morphology revealed to be non-GCB cell phenotype and all expressed IRF4/MUM1.

Two patients died with disease, four patients are alive and in complete remission following R-CHOP therapy, followed up for 42, 36, 31, and 38 months after the initial diagnosis, two patients have just recently been diagnosed and started receiving chemotherapy. Further studies including larger series are needed to fully understand the details of this disease, which can lead to new treatment modalities.

**Keyword:** Epstein Barr virus, large B cell lymphoma

---

**PROMOTER METHYLATION OF GADD45. IN DIFFUSE LARGE B-CELL LYMPHOMA**

Ilkay Cansu Barış1, Vildan Caner2, Nilay Şen Türk3, Hakan Ismail Sarı4, Sibel Kabukçu Hacıoğlu5, Gökhani Ozan Çetin6, Emre Tepeli7, Özge Can8, Gülseren Bağcı9

1Department of Pathology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
2Department of Pathology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
3Department of Haematology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
4Department of Medical Genetics, Faculty of Medicine, Pamukkale University, Denizli, Turkey
5Department of Medical Genetics, Faculty of Medicine, Pamukkale University, Denizli, Turkey
6Department of Pathology, Faculty of Medicine, Pamukkale University, Denizli, Turkey

**Background:** Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and is highly heterogenous from both clinical and molecular perspectives. The growth arrest and DNA damage-inducible (GADD) 45 gene family which consists of three members, GADD45a, GADD45b, and GADD45y are implicated in modulating the cellular response to various types of genotoxic/physiological stress. Although it has been reported that GADD45y is frequently methylated in various solid tumors, there is no detailed information about the methylation frequency of the gene in DLBCL.

**Objectives:** The aims of this study are to detect the methylation frequency of GADD45y in DLBCL and to assess the association between this epigenetic aberration and transcriptional inactivation of the gene at the protein level. We investigated GADD45y promoter methylation and its protein expression in 40 patients with DLBCL and 40 patients with reactive lymphoid hyperplasia.

**Methods:** Genomic DNAs were extracted from all FFPE tissue samples in both groups using a commercial kit (QIAamp DNA Mini kit, Qiagen). After bisulphite treatment, methylation-sensitive high resolution melting (HRM) analysis was used to determine the frequency of GADD45y methylation. GADD45y protein expression in both groups was determined by immunohistochemistry.

**Results:** The methylation frequencies of GADD45y in DLBCL and non-cancer group were 55% and 40%, respectively. There was a significant difference in GADD45y protein overexpression in both groups (P=0.000). Eighteen (45%) methylated samples did not express the GADD45y protein, whereas eight (20%) protein overexpression was seen in unmethylated samples in DLBCL. Although the frequency of methylation in patients with extranodal DLBCL was higher than those in patients with nodal DLBCL, there was no statistically significant difference between the two groups (P=0.508). GADD45y protein overexpression in patients with extranodal DLBCL was almost three times higher than those in patients with nodal DLBCL (P=0.323).

**Conclusion:** The findings suggested that GADD45y is frequently methylated and the epigenetic silencing of GADD45y by DNA methylation does not fully explain its decreased expression in DLBCL. Therefore, more detailed studies are required to determine other epigenetic changes that were responsible for the silencing of GADD45y, rarely mutated, in DLBCL.

**Keyword:** Diffuse large B-cell lymphoma, GADD45y
CD5(-) BLASTOID MANTLE CELL LYMPHOMA PRESENTING AS AN ORBITAL MASS: A CASE REPORT

Hülya Öztürk Nazlıoğlu1, Bülent Yaşar2, Vildan Özkocaman3
1Department of Pathology, Uludag University School of Medicine, Bursa, Turkey
2Department of Ophthalmology, Uludag University School of Medicine, Bursa, Turkey
3Department of Internal Medicine, Division of Hematology, Uludag University School of Medicine, Bursa, Turkey

Abstract: Mantle cell lymphoma (MCL) is a B-cell neoplasm with a nodal or extranodal presentation, composed of monomorphic small to medium-sized lymphoid cells, usually co-expressing CD5 and Cyclin D1. A minority of cases which are CD5(-) compose a group with diagnostic difficulty. Blastoid MCL is an aggressive morphologic variant. Orbital and adnexal region MCL presents in elderly males. The orbit and eyelid are frequently involved. There is a very high proportion of systemic involvement in general with MCL of the orbital and adnexal region. Most patients present with stage IV disease and have multiple relapses and short survival time. Here we report a case of CD5(-) blastoid mantle cell lymphoma presenting as an orbital mass.

Case: A 62-year-old man presented with a progressive right palpebral swelling of three months presentation. His right eye was protruded. Orbita MRI revealed a 5x3.5 cm orbital mass originating from the lacrimal gland, extending to retrobulbar region, and pressing the ocular bulb and optic nerve. Insiscal biopsy of the mass was consistent with a lymphoid neoplasm composed of middle sized lymphoid cells. Neoplastic cells had a diffusely infiltrating pattern and strong CD20 and Cyclin D1 expression. CD5 was negative. Positron Emission Tomography showed hypermetabolic lymph nodes in cervical, bilateral axillary and inguinal regions. Bone marrow was involved. Spleen and liver was not enlarged. The patient was treated with radiotherapy and chemotherapy (R-CHOP) and complete regression of the mass was achieved in control MRI, after three months following initial diagnosis.

Conclusion: Lymphoid neoplasms should be included in the differential of orbital masses and pathologists should be alert of neoplasms with unusual immunophenotypes such as CD5(-) MCL in order to reach a correct diagnosis.

Keyword: mantle cell lymphoma, orbita

PRIMARY MULTIFOCAL EXTRANODAL DIFFUSE LARGE B CELL LYMPHOMA; A CASE REPORT

Ebru Koca1, Mehmet Şahin Gülel2, Ayşun Halaçoğlu3, Selami Koçak Toprak4, Nefise Çağla Tarhan5, Ali Ayhan1, Sema Karakuş2
1Baskent University Hematology Department, Ankara, Turkey
2Baskent University Radiology Department, Ankara, Turkey
3Baskent University Obstetrics and Gynecology Department, Ankara, Turkey

Diffuse large B-cell lymphomas (DLBCL) account for approximately 40% of adult non-Hodgkin’s lymphomas. Approximately one quarter to one third of DLBCLs originate from tissues other than lymph nodes. We herein report a patient with multifocal extranodal involvements who presented like primary ovarian carcinoma. A 63 year old woman living in an underserved area of Turkey was referred to our center for multiple abdominal masses determined with ultrasonography. She had a history of skin lesions on her neck and subcutaneous nodules on the abdomen and breasts for several months. A preliminary diagnosis of dermatofibrosarcoma was done with skin biopsy before referral to our center. On physical examination she had skin lesion on the back of neck (Figure 1) and subcutaneous nodules on abdomen and breasts. She had normal blood count. CA-125 was 36,4 IU/ml (0-35). Thoracoabdominal tomography revealed a solid lesion of 129x124 mm in pelvis with no certain margins from uterus and ovaries, 3 cm paracolic nodular solid lesion, subcutaneous nodular metastatic lesions, bilateral suprarenal 2 cm lesions, left renal 61x48 mm nodular solid lesions and right breast metastases. She underwent total hysterectomy with bilateral salpingo-oophorectomy, lymph node dissection and omentectomy with a preliminary diagnosis of ovarian carcinoma. Pathology was consistent with non-germineral center phenotype DLBCL. Normal ovarian tissue wasn’t observed outside of neoplastic areas. Neoplastic cells were positive for CD20, BCL-2, BCL-6, and negative for CD10 CD3 and CD30. Ki67 index was 80-90%. A skin biopsy was also consistent with DLBCL. Additional work up with magnetic resonance imaging revealed 31x26x24 mm mass lesion destructing left orbita medial wall displacing medial rectus muscle. She also had a 55x41 mm mass lesion posterior to left scalen muscle. None of the imaging studies showed any lymph node involvement. A FDG PET/CT scan additionally showed gastric involvement. Bone marrow biopsy was negative for lymphoma involvement. Patient had high risk IPI. She received R-CHOP chemohetarp and intrethcel CNS prophylaxis. All her subcutaneous nodules resolved dramatically after first cycle, skin lesions totally faded after second cycle (Figure 1). She now has an excellent performance status. Primary extranodal lymphomas constitute one third of DLBCLs and treatment is no different than nodal lymphomas. Our patient had primary multifocal extranodal DLBCL presenting like ovarian carcinoma. Primary ovarian lymphoma is extremely rare accounting for 0.2% of all lymphomas in women. For our patient, it is not possible to know she had a primary ovarian lymphoma as she had multifocal involvements, thus there is also a probability that it might have spread from ovaries to different organs over several months.

Keyword: diffuse large B-cell lymphoma, primary extra nodal

Figure 1 Skin lesion before (left) and after (right) 2 cycles of R-CHOP chemotherapy
MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) OF THE THYROID GLAND: A CASE REPORT
Hülya Öztürk Nazlıoğlu1, TürKay Kirdak2
1Department of Pathology, Uludag University School of Medicine, Bursa, Turkey
2Department of Surgery, Uludag University School of Medicine, Bursa, Turkey

Introduction: Primary lymphoma of the thyroid gland is a rare malignant tumor constituting 1% to 2% of all thyroid malignancies and less than 2% of lymphomas. Most lymphomas of the thyroid gland are high grade lymphomas, particularly large B-cell and immunoblastic types. Low grade marginal zone lymphoma of MALT represent 15%-20% of all primary thyroid lymphomas. Thyroid lymphoma affects predominantly females over 70 years of age with a history of Hashimoto’s thyroiditis (HT). Hashimoto’s thyroiditis is considered as a risk factor for thyroid lymphoma development. The onset of malignant lymphoma likely is a consequence of the chronic antigenic stimulation of B lymphocytes that take place in the autoimmune disorder; this chronic stimulation probably leads to a population of lymphocytes that are more susceptible to neoplastic transformation.

Case: A 40-year-old woman with a prior history of HT presented with a complaint of rapidly growing painless neck mass. Fine needle aspiration biopsy was suspicious for malignancy favoring papillary carcinoma, Hurthle cell variant. Total thyroideectomy was performed and pathologic examination revealed neoplastic lymphoid infiltrations of papillary carcinoma, Hurthle cell change was identified in the thyroid gland. There were numerous reactive T lymphocytes accompanying neoplastic B cells. There was no malignant change in the epithelial component.

Conclusion: Primary marginal lymphoma of MALT of the thyroid gland is a rare disease that continues to produce diagnostic dilemmas. We report a case of primary MALT lymphoma of the thyroid with a prior history of HT, and highlight the morphologic features that are specifically thought to aid in the differentiation of reactive nonneoplastic lymphoid infiltrations from neoplastic lymphoid infiltrations of the thyroid gland.

Palliative Care—Supportive Therapy

THE IMPACT OF ELTROMBOPAG ADMINISTRATION ON THE CLINICAL COURSE OF SEVERE REFRACTORY FATAL ACQUIRED APLASTIC ANEMIA
Ayşe İlaşık, Eyüle Emiliaç, İbrahim Celalettin Haznedaroğlu, Salih Aksu, Nilgün Sayınalp, Yahya Büyükaşık, Hakan Göker, Osman İhimi Özebe
Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey

Objective: Severe aplastic anemia (SAA) has an aggressive clinical course and represents a “difficult-to-treat” situation with current medications. Eltrombopag is a c-mpl receptor agonist oral thrombopoietin-mimetic drug mainly active in immune thrombocytopenic purpura (ITP). We would like to share our experience about eltrombopag in two patients with refractory fatal acquired SAA.

Case #1: A 19-year-old male patient was admitted to our emergency room with the complaints of nasal bleeding and ecchymosis. Laboratory studies revealed pancytopenia. After his diagnosis was confirmed with bone marrow aspiration and biopsy as aplastic anemia steroid 1 mg/kg and 5 mg/kg cyclosporin were started. During his follow up acute vision loss developed and retinal hemorrhage was detected and platelet transfusion was started daily in an attempt to raise the platelet count over since enough response was not obtained with immunosuppressive treatment. Following the horse ATG at dose of 40 mg/kg for 4 days, he became more cytopenic and needed more frequently transfusions especially platelet suspensions. Despite multiple platelet transfusions, his platelet counts remained below 50x10^9/L and eltrombopag 50 mg/day started to patient. After one week of the eltrombopag initiation, the patient’s platelet counts remained above 50x10^9/L without any...
transfusion support. However, septic shock complicated the clinical picture and the patient died.

Case #2: A 44-year-old female patient with the history of bronchial asthma admitted to our emergency service with the complaint of epistaxis, bleeding from ears and visual loss. In her complete blood count Hb: 6.2 g/dL, leukocyte count: 2.2 x10⁹/L, platelet count: 4x10⁹/L and reticulocyte count: 1% with normal coagulation parameters. Her bone marrow aspiration and biopsy was consistent with aplastic anemia and cyclosporine-A were started. Because of her intracranial hemorrhage we did not plan ATG. During this period, she remained profoundly thrombocytopenic, requiring twice per day platelet transfusions to achieve platelet count below 100x10⁹/L and we started 50 mg/day eltrombopag. Two weeks after the initiation of the eltrombopag, her platelet transfusion requirement was reduced with platelet counts reaching the 80,000/μL range without transfusions. Her control MRI showed regression of intracranial hemorrhage. Her donor screening tests revealed a related HLA match donor, accordingly she was reduced with platelet counts reaching the 80,000/μL range without transfusions. Her donor screen suggested that eltrombopag could reduce transfusion requirements in patients with platelet transfusion dependent aplastic anemia. However, the drug had no impact on the morbidity or mortality in our patients with SAA.

**Keyword:** aplastic anemia, eltrombopag

**Poster No:** 00159  **Abstract:** 0125  **EFFICIENCY OF ANTIFUNGAL TREATMENT IN PATIENTS WITH HIGH RISK FEBRILE NEUTROPENIA**

**Zeynep Akçali**,  **Bahadır Dede**,  **Ülkü Ergene**

1. **Department of Internal Medicine, Celal Bayar University, Manisa, Turkey**
2. **Department of Public Health, Celal Bayar University, Manisa, Turkey**
3. **Department of Hematology, Celal Bayar University, Manisa, Turkey**

**Objectives:** Febrile neutropenia (FEN) is a life-threatening complication that is common in patients with hematological malignancies. In order to treat these infections early and right time are preferred instead of targeted antifungal therapy. High-risk group: the expected duration of neutropenia and the period of 10 days or longer than most of the PNL count <100/mm³ is an underlying hematological malignancy (acute leukemia, lymphoma, etc.) the presence of which had been scheduled to receive intensive chemotherapy has taken or prior history of hospitalization the fact that uncontrolled cancer, the presence of additional factors is designated as negative. The aim of this retrospective study is to evaluate efficiency of antifungal treatment in patients with high-risk febrile neutropenia.

**Methods:** Between January 2005 and March 2012, FEN of 78 febrile neutropenic patients was retrospectively analyzed in Manisa Celal Bayar University, Department of Hematology

**Results:** 43 (55%) patients were male and 35 (45%) patients were female. The mean age was 46.7±15.06 years and the median age was 45 years (20-76). The distribution of disease is AML, ALL, chronic leukemia, lymphoma and other hematologic malignancies and ratios were 50%, 12%, 7%, 15%, 6% respectively. In 78 patients, 135 FEN were evaluated. Within these 90 FEN were received antifungal agents. 45 FEN were not needed any antifungal treatment. The efficacy of first-line antifungal therapy was 72% (65/90 FEN). The efficacy of second-line antifungal therapy (i.e. refractory to or intolerant of prior antifungal therapy) was 97% (30/32 FEN). Empirical antifungal therapy was started early and changed by clinical, microbiological and serologic results for the high efficacy.

**Conclusion:** We concluded that the use of empirical antifungal therapy early according to the antifungal guidelines and changed by clinical, microbiological and serologic results should be most effective in patients with high-risk febrile neutropenia.

**Keyword:** Antifungal agents

**Poster No:** 00160  **Abstract:** 0126  **THE SIDE EFFECTS OF ANTIFUNGAL AGENTS IN NEUTROPENIC FEVER ATTACKS**

**Ülkü Ergene**,  **Zeynep Akçali**

1. **Department of Hematology, Celal Bayar University, Manisa, Turkey**
2. **Department of Internal Medicine, Celal Bayar University, Manisa, Turkey**

**Objectives:** Febrile neutropenia (FEN) is a life-threatening complication that is common in patients with hematological malignancies. In patients with persistent fever and neutropenia, antifungal agents are administered empirically for early treatment and prevention of systemic fungal infections. The aim of this retrospective study is to evaluate side effects of antifungal treatment in FEN.

**Methods:** Between January 2005 and March 2012, FEN of 78 febrile neutropenic patients was retrospectively analyzed in Manisa Celal Bayar University, Department of Hematology

**Results:** 43 (55%) patients were male and 35 (45%) patients were female. The mean age was 46.7±15.06 years and the median age was 45 years (20-76). The distribution of disease is AML, ALL, chronic leukemia, lymphoma and other hematologic malignancies and ratios were 50%, 12%, 7%, 15%, 6% respectively. In 78 patients, 135 FEN were evaluated. Within these 90 FEN were received antifungal agents. 45 FEN were not needed any antifungal treatment. The side effect of first-line antifungal therapy was 48% (43/90 antifungal used FEN). The side effect of second-line antifungal therapy was 42% (13/32). The side effects of first and second-line antifungal therapy were infusion related, metabolic and visual toxicity, hepatotoxicity, rash, diarrhea and their numbers and ratios were 3(5%), 49(86%), 2(3.6%), 1(1.8%), 1(1.8%), 1(1.8%) respectively.

**Conclusion:** The use of empirical antifungal therapy early according to the antifungal guidelines and monitoring by side effect should be most security in patients with high-risk febrile neutropenia.

**Keyword:** Antifungal agents
ABSTRACTS

354

**MULTIPLE BIOMARKERS IN THE DETECTION OF CARDIOTOXICITY INDUCED BY CONVENTIONAL AND HIGH-DOSE CHEMOTHERAPY FOR ACUTE LEUKEMIA**

Jan M. Horacek¹, Ladislav Jebavy², Martina Vasatova², Pavel Zak³, Milos Tichy³, Jaroslav Maly³

¹Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic; ²4th Department of Internal Medicine – Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic; ³Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove, Czech Republic

Background: Cardiotoxicity is a potentially serious complication of anticancer therapy that can significantly impair patient’s quality of life. The greatest risk for development of cardiotoxicity is represented by anthracyclines (ANT) and high-dose chemotherapy (HD-CT). Various methods including cardiac biomarkers have been recommended for monitoring of cardiotoxicity in oncology.

Objectives: The aim of our study was to assess cardiotoxicity of conventional and HD-CT with multiple biomarkers of cardiac injury – glycogen phosphorylase BB (GPBB), heart-type fatty acid-binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin.

Methods: A total of 47 adult acute leukemia patients were studied – 24 patients treated with conventional CT containing ANT (mean total cumulative dose 463.2 ± 114.3 mg/m²) and 23 patients treated with HD-CT containing ANT (mean total cumulative dose 463.2 ± 114.3 mg/m²) and 23 patients treated with HD-CT containing ANT (mean total cumulative dose 463.2 ± 114.3 mg/m²) followed by stem cell transplantation (SCT). All patients had normal liver and renal functions during the study. Cardiac biomarkers were measured prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group; after HD-CT and after SCT in the second group. Cardiac biomarkers were measured on Evidence Randox (GPBB, FABP, cTnI) and Elecsys Roche (cTnT, CK-MB mass, myoglobin) analyzers. Values above the reference range recommended by the manufacturers were considered elevated.

Results: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-off values in all patients. GPBB increased above the cut-off (7.30 µg/L) in 4 (16.7 %) patients after first CT and in 5 (20.8 %) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7 %) patients after HD-CT and remained elevated in 5 (21.7 %) patients after SCT. cTnl became elevated (above 0.40 µg/L) in 2 (8.3 %) patients after first and last CT with ANT. Both patients with cTnl positivity had elevated GPBB. Other tested biomarkers (H-FABP, cTnT, CK-MB mass, myoglobin) remained below the cut-off values during the study.

Conclusions: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by SCT. The predictive value for development of cardiomyopathy in the future is not known and will be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new biomarkers in the assessment of cardiotoxicity in hematooncology.

The work was supported by a long-term organization development plan 1011 (FMHS).

Keyword: cardiac biomarkers, chemotherapy

**THE DISTRIBUTION OF FUNGAL PATHOGENS ON NEUTROPENIC FEVER ATTACKS AND ANTFUNGAL TREATMENT**

Ülkü Ergene¹, Zeynep Açlı²

¹Department of Hematology, Celal Bayar University, Manisa, Turkey; ²Department of Internal Medicine, Celal Bayar University, Manisa, Turkey

Objectives: Febrile neutropenia (FEN) is a life threatening complication that is common in patients with hematologic malignancies. Invasive fungal infections (IFI) are serious cases of mortality in neutropenic patients. It is difficult to diagnose IFIs in neutropenic patients and this causes delay in diagnosis which has detrimental effects on prognosis. The aim of this retrospective study is to evaluate fungal pathogens in patients on febrile neutropenia.

Methods: Between January 2005 and March 2012, FEN of 78 febrile neutropenic patients was retrospectively analyzed in Manisa Celal Bayar University, Department of Hematology.

Results: 43 (55%) patients were male and 35 (45%) patients were female. The mean age was 46.7±15.06 years and the median age was 45 years (20-76). The distribution of disease is AML, ALL, chronic leukemia, lymphoma and other hematologic malignancies and ratios were 50%, 12%, 7%, 15%, 6% respectively. In our study 27 fungal pathogens (27/90) were isolated microbiologically and/or histopathologically in 27 patients. C.albicans, C.tropicalis, C.glabrata, C.crusei, Aspergillus, yeast species were found in 12(44%), 3(11%), 2(8%), 1(4%), 3(11%), 6(22%) respectively. The most isolated fungal pathogen was C.albicans (p=0.001). After the isolation of fungal pathogens antifungal treatment were given in accordance with the guidelines to the 27 patients (7 patients; liposomal amphotericin, 12 patients; caspofungin, 2 patients; voriconazol, 5 patients; fluconazol and 1 patient; posakonazol).

Conclusions: Within the scope of our study we could conclude that early diagnosis of fungal pathogens in FEN is important due to early treatment of IFI. Using antifungal agents after the correct isolation brings effective antifungal treatment so we could decrease mortality in FEN.

Keyword: Fungal pathogens

4th International Congress on Leukemia – Lymphoma – Myeloma
CASE OF A RETROPERITONEAL FIBROSIS PATIENT COMPLICATED WITH AUTOIMMUNE HEMOLYTIC ANEMIA

Mesut Ayer1, Hikmet Feyizoğlu2, Maksule Ulusoy2, Fatma Aylin Ayer1, Yeşim Gürkan2, Namik Yiğit1, Onur Kirkızlar1
1Haseki Training and Research Hospital, Hematology Outpatient Clinic, İstanbul, Turkey
2Haseki Training and Research Hospital, Internal Medicine Clinic, İstanbul, Turkey
3Dr. Ersin Arslan State Hospital, Hematology Department, Gaziantep, Turkey

Retroperitoneal fibrosis (RPF) is a rare disease (incidence:1/200.000) with fibrosis in retroperitoneal tissue and chronic inflammation. It commonly effects males, ages between 40-60.

A 45-year-old male patient applied to hospital with abdominal pain lasting over 20 days. We revealed blood urea 40mg/dl, creatinine 0.66 mg/dl, total bilirubine:0.48 mg/dl, hemoglobin:12.9 g/dl, leukocyte: 14,400/mm³, platelet: 525,000/mm³, ESR:102 mm/h and CRP: 19.9 mg/dl. We applied CT examination due to intermittent abdominal pain complaints. We revealed 9-10 cm mass lesions with soft tissue density at infrarenal area circulatting both abdominal aorta and proximal common iliac artery. These lesions were interpreted as RPF or lymphoproliferative disorder. We applied dynamic contrast MRI examination and the results were commented as RPF. On the 5.day of hospitalisation, the patient complained about abdominal pain with waist and back pain. His laboratory examination, Hgb 8.1 g/dl, LDH:2595 U/L, t.bilirubine:19.3 mg/dl, i.bilirubine:12.5 mg/dl, haptoglobin: 3.9 mg/dl and DAT was positive. Although we replaced with erytocyte suspension, hemoglobin levels decreased until 3.7 g/dl and creatinine levels increased to 3.5 mg/dl. He was taken to intensive care unife with diagnosis of acute hemolytic anemia complicated with acute renal failure. Applying steroid (1 gr/per day/3 days), intravenous immunglobin (0,5 gr/kg/day,3 days) and three cycle of plasmapheresis, hemoglobin levels increased and LDH levels decreased. We applied two cycle of hemodialysis. We continued steroid treatment with lower doses as 1 mg/per kg/per day and applied 4 more cycles of plasmapheresis. Creatinine levels of patient decreased and his urine output started to increase. We screened the patient for RF, ANA, p-ANCA, c-ANCA, ENA and anti-cardiolipin antibodies. They were all negative. His bone marrow biopsy, cytogenetic and flowcytometric examinations were normal. There was no sign of malignancy on CT and MRI of thorax and pelvic regions. After a month of the admission to hospital, his creatinine, LDH, hemoglobin, bilirubine and haptoglobin levels were all in normal ranges. His DAT was negative and we continued low doses of steroid therapy with 8 mg per day. Due to non obstructive RPF, no surgical intervention was planned. After a 6-month follow up, there was no sign of urinary system obstruction and hemolysis.

More than 70% of RPF cases are idiopathic. Fibrosis due to malignancy is nearly 8% of the cases. The association between autoimmune diseases and RPF is observed lately. Idiopathic RPF has a better prognosis and the best known treatment is steroids. Thanks to the steroid treatment, there can be an improvement on symptoms, retroperitoneal mass lesions and obstructive complications. Other immunsupresive treatment option are used for the patients resistant to steroid treatment. Surgical intervention is preferred for the patients with urinary system obstruction.

Keyword: Retroperitoneal fibrosis, autoimmune hemolytic anemia

DETERMINATION OF NURSE’S KNOWLEDGE ABOUT APLICATION, CARE AND COMPLICATIONS OF PERIPHERAL VENOUS CATHETERS, PORT CATHETERS AND CENTRAL VENOUS CATHETERS

Fatma Kesik, Bahar Demirci, Serkan Kadir Yalçın, Müzeyyen Arslan, Özlem Şahin Balçık
Fatih Üniversitesi Hastanesi, İstanbul, Turkey

Peripheral, central arterial, venousor port catheters are used for various purposes and also may lead various complications like infections or thrombosis. Central venous catheterization (CVC) is performed by a physician but preservation and following-up is done by the nurses. Study was carried out in Fatih University Hospital and Ankara Düşkapı Yıldırım Beyazıt University hospital including 668 nurses. We produced the questionnaire by investigating the literature for measuring the knowledge of nurses.

There were 31.8% (n=48) was in 18-25 age group, 42.4%(n=64) was 26-35 and 25.8%(n=39) was 36 and older age group and all participants were female.

When we evaluated the questionnaires about periphervenous catheter and central venous catheter implemention, maintenance, and complications differences between university and high school graduated came out. With increase of education the success rates was increased. In terms of questionnaire results university graduated nurses had %79.1 success rate and high school graduated nurses was %62,5 respectively and the difference between these two groups was significant (P<0.05). Contrarily about port catheterization there was no difference between groups.

There was also significant difference about PVC and CVC information between nurses considering professional experience and working service (P<0.05). However there was no significant difference about port catheterization information (P=0.05).

We evaluate the achievement scores of the nurses considering their satisfaction levels. But we did not find any difference.

One third of the participated nurses (n=55) were unsuccessful and 63,6% were successful about PVC and CVC. However 91% (n=138) of the nurses were failed or unsuccessful and 63,6% were successful about PVC and CVC. However 91% (n=138) of the nurses were failed or have no idea related to subject. As a result of questionnaire the average score was 72,3 (max: 100, min 43,75).

There were new developments new approaches to patients in nursing profession like all others. But nurses may be cannot follow this advancement because of intensive work or neglect. So in-service training was required for additional information and practice.

Keyword: Catheterisation, Nursing
Invasive fungal rhinosinusitis is usually seen in patients with compromised immune systems. The most frequently observed in patients with diabetes, the second is often observed in patients with leukemia. There are two forms; invasive and non invasive fungal sinusitis. Invasive form can be acute fulminant, granulomatous and chronic. In this article, we present a case with chronic invasive fungal rhinosinusitis that was followed for myelodysplastic syndrome.

The patient is a women aged 82 years who had admitted to hematology with weakness and fatigue in January 2012. Laboratory studies revealed WBC count of 1190 with 100 neutrophils, hemoglobin 8.2 g/dl, an MCV count of 90 FL and a platelet count of 13000. Bone marrow aspiration and biopsy was consistent with myelodysplastic syndrome multilineage dysplasia. The patient was treated with filgrastim and erythropoietin. Despite the increased maximal doses of erythropoietin alfa therapy, patient didn't respond to treatment so stopped erythropoietin. She supported with erythrocyte and platelet suspension. Ferritin value was > 1000ng/ml during the supportive therapy so the patient was treated with deferasirox.

Case was followed. Patient admitted with left cheek pain, erythema, swelling, nasal obstruction and palatal wound in January 2013. This symptoms were proceeded for two weeks. 37x35x42 mm sized mass was determined with MRI of paranasal sinus. Mass was completely filling the left maxillary sinus, extending the left nasal cavity, invading the left side of hard palate and orbital floor, demonstrating with environmental enhancement and primarily suggesting malignancy (Figure 1). Platelet value didn’t increase with random and platelet apheresis. Platelet alloimmunization developed and platelet suspension was needed. Patient has treated with intavenous vorikonazol currently. Loading dose is 2x6mg/kg/day and maintenance dose is 2x4 mg/kg/day. Following and treatment of the patient is proceeding in our clinic.

As a result, invasive fungal sinusitis may be seen acute fulminant or chronic in immunosuppressed patient and can mimic malignancy. The diagnostic value of CT and MRI is limited. The biopsy specimen should be examined as well as pathological and microbiological. Pathologist and microbiologist are warned in terms of fungal infection. Fungal cultures and pathological results aren't always diagnostic. Incorrect or retarted diagnosis may delay the treatment. For this reason if there is a clinical suspicion, the right approach will be life saving as soon as possible.

**Keyword:** Myelodysplastic Syndrome, Chronic Invasive Fungal Sinusitis
made with biopsy of lymphadenopathy. In regard to follow-up of the patients, anemia worsened and increased level of creatinine was found after follow-up of 4 years without treatment. Biopsy results of the patient for whom renal biopsy was performed because of suspicion of renal involvement is still being waited, and steroid treatment was scheduled to the patient after the result of the biopsy. Hodgkin lymphoma developed in the course of one patient. Complete remission occurred with 4 courses of ABVD chemotherapy. New mass lesion was found in lung parenchyma on imaging studies following 6th course of ABVD chemotherapy. This patient whose result of lung biopsy has come as pulmonary adenocarcinoma is still receiving chemotherapy in the oncology unit for lung cancer. Steroid treatment was given to two patients with complaints of fever, weight loss, fatigue due to anemia (hemoglobin level was 8 g/dL and 6 g/dL, respectively). Fever response occurred with steroid treatment in both patients and their symptoms were controlled. High rate of sedimentation and high level of globulin normalized in the patients with anemia resolved. In one patient receiving steroid treatment, chronic renal failure developed due to accompanying crescentic glomerulonephritis. The patient is still on chronic hemodialysis program. Steroid treatment is still continuing in both patients.

Conclusion: Although Rosai Dorfman syndrome is rare, lymphadenopathy should be kept in mind in differential diagnosis. It should be remembered that although it is a benign condition, it may be associated with other autoimmune conditions or malignancies at the time of diagnosis or during its course, and that it should be treated for symptoms due to such associated conditions and the patients should be followed for this.

Keyword: Lymphadenopathy, Rosai Dorfman Syndrome
Table 2. Increasing total drug costs and the cost per course of treatment according to chemotherapy protocols.

<table>
<thead>
<tr>
<th>Treatment protocol</th>
<th>Count of patients</th>
<th>Count of cure</th>
<th>Increasing drug cost</th>
<th>Cost per cure (TL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3+7</td>
<td>7</td>
<td>7</td>
<td>646</td>
<td>99.2</td>
</tr>
<tr>
<td>ABVD</td>
<td>4</td>
<td>11</td>
<td>363</td>
<td>33</td>
</tr>
<tr>
<td>AZAVIDINE</td>
<td>2</td>
<td>6</td>
<td>17642</td>
<td>2940.3</td>
</tr>
<tr>
<td>R-CHOP</td>
<td>20</td>
<td>92</td>
<td>23653</td>
<td>257.1</td>
</tr>
<tr>
<td>CHOP</td>
<td>2</td>
<td>13</td>
<td>372</td>
<td>28.6</td>
</tr>
<tr>
<td>CVP</td>
<td>2</td>
<td>8</td>
<td>41</td>
<td>5.1</td>
</tr>
<tr>
<td>DHAP</td>
<td>2</td>
<td>2</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>ESHAP</td>
<td>2</td>
<td>2</td>
<td>147</td>
<td>73.5</td>
</tr>
<tr>
<td>FLAG</td>
<td>5</td>
<td>5</td>
<td>2022</td>
<td>404.4</td>
</tr>
<tr>
<td>FLAG IDA</td>
<td>4</td>
<td>4</td>
<td>706</td>
<td>176.5</td>
</tr>
<tr>
<td>FLUDARABIN</td>
<td>1</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>HDAC</td>
<td>7</td>
<td>11</td>
<td>333</td>
<td>41.6</td>
</tr>
<tr>
<td>ICE</td>
<td>3</td>
<td>8</td>
<td>333</td>
<td>41.6</td>
</tr>
<tr>
<td>MAD</td>
<td>7</td>
<td>23</td>
<td>93776</td>
<td>4077.2</td>
</tr>
<tr>
<td>FC</td>
<td>1</td>
<td>1</td>
<td>376</td>
<td>376</td>
</tr>
<tr>
<td>VAD</td>
<td>6</td>
<td>21</td>
<td>728</td>
<td>34.6</td>
</tr>
<tr>
<td>HYPERCVAD</td>
<td>7</td>
<td>12</td>
<td>1292</td>
<td>100.1</td>
</tr>
<tr>
<td>SOLRIS</td>
<td>1</td>
<td>14</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TOTAL</td>
<td>83</td>
<td>249</td>
<td>142019</td>
<td></td>
</tr>
</tbody>
</table>

### Stem Cell Transplantation

**Poster No: 00168 Abstract:0117**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA-12 YEARS SINGLE CENTER EXPERIENCE**

**Zlate Stojanoski, Borce Georgievski, Sonja Genadieva Stavrik, Aleksandra Pivkova, Oliver Karanfliski, Lidija Cevreska**

**University Clinic of Hematology**

Background: multiple myeloma is a malignant neoplasm of plasma cells. Autologous stem cells transplantation (ASCT) has become the first line of therapy mainly because of the low transplant-related mortality and prolongation of event free survival resulting in improved quality of life. High-dose therapy (HDT) with ASCT should be part of primary treatment in newly diagnosed patients up to the age of 65 years with adequate performance status and organ function.

Aim: the aim of this study is to present our ten years experience in treatment of patients with multiple myeloma with ASCT.

Material-Methods: during a 12-years period we have performed 44 courses of HDT and consecutive ASCT in 39 patients with multiple myeloma (5 tandem transplantation). In this study we retrospectively analyzed the epidemiological characteristics of this group of patients. Results: Female:20 Male: 22 Median age: 53 years (from 43-64). High-dose Melphalan in doses 200mg/m² was used as conditioning regimen, in second (tandem) transplantation 140mg/m². Median count of infused CD34+ cells was 3,65x10⁸/kg. As a source of added stem cells we use phlebothomy in 3 patients. The median period from diagnosis to transplantations was 10 months. Of 39 patients, 24 (61%) are alive, 15 (39%) have died (4 renal failure, 4 multi-organ failure, 4 infections, 3 fatal cerebral bleeding). The disease-free survival was 24 months. OS was 50 months and EFS was 38 months. Conclusions: ASCT offer better results in survival and quality of life compared with patients treated only with standard chemotherapy.

**Keyword:** stem cell transplantation, multiple myeloma

**Poster No: 00169 Abstract:0135**

**MULTIPLE BIOMARKERS IN THE DETECTION OF CARDIOTOXICITY DURING STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES**

**Jan M. Horacek¹, Martina Vasatova², Radek Pudil³, Martin Jakl³, Pavel Zak³, Ladislav Jebavý¹**

¹Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic; ²4th Department of Internal Medicine – Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

²Institute of Clinical Biochemistry and Diagnostics, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

³1st Department of Internal Medicine – Cardioangiology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

²Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic; ¹Department of Internal Medicine, University of Defence, Faculty of Medicine, Hradec Kralove, Czech Republic

Background: Cardiotoxicity is a potentially serious complication of hematopoietic treatment. Preparative regimen (PR) followed by stem cell transplantation (SCT) represents a high risk for development of cardiotoxicity. Various methods including cardiac biomarkers have been recommended for monitoring of cardiotoxicity.

Objectives: The aim of the study was to assess cardiac toxicity during SCT with multiple biomarkers of cardiac injury – myoglobin, creatine kinase MB (CK-MB mass), cardiac troponin I (cTnI), heart-type fatty acid-binding protein (H-FABP), glycogen phosphorylase BB (GPBB). Experience with new perspective cardiac biomarkers (GPBB, H-FABP) in this setting is very limited.

Methods: A total of 53 patients (mean age 49.9 ± 12.3 years, median 54 years, 33 males) transplanted for various hematological malignancies were studied. The diagnoses were as follows: AML 27, MM 12, NHL 5, HL 4, ALL 3, CML 1, MDS 1. Thirty transplants were autologous, 23 allogeneic. Cardiac biomarkers were measured on Randox Evidence analyzer the day after completion of preparative regimen (after PR) and the day after infusion of stem cell grafts (after SCT). Values above the reference range recommended by the manufacturer were considered elevated.

Results: We found significant elevations in GPBB (above 7.30 µg/L) in 8 (15.1 %) patients after PR and in 9 (17.0 %) after SCT. H-FABP increased slightly above the
cut-off after SCT in 1 (1.9 %) patient. Other cardiac biomarkers (myoglobin, CK-MB mass, cTnI) remained within the reference ranges in all patients. We found a significant correlation between elevation in GPBB and diastolic left ventricular (LV) dysfunction on echocardiography (r = 0.603; p < 0.0001). No patient manifested clinical cardiotoxicity in the peri-transplant period.

Conclusions: Our results suggest that administration of PR followed by SCT could be associated with myocardial injury manifested by increased release of GPBB from cardiomyocytes which could correlate with diastolic LV dysfunction on echocardiography. In asymptomatic patients, these findings could be considered a sign of acute subclinical cardiotoxicity. Whether these acute changes will have predictive value for development of treatment-related cardiomyopathy in the future is not clear and will be evaluated during a prospective follow-up. Further studies in a larger number of patients will be needed to confirm our results and define the potential role of new biomarkers of cardiac injury in this context.

The work was supported by a long-term organization development plan 1011 (FMHS).

**Keyword:** cardiac biomarkers, stem cell transplantation

Poster No: 00170 Abstract:0142

**WHEN AND HOW SHOULD A PATIENT WITH MYELODYSPLASTIC SYNDROME BE TRANSPLANTED?**

H. Joachim Deeg

Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Patients with lower risk MDS tend to have a more indolent, yet still progressive course. In fact, the presence of severe neutropenia or thrombocytopenia may be an indication for HCT, particularly in younger individuals even with a low International Prognostic Scoring System (IPSS) score since none of the non-HCT therapies have been shown to be curative. Red blood cell transfusion dependence should also be considered in this context. Transfusion dependence is also linked to marrow fibrosis, which is associated with more rapid progression of MDS, and we showed recently that MDS patients with marrow fibrosis who are transplanted at a more advanced disease stage have an inferior outcome compared to patients without fibrosis. Whether chelation therapy of iron overload improves outcomes after HCT, has yet to be determined.

The decision to proceed to HCT is easier in patients with advanced/high risk disease. Patients with RAEB-1 or RAEB-2 patients in WPSS categories intermediate, high and very high risk, and patients with intermediate to very poor risk cytogenetics (by 5-group classification) should definitely be considered for HCT.

Patients with therapy-related MDS should also be offered transplantation as it has been shown that, once adjusted for the patient’s karyotype, the probability of transplant success is similar to that in patients with de novo MDS.

Optimal timing of HCT for MDS has remained a controversial issue. The probability of relapse increases progressively with increased IPSS or WPSS scores, the major determining parameters being karyotype and myeloblast count. Patients with high or intermediate-2 risk by IPSS who have HLA-identical sibling donors and are prepared for HCT with high intensity conditioning regimens, appear to benefit from early HCT, while patients with low or intermediate 1 risk may have a longer life expectancy if HCT is delayed until evidence of disease progression.

Post-HCT relapse has remained a challenge, particularly in patients with high risk disease, especially those with poor risk cytogenetics. Intensification of the conditioning regimens has decreased post-HCT relapse, but has also increased toxicity and NRM. Very little, if any, toxicity was observed with a regimen composed of Flu (3 × 30 mg/m²) and 2 Gy of TBI, but the cumulative incidence of relapse was more than 50% at 3 years. Others used a regimen of Flu + melphalan and noted a relapse incidence of less than 25% at 3 years, but a NRM of 40%.

Encouraging results have been reported recently with regimens including treosulfan. In a trial conducted at our Center 60 patients with MDS or AML were prepared with a regimen of Fludarabine (30 mg/m² × 5) and treosulfan (12g or 14 g/m² × 3) for HCT from HLA-matched related or unrelated donors.

Additional studies will need to determine the impact of novel non-transplant therapy on the decision about and the timing of HCT.

**Keyword:** Mds, transplantation

Poster No: 00171 Abstract:0158

**HODGKIN LYMPHOMA BUT NOT NON-HODGKIN LYMPHOMA IS INDEPENDENT RISK FACTOR FOR POOR STEM CELL MOBILIZATION**

Asu Fergun Yılmaz, Ayhan Dönmez, Murat Tombuloglu

Ege University Medical School, Department of Hematology, Izmir, Turkey

Objective: Poor mobilization is an important problem in autologous stem cell transplantation. The ratio of poor mobilization was higher in lymphoma patients. In this study we tried to identify the possible risk factors for poor mobilization at lymphoma patients.

Method: We retrospectively analyzed 57 lymphoma patients who were treated by autologous stem cell transplantation between 1998 – 2011. We searched the relation between mobilization and different variables (diagnosis, type of the disease, age, sex, weight, bone marrow involvement, radiotherapy, treatment protocols, the number of the chemotherapy cycles and the rituximab administration) by the multivariate test (logistic regression). p values less than 0.05 were considered as significant. The data were analyzed using computer software (SPSS 16.0, SPPS, Inc., Chicago, IL). Mobilization insufficiency was defined as the peripheral blood CD34+ cell count less than 10/µl during the post-mobilization period or collected CD34+ cell count less than 2.5×106/kg.

Results: The 57 patients diagnosed as lymphoma (38 non- Hodgkin and 19 hodgkin lymphoma) were composed of 34 males and 23 females. Their median age was 44 (range, 19 - 66) years old. A poor mobilization was documented in 13 patients (22.8 %); 5 Hodgkin lymphoma patients; 25% and 8 non-Non Hodgkin lymphoma patients: 21.6 %). Bone marrow involvement (OR = 46.34, p = 0.003), being diagnosed as Hodgkin lymphoma (OR = 24.33, p = 0.03), and treatment with more than 10 cycles of chemotherapy (OR = 14.92, p = 0.02) were found as risk factors for poor mobilization. When we excluded patients with bone marrow involvement, the ratio of poor mobilization was 11.5 % for non – Hodgkin Lymphoma and 22.2 % for Hodgkin Lymphoma.
Discussion: For the lymphoma patients the most important factor for poor mobilization was bone marrow involvement. In this present study, we documented that the increased risk for poor mobilization at non-NHL Hodgkin lymphoma patients was due to bone marrow involvement. We could conclude that the increased risk of poor mobilization at Hodgkin lymphoma patients (OR = 24.3) was independent of bone marrow involvement unlike non-Hodgkin lymphoma patients. At these patients other factors like the nature of the disease, the chemotherapeutic drugs specific to Hodgkin lymphoma, or the characteristics of the patients should be investigated for poor mobilization.

**Keyword:** mobilization, lymphoma

**Poster No: 00172 Abstract:0175**

**FACTORS AFFECTING LYMPHOCYTE RECOVERY AFTER BONE MARROW TRANSPLANTATION**


*The University of Texas, MD Anderson Cancer Center, USA*

Recovery of the immune system is of paramount importance for the success of allogeneic stem cell transplantation (ASCT). The incidence of post-engraftment infections is mainly due to a delayed reconstitution of lymphocytes. Several groups including ours reported that early lymphocyte recovery after ASCT was associated with improved outcomes. The factors affecting lymphocyte recovery after bone marrow transplantation (BMT) and its influence on outcomes are not well studied.

554 pts with acute leukemia (452 AML/MDS and 102 ALL) who underwent ASCT from bone marrow grafts at MD Anderson Cancer Center between 01/1999 and 12/2010 were included. Eighteen pts who had primary graft failure were excluded. Demographics, remission status at the time of BMT, preparative regimen, graft-versus-host disease (GVHD) prophylaxis, donor type, graft CD34+ and CD3+ cell contents, data on engraftment, response, GVHD, progression, and survival were gathered from institutional databases. Early lymphocyte recovery (ELR) was defined as achieving absolute lymphocyte count of 1000/µL (ALC1000) by day 100. Haploidentical donor was defined as a related donor with ≥3 HLA allele mismatches.

P<sub>t</sub> age, graft CD34+/CD3+ cell content, and remission status did not affect lymphocyte recovery. ALL diagnosis, TBI-based or fludarabine-melphalan (>140 mg/m², FM>140) ablative regimens, post-BMT cyclophosphamide for GVHD prophylaxis, and not receiving ATG were significantly associated with late lymphocyte recovery on univariate analysis. There was a trend of higher NRM in patients who received TBI-based ablative conditioning (p=0.07). Pt age, graft cellular content, and GVHD prophylaxis type did not affect NRM. A Cox proportional hazards model confirmed ELC (HR: 0.2 [0.1-0.5]) and CR status (HR: 0.3 [0.2-0.7]) to be independent prognostic factors for NRM.

In conclusion, early lymphocyte recovery is an independent prognostic factor for NRM after BMT and is influenced by conditioning regimen but not by the bone marrow graft cellular content.

**Keyword:** Stem cell transplantation

**Poster No: 00173 Abstract:0185**

**FLAMSA-BASED SEQUENTIAL CONDITIONING THERAPY AS SALVAGE TREATMENT FOR HEAVILY PRETREATED PATIENTS WITH LEUKEMIA: A SINGLE CENTRE EXPERIENCE**

Gözde Cengiz Seval, Pervin Topçuoglu, Önder Arslan, Osman Ihan, Hamdi Akan, Meral Beksaç, Günhan Gürman, Muhtı Özcan

*Ankara University Faculty of Medicine Department of Hematology, Ankara, Turkiye*

Aim: The aim of this retrospective single-centre study was to examine the allogenic HSCT results based on FLAMSA cytoablativertive therapy followed by a reduced intensity or myeloablative conditioning regimen.

Patients: Between 2007 and 2012, a total of 20 patients (17 de novo or secondary AML, 2 ALL, 1 Mantle cell lymphoma; all with active refractory disease) were treated with the FLAMSA (fludarabine, amsacrine, and cytarabine) followed by a reduced intensity regimen (n=19) or myeloablative regimen (n=1) (Table 1). The median age was 41 years (range 28-48.5 y); three patients were females and 17 males. In our cohort, three patients underwent the second allo-HSCT due to relapse of acute myeloid leukemia. Donors were HLA-identical siblings in 11 and unrelated donors in 10 patients. The allograft source was peripheral blood stem cells in 17 patients; two patient received cord blood and one patient received bone marrow.

Results: Twelve patients reached complete remission (CR). Of these eight patients relapsed, but CR was re-achieved in two patients after chemotherapy and donor lymphocyte infusions. After a median follow up of 102 days (95% CI), the incidence of non-relapse mortality was 30%. Median time from diagnosis to alloHSCT was 18.2
months (range: 8.0-24.3 months). The median number of transplanted cells was 5.38x10^6 CD34+ cells/kg (range 1.3-9.9 x10^6). Eleven patients (55%) died from reasons not related to leukemia before day +100 (Table 1). Acute GvHD occurred in nine patients, reaching grade I in 1, grade II in 1, and grade III and IV in 7 cases. Of the 10 patients who survived more than day 100 chronic GvHD developed in 7 patients. The estimated 1-year overall survival from the transplantation was 40%±11% (median: 3.4 months, 95%CI).

Conclusion: Although 60% of CR rate makes this approach attractive, high rates of relapse and TRM needs to be improved new transplant modalities.

**Keyword:** FLAMSA, allogenic HSCT

**Table 1. Patients’ characteristics and transplant outcome**

<table>
<thead>
<tr>
<th>Gender (M/F) (n)</th>
<th>17/3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (years (range))</td>
<td>41 (28-48.5)</td>
</tr>
<tr>
<td>Diagnosis (n)</td>
<td>14/3</td>
</tr>
<tr>
<td>AML (De novo/Secondary)</td>
<td>2</td>
</tr>
<tr>
<td>MDS</td>
<td>1</td>
</tr>
<tr>
<td>Treatment cycles prior to transp. (median±SD)</td>
<td>3 (1-8)</td>
</tr>
<tr>
<td>Sorror comorbidity index (median±SD)</td>
<td>2 (0-7)</td>
</tr>
<tr>
<td>Donor type (n)</td>
<td>10</td>
</tr>
<tr>
<td>HLA-matched sibling or related donor</td>
<td>10</td>
</tr>
<tr>
<td>HLA-mismatched unrelated donor</td>
<td>8</td>
</tr>
<tr>
<td>Unrelated cord blood</td>
<td>2</td>
</tr>
<tr>
<td>Conditioning regimen</td>
<td>1</td>
</tr>
<tr>
<td>ATG + TBI</td>
<td>11</td>
</tr>
<tr>
<td>Cy + TBI</td>
<td>6</td>
</tr>
<tr>
<td>FB + Bu</td>
<td>1</td>
</tr>
<tr>
<td>Prophylaxis for GvHD</td>
<td>1</td>
</tr>
<tr>
<td>CSA + MMF</td>
<td>13</td>
</tr>
<tr>
<td>CSA + Mtx</td>
<td>6</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>1</td>
</tr>
</tbody>
</table>

**Engraftment kinetics (median±SD)**

| Neutrophil (0.5x10^9/L) | 16 (10-39) |
| Platelet (20x10^9/L) | 15 (11-48) |

**Transplant-related mortality**

| Day +100 | 1 engraftment failure |
| Causes of death | 2 sepsis |
| | 1 congestive heart failure and sepsis |
| | 1 GVHD and fungal infection |
| | 1 Acute GvHD and myocardial infarction |

One-year overall survival 40±11%

---

**GRANULOCYTIC SARCOMA AT CHRONIC MYELOID LEUKEMIA PATIENT WHO WAS TREATED WITH ALLOGENEIC TRANSPLANTATION**

Asu Fergun Yılmaz1, Ajda Ersoy1, Melda Cömert1, Nazan Özsan2, Seckin Çağrın1, Mahmut Töbü1, Filiz Vural1, Fahri Şahin1, Güray Saydam1

1Ege University of medicine, Department of Hematology, Izmir, Turkey
2Ege University of medicine, Department of Pathology, Izmir, Turkey

Introduction: Granulocytic sarcoma is an extramedullary tumoral lesion consists of immature myeloid cells. It can accompany with acute myeloid leukemia, chronic myeloproliferative neoplasm and myelodysplastic syndrome. It can be seen at the diagnosis or during the follow up period. Here, we report a case of chronic myeloid leukemia who was treated with allogeneic stem cell transplantation and relapsed with granulocytic sarcoma.

Case: A 33-year old male patient was diagnosed as Ph (+) CML in 2003 September. He was treated with hydroxyurea and interferon. In 2004 February 400 mg/day imatinib mesilate treatment was initiated. In January 2007, the dose of imatinib was titrated to 800mg/day due to progression of disease to accelerated phase. In 2007 September, allogeneic stem cell transplantation from HLA full-matched related donor was performed due to lack of response. Full donor chimerism and complete cytogenetic response was obtained after the transplantation without major molecular response and 100 mg/day Dasatinib was administered. We achieved major molecular response six months after the dasatinib treatment and he was followed up with major molecular and complete cytogenetic responses until April 2012. At that time, rapidly progressive tumoral lesion of 20x15 cm was observed at his right shoulder. The biopsy revealed granulocytic sarcoma. The bone marrow biopsy revealed remission with a cyctogenetic analysis of 46XX. The bcr–abl analysis of bone marrow with RT-PCR method was also negative. He was treated with radiotherapy and standard doses Ara C + İdarubicine induction chemotherapy for 2 cycles and more than 90% regression was achieved. But the lesion grew up rapidly in a few weeks and FLAG-İda chemotherapy was initiated. He died of sepsis during the time of chemotherapy.

Conclusion: Relapse of disease with only granulocytic sarcoma is rare in patients who treated with allogeneic stem cell transplantation. Even though, without systemic disease involvement, granulocytic sarcoma has an aggressive course, usually no response was achieved to combination therapies. Donor lymphocyte infusions or retransplantation can be used as a treatment option.

**Keyword:** granulocytic sarcoma

---

**Figure 1. Granulocytic sarcoma at presentation**
EXTENSIVE CHRONIC GVHD TRIGGERED BY LENALIDOMIDE MAINTENANCE AFTER NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN A PATIENT WITH MULTIPLE MYELOMA

Ipek Yonul, Emre Osmanbasoglu, Sevgi Kalayoglu, Besik, Deniz Sargun
Istanbul University Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey

Allo-SCT may be the only treatment in MM with potential chance of cure. Immune-modulator novel anti-myeloma agents with potential to induce graft-versus-myeloma (GVM) effect and hence improve disease outcome are of special therapeutic interest.

A 53 year old man diagnosed with stage III-A IgG kappa MM in April 2005 received 6 courses of VAD and PR was obtained. One year later, for relapse, thal/dex was started and resulted in PR after 2 months. In January 2007, ASCT with 200 mg/m2 melphalan was performed and VGPR was achieved after 6 months. In March 2009, 2nd relapse was treated with 8 courses of vel/dex and resulted in VGPR. For 3rd relapse in July 2010, 2 courses of len/dex achieved PR and was completed to 12 courses. 4th relapse in October 2011 was treated with 4 courses of V/TCD and PR was obtained. He underwent nonmyeloablative (NMA) allo-SCT from matched related donor in February 2012 with fludarabine and melphalan as CR and CSAs and MTX as GVHD prophylaxis. On day +30, complete chimerism was shown. Because of renal dysfunction, CSAs was replaced by MMF on day +75. By day +100, patient had no active MM, but MMF was tapered due to positive serum immunofixation test and 5-10% plasma cells in bone marrow. By day +120, M-protein increased from 0.54 to 0.83 g/dl and MMF was discontinued to further induce GVVM. One month later, due to mild anemia and an increase in M-protein to 0.88 g/dl, lenalidomide maintenance 10 mg/day on days 1-21, q 28 days and dexamethasone 40 mg/week was started. After 2 cycles on 7th month of allo-SCT, patient presented with papular skin changes on anterior torso, hyperkeratotic changes on lower labial mucosa, symptoms of dry eyes and elevated liver enzymes. Schirmer’s test was positive and liver biopsy showed severe bile duct injury and infiltration of some portal tracts by mononuclear cells. Due to extensive chronic GVHD, len/dex was stopped and methylprednisolone 2 mg/kg/day was started. Within 3 weeks, there was regression in skin rash, mucosal changes and liver enzymes. Patient is still under follow up with no active disease.

Both thalidomide and bortezomib are effective in relapse after allo-SCT, without excessive stimulation of GVHD. Impressive results were obtained with lenalidomide as salvage therapy for symptomatic disease after allo-SCT. Hovon 76 trial showed lenalidomide maintenance after allo-SCT improved response in 37% of patients with a 1-year PFS of 69%. Yet, this trial reported early lenalidomide treatment after an NMA allo-SCT is not feasible due to development of GVHD, which caused to stop treatment prematurely in 43% of patients. Increased frequency of HLA-DR+ T cells and regulatory T cells with lenalidomide is accounted for GVHD. In lenalidomide associated GVHD, most common sites of involvement were skin and liver. Yet, liver involvement had not been confirmed by biopsy. To our knowledge, this is the first case, in which liver GVHD due to lenalidomide maintenance was histologically proven.

Keyword: Extensive chronic GVHD, lenalidomide maintenance
after alloSCT. Interestingly, there is preclinical data implying targeting CD30 on T cells may abrogate GVHD, so one could hypothesize brentuximab vedotin could yield a 2-fold benefit for patients with relapse and GVHD, though there are no clinical data to date supporting this premise.

**Keyword:** brentuximab vedotin, relapsed Hodgkin lymphoma after allogeneic stem cell transplantation

---

**ABSTRACTS**

**Poster No:** 00177  **Abstract:** 0272

**Antithymocyte globulin (ATG) or Antilymphocyte globulin (ALG) for treatment of steroid refractory acute graft versus host disease (GVHD)**

Mehmet Özen1, Pervin Topçuoğlu1, Güzin Çakmak2, Ayşę Hilal Erdoğan2, Önder Arslan1, Osman Ilhan1, Nahide Konuk1, Meral Beksaç1, Günhan Gürman1, Muhıt Özcan1

1Ankara University, School of Medicine, Dept of Hematology, Ankara, Turkey
2Ankara University, School of Medicine, Dept of Internal Medicine, Ankara, Turkey

**Introduction:** Currently there is no consensus of treatment for steroid-refractory acute GvHD. Antithymocyte globulin (ATG) is the most common form of immunosuppression used in this setting. We report our institution’s experience treating steroid resistant acute GvHD in 26 patients between Jan 2000 and Dec 2012. Median age was 33 years (19-54y). The gender of patients was 10 females and 16 males. The patients’ and donors’ characteristics and response to the treatment were shown in Table. Results: Acute severe GvHD (grade III-IV) developed median 22 days (8-70 days) after the transplantation (n=23) or donor lymphocyte infusion (n=3). For secondary treatment of acute GvHD, ATG (ATG fresenius®) (n=22) or ALG (equine Pastuer Merriux®) (n=4) with corticosteroids was usually administered by intravenous infusion at a dose of 10 mg /kg/day consecutively five days. From the beginning of acute GvHD to the first doses of infusion of ATG or ALG was median 22 days (8-70 days) after the transplantation.

**Table 1.** Characteristic and responses

<table>
<thead>
<tr>
<th>Feature</th>
<th>Patients</th>
<th>Median age (range), year</th>
<th>Gender (MF)</th>
<th>Donors</th>
<th>Median age (range), year</th>
<th>Gender (MF)</th>
</tr>
</thead>
</table>

In responsive group (n=11), all the patients died of several reasons such as infection (n=7), chronic GvHD (n=3) and liver failure (n=1). In non-responsive group (n=16) 14 patients were death. Thirteen out of them systemic infection added to acute progressive GvHD in early period. But one patient died of sudden death nine years after acute GvHD. Only one patient is alive today.

**Conclusion:** Steroid refractory acute GvHD is one of the severe mortal complications of allogeneic HSCT. In our retrospective evaluation ATG or ALG seems to be effective on GvHD, even though anti-globulin treatment did not change the survival due to opportunistic infections.

**Keyword:** Graft versus host disease, transplantation

---

**WHICH SHOULD BE TAKEN INTO CONSIDERATION WHEN DMSO IS USED FOR CRYOPRESERVATION VOLUME OR CELL COUNT?**

Meltem Kurt Yüksel1, Özlem Kıktaş1, Mevlude Kurdal1, Ibrahim Tek1, Selami Koçak Toprak1, Devrim Özbeğ1, Alpay Azap2, Osman Ilhan3, Önder Arslan1, Muhıt Özcan3

1Private Medicana International Ankara Hospital Stem Cell Transplantation Unit, Ankara Turkey
2Ankara University School Of Medicine, Department of Infectious Disease and Clinical Microbiology, Ankara Turkey
3Ankara University School of Medicine, Stem Cell Transplantation Unit, Ankara Turkey
4Başkent University School of Medicine, Hematology Department, Ankara Turkey

Dimethylsulfoxide (DMSO) is toxic to the cells. Although it is used for cryopreservation, it has not been approved by FDA. 10% concentration is used for cryopreservation mostly. However, 8% concentration and combinaton with HES and albumin is also used. There is no standart procedure for cryopreservation.

**Aim:** To evaluate the viability and engraftment kinetics of the products those contain %10 DMSO but different amounts of DMSO and CD34 + hematopoietic stem cells.

**Materials-Methods:** 60 patients whom underwent autologous transplantation were evaluated. The correlation between the amount of DMSO and other parameters was tested by Spearman correlation test. A statistical software (STATA 11.0, TX-USA) was used. The average age of the patients was 52.64 (24-73). Male to female ratio was 38:21.

**Results:** The diagnosis of the patients were Multiple Myeloma, n=31, Non Hodgkin Lymphoma n= 24, Hodgkin Lymphoma n= 4, Acute myeloid leukemia n=1. The number of patients who have product in 1, 2, 3 and 4 cryobags were n=28, n=23, n=8 and n=1 respectively. All of the products contain 10% DMSO. The amount of total DMSO was 22.49 (7-48ml). The total CD34+ cell count was 6.3x10^6/kg (2.5-18x10^6/kg). The DMSO amount was 22.49 (7-48ml).
per CD34+ hematopoetic progenitor cell is 4.72 ml (0.39-17.78ml). The viability of the cells were 80.84 % (73-89%). The blood LDH level on the first day after transplantation is 1051.22 IU/L (205-6237)Although it was not statistically significant, the viability of cells was inversely correlated with the amount of DMSO (Spearman’s rho = -0.1363, P=0.3121). A significant correlation was found between the amount of DMSO and the LDH level on day one after the transplantation (Spearman’s rho = 0.5945, P<0.001).Neutrophils engrafted on day 11 (8-23day) and platelets engrafted on day 14 (9-37 day) in all patients.

Conclusion: Although most centers use 10% DMSO, the adverse effect of the toxicity on the cells can increase to unexpected levels after a critical amount.

Keyword: cryopreservation, viability

Poster No: 00179 Abstract:0289

EFFECT OF RITUXIMAB ON LYMPHOCYTE RECOVERY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Süleyman Tümküya1, Günver Hayri Özsan2, Ömür Gökmen Sevindik2, Abdullah Katgr2, Şerife Medeni Solmaz2, Celal Acar2, İnci Alacacioglu3, Özdönüşkin2, Mehmet Ali Ozcan2, Fatih Demirkân2, Bülent Ündar2

Dokuz Eylül University Internal Medicine, İzmir
Dokuz Eylül University Hematology Department, İzmir

It has been previously shown that early recovery of lymphocytes predicts superior survival after autologous stem cell transplantation. On the other hand it is well known that rituximab treated patients has a B lymphocyte depletion for a period (around two years). Here we studied the effect of Rituximab therapy on lymphocyte recovery after autologous stem cell transplantation. Total 59 patient were analyzed. 23 of them received Rituximab prior to the transplantation (15 diffuse large B cell lymphoma, 5 mantle cell lymphoma, 1 marginal zone lymphoma and 2 t-cell rich B cell lymphoma) and 26 did not receive Rituximab before transplantation (27 Hodgkin lymphoma and 9 t-cell NHL). In both groups patients received median three courses of chemotherapy prior the transplantation. Median cycle of Rituximab was 6 months (3-12 months) in Rituximab group. Median time elapsed from last Rituximab dose to transplantation was 5 (1-37) months. Absolute lymphocyte count was 200 (0-2600)/μL in rituximab group and 300 (0-5300) in Rituximab naïve group at day 15 after reinfusion (p=0.2). Absolute lymphocyte count was 2000 (350-7800)/μL in Rituximab group and 1800 (300-5200) in Rituximab naïve group at day 100 after reinfusion (p=0.508). Our results suggest that Rituximab had no apparent effect on lymphocyte recovery of patients diagnosed with lymphoma undergone autologous stem cell transplantation. Additionally its in-vivo purging effect could have beneficial effect on the transplantation results.

Keyword: Stem cell transplantation, rituximab

Poster No: 00180 Abstract:0291

AN UNEXPECTED CAUSE OF PERSISTANT NEUTROPENIC FEVER IN A MYELODYSPLASTIC SYNDROME PATIENT: MESENTERIC PANNICULITIS
Emine Tülay Öüzçelik1, Fehmi Hindilerden2, Nuri Başar Hasbal3, Özgür Ceyhan4, Mutlu Arat2

1Şişli Florence Nightingale Hastanesi, Hematopoeitk Kök Hücresi Nakil Ünitesi, İstanbul, Turkey
2İstanbul Bilim Üniversitesi, HASTALKARN ABİ, HEMATOLOJİ BİLİM DALI, İstanbul, Turkey
3Şişli Florence Nightingale Hastanesı, Radyoloji Bölümü, İstanbul, Turkey

Mesenteric panniculitis (MP) is a rare disorder characterized by inflammatory process in the mesenteric fat. Although the disease is considered idiopathic and benign, it has been associated with autoimmunity, trauma, neoplastic etiologies. Patients may present with abdominal pain, fever or intestinal obstruction. Following histological diagnosis, treatment depends on individual patient status and includes surgery, immunosuppressive therapy or conservative approach. Herein, we report a patient with MDS who had an unexpected diagnosis of mesenteric panniculitis as the cause of persistant neutropenic fever.

A 57-year-old male diagnosed with MDS-RCDM was admitted for allogeneic HSCT. He complained of right upper quadrant pain and one month long fever reaching to 390C. He had previously received several antimicrobials and antifungal therapies for febrile neutropenia with no success. Microbiological and radiological investigations were performed to identify origin of fever. No microbiological agent was identified. Chest CT was normal. However, contrast enhanced abdominal CT showed a lesion with 101x52 mm in inferior neighbourhood of pancreas composed of inhomogeneous fatty tissue (Figure). Inflamed mass surrounded mesenteric vascular structures and was in close vicinity of superior mesenteric vein and artery. Findings were suggestive of mesenteric panniculitis. Due to deep localisation of the lesion and refractory thrombocytopenia, biopsy could not be performed. Colonoscopy, tumor markers and rheumatological serology were normal. Methylprednisolone (MPred) 1 mg/kg/day was started. Fever completely resolved and there was 90% relief of abdominal pain. MPred was subsequently tapered and stopped on 10th day as conditioning regimen (BU/CY) was initiated. However, fever recurred immediately following drug withdrawal. MPred was restarted and resulted in defervescence. On day +17, MPred was stopped again due to fever recurrence occurring one day later. Cultures remained negative and fever was attributed to mesenteric panniculitis. Steroid was reinitated and resulted in rapid defervescence. Patient was discharged on MPred treatment. Control CT performed 6 weeks after initial evaluation showed mild decrease in size of mass lesion with a diameter of 82x46 mm. At last follow up on day +60, fever did not recur under steroid treatment. In our case, lack of histological evaluation is a matter of debate however the lesion appeared inflammatory. This case is interesting because MP treatment was steroid dependent and despite myeloablative and immunosuppressive conditioning regimen, there was only response to steroid therapy. To our knowledge, there is no report of a case of MP undergoing HSCT. Long term follow up of this patient will help to clarify contribution of HSCT to the course of MP.
In conclusion in febrile neutropenic patients with persistant fever as an unexpected, extraordinary and rare cause ‘MP’ should be included in differential diagnosis.

**Keyword:** Mesenteric panniculitis, HSCT

---

**Poster No: 00181 Abstract:0293**

**ALLOGENIC PERIPHERAL STEM CELL TRANSPLANTATION AFTER REDUCED-INTENSITY CONDITIONING WITH BUSULFAN, FLUDARABINE, AND ATG IN MYELOFIBROSIS**

Hakan Özdoğu, Can Boğa, Mahmut Yeral, Süheyl Asma, İlknur Koçanolu
Adana Adult Bone Marrow Center, Department of Hematology, Baskent University, Adana, Turkey.

Busulfan, fludarabine, and antithymocyte globulin as a reduced-intensity conditioning is widely used for allogeneic stem cell transplantation (SCT). We report the results of reduced-intensity conditioning followed by allogenic peripheral SCT in 5 patients with primary myelofibrosis at diagnosis. All patients have intermediate group regarding Cervantes Risk Scoring System. The median age was 50 (35-57) years. Although all patients were transfusion-dependent, among five patients one had severe transfusional hemosiderosis due to ineffective iron chelation therapy. Stem cell source was HLA-matched sibling donors for all patients. The patients received conditioning regimen consisted of fludarabine 150-180 mg/m², busulfan 9.6 mg/kg, and antithymocyte globulin (ATG Fresenius) 15 mg/kg followed by peripheral blood stem cell alografting. The dose of stem cell infused was minimum 4x10⁶ CD34+ cell/µL. They received cyclosporine and mucopentolate mofetil for GVHD prophylaxis. Leukocyte engraftment occurred by day +13 (8-17) and platelet engraftment +14 (12-22) post transplant. While four patients had full donor chimerism by day +30, one patient had on day +180. The incidence of acute and chronic GVHD were 16 % and 50 % respectively. Transplant related mortality was 16%. With the median follow-up of 15.6 (1.4-38.3) months, estimated one year event-free survival was 83 % and the overall survival was 83 %. One patient had severe back pain associate with mucophenolate and required drug interruption. One patient who had high EBMT transplant risk score developed venoocclusive disease and died on day +41 because of multi-organ failure. In conclusion, Flu-Bu-ATG protocol, as a reduced-intensity dose regimen, can provide effective disease control in myelofibrosis with acceptable non-relapse mortality and toxicity profile.

**Keyword:** Myelofibrosis, Allogeneic PSCT

---

**Poster No: 00182 Abstract:0302**

**BONE MARROW HISTOLOGY DOES NOT PREDICT THE MOBILIZATION SUCCESS WHICH IMPLIES THE IMPORTANCE OF “ON DEMAND” USE OF PLERIXAFOR**

Sebnem İzmır Güner1, Perihan Sinem Özdemir1, Ahmet Çetin1, Songül Özdemir1, Sevgi Kalayoğlu Beşişik2
1Bağcıllevler Private MedicalPark Hospital, Adult Bone Marrow Transplantation Unit, Istanbul, Turkey
2Istanbul University, Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology

**Introduction:** Patients with advanced or treatment-refractory Hodgkin disease and non-Hodgkin lymphoma (NHL) and patients with multiple myeloma (MM) may be successfully treated with high-dose chemotherapy followed by autologous transplantation of PBSC. Successful engraftment of PBSC is well correlated with the number of CD34 + stem cells infused. PBSC are mobilized into the periphery blood by treating patients with granulocyte-CSF (G-CSF) for 5–7 days or with disease-specific, non-myeloablative chemotherapy, often in combination with G-CSF before leukapheresis.

The minimum number of CD34 + cells required for a single auto-SCT is generally considered to be 2–2.5_10⁶ CD34 + cells/kg.

Plerixafor (formerly AMD3100) is a CXCR4 chemokine antagonist that has been shown to increase the number of circulating CD34+cells in healthy volunteers and cancer patients when administered alone or with G-CSF. When plerixafor (0.24 mg/kg) was given after 5 days of G-CSF (5 mcg/kg/day 2x1) to NHL and MM patients, the apheresis yields were significantly higher when compared with patients receiving G-CSF alone.

**Methods-Results:** We report August 2010 - February 2013 between four patients (M / F: 3/1, mean age: 52, age range 34-67) data were compiled.

One of these patient, who was MM, autologous stem cell transplantation were evaluated for the second time. Multiple myeloma diagnostic frequency range (n = 1), Hodgkin’s lymphoma (n = 1), non-Hodgkin’s lymphoma (n = 1), chronic lymphocytic leukemia (n = 1) was determined.

In order to achieve the target stem cell, an average of 2 days (n = 4) apheresis was sufficient, in 1 patient, 3 days, 2 days in 2 patients, 1 patient has 1 day of apheresis.

Content of stem cell apheresis product of 4.03 million / kg (0 to 12.94 million / kg), respectively.

Mobilization could not be successful in 2 patients. These patients diagnose were MM and KLL.

MM diagnosed patient respond after 4 cycles of VAD complete response status. Then he had a autologous stem cell transplantation. After 3 months his disease repeat
and he evaluated for the second time of autologous stem cell transplantation.

The second patient KLL diagnosed patient had eight cycles of CHOP therapy after 4 cycles of Rituximab he had a complete remission. After the first repeat of the disease he had 2 cycles with minimal response to the Cyclophosphamide + G-CSF, after 4 cycles of Fludarabine + Cyclophosphamide he had partial response then he evaluated for the second time of autologous stem cell transplantation.

In none of the patients developed grade 4 adverse event during kemomobilization.

**Conclusion:** Bone marrow histology may predict mobilization failure. In the era of plerixafor, according to the peripheral CD34+ cell count, preemptive use of plerixafor can overcome this problem but not always. Preemptive use provides reduced cost and morbidity.

**Keyword:** plerixafor, Bone marrow

Poster No: 00183 Abstract:0308

**RESULTS OF AUTOLOGOUS PSCT FOLLOWED BY HIGH DOSE MITOXANTRONE AND MELPHALAN IN PATIENTS WITH LYMPHOBLASTIC LYMPHOMA**
Mahmut Yeral, Can Boğa, Hakan Özdoğan, Mutlu Kasar, Nurhlal Turgut, Çigdem Gereklioğlu
Adana Adult Bone Marrow Center, Department of Hematology, Baskent University, Adana, Turkey

Lymphoblastic lymphoma (LBL) is an uncommon malignancy accounting for <2% of non-Hodgkin’s lymphoma. This type of lymphoma is considered a precursor B-cell/T-cell neoplasm and thought to be the nodal/ extranodal presentation of acute lymphoblastic leukemia. Despite high initial remission rates with Hiper-CVAD, 40-60% of adults eventually relapse. Several studies have examined the role of both autologous and allogeneic peripheral stem cell transplantation (PSCT) in first and second remission, as well as in patients with refractory disease.

Patients and Metod: We evaluated the outcome of 5 patients (1 F, 4 M) with T cell LBL after high dose therapy following autologous PSCT between 2005 and 2012 in the Clinical Unit. Treatment regimens were hiper-CVAD in three patients and CHOEP in one patient. All of them had chemosensitive disease and went into complete remission prior to transplantation. One patient was primary refractory to the CHOP treatment and he was in partial remission (PR) after ESHAP salvage therapy. The Conditioning regimens were mitoxantrone 60 mg/m² and melphalan 180 mg/m² in five patients for otologus transplantation.

Results: Median follow-up of the patients were 11 months (range 4–33 months). For all patients, estimated 100 day, one year and two years event-free survival were 80 %, 80% and 60% and the overall survival were 100%, 80% and 80% respectively. One patient who has in PR prior to transplantation relapsed at 18 month and died at 33 month. The patient who has bulky and central nervous system involvement at diagnosis relapsed at 3 month and died at 8 month post transplantation.

Conclusion: Despite the small number of patients in this study, high dose mitoxantrone and melphalan followed by autologous PSCT seems to be an effective treatment option that can achieve complete remission for patients with LBL.

**Keyword:** Lymphoblastic lymphoma, autologous PSCT,
In conclusion, we speculate that the inhibitor gene KIR2DL3 might impede lysis of leukemic cells by suppressing activity of NK cells and by this way contribute to disease pathogenesis. The low frequencies of KIR2DL5, KIR2DS1, KIR2DS3, KIR3DS1 genes among high risk CLL patients as compared to low-intermediate patients suggest that these genes might prevent disease progression and result a more indolent behaviour. On the other hand the lower median number of activator genes in high risk CLL patients supports the idea that activator KIR genes prevents disease progression in CLL.

Keyword: Chronic lymphocytic leukemia, KIR genes
4th International Congress on Leukemia – Lymphoma – Myeloma

May 22 – 25, 2013 • Istanbul, Turkey

AUTHOR INDEX
A

Abdulrezzak, Ümmühân 305
Acar, Celal 315, 346, 364
Açıkalan, Arbil 317
Açık, Didar Yanardağ 348
Adadalet, İbrahim 293
Adıgüzel, Cafer 285, 312, 314
Agapidou, Alexandra 284
Ahmed, Ebtessam 281
Akalın, Esma Seda 309
Akan, Hamdi 360
Ak, Nejat 295, 296
Akay, Aynur 282
Akcaba, Ali Haydar 280
Açtaş, Zeynep 353, 354
Akdeniz, Aysan 345
Akgül, Sebahat Usta 310
Aki, Hilal 293, 336, 338, 339
Akin, Dilara Fatma 295, 296
Akin, Haluk 347
Akker, Mustafa 272
Akkoysunlu, Yasemin 347
Akşit, Seral 366
Ak, Recpe 284
Aksu, Salih 291, 302, 352
Aktaş, Melih 362
Akyazi, Elif 311
Akyıldız, Ümit 342
Alacagöçü, İnci 300, 301, 315, 318, 346, 364
Alakoç, Yeşim Doğan 325
Alanoğlu, Güçhan 307
Albayrak, Aynur 287
Albayrak, Murat 287
Ali, Rdvan 286, 315, 320
Alizadeh, Shaban 298
Anacak, Yavuz 278, 332
Andjelic, Bosko 307
Ansell, Stephen M. 291
Antic, Darko 307
Apak, Hilmi 274
Arat, Mutlu 322, 364
Ar, Cem 300
Ar, Mehmet 332
Arguden, Yelda Tarkan 300
Ar, U. Cem 329
Ar, Mehli Can 323
Arslan, Müzeyyen 355
Arslan, Önder 346, 360, 363
Arslan, Öykü 324, 308, 319, 335
Ashlock, Britanny 334
Aslan, Turan 347
Aslan, Vedat 287
Asma, Süheyl 365
Atabay, Berna 283
Ataş, İskırgıç 312, 314
Atalay, Figen 331
Atay, Hilmi 311
Atesoğlu, Elif Birtaş 316, 333
Attı, Esra 342
Ayan, İnci 343
Aydın, Burçin 271, 277
Aydın, Filiz 310, 313
Aydın, Men, Yeşim 278, 279
Aydın, Seniz Öngören 329
Aydın, Yıldız 329
Aydöğdu, İsmet 271
Ayer, Fatma Aylin 302, 355
Ayer, Mesut 302, 355
Ayan, Ali 351
Ayllı, Meltem 310
Ayyıldız, Orhan 348
Azap, Alpay 363
Azzam, Hanan 298

B

Bağcı, Gülseren 350
Bahçe, Muhterem 329
Balakan, Ozan 348
Balçık, Özlem Şahin 340, 342, 355
Balkan, Can 278, 279, 283
Balkanlı, Sülleyman 305
Bal, Zümrüt Şahbudak 281
Banchero, Agustina 344
Bariş, İkbal Cansu 350
Başal, Yeşim 356
Başlar, Zafer 283, 329
Bat, Taha 366
Bayır, Duygu 297
Baykal, Can 303
Bayrak, Reyan 342
Bayraktar, Soley 334
Bayraktar, Ulas Darda 334, 336
Bayram, Korhan Barış 273
Bektaş, Meral 360, 363
Bektaş, Özen 341
Benekli, Mustafa 348
Bener, Sadi 318
Berber, Ufuk 319, 336, 337, 338
Beşir, Seydi Kâylağoğlu 309, 310, 313, 362, 365
Bila, Jelena 307
Bilgil, Fahri 276
Bilgin, Aynur Uğur 287, 341
Bilgir, Oktay 274, 308, 319, 335
Bodrozic, Jelena 307
Boğa, Can 365, 366
Bolaman, Zahit 285, 292
Boruban, Melih Cem 348
Bot, Freek 327
Boyacıgil, Senay 325
Boztepe, Burcu 345
Bör, Özcan 283
Bulut, Sanem Dereli 340
Burhan, Turgut 341
Büyükaşık, Yahya 291, 302, 352
Büyükaçı, Mustafa 283
Büyükkaba, Mitat 323
Büyükkaya, Piltan 278, 331
Büyükececi, Filiz 304, 317

C

Cabral, Lisa 334
Cabral, Pablo 344
Cadievskaia, Lazar 289, 290, 324, 349
Camacho, Ximena 344
Caner, Vildan 350
Can, Esra Sarpbacak 287
Can, Özge 350
Celkan, Tirage 283, 293, 339
Celkan, Tirage Tülin 274
Ceren, Fonda 286, 293, 330
Cevreska, Lidiya 284, 289, 290, 319, 320, 324, 349, 358
Ceyhan, Özgür 364
Chabalgoity, José A. 344
Chae, Yee Soo 330
Champlin, Richard E. 360
Chen, Robert W. 291
Choi, Chul Won 330
Ciureka, Stefan O. 360
Clench, Malcolm 295, 296
Colovic, Milica 318
Colovic, Natasa 294
Connors, Joseph M. 291
Costantini, Renato Mariano 290
Cömert, Melda 271, 273, 288, 303, 304, 309, 332, 356, 361
Cross, Neil 295
Cross, Neil A. 275, 276
Cuik, Vladimir 343
Cvetkovic, Bora 289
Cvetkovic, Zorica 289

Ç

Çağırkan, Seçkin 323, 350, 361
Çağlayan, Günsüm Akgün 274, 308, 319, 335
Çakir, Fatma Betül 343
Çakmakçı, Handan 279
Çakmakçı, Güzin 363
Çalışkan, Ali Riza 357
Çalli, Aylin Örgen 318
Çekdemir, Demet 356
Çelebi, Harika 287
Çelik, Ali 300
Çelik, Yahya 272
Çerçi, Süreyya 307
Çetin, Ahmet 365
Çetin, Gökhan Özcan 350
Çetin, Özcan 283
Çetin, Güven 313, 323, 347
Çetin, Mustafa 305
Çevik, İhsan Ünal 310
Çinar, Suzan 271, 277
Çirakoglu, Ayse 283, 300
Çoban, Eyüp 273
Çoğulu, Özgür 321
AUTHOR INDEX

D
Dağdaş, Simten 286, 293, 330
Dahlawi, Hyatham Ahmad 296
Dalay, Nejat 299
Dal, Sinan 348
Dede, Bahadır 353
Dede, Fatih 293
Deeg, H. Joachim 359
Delcastello, Buket Erer 278
Demirci, Bahar 355
Demir, Fatma 279
Demiralp, Emel Ekşioğlu 285
Demir, Ömer 317, 359
Demiröz, Ahu Senem 338
Deniz, Günnur 271, 277
Deniz, Kemal 305
Deveci, Burak 357
Devecioğlu, Ömer 283
Deviren, Ayhan 300
Dias, Luis A. 334
Dierck, Kevin 272
Dimovski, Aleksandar 290, 319, 320
Dittmer, Dirk P. 334
Djukic, Nikola 289
Djunic, Irena 289
Djurišević, Teodora Karan 318
Doğan, İbrahim Öner 340
Doğan, Ömer 343
Doğan, Öner İbrahim 303
Doğan, Ömer 317
Doğan, Ömer İbrahim 340
Dolgu, Anıl Barak 329
Dönmez, Ayhan 288, 317, 359
Dukovski, Dusko 284, 289, 290, 319, 324, 349
Duyu, Muhterem 279
Eftimov, Aleksandar 290, 319, 320
Ege, Fahrettin 310
Ekinci, İskender 323, 347
Eleçović, Alihsan 276, 277
Elezović, Ivo 307
Eliaçık, Eylem 291, 352
Elverdi, Tuğrul 310, 336
Emer, Zafer 278
Engert, Andreas 291
Erlabilin, Yücel 302
Erdogân, Beyza Doğanay 298
Erduran, Erol 283
Eren, Seda 283
Ergene, Ülkü 276, 277, 353, 354
Ergin, Mehmet Ali 271
Ergün, Ali 348
Ergüzel, Nurettin 302
Ergüzel, Nurettin 302
Erdogdu, Ayşen 302
Ertan, Muhammet 302
Ertugrul, Fatih 302
Eroğlu, Ayşe Hilal 363
Eroğlu, Celalettin 305
Ersal, Tubas 286, 320
Ersoy, Ajda 361
Ersöz, Ajda Güneş 303, 304
Eser, Ali 312, 314
Eser, Bülent 305
Eskazan, A. Emre 329
Ester, Üstün 295
F
Falay, Mesude 330
Ferhaňoğlu, Ahmet Burhan 306
Ferhaňoğlu, Burhan 329, 334
Fernández, Marcelo 344
Feyzőglu, Hikmet 355
Filic, Dusica 342
Fouda, Ashraf 298
G
Gadisseur, Alain 325, 327
Gambini, Juan Pablo 344
Garcia, Maria Fernanda 344
Garypidou, Vasileia 284
Gemici, Alihsan 276, 277
Georgievski, Borce 349, 358
Gerasimos, Çiğdem 366
Gisslinger, Heinz 322
Gocalhino, Marco Di 290
God, Enas 298
Goncharova, Natalia 299
Gopal, Ajay K. 291
Gotic, Mirjana 307
Göker, Hakan 291, 302, 352
Gökçözeroğlu, Zafer 317, 323, 356
Gökşel, Suha 338
Gönderen, Aysun 293
Görgün, Ömer 343
Gözmen, Salih 279, 324
Group, On Behalf Serbian Myeloma 307
Gülel, Mehmet Şahin 351
Gülen, Hüseyin 311
Güler, Elif 324
Güler, Nil 311
Güler, Ömer 324
Güney, İbrahim 341
Gün, İsmet 319
Güngör, Cemal 312, 314
Güngöz, Zafer 317, 323, 356
Güney, İbrahim 341
Gün, İsmet 319
Gürsoy, Soner 309
Güvenç, Serkan 322
H
Hacihanefioglu, Abdullah 316, 333
Hacihanefioglu, Seniha 283, 300
Hacigoğlu, Sibel Kabukçu 350
Haholu, Aptullah 319, 336, 337, 338
Halaçoğlu, Aysu 288, 351
Hallaç, Metin 293
Hancer, Veyser Sabri 322
Hasbal, Nuri Barış 322, 364
Haznedaroğlu, İbrahim C. 291
Haznedaroğlu, İbrahim Celalettin 302, 352
Hebeda, Konnie 328
Hekimgil, Mine 273, 288, 309, 332, 347, 350
Hz, Semra 282
Hindilerden, Fehmi 322, 340, 364
Horacek, Jan M. 282, 315, 354, 358
Hortsmann, Martin 272
I-İ
Ilhan, Osman 363
Irken, Gülersu 279
İrmak, Gönül 286, 320
İşik, Ayşe 291, 352
İşkdoğan, Abdurrahman 348
İvanovski, Martin 284, 289, 290, 319, 320, 324, 349
İlhan, Osman 360, 363
İnal, Ali 348
İnalöz, Serhat 348
Irken, Gülersu 282, 324
J
Jaff, Mohamad Salih 297
Jakl, Martin 358
Jebavy, Ladislav 282, 315, 354, 358
Jelicic, Jelena 307
K
Kadıköy, Gürgan 285, 292
Kahraman, Selda 311, 356
Kalafatçılar, Ayşe İpek 282
Kamer, Arun 278
Kamer, Serra Arun 273, 332
Kang, Hye Jin 330
Kantorčić, Bülent 312, 314
Kaplan, Muhammed Ali 348
Karabulut, Yasemin Yuyucu 325
Karaca, Ayşegül Yilmaz 302
Karaca, Emin 321, 347
Karaca, Halit 305
Karadax, Nihat 279, 281
Karadaxhan, İlhan 307
Karakuş, Sema 288, 351
Karakuş, Volkan 280, 357
Karafili, Oliver 358
AUTHOR INDEX

Karapınar, Bülent 279
Karapınar, Deniz Yılmaz 279, 281
Karapınar, Tuba 279
Karataş, Sonay Güven 342
Kasap, Muğlun 366
Kate, Fibo Ten 328
Kate, Fibo W. J. Ten 328
Katırcı, Abdullah 300, 301, 315, 346, 364
Kavaklı, Kaan 278, 279
Kaviani, Saeed 298
Kaya, Emel 288
Kaya, Emin 271
Kaygusuz, Işık 285
Kaymaz, Sami 355
Kaymak, Yılmaz 298
Kebriaei, Partow 360
Kebudi, Rejin 343
Keklik, Fatma 304
Keklik, Muzaffer 305
Kelkitli, Engin 311
Kesik, Fatma 355
Keski, Hakan 316, 333
Khatib, Zahra Kashani 298
Kılınç, Yurdanur 283
Kırdak, Türkay 352
Kırkızlar, Onur 302, 355
Kızılkılıç, Ebru 331
Kim, Jeong A. 330
Kim, Jin Seok 330
Kim, Won Seog 330
Koca, Ebru 288, 351
Koç, Ahmet 283
Koka, Aida 274
Kontaş, Olgu Git 305
Konuk, Nihat 367
Koşar, Ali 340, 342
Koudstaal, Peter J. 327
Kouhkan, Fatemeh 298
Kozanoğlu, İlknur 365
Köktaş, Özlem 363
Köroğlu, A. Emin 325
Köse, Evrim Doğan 351
Kuku, İrfan 271
Kundak, Çağatay 306
Kupcu, Sümeyra 282, 315
Kurbal, Melih De 363
Kurt, Burcu 340
Kurt, Hüsnü 340
Kurtulmuş, Avşar 280, 357
Kurtoglu, Umut Kural 294
Kuru, Dilhan 283, 300
Kuzu, Gülsün 305
Kuzu, İhsan 325
Küçükçay, Derya Din 322
Küçükçüker, Mehmet 348
Küçükçüker, Umut Can 271, 277
Küçükçüker, Betül Bolat 318
Kürekçi, A. Emin 295, 296
Kürekçi, Emin 283
Kwak, Jae Yong 330

L

Laleli, Yahya 334
Laleli, Yahya Rauf 306
Lam, King 326, 328
Lanuti, Paola 290
Larsen, Emily K. 291
Laucat, Frédéric Rieux 339
Laurenti, Luca 290
Lee, Jae Hoon 330
Lee, Je Jung 330
Leone, Giuseppe 290
Loiko, Valery 299

M

Mahbub, Aman 275, 276
Mahfouz, Rabab 298
Mahy, Nicola Jordan 275, 276
Mahy, Nikkie Jordan 296
Maitre, Christine Le 295, 296
Maitre, Christine L. Le 275, 276
Maly, Jaroslav 354
Marinitch, Dimitry 299
Markala, Dimitra 284
Markovic, Katarina 342, 343
Markovic, Nevenka 342, 343
Matevska, Nadica 319, 320
Medeni, Şerife Solmaz 346
Mehtap, Özgür 316, 333
Menin, Dilek 279
Michiels, Jan Jacques 325, 326, 327, 328
Mihajlebic, Biljana 307
Milivojevic, Zoran 342, 343
Mitrovcic, Mirjana 294
Monem, Tarek Abdel 281
Moreno, Maria 344
Mucuncuoglu, Mine 295
Mutfuoglu, Ekrem 348

N

Naclaci, Melih 283, 303, 310, 321, 340
Nazihoglu, Hulya Ozturk 315, 320, 351, 352
Ng, Özen Hatunraz 302
Nikcevic, Gordana 318
Nikolic, Branka Bonaci 342
Novkovic, Aleksandra 294

O

Ogur, Gönül 311
Oh, Sung Yong 330
Okan, Vahap 348
Olcay, Laie 283
Olgun, Yüksel 282
Onan, Engin 317
Oran, Mustafa 297, 341
Orçim, Esmahan 282
Osmansaçı, Emre 310, 313, 321, 362

Ö

Öksüzoglu, Berna 348
Öneç, Birgül 287
Öngören, Şeniz 300, 336, 338
Ören, Hale 279, 282, 283, 324
Ornek, Serdar 306, 334
Özatlı, Düzgün 311, 331
Özbalak, Murat 306, 329, 334
Özbek, Devrim 363
Özbek, Namık 363
Özbek, Uğur 274, 302
Öz, Bülent 336
Özcan, Mehmet Ali 300, 301, 315, 346, 364
Özcan, Muhit 346, 360, 363
Özcebe, Osman 306
Özcebe, Osman Ilhami 302, 352
Özçelik, Emine Tülay 364
Özçelik, Tülay 322
Özdemir, Gülşen 274
Özdemircan, Füsun 273, 317, 318, 323
Özdemirli, Metin 334
Özdemir, Meltem 331
Özdemir, Nihal 293, 339
Özdemir, Nuriye 348
Özdemir, Özlem Erdal 311
Özdemir, Perihan Sinem 365
Özdemir, Songül 365
Özdöğru, Hakan 365, 366
Özen, Mehmet 346, 363
Özer, Özen 313
Özet, Gülsüm 286, 293, 330
Özkal, Fahri 286, 320
Özkaya, Tuba 323, 347
Özkaya, Mesut 348
Özkay, Ferda 347
Özkocaman, Vildan 286, 320, 351
Özmur, Meltem 341
Özsan, Güner Hayri 300, 315, 346, 364
Özsan, Hayr Güner 301
Özsan, Nazan 273, 304, 321, 332, 350, 361
Öztürk, Berna 293
Özyürek, Emel 283

P

Pagotto, Sara 290
Pamuk, Gülsüm Emel 272, 284
Papadopoulos, Theodora 284
Patroğlu, Türkân 283
Pavlovic, Sonja 318
Paydaş, Semra 317
Payzin, Kadriye Bahriye 273, 318
Pehlivan, Mustafa 348
Pektaş, Gökhan 285, 292
Pepedil, Funda 285
Pepe, Felice 290
Pereira, Denise 334
Pernudi, Allan Xavier 272
Perunicic, Maja 342
Petrovic, Maja Stojiljkovic 318
Petruveska, Gordana 343
Pişkin, Özden 300, 301, 315, 346, 364
Pivkova, Aleksandra 349, 358
Polat, Aziz 283
Polat, Süleyha Hilmioğlu 279
Porcal, Williams 344
Pudil, Radek 358
Pur, Saeed Nasouhi 278
Raafat, Nermin 281
Radulovic, Stanko 342, 343
Raeve, Hendrik De 326, 328
Rajic, Miodrag 343
Ramos, Juan C. 334
Reisli, İsmail 287
Riva, Eloísa 344
Rondon, Gabriela 360
Ruban, Güray 273, 303, 304, 317, 332, 350, 356, 361
Saydam, Güray 279, 302, 352, 356, 364
Saygın, Caner 293, 302, 352
Sayinoğlu, Kaan 318
Savas, Ömer Önder 286, 293, 330
Saydam, Güray 273, 303, 304, 317, 332, 350, 356, 361
Saygin, Caner 293, 336, 338, 339
Saynaptor, Nilgün 291, 302, 352
Sayitoğlu, Müge 274, 302
School, Hacettepe Medical 291
Schroyens, Wilfried 327
Scorilas, Andreas 318
Seval, Güldane Cengiz 310, 346, 360
Sevindik, Oğuz Gökmenc 300, 301, 315, 346, 364
Shafiek, Hala 298
Shouma, Amany 298
Sievers, Eric L. 291
Simjanovska, Marija Popova 284, 289, 290, 319, 324, 349
Sipahi, Kadir 295
Sivgin, Serdar 305
Small, Sarah Haywood 295
Small, Sarah L. Haywood 275, 276
Smiljanic, Mihajlo 307
Smith, Scott E. 291
Soleimani, Masoud 298
Soliman, Othman 298
Solmaz, Şerife Medeni 300, 301, 315, 364
Sop, Gülten 323
Soyer, Nur 319,356
Soyer, Özge 287
Soysal, Teoman 329
Söker, Murat 283
Sönmez, Mehmet 305
Spasovski, Vesna 318
Srzentic, Sanja 318
Stankovic, Svetlana 342
Stankovic, Svetlana 284, 349
Stasi, Antonio Di 360
Stavridis, Irina Panovska 284, 289, 290, 319, 320, 349
Stavrakos, Sonja Genadieva 358
Stojanovski, Zlate 358
Stojanovic, Aleksandar 290, 324, 349
Stojanovic, Vesna 343
Subari, Salih 348
Suh, Cheolwon 330
Suner, Ali 348
Sunun, Cenk 286, 293, 330
Şahin, Fahri 273, 303, 304, 317, 332, 361
Şahin, Handan Haydaroğlu 348
Şahintürk, Yasin 280, 357
Şeker, Mesut 348
Şener, Sener 348
Şengöz, Nur Şinem 288
Şen, Semra 281
Şimşek, Eda Tanrıkkulu 340
Şirin, Ferda 295
Tahrali, İlhan 271, 277
Tannrikulu, Funda Pemde 312, 314
Tapan, Ümit 272
Tarkan, Nefise Çağla 351
Tarkan, Pınar 316, 333
Tasios, Kadri 295
Tayyip, Serdar 305
Tepkin, Didem 348
Toglu, Ali 305
Tokatlı, İlyas 334
Tokgöz, Gül 286, 330
Tombak, Anıl 345
Tombuloğlu, Murat 273, 288, 304, 347, 359
Tomlin, Dragica 294, 307
Tonyali, Önder 348
Toomey, Ngoc 334
Topçuoglu, Pervin 346, 360
Toprak, Selami Koçak 288, 351, 363
Torun, Bekir 280
Torun, Didem 296
Tosevic, Natala 294, 318
Töböl, Mahmut 309, 321, 361
Trajkova, Sanja 284, 289, 290, 319, 320, 324, 349
Trocchimüt, Magdalena 272
Tuğular, Tülin 285
Tuğular, Tülin Furatlı 312, 314
Tulunay, Ayşin 285
Tuna, Ahmet 320
Tunc, Bahattin 283
Tuncer, Sevilay 287
Turan, Esra 309
Turgut, Burhan 297
Turgut, Mehmet 278, 311
Turgut, Nurhilal 366
Tutal, Emre 288
Tüfekçi, Özlem 279, 282, 324
Tümkaya, Süleyman 364
Türkel, Recep 331
Türk, Nilay Şen 350
Tüysüz, Gülen 274, 293, 339
Tüzünner, Nüket 293
Tüzünner, Nükket 298
Tüzünner, Nükhet 329
Tzimou, Maria 284
Uçar, Mehmet Ali 345
Ugrin, Milena 318
Ulusoy, Mabule 302, 355
Uncu, Dogan 348
Urakçi, Zuhat 348
Uras, Fikriye 285
Uslu, Meltem 309
Uyanik, Mehmet Sevki 284
Uygun, Özhan 348
Uysal, Akın 346
Uz, Burak 302
Uzunarslan, Didem 293, 339
Uzunarslan, Didem 336, 338
Ümit, Hasan 272
Ünal, Ali 305
Ünal, Selma 283
Ündar, Bülent 300, 301, 315, 346, 364
Üyeturk, Ümmügül 348
Vakalopoulou, Sofia 328
Vasatova, Martina 282, 315, 354, 358
AUTHOR INDEX

Vejlanovska, Aleksandra Pivkova 319, 320
Vergin, Canan 283
Veronese, Angelo 290
Veschi, Serena 290
Vidovic, Ana 294, 307
Virijevic, Marijana 294
Visone, Rosa 290
Vukovic, Nada Suvajdzic 294
Vural, Filiz 273, 303, 332, 356, 361

W-X

Walt, Jon Van Der 326
Xadjiaaggelidou, Christina 284

Y

Yahia, Sohier 298
Yalcin, Kadir Serkan 342
Yalcin, Serkan Kadir 355
Yalniz, Zubeyde 299
Yavasoglu, Irfan 285, 292
Yavuz, Akif Selim 299, 321, 362
Yazici, Bulent 351
Yazici, Omer Kemal 348
Yazici, Pinar 279
Yenerel, Mustafa Nuri 362
Yenigurbuz, Fatma Demir 324
Yeral, Mahmut 365, 366
Yetisyigit, Tarkan 297, 341
Yetkin, Funda 271
Yhim, Ho Young 330
Yildirim, Zeki 340
Yildiz, Eren 340
Yildiz, Levent 278
Yilmaz, Abdullah 271, 277
Yilmaz, Asu Fergun 273, 303, 304, 332, 356, 359, 361
Yilmaz, Guven 312, 314
Yilmaz, Mehmet 348
Yilmaz, Shebnum 279, 339
Yilmaz, Sükriye 300
Yigit, Namik 355
Younes, Anas 291
Yonal, Ipak 303, 313, 321, 340, 362
Yuskselen, Özen Özdén 356
Yüksel, Meltem Kurt 363

Z

Zaini, Rana Ghazi 295
Zak, Pavel 282, 315, 354, 358
Zukic, Branka 318
Zulfikar, Bulent 343